

Table of Contents

Section I Corporate Overview

- A. Bidder Identification and Information
- B. Financial Statements_UHG Annual Report 10-K
- C. Change of Ownership
- D. Office Location
- E. Relationship With the State
- F. Bidders Employee Relations to State
- G. Contract Performance
- H. Summary of Bidders Corporate Experience
- I. Summary of Bidders Personnel Management Approach
- J. Subcontractors
- K. Pending Litigation
- L. Bankruptcy
- M. Financial Ratings

Section II Technical Response

- A. RFP Section II – Terms and Conditions
- B. RFP Section III – Vendor Duties
- C. RFP Section IV – Payment
- D. RFP Section V - Project Description and Scope of Work
- E. Attachment C – Confirmations and Questionnaire
- F. Formulary Disruption Analysis
- G. Network Disruption Analysis
- H. Attachment D – Performance Guarantees



optum.com
11000 Optum Circle, Eden Prairie, MN 55344

Freedom of Information Act

The following Freedom of Information Act exemption language applies to Optum Rx proposal submissions:

- Protected from Disclosure Under Federal [and State] Law.
- Exempt from the Freedom of Information Act. See 5 U.S.C. §552(b).
- Contains Confidential Commercial/Financial and Other Protected Information.

The information contained in this proposal submission includes trade secrets, is confidential and proprietary. As such, this information is valuable to Optum Rx, and Optum Rx would be harmed if the information was obtained by competitors and other entities with which it negotiates. Public release of any information contained within this proposal is restricted to non-confidential, non-proprietary items and can only occur with advance written notice that allows Optum Rx with the opportunity to take appropriate steps to prevent disclosure, obtain a protective order, or provide a redacted version.

- I. Detailed Project Work Plan_Implementation Plan
- J. Contractual Agreement Form_Signed

Section III Attachments

- A. Optum Rx Sample Contract
- B. Attachment B – BAA_Optum Rx
- C. Client Management Team Biographies

Section IV Questionnaire Exhibits

- A. Standard Rebate Reporting Package
- B. APAS Analysis
- C. Member Communication Samples
- D. Sample Score Card
- E. Premium Formulary Abridged
- F. Premium Formulary with NDC and UM Flags
- G. Sample iQPR Report
- H. PA, ST and QL Lists
- I. Sample CDUR Report
- J. Provider Detailing Hub Report
- K. GeoAccess_State of Nebraska
- L. Specialty Drug List
- M. RxTrack Standard Reporting Catalog
- N. Sample Client Reconciliation Report
- O. ERISA Disclosure 2025 Attestation_Signed



optum.com
11000 Optum Circle, Eden Prairie, MN 55344

Freedom of Information Act

The following Freedom of Information Act exemption language applies to Optum Rx proposal submissions:

- Protected from Disclosure Under Federal [and State] Law.
- Exempt from the Freedom of Information Act. See 5 U.S.C. §552(b).
- Contains Confidential Commercial/Financial and Other Protected Information.

The information contained in this proposal submission includes trade secrets, is confidential and proprietary. As such, this information is valuable to Optum Rx, and Optum Rx would be harmed if the information was obtained by competitors and other entities with which it negotiates. Public release of any information contained within this proposal is restricted to non-confidential, non-proprietary items and can only occur with advance written notice that allows Optum Rx with the opportunity to take appropriate steps to prevent disclosure, obtain a protective order, or provide a redacted version.



July 18, 2025

Brook Taylor
Procurement Contract Officer
State Purchasing Bureau
1526 K Street, Suite 130
Lincoln, NE 68508

Hello,

I am pleased to submit Optum Rx's proposal to the State of Nebraska (the State) for pharmacy benefit management services (PBM). We deeply value the trust and collaboration we have built together and want to continue the progress we've made to achieve greater success together. The attached proposal outlines how we will continue to deliver the full scope of PBM services you require – rooted in our core competencies and industry leading expertise – to manage total member cost of care, drive better health outcomes and control pharmacy trend. With our proven performance, differentiated capabilities and best in class collaborative approach, we are confident in our ability to help accelerate the State's strategies and goals. We aim to:

- Improve access, affordability and member choice while enhancing outcomes with a focus on lowest net cost and lowering total cost of care.
- Deliver self-service reporting tools like RxTrack that offer visibility into performance and empower the State to support members on their health journey through data-driven insights.
- Set a new standard for transparency, empowering you and your members to be clear and confident on your health care journey.
- Continuing on the success of our partnership, bringing forward innovation that moves your strategy and goals forward.

Modern health care brings many challenges, including complexity and ever-increasing costs. The traditional ways of managing the system have not delivered the simplicity, transparency, and outcomes required today – or the exceptional service your members expect. We continue to invest in and build innovative solutions that lower costs without compromising quality or service. We build smarter connections between employers, payers, members and providers – connections that drive success through trusting relationships rather than repeated transactions. Our approach offers:

- Collaboration to understand your goals, delivering programs and analytics for holistic, personalized, and equitable care with the ability to align plan features with your benefit strategy and priorities.
- Empowerment to manage drug costs through enhanced dashboards with proactive communication of lower cost options and price transparency along with the flexibility for you to choose the programs that work best for the unique health care needs facing your members.



- Cost and trend management that brings your plan's data to life and ties the components of our comprehensive pharmacy offering together for focused strategies that reflect your cost containment objectives.

Thank you for your interest in continuing your relationship with Optum Rx. Together, we can build on the strength of our long-standing partnership to deliver lasting impact, supporting better outcomes, greater affordability, and continued innovation for the people you serve. Please contact me at (443) 739-4028 or at Jeff.Gottlieb@optum.com with any questions about our response. We look forward to meeting with you soon to further demonstrate our commitment to the State's success.

Sincerely,

A handwritten signature in dark ink, appearing to read "Jeffrey Gottlieb".

Jeffrey Gottlieb
Area Vice President of Public Sector Sales
Optum Rx

COST SHEET

SOLICITATION NUMBER 122436 O5

Pharmacy Benefit Management Services Fees

Bidder: Optum Rx

Financial Proposal Work Sheet: Enter the per Member per Month (PMPM) fees for Section I - Standard Services below for the plan designs currently in place.

Fees on any other basis, (i.e., as a percentage of claims, on a per claim basis or a combination) will NOT be considered. The ASO Fees are to be guaranteed for the three (3) year contract period. Any ancillary service relating to the administration of the health plan not specifically identified in bidder's proposal is assumed to be included in the ASO fee. All services covered under the fee should be listed. **IF THE FEE STRUCTURE IS DIFFERENT BY PLAN, COMPLETE THIS SCHEDULE FOR EACH PLAN AND LABEL EACH SCHEDULE ACCORDINGLY.** Enrollment figures represent estimated counts.

CONFIDENTIAL, PROPRIETARY AND TRADE SECRET INFORMATION OF OPTUM RX

Section I - Pharmacy Benefit Management Services Fees	Initial Contract Term			1st Option Year	2nd Option Year
	Year 1	Year 2	Year 3	Year 4	Year 5
	Estimated Number of Enrolled Employees	Estimated Number of Enrolled Employees	Estimated Number of Enrolled Employees	Estimated Number of Enrolled Employees	Estimated Number of Enrolled Employees
Number of Enrolled Members =>	28,386	28,386	28,386	28,386	28,386
PBM Fees per Member per Month (PMPM)	\$1.37	\$1.51	\$1.66	\$1.81	\$1.96
Pharmacy Benefit Management and Administration Fee					
Toll Free Phone Lines					
Monthly Data Feeds to Fund or Designee(s)					
Prospective /Concurrent/Retro DUR					
Standard Reports					
Ad Hoc Reports					
COB Program					
First Level Appeals					
Second Level Appeals					
Urgent Appeals					
Formulary and Rebate Administration					
Prior Authorization Program					
Fraud and Abuse Program					
Step Therapy Program					
Quantity Limitations					
Dose Optimization					
Medication Management					
Custom System Overrides					
Manual Claim Processing					
Annual EOB Statements					
Retro Termination Letters					
Member-submit Claims					
Drug Notification Letters					
Member Formulary Guides					
Member ID Cards					
Member Mailing Postage					
Enrollment Packet Mailing					
Audit Recovery Fees					
E-Prescribing					
Vaccine Services					
Section I - Standard Services MONTHLY TOTAL	\$38,888.82	\$42,862.86	\$47,120.76	\$51,378.66	\$55,636.56

CONFIDENTIAL, PROPRIETARY AND TRADE SECRET INFORMATION OF OPTUM RX

Section II - Credits/Allowances		Initial Contract Term			1st Option Year	2nd Option Year
		Year 1	Year 2	Year 3	Year 4	Year 5
		Self-Funded Population	Self-Funded Population	Self-Funded Population	Self-Funded Population	Self-Funded Population
Indicate your willingness to offer the listed credits/allowances ("Y/N"). If "Y", then indicate the annual dollar amount of the credit/allowance for each plan year.						
Description	Y/N	28,386	28,386	28,386	28,386	28,386
One-time Implementation Credit	Y	\$47,027.00	\$47,027.00	\$47,027.00	\$47,027.00	\$47,027.00
General Pharmacy Program Management - including communication expenses, clinical programs, consulting fees or be used as a credit against claim invoices.	Y	\$141,080.00	\$141,080.00	\$141,080.00	\$141,080.00	\$141,080.00
Other . . .						
Section II - Credits/Allowances ANNUAL TOTAL		\$188,107.00	\$188,107.00	\$188,107.00	\$188,107.00	\$188,107.00

CONFIDENTIAL, PROPRIETARY AND TRADE SECRET INFORMATION OF OPTUM RX

Section III - Additional and/or Optional Programs/Services		Initial Contract Term			1st Option Year	2nd Option Year
		Year 1	Year 2	Year 3	Year 4	Year 5
		Self-Funded Population	Self-Funded Population	Self-Funded Population	Self-Funded Population	Self-Funded Population
List and describe any additional and/or optional services proposed, the associated administration charges, and the average expected monthly total for each service. Add lines, as needed to accommodate all fees.						
<i>Note: This section will not count toward Evaluation Scoring.</i>						
Service Description	Service Fee and Structure (PSPM, PMPM, X% of Savings, etc.)	Estimated Monthly Total	Estimated Monthly Total	Estimated Monthly Total	Estimated Monthly Total	Estimated Monthly Total
Please refer to the Pricing Summary attached.						

Section III - Additional/Optional Services MONTHLY TOTAL		\$0.00	\$0.00	\$0.00	\$0.00	\$0.00

COST SHEET
SOLICITATION NUMBER 122436 05
PBM Pricing Guarantees

Bidder: **Optum Rx**

Prescription Drug Pricing and Rebates:

AWP Reimbursement Basis—Complete the following table using the drug reimbursement that your organization is willing to guarantee, on a dollar-for-dollar basis, for each year of the contract. Columns marked "AWP Discount" are to be completed using a discount from 100% AWP and dispensing fee logic. All guarantees must be based on the AWP unit cost dispensed at the point of sale, and post September 26, 2009 AWP rollback, including usual & customary and zero-balance claims prior to the impact of member cost sharing. Generic discount guarantee must include all single-source as well as multi-source generic drugs.

The aggregate brand discount guarantee for specialty drugs should include biosimilar specialty drugs. In addition to the aggregate specialty drug discount and rebate guarantees, please provide separately a list of all specialty drugs and their individual discount guarantees.

Specialty drug pricing must be based on an open (non-exclusive) basis.

CONFIDENTIAL, PROPRIETARY AND TRADE SECRET INFORMATION OF OPTUM RX

Self-Funded Population
Pharmacy Network

Guaranteed Pricing for Non-Specialty Medications

Channel	Retail	Retail	Mail
Day Supply (DS)	</=30 DS	31 - 90 DS	>0 DS
AWP Discount for All Brands			
Year 1	19.50%	20.20%	20.20%
Year 2	19.50%	20.20%	20.20%
Year 3	19.50%	20.20%	20.20%
Year 4	19.50%	20.20%	20.20%
Year 5	19.50%	20.20%	20.20%
AWP Discount for All Generics Including Single-Source			
Year 1	89.40%	91.50%	91.50%
Year 2	89.40%	91.50%	91.50%
Year 3	89.40%	91.50%	91.50%
Year 4	89.40%	91.50%	91.50%
Year 5	89.40%	91.50%	91.50%
Dispensing Fee/Rx			
Year 1	\$0.50	\$0.00	\$0.00
Year 2	\$0.50	\$0.00	\$0.00
Year 3	\$0.50	\$0.00	\$0.00
Year 4	\$0.50	\$0.00	\$0.00
Year 5	\$0.50	\$0.00	\$0.00

CONFIDENTIAL, PROPRIETARY AND TRADE SECRET INFORMATION OF OPTUM RX

Specialty Pharmacy

Guarantee Pricing for Specialty Medications

Channel	Retail	Retail	Mail
Day Supply (DS)	</=30 DS	31 - 90 DS	>0 DS
AWP Discount for All Brands			
Year 1	LDD = 14%, Non-LDD- 18.50%	LDD = 14%, Non-LDD- 18.50%	LDD = 14%, Non-LDD- 18.50%
Year 2	LDD = 14%, Non-LDD- 18.50%	LDD = 14%, Non-LDD- 18.50%	LDD = 14%, Non-LDD- 18.50%
Year 3	LDD = 14%, Non-LDD- 18.50%	LDD = 14%, Non-LDD- 18.50%	LDD = 14%, Non-LDD- 18.50%
Year 4	LDD = 14%, Non-LDD- 18.50%	LDD = 14%, Non-LDD- 18.50%	LDD = 14%, Non-LDD- 18.50%
Year 5	LDD = 14%, Non-LDD- 18.50%	LDD = 14%, Non-LDD- 18.50%	LDD = 14%, Non-LDD- 18.50%
AWP Discount for All Generics			
Year 1	80.00%	80.00%	80.00%
Year 2	80.00%	80.00%	80.00%
Year 3	80.00%	80.00%	80.00%
Year 4	80.00%	80.00%	80.00%
Year 5	80.00%	80.00%	80.00%

Dispensing Fee/Rx				
	Year 1	0	0	0
	Year 2	0	0	0
	Year 3	0	0	0
	Year 4	0	0	0
	Year 5	0	0	0
Rebates & Other Manufacturer Revenue				
	%-Share	100%		
Guaranteed Minimum Per Brand Claim Rebate Guarantees				
Non-Specialty Medications				
	Year 1	\$490	\$1,160	\$1,210
	Year 2	\$550	\$1,305	\$1,355
	Year 3	\$615	\$1,440	\$1,490
	Year 4	\$615	\$1,440	\$1,490
	Year 5	\$615	\$1,440	\$1,490
Specialty Medications				
	Year 1	\$3,900	\$3,900	\$3,900
	Year 2	\$4,194	\$4,194	\$4,194
	Year 3	\$4,352	\$4,352	\$4,352
	Year 4	\$4,352	\$4,352	\$4,352
	Year 5	\$4,352	\$4,352	\$4,352


Client: State of Nebraska

Members: 28,216

Pricing Model: Pass-Through

Implementation Date: July 1, 2026

Term of Contract:

Year 1: 07/01/2026 to 06/30/2027

Year 2: 07/01/2027 to 06/30/2028

Year 3: 07/01/2028 to 06/30/2029

Administrative Fee

	Administrative Fee
Base Administrative Fee	\$1.37 \$1.51 \$1.66 PMPM

PMPM = Per Member Per Month

Broad Retail Network Pharmacy

	Brand Drug Discount	Brand Drug Dispensing Fee	Generic Drug Discount	Generic Drug Dispensing Fee
Year 1	AWP-19.50%	\$0.50 PNPC	AWP-89.40%	\$0.50 PNPC
Year 2	AWP-19.50%	\$0.50 PNPC	AWP-89.40%	\$0.50 PNPC
Year 3	AWP-19.50%	\$0.50 PNPC	AWP-89.40%	\$0.50 PNPC

Broad Retail 90 Network Pharmacy

	Brand Drug Discount	Brand Drug Dispensing Fee	Generic Drug Discount	Generic Drug Dispensing Fee
Year 1	AWP-20.20%	\$0.00 PNPC	AWP-91.50%	\$0.00 PNPC
Year 2	AWP-20.20%	\$0.00 PNPC	AWP-91.50%	\$0.00 PNPC
Year 3	AWP-20.20%	\$0.00 PNPC	AWP-91.50%	\$0.00 PNPC

Home Delivery Pharmacy

	Brand Drug Discount	Brand Drug Dispensing Fee	Generic Drug Discount	Generic Drug Dispensing Fee
Year 1	AWP-20.20%	\$0.00 PNPC	AWP-91.50%	\$0.00 PNPC
Year 2	AWP-20.20%	\$0.00 PNPC	AWP-91.50%	\$0.00 PNPC
Year 3	AWP-20.20%	\$0.00 PNPC	AWP-91.50%	\$0.00 PNPC

Specialty Pharmacy ¹		
Brand and Generic Drugs Guarantee	Discount	Dispensing Fee
Non-Limited Distribution Brand Drug		
Year 1	AWP-18.50%	\$0.00 PNPC
Year 2	AWP-18.50%	\$0.00 PNPC
Year 3	AWP-18.50%	\$0.00 PNPC
Generic Drug		
Year 1	AWP-80.00%	\$0.00 PNPC
Year 2	AWP-80.00%	\$0.00 PNPC
Year 3	AWP-80.00%	\$0.00 PNPC
Limited Distribution Brand Drug		
Year 1	AWP-14.00%	\$0.00 PNPC
Year 2	AWP-14.00%	\$0.00 PNPC
Year 3	AWP-14.00%	\$0.00 PNPC

1. Notwithstanding anything herein to the contrary, Specialty Drug discount and dispensing fee guarantees are reconciled in the aggregate. Any excess achieved in one may be credited to any other Specialty Drug ingredient cost discount or dispensing fee guarantee listed herein.

Rebate Management – Premium				
Rebate Guaranteed Amount	Retail Pharmacy	Retail 90 Pharmacy	Home Delivery	Specialty
Year 1	\$490.00 PNPB	\$1,160.00 PNPB	\$1,210.00 PNPB	\$3,900.00 PNPB
Year 2	\$550.00 PNPB	\$1,305.00 PNPB	\$1,355.00 PNPB	\$4,194.00 PNPB
Year 3	\$615.00 PNPB	\$1,440.00 PNPB	\$1,490.00 PNPB	\$4,352.00 PNPB

PNPB = Per Net Paid Brand Drug covered by Client's benefit design or formulary.



Credits and Allowances:

General Terms Applicable to All Credits	The Credits described herein are hereby made available to Client. Optum Rx and Client agree to each comply with their respective obligations as necessary to establish and maintain the applicable safe harbors to the Federal Anti-Kickback Statute set forth at 42 C.F.R. §1001.952. It is the intention of the parties that, in establishing the terms of the Credits, neither Optum Rx nor Client gives or receive any remuneration in return for or to induce the provision or acceptance of business for which payment may be made in whole or in part by a federal health care program on a fee-for-service or cost basis. In addition, neither OptumRx nor Client shall shift the financial burden of the Credits to the extent that increased payments are claimed from any federal health care program. To the extent required by Laws, Client agrees to fully and accurately disclose and report any such discount, rebate, credit or allowance to Medicare, Medicaid or other government health care programs as a discount against the price of the Prescription Drugs provided under this Agreement. In connection with the foregoing, the following Credits are made available to Client to reimburse the fair market value of agreeable expenses, items, and services described below related to transitioning, administering, and implementing the pharmacy benefit (collectively “the Credits”).
Implementation Allowance	Optum Rx shall provide Client with a one-time implementation allowance of up to \$5.00 per net new Member to cover expenses associated with the transition of services to Optum Rx. This allowance may be used by Client to offset legitimate, necessary and commercially reasonable expenses that are related to the Client's transition from its previous pharmacy benefit manager to Optum Rx. Client shall be responsible for all other transition expenses in excess of the implementation credit herein provided to Client. Eligible expenses shall include any printing or postage related to special communications required for the transition, customized ID cards, customized programming or, upon mutual agreement, third-party transitional consulting expenses. The implementation allowance must be utilized within the first six months after the Effective Date. Client will be required to submit documentation to support the expenses it may seek reimbursement for. If Client terminates this Agreement for any reason before the end of the Initial Term, Client shall refund to Optum Rx within 30 days after the effective date of such termination the full implementation allowance. It is the intention of the parties that, for the purposes of the Federal Anti-Kickback Statute, this implementation allowance shall constitute and shall be treated as a discount against the price of drugs within the meaning of 42 U.S.C. 1320a – 7b(b)(3)(A). To the extent required by Laws or contractual commitment, Client agrees to fully and accurately disclose and report any such discount to Medicare, Medicaid or other government health care programs as a discount against the price of the Prescription Drugs provided under this Agreement.
Pharmacy Management Allowance	Client shall receive a pharmacy management allowance (PMA) of up to \$5.00 per Member annually, which must be utilized within the applicable year and will not carry over to the following year. This PMA allowance is to be used by Client to offset the cost of actions intended to maximize the value of the pharmacy program. Funds may be used for items including, but not restricted to, programming for customization, design and implementation of clinical or other programs, communications, documented expenses related to staff education and industry conference attendance, auditing, data integration and analytics, consulting fees (excluding market checks), and engagement of relevant vendors that impact the pharmacy program strategy and results. Client will be required to submit documentation to support the expenses for which it seeks reimbursement. If Client terminates this Agreement for any reason before the end of the Initial Term, Client shall refund to Optum Rx within 30 days after the effective date of such termination the full PMA allowance applicable to the year of termination. It is the intention of the parties that, for the purposes of the Federal Anti-Kickback Statute, this PMA allowance shall constitute and shall be treated as a discount against the price of drugs within the meaning of 42 U.S.C. 1320a-7b(b)(3)(A). To the extent required by Laws or contractual commitment, Client agrees to fully and accurately disclose and report any such discount to Medicare, Medicaid or other government health care programs as a discount against the price of the Prescription Drugs provided under this Agreement.

General Financial Terms

General Terms:

- This pricing proposal is valid from the date of this proposal.
- The Agreement must be signed at least 90 days before the Effective Date of the pricing.
- The Agreement Effective Date will be July 1st, 2026 with prior notice of award 120 days before the Agreement Effective Date.
- This pricing proposal is for a three (3) year contract term, subject to the terms and conditions in this pricing proposal.
- Offer is valid for a minimum of 28,216 total Members as of the Agreement Effective Date.
- Under the Pass-Through Pricing Model, Client shall pay the actual retail pharmacy rates paid by Optum Rx for Prescription Drugs electronically processed and dispensed to a Member through Optum Rx's retail Pharmacy Network, which are estimated to be the effective rates set forth above. Optum Rx's compensation for its services shall be the Claims Administration Fees set forth above. In the event Client enrolls in additional services, incremental Administrative Fees may apply.
- The Member will pay the lower of (i) Member Cost-Sharing Amount, (ii) Client contracted rate, plus dispensing fee; or (iii) the pharmacy's Usual and Customary charge for the product.
- Optum Rx applies, where applicable, zero balance pricing logic, also referred to as minimum copay. The Member will pay the lower of (i) Member Cost-Sharing Amount or (ii) the pharmacy's Usual and Customary charge for the product.
- Discounted ingredient costs are based upon: (i) published AWP and (ii) the actual 11 digit National Drug Code, specific to the quantity dispensed submitted by a Network Pharmacy at the time of adjudication.
- Retail 90 pricing applies to retail Claims with greater than 83 days' supply.

Guarantee Reconciliation:

- Discount and dispensing fee guarantees apply to Network Pharmacies that adjudicate covered Prescription Drugs in accordance with Optum Rx's lower of logic (i.e. lesser of MAC, U&C, submitted cost, or contracted discount rate) and contracted dispensing fee rates. Discount and dispensing fee guarantees are reconciled at the component level and are effective average annual rates. Such discount and dispensing fee guarantees are not reconciled on an individual Claim basis. Excess discounts in one line-item category cannot be credited to another category for purposes of satisfying the guarantee applicable to the other category, however, retail 30/90 generic guarantees will be reconciled together as one component. Any credits due to Client relating to the discount guarantees set forth above shall be issued ninety (90) days after the measurement period.

General Pricing Terms:

- The financial guarantees herein are annual guarantees, Optum Rx will have no obligation to Client for any financial commitment associated with any partial contract year (i.e. a period of time that is less than 12-months).
- The effective overall Generic Drug discount rate includes MAC, and non-MAC Generic Drug Claims subject to the discount and dispensing fee guarantee exclusions set forth herein.
- Compound Prescription Drug Claims, 340B Claims, OTC's, Indian health services and tribal Claims, direct member reimbursement Claims, coordination of benefit Claims, long term care Claims, infusion Claims, Claims with ancillary charges such as vaccines, Claims filled at in-house or Client-owned pharmacies, fraudulent Claims, covid test kits, and covid anti-virals, Claims subject to State mandated minimum pharmacy reimbursement requirements, and Claims filled outside the Optum Rx Pharmacy Network will be excluded from the discount and dispensing fee guarantees. Additionally, claims in Puerto Rico, Guam, Northern Mariana Islands, Virgin Islands, Hawaii, Massachusetts, and Alaska will be excluded from the guarantees.
- Usual & Customary Claims are excluded in the discount guarantees.
- Zero balance Claims are included in the discount guarantees prior to the application of Member Cost-Sharing Amount.

- Compound Prescription Drugs shall be adjudicated using the standards in the most recent version of NCPDP guidelines which includes individual multi-ingredient pricing, the lower of U&C, MAC, or AWP minus and a dispensing fee of \$10. Multi-ingredient Compound Prescription Drugs filled through NCCP approved providers may also be charged a level of effort (LOE) compounding fee based on the Claim's LOE code.
- Claims filled at multi-pack pharmacies, including Optum affiliated multi-pack pharmacies, are included in the Retail 30 guarantee.
- Optum Rx may, from time to time, receive and retain reimbursement from pharmacies for its costs in connection with transmitting Claims and discounts on its own behalf from wholesalers and Drug Manufacturers as a purchaser of pharmaceutical products for its Home Delivery and Specialty Pharmacies.

Home Delivery Pharmacy:

- Specialty guarantees include Claims filled at Optum Specialty Pharmacy and retail pharmacies.
- Non-specialty Claims filled at Optum Specialty Pharmacy are reconciled under the retail guarantees.

Specialty Pharmacy:

- Optum Specialty Pharmacy shall be the exclusive specialty providers under this Agreement and Members will receive Specialty Drug Covered Prescription Services only from Optum Specialty Pharmacy not any other retail, Home Delivery, or specialty pharmacy. Notwithstanding the foregoing, Limited Distribution Drugs not dispensed by Optum Specialty Pharmacy may be obtained from other Network Pharmacies. Under an exclusive arrangement, grace fills at retail will not be allowed. The Specialty Drug List will be provided to Client upon request and may be updated from time to time.
- Retail and Home Delivery guarantees exclude Specialty Drug Claims.

Rebate Terms:

- "Rebate" means any retrospective formulary rebate payment, [or price protection or Manufacturer Administration Fee] that Optum Rx receives from Drug Manufacturers, pursuant to the terms of a rebate contract independently negotiated by Optum Rx on its own behalf, that is contingent upon and directly related to the use of a valid Prescription Drug by a Member during the Term. "Rebate" does not include any discount, price concession or other direct or indirect compensation the Optum Rx Specialty Pharmacy, Home Delivery Pharmacy, or a group purchasing organization receives for the purchase of Prescription Drug inventories or for the provision of any product, service, (including clinical services, care management, or other services tied to the dispensing of products) or tool, including analytical services used in the review of data.
- Optum Rx will remit to Client 100% of the Rebates received by Optum Rx. Optum Rx guarantees that the Rebates remitted to Client during a contract year shall not be less than the Per Net Paid Brand Drug Claim (PNPBDC) Rebate amounts specified in the Rebate table above ("Guaranteed Rebate Amount"). In the event that the Rebates paid to Client during a contract year are less than the Guaranteed Rebate Amount, Optum Rx shall pay to Client, as an additional rebate from Optum Rx, the amount of such deficiency within 150 days following the end of the contract year. Optum Rx may withhold Rebates until this Agreement is signed.
- Rebate Credit: As determined by Optum Rx, when reconciling Guaranteed Rebate Amounts, Optum Rx may add Rebate Credit. "Rebate Credit" is a credit applied towards the achievement of the Guaranteed Rebate Amount. The Rebate Credit applies whenever there is a change impacting the level of Rebates expected as a result of the availability of clinically comparable lower rebated drugs. The Rebate Credit is calculated as the difference between the expected Rebate revenue associated with the original rebated product or high WAC alternative (e.g. an originator brand drug, originator biologic, or high WAC product) and the actual Rebate amount received. A Rebate Credit eligible reduction in Rebates may result from: (i) the introduction of a biosimilar or authorized brand alternative; (ii) WAC reduction on a brand drug subject to rebates; (iii) WAC change of a biosimilar; (iv) utilization shifts between biosimilars, the originator biologic, or a low WAC alternative; or (v) the launch of a lower cost non-Generic Drug.
- Calculation of the Guaranteed Rebate Amount excludes ineligible Claims, such as: Claims where the plan is not the primary payer; Vaccines; House generic Claims (DAW 5); Compounds; direct member



reimbursement Claims; 340B Claims, Claims from long term care or federal government pharmacies; Consumer card or discount card program Claims; or Covid test kits, and Covid anti-virals, or; if applicable, Claims associated with any Client initiated split fill or medical benefit optimization program. The Guaranteed Rebate Amount is reconciled in the aggregate annually.

- The financial guarantees set forth in this exhibit are subject to all of the terms contained in this exhibit.
- Upon request Optum Rx offers 100% pass-through prescription drug and rebate pricing options in accordance with applicable law.

Pricing Conditions/Reservations of Rights:

- Client Directed Change: At any time between the date of the RFP and the Effective Date or during the Term or the Agreement, Optum Rx may adjust affected financial provision (effective as of the date of the change) for Client or Client's customer(s), if any of the following occur: (a) Client or Client's customer makes any change to its formulary, utilization management or clinical programs, Benefit Plan, Cost Share, exclusions, specialty drug list, or makes a change that impacts a pharmacy network guarantee; (b) any unexpected releases of Generic Drugs to market or the withdrawal or recall of existing Brand Drugs; (c) formulary changes initiated by Optum Rx that promote overall lower net costs, but reduce Rebates; (d) there is a change impacting the availability or amount of Rebates offered by Drug Manufacturers, including changes related to the elimination or material modification of a Drug Manufacturer's historic models or practices related to the provision of Rebates, which may include changes in historic practices regarding rejection of Claims submitted by Optum Rx for Rebates; or (e) either (i) more than ten percent (10%) of the Rebate value of Claims submitted by Optum Rx to Drug Manufacturers for Rebates are denied by Drug Manufacturers for reasons that such Claims are subject to any federal discount program (e.g., 340B, ITU, etc. ("Federal Discount Program Discounts"); or (ii) Client adopts any formulary, utilization or optimization program for Claims subject to Federal Discount Program Discount that impacts the availability or amount of Rebates.
- Market Event: At any time between the date of the RFP and the Effective Date or during the Term of the Agreement, Optum Rx reserves the right to modify or amend the financial provisions of this Agreement in the event of an external event or industry change impacting Optum Rx's performance under the Agreement, including but not limited to: (a) any government imposed change in federal, state or local laws or interpretation thereof or industry wide change that makes Optum Rx's performance of its duties hereunder materially more burdensome or expensive, including changes to the AWP benchmark or methodology; or (b) the unexpected movement of a branded product to off-patent or if Generic Drugs, Authorized Brand Alternative Drugs, low priced Brand Drugs or over-the-counter substitutes become available; (c) the addition of biosimilar products to the Client's formulary that were not underwritten into ORx's financial offer as of the date of this proposal; or (d) if there is a change impacting the availability or amount of Rebates offered by Drug Manufacturers, including changes related to the elimination or material modification of a Drug Manufacturer's historic models or practices related to the provision of Rebates. The pricing guarantees included in Optum Rx's offer account for the known rebate impacts of the Inflation Reduction Act's AMP Cap provision. Accordingly, as of the date of this offer, the actual manufacturer rebate related reductions in affected classes (i.e. insulin & respiratory products) is underwritten into ORx's financial offer. Any subsequent manufacturer action occurring after the date of Optum Rx's offer, may require equitable adjustment of the pricing guarantees.
- Change in Scope: At any time between the date of the RFP and the Effective Date or during the Term of the Agreement, Optum Rx reserves the right to modify or amend the financial provisions of this Agreement if any of the following occur: (i) a change in the scope of services to be performed under this Agreement, including, but not limited to, a change in the Plan Specifications or the exclusion of a service line (i.e. retail & Home Delivery) from Client's service selection; (ii) a change of greater than 20% in the total number of Members from the number provided to Optum Rx during pricing negotiations; (iii) any substantive change in Client's formulary, Member Cost Share, Benefit Plan design, exclusions, utilization management programs, or administrative edits; or (iv) Optum Rx is no longer the exclusive Specialty Pharmacy provider. For modifications or amendments made pursuant to (i), (ii), (iii), or (iv) above, Client agrees to provide Optum Rx at least ninety (90) days' notice prior to making any changes. In the event the pricing needs to be modified, Optum Rx shall provide Client with notification of any pricing modifications 45 days prior to implementation.
- The effective date of any changes to Rebate arrangements shall be effective as of the date of the change.

Market Check. Following the initial eighteen (18) months of this Agreement, State of Nebraska's Plan may conduct one market check during the Initial Term to confirm its financial terms are competitive with those currently available in the market for a substantially similar customer. Such analysis shall be conducted by a mutually agreed upon third party, including no less than four substantially similar customers under active contracts, that account for the following comparison plan factors which must be the same or similar in relation to State of Nebraska: (a) life count within 10% of total membership; (b) same customer type (direct, coalition, TPA, health plan, etc.); (c) same line(s) of business (commercial, Medicare, Medicaid, etc.); (d) same types of services (retail, home delivery, specialty, etc.); (e) comparison of pricing for the same contract year; (f) same or similar plan design, networks, Formulary, clinical and trend programs, and mix and utilization; (g) pricing quoted within past six-month period; and (h) other relevant factors necessary to provide an appropriate comparison (collectively the "Comparison Plan Factors").

The market check will compare the aggregate value of pricing terms including the combined net value of: (i) ingredient cost discounts and dispensing fees from retail pharmacies, home delivery pharmacies, and specialty pharmacies; (ii) rebates, including manufacturer derived administrative fees; (iii) administrative fees; and (iv) Client credits. Client's analysis shall be evaluated on the basis of total aggregate comparison of all pricing terms offered by a single vendor to a single plan and not on the basis of individual or best price points available from multiple vendors to a single plan or a single vendor to multiple plans. A copy of Client's current market price analysis will be submitted to Optum Rx. Consultant shall provide a reasonably detailed description of the methods and assumptions used in the analysis including the methods and assumptions related to the calculation of the individual pricing components. Optum Rx shall have a reasonable opportunity (i.e., not more than thirty (30) business days after all information necessary to perform its analysis is received) to evaluate the report. In a mutually agreeable format, Client, or its designee, shall provide any information necessary for Optum Rx to validate Client's compliance with the terms of this Section including, but not limited to, relevant details about any benchmark plans (inclusive of any Comparison Plan Factors) Client relied upon in selecting any price point(s)/financial guarantees used to develop Client's market check report.

If the parties agree that the market check report validates an annualized savings of greater than three percent between the median of the financial terms for such substantially similar customers and State of Nebraska's financial terms, the parties will negotiate in good faith a revision to the Agreement's financial terms. Any revisions to financial terms, resulting from the parties' negotiations, are effective the first day of the following contract year, subject to the parties having executed an amendment to the Agreement at least 60 days prior to the effective date. If Optum Rx is unable or unwilling to offer revised pricing terms after good faith negotiations, either party may terminate the Agreement upon at least one hundred eighty (180) days' notice of termination to the other party. If Client terminates within the first three (3) years of the Initial Term of the Agreement, Client will reimburse Optum Rx for any allowances paid or credited to Client by Optum Rx, prorated monthly over the first three (3) years of the Initial Term.

Standard Services (Included in Base + Administrative Fee)

Claims Processing Services

- Eligibility management
- Eligibility verification
- Online electronic Claims processing/administration
- Data retention – 15 months
- Operational Online Data – 12 months
- Accumulator for deductibles and maximums data – batch method
- Real-Time Audit System – filters 100 percent of claims before payment
- Enhanced Savings Program
- Lower Cost Alternatives
- PreCheck MyScript ePrescribing

Termination Services and File Transfer

- Up to 12 files included in standard format, \$1,500 per additional file thereafter

Optum Rx Pharmacy Network Services

- Administration of the Optum Rx Pharmacy Network
- Pharmacy Help Desk – available 24 hours a day, seven days a week



Pharmaceutical Manufacturer Rebate Services

- Optum Rx Standard Formularies
- Collection and Distribution of Manufacturer Rebates

Clinical Services

- Administrative Prior Authorization, Step Therapy, Quantity Limits
- Drug Recall Reporting
- Concurrent Drug Utilization Review (CDUR)
- Administration of Optum Rx Formularies
- Administration of Optum Rx standard Utilization Management programs

Benefit Plan Administration

Member Services

- Toll-free Member Services Help Desk - available 24 hours a day, seven days a week
- Member Website and mobile app

Client Services

- Client Management Team
- Implementation support
- Standard Reporting Package

Member Communications

- Welcome Booklet with ID cards (two per family); Postage, shipping and handling cost are pass through

Online Client Access to Member Eligibility

- Verifying, entering, and updating member eligibility
- Viewing Member Claims history

Online Client Website Access

- Access to general and plan-specific information
- Setup and training for up to twenty users
- \$400 per additional license each year
- Website access through optumrx.com
 - Pharmacy locator, refill Home Delivery Pharmacy, claims history
 - Health, wellness and disease education

Home Delivery/Mail Service and Specialty Pharmacy

- Standard postage included
- Member directed Home Delivery express shipments may incur additional charge

Clinical Services (Included and Available at Additional Charge)¹

Clinical Prior Authorizations	
Technician/Pharmacist Review	\$50 per review on-shore; \$65 per review designated team + on-shore
Technician/Pharmacist Review (GLP-1)	\$20 per review incremental fee (assumes Client's adoption of Optum Rx's standard clinical criteria)
State-mandated Physician Review	\$135 per review on-shore
Prior Authorization Appeals	
Internal Clinical Appeals Not Requiring Physician Review	\$160 per review
Internal Clinical Appeals Requiring Physician Review	\$350 per review
External clinical appeal	\$550 per review
Peer to Peer Physician/Pharmacist Review	
Peer to Peer Review Service	\$75 per review (Pharmacist)
Physician Review Service	\$150 per review (Physician)
Administration of Appeals Process Managed by Client	\$35 per review
Optum Rx Medical Insights Management	
Optum Rx Medical Insights Management	\$0.25 PMPM
Performance Guarantee	Included
Optum Rx Medication Safety Management	
Optum Rx Medication Safety Management	\$0.11 PMPM
Performance Guarantee	Included
Optum Rx Care Gap Management	
Optum Rx Care Gap Management	\$0.05 PMPM
Performance Guarantee	Included
Meds on Track	
Top 3 Conditions + Chronic Non-Specialty + Specialty Medications + Behavior Health Medications + Meds on Track for Medication Assisted Therapy	\$0.26 PMPM
Top 3 Conditions + Chronic Non-Specialty + Specialty Medications	\$0.19 PMPM
Top 3 Conditions	\$0.14 PMPM
Performance Guarantee	Included
Meds on Track Behavior Health conditions + Optum Rx Meds on Track Program for Medication Assisted Therapy (MAT) - ROI not offered for this program.	\$0.13 PMPM

Diabetes Management Program Options	
High-Risk member counseling + Meds on Track+ Care Gap Management programs	\$195.00 per counseled member per year + \$0.08 PMPM
High-Risk member counseling + Meds on Track	\$195.00 per counseled member per year + \$0.06 PMPM
High-Risk member counseling + Care Gap Management programs	\$195.00 per counseled member per year + \$0.02 PMPM
High-Risk member counseling	\$195.00 PMPM
Opioid Risk Management Solution	
Utilization Management	Standard UM/transactional fees
Enhanced cDUR	Standard included. Customization: \$1,000 per edit.
Enhanced Benefit Design	
Adjust Refill Window	Standard included. Customization: \$1,000 per edit.
Enhanced DEA edit by scope of practice	Standard included. Customization: \$1,000 per edit.
Opioid Risk Management Solution (Add-On offerings)	
Refill Window 90% Scheduled II-V Controlled Drugs (80% Specialty-Mail)	Included
Comprehensive UM option	Included, PA fees will apply
UM à la carte option	Included, PA fees will apply
Opioid Risk Management Solution (Buy-Up offerings)	
Member Education	\$0.04 PMPM
Retrospective Intervention on Abused Meds	\$0.07 PMPM
Intensive Case Management	\$0.04 PMPM
Opioid Risk Management Solution (Member Opioid Risk Analysis)	
Monthly Subscription	\$250.00 per month + \$1500.00 implementation fee
One-Time Request	\$3000.00 per request
Personalized Rx Counselor Program	
On Demand Comprehensive Medication Review	\$0.05 PMPM + \$100 per On Demand CMR consultation
Comprehensive Medication Review + Targeted Medication Review	\$0.27 PMPM
Comprehensive Medication Review + Targeted Medication Review Performance Guarantees	Included
Comprehensive Medication Review + Targeted Medication Review + On Demand Comprehensive Medication Review	\$0.27 PMPM + \$100 per On Demand CMR consultation
Comprehensive Medication Review + Targeted Medication Review + On Demand Comprehensive Medication Review Performance Guarantees	Included



Orphan Drug Management Program	\$300 per counseled member per year
Clinical Analytics Services	Quoted upon request
Trend Forecast	Quoted upon request
Custom Formulary and Utilization Management Services	Quoted upon request
Pharmacy & Therapeutics (P&T) Support Services	Quoted upon request
Custom Publication Support Services	Quoted upon request
This is not an inclusive list. Optum Rx may charge for any products or services not specifically represented herein.	

¹ All pricing is reflective of the current program, subsequent program enhancements, if any, may require an additional charge.

Additional Fees as Applicable

Variable Copay Program (ORx Specialty Pharmacy)	\$150 per impacted Rx ¹
Variable Copy Program (ORx Specialty Pharmacy + ORx Home Delivery Pharmacy)	\$150 per impacted specialty Rx \$50 per impacted non-specialty Rx
Client Website Additional Users	20 included, \$400 per year per additional user
Direct Member Reimbursement (DMR)	\$2.50 per processed Claim plus the Administrative Fee
Ad-hoc Reporting	\$150 per hour, with a minimum of \$500
Manual Eligibility Maintenance	\$0.50 per record
ID cards - Subsequent mailings, replacements, or additional	\$2 per ID card plus postage, shipping and handling
Explanation of Benefits (EOB)	\$2 per EOB plus postage, shipping and handling
Custom Mailings	Production plus postage, shipping and handling
Investigatory Audit	25% of recovered amount
Retail Pharmacy Audit Administration	No administrative or retention fees
Advanced Pharmacy Audit Services	10,000 – 24,999 lives = \$0.100 PNPNC
RxTRACK License Fee	15 customer users included 5 vendor users included \$100 per additional annual fee
RDS Support Services	\$1.25 PMPM
Integrated Accumulator - Near Real Time Method	\$0.15 PMPM
Rebate Hub - Rebate Estimate Tool & Dashboards	\$0.14 PMPM (5 users includes one virtual training session per year)
Custom Specialty Drug List Management	\$75,000 per year
Shipping & Handling of Temperature Sensitive Products	\$27.30 per impacted Rx
This is not an inclusive list. Optum Rx may charge for any products or services not specifically represented herein.	

¹ A onetime \$1 per Member implementation fee, capped at \$10,000, shall apply, if the Variable Copy Program is required to integrate with any Client owned or in-house pharmacy.

a. BIDDER IDENTIFICATION AND INFORMATION

The bidder should provide the full company or corporate name, address of the company's headquarters, entity organization (corporation, partnership, proprietorship), state in which the bidder is incorporated or otherwise organized to do business, (including whether the Bidder is in good standing in the state in which it is formed or incorporated), year in which the bidder first organized to do business and whether the name and form of organization has changed since first organized. The Bidder should also provide this information for the branch or local office or other subordinate element that will perform or assist in performing the work on this contract.

OptumRx, Inc. (Optum Rx) is a wholly owned subsidiary of OptumRx Holdings, LLC.

Corporate Address: 11000 Optum Circle, Eden Prairie, MN 55344

Entity: Corporation

State of Incorporation: California

OptumRx, Inc. is authorized to do business in all 50 states.

From our inception in 1989 to the establishment of Optum Rx in 2011 to today, we have worked closely with our customers to provide high-quality pharmacy care services designed to promote optimized care. We manage over 1.6 billion pharmacy claims annually and serve more than 62 million members across a broad spectrum of customers, including public and government entities, health plans, Medicare and Medicaid plan sponsors, employer groups, collective bargaining groups and third-party administrators. We are more than a pharmacy benefit manager—we are a pharmacy care services company focused on driving transformative change and delivering quality holistic care.

Our history timeline illustrates our adaptive and innovative strength, capitalizing on ways to make the health care system work better for everyone.

Year	Milestone
1989	Established as part of PacifiCare Health Systems, Inc.
1995	Acquired Prescription Solutions
2001	Adopted the Prescription Solutions Name
2005	Acquired as subsidiary of UnitedHealth Group
2008	Acquired Fiserv's health-related businesses, including the pharmacy benefit management division, Innoviant
2011	Changed name to OptumRx, Inc. and became a part of Optum, a UnitedHealth Group health services business
2015	Combined with Catamaran, making us the nation's third largest PBM
2015	Acquired AxelaCare Health Solutions, a leading provider of home infusion solutions
2016	Acquired Helios, a workers' compensation health care services company

Year	Milestone
2018	Acquired Avella, an oncology-focused specialty pharmacy and provider of compounding services and custom pharmaceutical therapies to hospitals and physicians
2018	Combined with Genoa Healthcare, a provider of pharmacy, telepsychiatry and medication management services for individuals with behavioral health and other complex, chronic health conditions
2020	Acquired Diplomat, a provider of specialty and infusion pharmacy services and pharmacy solutions
2020	Acquired divvyDOSE, a full-service delivery pharmacy focused on serving individuals with multiple chronic conditions through multi-dose packaging solutions
2021	Launched Optum Frontier Therapies, a pharmacy services business to serve the needs of people with rare diseases while creating access to therapies at the frontier of health care
2022	Completed Optum combination with Change Healthcare
2024	CPS Solutions, LLC (CPS) joins Optum Rx and PharmScript joins Genoa Healthcare
2025	FlexCare Infusion Centers joins Optum Infusion Pharmacy, adding multi-state ambulatory infusion center services to our offering in support of member site of care choice

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-K

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2024

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission file number: 1-10864

UNITEDHEALTH GROUP

UnitedHealth Group Incorporated
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

41-1321939
(I.R.S. Employer
Identification No.)

1 Health Drive
Eden Prairie, Minnesota 55344
(Address of principal executive offices) (Zip Code)

655 New York Avenue NW
Washington, DC 20001
(Address of principal executive offices) (Zip Code)

(800) 328-5979
(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$.01 par value	UNH	New York Stock Exchange

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☒	Accelerated filer	☐	Non-accelerated filer	☐
Smaller reporting company	☐			Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒
The aggregate market value of voting stock held by non-affiliates of the registrant as of June 30, 2024 was \$468,433,146,650 (based on the last reported sale price of \$509.26 per share on June 30, 2024 as reported on the New York Stock Exchange), excluding only shares of voting stock held beneficially by directors, executive officers and subsidiaries of the registrant.
As of January 31, 2025, there were 914,712,333 shares of the registrant's Common Stock, \$.01 par value per share, issued and outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

The information required by Part III of this report, to the extent not set forth herein, is incorporated by reference from the registrant's definitive proxy statement relating to its 2025 Annual Meeting of Shareholders. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.

UNITEDHEALTH GROUP

Table of Contents

	<u>Page</u>
Part I	
Item 1. Business	1
Item 1A. Risk Factors	10
Item 1B. Unresolved Staff Comments	20
Item 1C. Cybersecurity	21
Item 2. Properties	22
Item 3. Legal Proceedings	22
Item 4. Mine Safety Disclosures	22
Part II	
Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	22
Item 6. Reserved	23
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations ..	24
Item 7A. Quantitative and Qualitative Disclosures About Market Risk	36
Item 8. Financial Statements and Supplementary Data	37
Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure ..	67
Item 9A. Controls and Procedures	67
Item 9B. Other Information	69
Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections	69
Part III	
Item 10. Directors, Executive Officers and Corporate Governance	69
Item 11. Executive Compensation	70
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	70
Item 13. Certain Relationships and Related Transactions, and Director Independence	70
Item 14. Principal Accountant Fees and Services	70
Part IV	
Item 15. Exhibit and Financial Statement Schedules	71
Item 16. Form 10-K Summary	79
Signatures	80

PART I

ITEM 1. BUSINESS

OUR BUSINESSES

Overview

The terms “we,” “our,” “us,” “its,” “UnitedHealth Group,” or the “Company” used in this report refer to UnitedHealth Group Incorporated and its subsidiaries.

UnitedHealth Group Incorporated is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. Our two distinct, yet complementary businesses — Optum and UnitedHealthcare — are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations we are privileged to serve.

The ability to analyze complex data and apply deep health care expertise and insights allows us to serve patients, consumers, care providers, businesses, communities and governments with more innovative products and complete, end-to-end offerings for many of the biggest challenges facing health care today.

Optum seeks to create a higher-performing, value-oriented and more connected approach to health care. Bringing together clinical expertise, technology and data to make care simpler, more effective and more affordable, we seek to advance whole-person health, creating a seamless consumer experience and supporting clinicians with insights to deliver personalized, evidence-based care. Optum serves the broad health care marketplace, including patients and consumers, payers, care providers, employers, governments and life sciences companies, through its Optum Health, Optum Insight and Optum Rx businesses. These businesses improve overall health system performance by optimizing health care quality and delivery, reducing costs and improving patient, consumer and provider experience, leveraging distinctive capabilities in data and analytics, pharmacy care services, health care operations, population health and health financial services.

UnitedHealthcare offers a full range of health benefits, designed to simplify the health care experience and make it more affordable for consumers to access high-quality care. UnitedHealthcare Employer & Individual serves consumers and employers, ranging from sole proprietorships to large, multi-site and national employers and public sector employers. UnitedHealthcare Medicare & Retirement delivers health and well-being benefits to seniors and other Medicare eligible consumers. UnitedHealthcare Community & State serves consumers who are economically disadvantaged, the medically underserved and those without the benefit of employer sponsored health benefits coverage.

We have four reportable segments:

- Optum Health;
- Optum Insight;
- Optum Rx; and
- UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and UnitedHealthcare Community & State.

Optum

Optum is an information and technology-enabled health services business serving the broad health care marketplace, including:

- Those who need care: patients who need the right care, information, resources, products and engagement to improve their health, achieve their health goals and receive an improved patient experience that is personalized, comprehensive and delivered in all care settings, including in-home and virtually.
- Those who provide care: physicians, hospitals, pharmacies and others seeking to improve the health system and reduce the administrative burden, allowing for providers to focus time on patients leading to the best possible patient care and experiences while achieving better health outcomes at lower costs. Improved health outcomes are achieved by utilizing our clinical expertise, data and analytics to better understand, treat and prevent consumers’ health conditions and ensure they receive the best evidence-based care.
- Those who pay for care: consumers; employers; health plans; and state, federal and municipal agencies devoted to ensuring the people they sponsor receive high-quality care, administered and delivered efficiently and effectively, all while driving health equity so that every individual, family and community has access to the care they need.
- Those who innovate for care: global life sciences organizations dedicated to developing more effective approaches to care, enabling technologies and medicines to improve care delivery and health outcomes.

Optum operates three business segments which combine distinctive capabilities in value-based care, population health, health care operations, data and analytics and pharmacy care services:

- Optum Health delivers patient-centered care, care management, wellness and consumer engagement, and health financial services;
- Optum Insight offers data, analytics, research, consulting, technology and managed services solutions; and
- Optum Rx provides diversified pharmacy care services.

Optum Health

Optum Health provides comprehensive and patient-centered care, addressing the physical, mental, social, and financial well-being of 100 million consumers and serves more than 100 health payer partners. We engage people in the most appropriate care settings, including clinical sites, in-home and virtual. Optum Health delivers primary, specialty and surgical care; helps patients and providers navigate and address complex, chronic and behavioral health needs; offers post-acute care planning services; and serves consumers and care providers through advanced, on-demand digital health technologies, such as telehealth and remote patient monitoring, and innovative health care financial services. Optum Health works directly with patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities to provide high quality, accessible and equitable care with improved health outcomes and reduced total cost of care. Optum Health enables care providers to transition from traditional fee-for-service payment models to performance-based delivery and payment models designed to improve patient health outcomes and experience through value-based care.

Optum Health offerings include fully accountable value-based arrangements, where Optum Health assumes responsibility for health care costs in exchange for a monthly premium. Offerings also include administrative fee arrangements, where Optum Health manages or administers products and services in exchange for a monthly fee, and fee-for-service arrangements, where Optum Health delivers health-related products and medical services for patients at a contracted fee.

Optum Financial, including Optum Bank, serves consumers through more than 27 million consumer accounts with \$24 billion in assets under management as of December 31, 2024. Organizations across the health system rely on Optum Financial to manage and improve payment flows through its highly automated, scalable, end-to-end digital payment and financing systems and integrated card solutions. For financial services offerings, Optum Financial charges fees and earns investment income on managed funds.

Optum Health sells its products primarily through its direct sales force, strategic collaborations and external producers in three key areas: employers, including large, mid-sized and small employers; payers including health plans, third-party administrators (TPAs), underwriter/stop-loss carriers and individual product intermediaries; and public entities, including the U.S. Departments of Health and Human Services (HHS), Veterans Affairs, Defense, and other federal, state and local health care agencies.

Optum Insight

Optum Insight connects the health care system with services, analytics and platforms that make clinical, administrative and financial processes simpler and more efficient for all participants in the health care system. Hospital systems, physicians, health plans, public entities, life sciences companies and other organizations comprising the health care industry depend on Optum Insight to help them improve performance and reduce costs through administrative efficiency and payment simplification, advance care quality through evidence-based standards built directly into clinical workflows, meet compliance mandates and modernize their core operating systems to meet the changing needs of the health system.

Health Systems. Serves hospitals, physicians and other care providers to improve operating performance, better coordinate care and reduce administrative costs through technology and services to improve population health management, patient engagement, revenue cycle management and strategic growth plans.

Health Plans. Serves health plans by improving financial performance and enhancing outcomes through proactive analytics, a comprehensive payment integrity portfolio and technology-enabled and staff-supported risk and quality services. Optum Insight helps health plans navigate a dynamic environment defined by shifts in employer vs. public-sector coverage, the demand for affordable benefit plans and the need to leverage new technology to reduce complexity.

State Governments. Provides advanced technology and analytics services to modernize the administration of critical safety net programs, such as Medicaid, while improving cost predictability.

Life Sciences Companies. Combines data and analytics expertise with comprehensive technologies and health care knowledge to help life sciences companies, including those in pharmaceuticals and medical technology, adopt a more comprehensive approach to advancing therapeutic discoveries and improving clinical outcomes.

Many of Optum Insight's software and information products and professional services are delivered over extended periods, often several years. Optum Insight maintains an order backlog to track unearned revenues under these long-term arrangements. The backlog consists of estimated revenue from signed contracts, other legally binding agreements and anticipated contract renewals based on historical experience with Optum Insight's customers. Optum Insight's aggregate backlog as of December 31, 2024 was approximately \$32.8 billion, of which \$19.8 billion is expected to be realized within the next 12 months. The aggregate backlog includes \$12.5 billion related to affiliated agreements. Optum Insight's aggregate backlog as of December 31, 2023, was \$32.1 billion, including \$11.9 billion related to affiliated agreements.

Optum Insight's products and services are sold primarily through a direct sales force. Optum Insight's products are also supported and distributed through an array of alliances and business partnerships with other technology vendors, who integrate and interface Optum Insight's products with their applications.

Optum Rx

Optum Rx provides a full spectrum of pharmacy care services through its network of more than 65,000 retail pharmacies, through home delivery, specialty and community health pharmacies, the provision of in-home and community-based infusion services and through rare disease and gene therapy support services. It also offers direct-to-consumer solutions.

Optum Rx manages a broad range of prescription drug spend, including widely available retail drugs as well as limited and ultra-limited distribution drugs in oncology, HIV, pain management and ophthalmology. Optum Rx serves the growing pharmacy needs of people with behavioral health and substance use disorders. In 2024, Optum Rx managed \$178 billion in pharmaceutical spending, including \$74 billion in specialty pharmaceutical spending.

Optum Rx serves health benefits providers, large national employer plans, unions and trusts, purchasing coalitions and public-sector entities. Optum Rx sells its services through direct sales, health insurance brokers and other health care consultants.

Optum Rx offers multiple clinical programs, digital tools and services to help clients manage overall pharmacy and health care costs in a clinically appropriate manner which are designed to deliver improved consumer experiences, better health outcomes and a lower total cost of care. Optum Rx provides various utilization management, medication management, quality assurance, adherence and counseling programs to complement each client's plan design and clinical strategies. Optum Rx is accelerating the integration of medical, pharmacy and behavioral care and treating the whole patient by embedding our pharmacists as key members of the patient care team.

UnitedHealthcare

Through its health benefits offerings, UnitedHealthcare is enabling better health, creating a better health care experience for its customers and helping to control rising health care costs. UnitedHealthcare's market position is built on:

- strong local-market relationships;
- the breadth of product offerings, based upon extensive expertise in distinct market segments in health care;
- service and advanced technology, including digital consumer engagement;
- competitive medical and operating cost positions;
- effective clinical engagement; and
- innovation for customers and consumers.

UnitedHealthcare arranges for discounted access to care through its extensive networks and uses Optum's capabilities to help coordinate and provide patient care, improve affordability of medical care, analyze cost trends, manage pharmacy care services, work with care providers more effectively and create a simpler and more satisfying consumer and physician experience.

UnitedHealthcare is subject to extensive government regulation. See further discussion of our regulatory environment below under "Government Regulation" and in Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations."

UnitedHealthcare Employer & Individual

Domestically, UnitedHealthcare Employer & Individual offers a comprehensive array of consumer-oriented health benefit plans and services for large national employers, public sector employers, mid-sized employers, small businesses, and individuals. As of December 31, 2024, UnitedHealthcare Employer & Individual provides access to medical services for 29.7 million people.

Through its risk-based product offerings, UnitedHealthcare Employer & Individual assumes the risk of both medical and administrative costs for its customers in return for a monthly premium which is typically a fixed rate per individual served for a one-year period. Through its administrative and other management services arrangements to customers who elect to self-fund the health care costs of their employees and employees' dependents, UnitedHealthcare Employer & Individual receives a fixed

monthly service fee per individual served. These customers retain the risk of financing medical benefits for their employees and employees' dependents, while UnitedHealthcare Employer & Individual provides services such as coordination and facilitation of medical and related services to customers, consumers and health care professionals, administration of transaction processing and access to a contracted network of physicians, hospitals and other health care professionals, including dental and vision professionals. UnitedHealthcare Employer & Individual is focused on providing informed benefit solutions that create customized plan designs and clinical programs for employers that contribute to well-being and reduce the total cost of care along with providing simpler consumer experiences in response to market dynamics.

UnitedHealthcare Employer & Individual typically distributes its products through a variety of channels, dependent upon the specific product, including: through consultants or direct sales, in collaboration with brokers and agents, through wholesale agents or agencies who contract with health insurance carriers to distribute individual or group benefits, through professional employer organizations and associations and through both multi-carrier and its own proprietary private exchange marketplaces.

UnitedHealthcare Employer & Individual's major product families include consumer engagement products, such as high-deductible consumer driven benefit plans and a variety of innovative consumer centric products; traditional products; clinical and pharmacy products; and specialty benefits, such as vision, dental, accident protection, critical illness, disability and hospital indemnity offerings.

UnitedHealthcare Medicare & Retirement

UnitedHealthcare Medicare & Retirement provides health and well-being services to seniors and other Medicare eligible consumers, addressing their unique needs. UnitedHealthcare Medicare & Retirement has distinct benefit designs, pricing, underwriting, clinical program management and marketing capabilities dedicated to health products and services in this market.

UnitedHealthcare Medicare & Retirement offers a selection of products allowing people choice in obtaining the health coverage and services they need as their circumstances change. These offerings include care management and health system navigator services, clinical management programs, nurse health line services, 24-hour access to health care information, access to discounted health services from a network of care providers and administrative services.

UnitedHealthcare Medicare & Retirement has extensive distribution capabilities and experience, including direct marketing to consumers on behalf of its key clients, a membership organization, and state and U.S. government agencies. Products are also offered through agents, employer groups and digital channels.

Major product categories include:

Medicare Advantage. Provides health care coverage for seniors and other eligible Medicare beneficiaries through the Medicare Advantage program administered by the Centers for Medicare & Medicaid Services (CMS), including Medicare Advantage HMO plans, Preferred Provider Organization (PPO) plans, Point-of-Service plans, Private-Fee-for-Service plans and Special Needs Plans (SNPs). Under the Medicare Advantage program, UnitedHealthcare Medicare & Retirement provides health benefits coverage in exchange for a fixed monthly premium per member from CMS plus, in some cases, monthly consumer premiums. Premium amounts received from CMS vary based on the geographic areas in which individuals reside; demographic factors such as age, gender and institutionalized status; and the health status of the individual. UnitedHealthcare Medicare & Retirement served 7.8 million people through its Medicare Advantage products as of December 31, 2024.

We have continued to enhance our offerings, focusing on more digital and physical care resources in the home, expanding our concierge navigation services and enabling the home as a safe and effective setting for care. For example, through our HouseCalls program, nurse practitioners performed 2.9 million clinical preventive home care visits in 2024 to address unmet care opportunities and close gaps in care.

Medicare Part D. Provides Medicare Part D benefits to beneficiaries through its Medicare Advantage and stand-alone Medicare Part D plans. The stand-alone Medicare Part D plans address a large spectrum of people's needs and preferences for their prescription drug coverage, including low-cost prescription options. As of December 31, 2024, UnitedHealthcare enrolled 10.1 million people in the Medicare Part D programs, including 3.1 million individuals in stand-alone Medicare Part D plans, with the remainder in Medicare Advantage plans incorporating Medicare Part D coverage.

Medicare Supplement. Provides a full range of supplemental products at diverse price points. These products cover various levels of coinsurance and deductible gaps to which seniors are exposed in the traditional Medicare program. UnitedHealthcare Medicare & Retirement served 4.3 million seniors nationwide through various Medicare Supplement products as of December 31, 2024.

Premium revenues from CMS represented 40% of UnitedHealth Group's total consolidated revenues for the year ended December 31, 2024, most of which were generated by UnitedHealthcare Medicare & Retirement.

UnitedHealthcare Community & State

UnitedHealthcare Community & State is dedicated to serving state programs caring for the economically disadvantaged, the medically underserved and those without the benefit of employer-funded health care coverage, typically in exchange for a monthly premium per member from the state program. UnitedHealthcare Community & State's primary customers oversee Medicaid plans, including Temporary Assistance to Needy Families; Children's Health Insurance Programs (CHIP); Dual SNPs (DSNPs); Long-Term Services and Supports (LTSS); Aged, Blind and Disabled; and other federal, state and community health care programs. As of December 31, 2024, UnitedHealthcare Community & State participated in programs in 33 states and the District of Columbia, and served more than 7.4 million people; including 1.2 million people through Medicaid expansion programs in 20 states under the Patient Protection and Affordable Care Act (ACA).

States using managed care services for Medicaid beneficiaries select health plans by using a formal bid process or by awarding individual contracts. These health plans and care programs are designed to address the complex needs of the populations they serve, including the chronically ill, people with disabilities and people with a higher risk of medical, behavioral and social conditions. UnitedHealthcare Community & State administers benefits for the unique needs of children, pregnant women, adults, seniors and those who are institutionalized or are nursing home eligible. These individuals often live in medically underserved areas and are less likely to have a consistent relationship with the medical community or a care provider. They also often face significant social and economic challenges.

GOVERNMENT REGULATION

Our businesses are subject to comprehensive U.S. federal and state and international laws and regulations. We are regulated by agencies which generally have discretion to issue regulations and interpret and enforce laws and rules. U.S. federal and state and international governments continue to consider and enact various legislative and regulatory proposals which could materially impact certain aspects of the health care system. New laws, regulations and rules, or changes in the interpretation of existing laws, regulations and rules, including as a result of changes in the political environment, could adversely affect our businesses.

See Part I, Item 1A, "Risk Factors" for a discussion of the risks related to our compliance with U.S. federal and state and international laws and regulations.

U.S. Federal Laws and Regulation

When we contract with the federal government, we are subject to federal laws and regulations relating to the award, administration and performance of U.S. government contracts. CMS regulates our UnitedHealthcare businesses and certain aspects of our Optum businesses. Payments by CMS to our businesses are subject to regulations, including those governing fee-for-service and the submission of information relating to the health status of enrollees for purposes of determining the amounts of certain payments to us. CMS also has the right to audit our performance to determine our compliance with CMS contracts and regulations and the quality of care we provide to Medicare beneficiaries. Our commercial business is further subject to CMS audits related to medical loss ratios (MLRs) and risk adjustment data.

UnitedHealthcare Community & State has Medicaid and CHIP contracts, which are subject to federal regulations regarding services to be provided to Medicaid enrollees, payment for those services and other aspects of these programs. There are many regulations affecting Medicare and Medicaid compliance, and the regulatory environment with respect to these programs is complex.

Our businesses are also subject to laws and regulations relating to consumer protection, anti-fraud and abuse, anti-kickbacks, false claims, prohibited referrals, inappropriate reduction or limitation of health care services, anti-money laundering and securities and antitrust compliance.

Privacy, Security and Data Standards Regulation. Certain of our operations are subject to regulation under the administrative simplification provisions of the Health Insurance Portability and Accountability Act of 1996, as amended (HIPAA), which apply to both the group and individual health insurance markets, including self-funded employee benefit plans. Federal regulations related to HIPAA contain minimum standards for electronic transactions and code sets and for the privacy and security of protected health information.

Our businesses must comply with the Health Information Technology for Economic and Clinical Health Act (HITECH), which regulates matters relating to privacy, security and data standards. HITECH imposes requirements on uses and disclosures of health information; includes contracting requirements for HIPAA business associate agreements; extends parts of HIPAA privacy and security provisions to business associates; adds federal data breach notification requirements for covered entities and business associates and reporting requirements to HHS and the Federal Trade Commission (FTC) and, in some cases, to the local media; strengthens enforcement and imposes higher financial penalties for HIPAA violations and, in certain cases, imposes criminal penalties for individuals, including employees. In the conduct of our business, depending on the circumstances, we may act as either a covered entity or a business associate.

The use and disclosure of individually identifiable health data by our businesses are also regulated in some instances by other federal laws, including the Gramm-Leach-Bliley Act (GLBA) or state statutes implementing GLBA. These federal laws and state statutes generally require insurers to provide customers with notice regarding how their non-public personal health and financial information is used and the opportunity to “opt out” of certain disclosures before the insurer shares such information with a third party, and generally prescribe safeguards for the protection of personal information. Neither the GLBA nor HIPAA privacy regulations preempt more stringent state laws and regulations, which may apply to us, as discussed below. Federal consumer protection laws may also apply in some instances to privacy and security practices related to personally identifiable information.

ERISA. The Employee Retirement Income Security Act of 1974, as amended (ERISA), regulates how our services are provided to or through certain types of employer-sponsored health benefit plans. ERISA is a set of laws and regulations subject to interpretation by the U.S. Department of Labor (DOL) as well as the federal courts. ERISA sets forth standards on how our business units may do business with employers who sponsor employee health benefit plans, particularly those who maintain self-funded plans. Regulations established by the DOL subject us to additional requirements for administration of benefits, claims payment and member appeals under health care plans governed by ERISA.

State Laws and Regulation

Health Care Regulation. Our insurance and HMO subsidiaries must be licensed by the jurisdictions in which they conduct business. All of the states in which our subsidiaries offer insurance and HMO products regulate those products and operations. The states require periodic financial reports and establish minimum capital or restricted cash reserve requirements. The National Association of Insurance Commissioners (NAIC) has adopted model regulations, which require expanded governance practices and risk and solvency assessment reporting. Most states have adopted these or similar measures to expand the scope of regulations relating to corporate governance and internal control activities of HMOs and insurance companies. We are required to maintain a risk management framework and file a confidential self-assessment report with state insurance regulators. We file reports annually with Connecticut, our lead regulator, and with New York, as required by the state’s regulation.

Our health plans and insurance companies are regulated under state insurance holding company regulations. Such regulations generally require registration with applicable state departments of insurance and the filing of reports describing capital structure, ownership, financial condition, certain affiliated transactions and general business operations. Most state insurance holding company laws and regulations require prior regulatory approval of acquisitions and material affiliated transfers of assets, as well as transactions between the regulated companies and their parent holding companies or affiliates. These laws may restrict the ability of our regulated subsidiaries to pay dividends to our holding companies.

Some of our business activity is subject to other health care-related regulations and requirements, including PPO, Managed Care Organization (MCO), utilization review (UR), TPA, pharmacy care services, durable medical equipment or care provider-related regulations and licensure requirements. These regulations differ from state to state and may contain network, contracting, product and rate, licensing and financial and reporting requirements. Health care-related laws and regulations set specific standards for delivery of services, appeals, grievances and payment of claims, adequacy of health care professional networks, fraud prevention, protection of consumer health information, pricing and underwriting practices and covered benefits and services. State health care anti-fraud and abuse prohibitions encompass a wide range of activities, including kickbacks for referral of members, billing for unnecessary medical services and improper marketing. Certain of our businesses are subject to state general agent, broker and sales distribution laws and regulations. UnitedHealthcare Community & State and certain of our Optum businesses are subject to regulation by state Medicaid agencies which oversee the provision of benefits to our Medicaid and CHIP beneficiaries and to our beneficiaries dually eligible for Medicare and Medicaid. We also contract with state governmental entities and are subject to state laws and regulations relating to the award, administration and performance of state government contracts.

State Privacy and Security Regulations. A number of states have adopted laws and regulations which may affect our privacy and security practices, such as state laws governing the use, disclosure and protection of social security numbers and protected health information or which are designed to implement GLBA or protect credit card account data. State and local authorities increasingly focus on the importance of protecting individuals from identity theft, with a significant number of states enacting laws requiring businesses to meet minimum cyber-security standards and notify individuals of security breaches involving personal information. State consumer protection laws may also apply to privacy and security practices related to personally identifiable information, including information related to consumers and care providers. Different approaches to state privacy and insurance regulation and varying enforcement philosophies may materially and adversely affect our ability to standardize our products and services across state lines. See Part I, Item 1A, “Risk Factors” for a discussion of the risks related to compliance with state privacy and security regulations.

Corporate Practice of Medicine and Fee-Splitting Laws. Certain of our businesses function as direct medical service providers and, as such, are subject to additional laws and regulations. Some states have corporate practice of medicine laws prohibiting specific types of entities from practicing medicine or employing physicians to practice medicine. Moreover, some states prohibit certain entities from engaging in fee-splitting practices, which involve sharing in the fees or revenues of a professional practice. These prohibitions may be statutory or regulatory, or may be imposed through judicial or regulatory interpretation. The laws, regulations and interpretations in certain states have been subject to limited judicial and regulatory interpretation and are subject to change.

Pharmacy and Pharmacy Benefits Management (PBM) Regulations

Optum Rx's businesses include home delivery, specialty and compounding pharmacies, as well as clinic-based pharmacies which must be licensed as pharmacies in the states in which they are located. Certain of our pharmacies must also register with the U.S. Drug Enforcement Administration (DEA) and individual state controlled substance authorities to dispense controlled substances. In addition to adhering to the laws and regulations in the states where our pharmacies are located, we also are required to comply with laws and regulations in some non-resident states where we deliver pharmaceuticals, including those requiring us to register with the board of pharmacy in the non-resident state. These non-resident states generally expect our pharmacies to follow the laws of the state in which the pharmacies are located, but some non-resident states also require us to comply with their laws where pharmaceuticals are delivered. Additionally, certain of our pharmacies which participate in programs for Medicare and state Medicaid providers are required to comply with applicable Medicare and Medicaid provider rules and regulations. Other laws and regulations affecting our pharmacies include federal and state statutes and regulations governing the labeling, packaging, advertising and adulteration of prescription drugs and dispensing of controlled substances. See Part I, Item 1A, "Risk Factors" for a discussion of the risks related to our pharmacy care services businesses.

Federal and state legislation regulating PBM activities affects both our ability to limit access to a pharmacy provider network or remove network providers. Additionally, many states limit our ability to manage and establish maximum allowable costs for generic prescription drugs. With respect to formulary services, a number of government entities, including CMS, HHS and state departments of insurance, regulate the administration of prescription drug benefits offered through federal or state exchanges. Many states also regulate the scope of prescription drug coverage, as well as the delivery channels to receive such prescriptions, for insurers, MCOs and Medicaid managed care plans. These regulations could limit or preclude (i) certain plan designs, (ii) limited networks, (iii) use of particular care providers or distribution channels, (iv) copayment differentials among providers and (v) formulary tiering practices.

Legislation seeking to regulate PBM activities introduced or enacted at the federal or state level could impact our business practices with others in the pharmacy supply chain, including pharmaceutical manufacturers and network providers. In addition, organizations like the NAIC periodically issue model regulations while credentialing organizations, like the National Committee for Quality Assurance (NCQA) and the Utilization Review Accreditation Commission (URAC), may establish standards impacting PBM pharmacy activities. Although these model regulations and standards do not have the force of law, they may influence states to adopt their recommendations and impact the services we deliver to our clients.

Consumer Protection Laws

Certain of our businesses participate in direct-to-consumer activities and are subject to regulations applicable to online communications and other general consumer protection laws and regulations such as the Federal Tort Claims Act, the Federal Postal Service Act and the FTC's Telemarketing Sales Rule. Most states also have similar consumer protection laws.

Certain laws, such as the Telephone Consumer Protection Act, give the FTC, the Federal Communications Commission (FCC) and state attorneys general the ability to regulate, and bring enforcement actions relating to, telemarketing practices and certain automated outbound contacts such as phone calls, texts or emails. Under certain circumstances, these laws may provide consumers with a private right of action. Violations of these laws could result in substantial statutory penalties and other sanctions.

Banking Regulation

Optum Bank is subject to regulation by federal banking regulators, including the Federal Deposit Insurance Corporation (FDIC), which performs annual examinations to ensure the bank is operating in accordance with federal safety and soundness requirements, and the Consumer Financial Protection Bureau, which may perform periodic examinations to ensure the bank is in compliance with applicable consumer protection statutes, regulations and agency guidelines. Optum Bank is also subject to supervision and regulation by the Utah State Department of Financial Institutions, which carries out annual examinations to ensure the bank is operating in accordance with state safety and soundness requirements and performs periodic examinations of the bank's compliance with applicable state banking statutes, regulations and agency guidelines. In the event of unfavorable examination results from any of these agencies, the bank could become subject to increased operational expenses and capital requirements, enhanced governmental oversight and monetary penalties.

Non-U.S. Regulation

Certain of our businesses operate internationally and are subject to regulation in the jurisdictions in which they are organized or conduct business. These regulatory regimes vary from jurisdiction to jurisdiction. In addition, our non-U.S. businesses and operations are subject to U.S. laws regulating the conduct and activities of U.S.-based businesses operating outside the United States, such as the Foreign Corrupt Practices Act (FCPA), which prohibits offering, promising, providing or authorizing others to give anything of value to a foreign government official to obtain or retain business or otherwise secure a business advantage.

COMPETITION

As a diversified health care company, we operate in highly competitive markets across the full expanse of health care benefits and services. Our competitors include organizations ranging from startups to highly sophisticated Fortune 50 global enterprises, for-profit and non-profit companies, and private and government-sponsored entities. New entrants to our markets and business combinations among our competitors and suppliers also contribute to a dynamic and competitive environment. We compete fundamentally on the quality and value we provide to those we serve which can include elements such as product and service innovation; use of technology; consumer and provider engagement and satisfaction; and sales, marketing and pricing. See Part I, Item 1A, “Risk Factors” for additional discussion of our risks related to competition.

INTELLECTUAL PROPERTY RIGHTS

We have obtained trademark registration for the UnitedHealth Group, Optum and UnitedHealthcare names and logos. We own registrations for certain of our other trademarks in the United States and abroad. We hold a portfolio of patents and have patent applications pending from time to time. We are not substantially dependent on any single patent or group of related patents.

Unless otherwise noted, trademarks appearing in this report are trademarks owned by us. We disclaim any proprietary interest in the marks and names of others.

HUMAN CAPITAL RESOURCES

Our nearly 400,000 employees, as of December 31, 2024, including more than 140,000 clinical professionals, are guided by our mission to help people live healthier lives and help make the health system work better for everyone. Our mission and cultural values of integrity, compassion, inclusion, relationships, innovation, performance and quality align with our long-term business strategy to increase access to care, make care more affordable, enhance the care experience, improve health outcomes and advance health equity. Our mission and values attract individuals who are determined to make a difference – individuals whose talent, innovation, engagement and empowerment are critical in our ability to achieve our mission.

We are committed to developing our people and culture by creating an inclusive environment where people of diverse talents, backgrounds, experiences and perspectives make us better. Our approach is data-driven and leader-led and uses enterprise and business scorecards to ensure our leaders are accountable for a consistent focus on hiring, developing, advancing and retaining diverse talent. We have embedded inclusion and diversity throughout our culture, including in our talent acquisition and talent management practices; leadership development; careers; learning and skills; and systems and processes. We strive to maintain a skilled, sustainable and diverse talent pipeline by building strong strategic partnerships and outreach through early career programs, internships and apprenticeships. We support career coaching, mentorship and accelerated leadership development programs to ensure mobility and advancement for our diverse talent. To foster an engaged workforce and an inclusive culture, we invest in a broad array of skills-based learning and culture development programs. We rely on a shared leadership framework, which clearly and objectively defines our expectations, enables an environment where everyone has the opportunity to learn and grow, and helps us identify, develop and deploy talent to help achieve our mission.

We prioritize pay equity by objectively and regularly evaluating and reviewing our compensation practices by performance, age, experience, gender, ethnicity and race. Receiving on-going feedback from our team members is another way to strengthen and reinforce a culture of inclusion. Our Employee Experience Index measures an employee’s sense of commitment and belonging to our company and is a metric in the Stewardship section of our annual incentive plan. Our Sustainability Report, which can be accessed on our website at www.unitedhealthgroup.com, provides further information about our people and culture.

INFORMATION ABOUT OUR EXECUTIVE OFFICERS

The following sets forth certain information regarding our executive officers as of February 27, 2025, including the business experience of each executive officer during the past five years:

Name	Age	Position
Andrew Witty	60	Chief Executive Officer
John Rex	63	President and Chief Financial Officer
Heather Cianfrocco	51	Chief Executive Officer, Optum
Erin McSweeney	60	Executive Vice President and Chief People Officer
Timothy Noel	53	Chief Executive Officer, UnitedHealthcare
Thomas Roos	52	Senior Vice President and Chief Accounting Officer
Christopher Zaetta	53	Executive Vice President and Chief Legal Officer and Corporate Secretary

Our Board of Directors elects executive officers annually. Our executive officers serve until their successors are duly elected and qualified, or until their earlier death, resignation, removal or disqualification.

Andrew Witty has served as Chief Executive Officer and a member of the Board of Directors of UnitedHealth Group since February 2021. Previously, Andrew served as Chief Executive Officer of Optum from July 2018 to April 2021, President of UnitedHealth Group from November 2019 to February 2021 and as a UnitedHealth Group director from August 2017 to March 2018. Prior to joining UnitedHealth Group, he was Chief Executive Officer and a board member of GlaxoSmithKline, a global pharmaceutical company, from 2008 to 2017.

John Rex has served as President and Chief Financial Officer of UnitedHealth Group since April 2024. Previously, John served as Chief Financial Officer of UnitedHealth Group since June 2016. From March 2012 to June 2016, he served as Executive Vice President and Chief Financial Officer of Optum. Prior to joining Optum in 2012, John was a Managing Director at JP Morgan, a global financial services firm.

Heather Cianfrocco has served as Chief Executive Officer of Optum since April 2024. Previously, Heather served as Optum's President and held numerous leadership roles since joining UnitedHealth Group from 2008 until April 2024, including serving as Chief Executive Officer of Optum Rx, Chief Executive Officer for Optum's Health Services and Chief Executive Officer of UnitedHealthcare Community & State.

Erin McSweeney has served as Executive Vice President and Chief People Officer of UnitedHealth Group since March 2022. From February 2021 to March 2022, Erin served as chief of staff to UnitedHealth Group's Office of the Chief Executive. From January 2017 to February 2021, she served as Executive Vice President and Chief Human Resources Officer at Optum. Prior to joining UnitedHealth Group, Erin was Executive Vice President and Chief Human Resources Officer for EMC Corporation, an international technology company.

Tim Noel has served as Chief Executive Officer of UnitedHealthcare since January 2025. Previously, Tim served as Chief Executive Officer of UnitedHealthcare's Medicare & Retirement business and held numerous leadership roles since joining UnitedHealth Group from 2007 until January 2025, including serving as Chief Financial Officer and Senior Vice President of federal products for Medicare & Retirement.

Tom Roos has served as Senior Vice President and Chief Accounting Officer of UnitedHealth Group since August 2015. Prior to joining UnitedHealth Group, Tom was a Partner at Deloitte & Touche LLP, an independent registered public accounting firm.

Chris Zaetta has served as Executive Vice President, Chief Legal Officer and Corporate Secretary of UnitedHealth Group since May 2024. Previously, Chris served as Chief Legal Officer of Optum from September 2020 until May 2024. Prior to joining Optum in 2020, Chris was Vice President at Johnson & Johnson, a pharmaceutical company. Chris also held several leadership roles at UnitedHealth Group from May 2011 to September 2019, including Head of Litigation and General Counsel of the organization's government businesses.

ADDITIONAL INFORMATION

Our executive offices are located at 1 Health Drive, Eden Prairie, Minnesota 55344 and 655 New York Avenue, Washington, DC 20001; our telephone number is (800) 328-5979. You can access our website at www.unitedhealthgroup.com to learn more about our company. We make periodic and current reports and amendments available, free of charge, on our website, as soon as reasonably practicable after we file or furnish these reports to the Securities and Exchange Commission (SEC). Information on or linked to our website is neither part of nor incorporated by reference into this Annual Report on Form 10-K or any other SEC filings.

ITEM 1A. RISK FACTORS

CAUTIONARY STATEMENTS

The statements, estimates, projections or outlook contained in this Annual Report on Form 10-K include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). When used in this Annual Report on Form 10-K and in future filings by us with the SEC, in our news releases, presentations to securities analysts or investors, and in oral statements made by or with the approval of one of our executive officers, the words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “forecast,” “outlook,” “plan,” “project,” “should” or similar words or phrases are intended to identify such forward-looking statements. These statements are intended to take advantage of the “safe harbor” provisions of the PSLRA. These forward-looking statements involve risks and uncertainties which may cause our actual results to differ materially from the expectations expressed or implied in the forward-looking statements. Any forward-looking statement in this report speaks only as of the date of this report and, except as required by law, we undertake no obligation to update any forward-looking statement to reflect events or circumstances, including unanticipated events, after the date of this report.

The following discussion contains cautionary statements regarding our business, which investors and others should consider. We do not undertake to address in future filings with the SEC or other communications regarding our business or results of operations how any of these factors may have caused our results to differ from discussions or information contained in our previous filings or communications. In addition, any of the matters discussed below may have affected past, as well as current, forward-looking statements about future results. Any or all forward-looking statements in this Annual Report on Form 10-K and in any other SEC filings or public statements we make may turn out to be wrong. Our forward-looking statements can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. Many factors discussed below will be important in determining our future results. By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions which are difficult to predict or quantify.

Risks Related to Our Business and Our Industry

If we fail to estimate, price for and manage our medical costs or design benefits in an effective manner, the profitability of our risk-based products and services could decline and could materially and adversely affect our results of operations, financial position and cash flows.

Through our risk-based benefit products, we assume the risk of both medical and administrative costs for our customers in return for monthly premiums. The profitability of our products depends in large part on our ability to predict and effectively price for and manage medical costs. Our Optum Health business also enters into fully accountable value-based arrangements with payers. Premium revenues from risk-based products constitute nearly 80% of our total consolidated revenues. Estimates of benefit expense payments involve extensive judgement and are subject to considerable inherent variability. Relatively small differences between predicted and actual medical costs, or utilization rates as a percentage of revenues, have resulted and in the future may result in significant changes in our financial results. If we fail to predict accurately, or effectively price for or manage, the costs of providing care under risk-based arrangements, our results of operations could be materially and adversely affected.

We manage medical costs through underwriting criteria, product design, negotiation of competitive provider contracts and care management programs. Total medical costs are affected by the number of individual services rendered, the cost of each service and the type of service rendered. Although we base the premiums we charge on our estimates of future medical costs over the fixed contract period, many factors may cause, and have previously caused, actual costs to exceed those estimated and reflected in premiums or bids. These factors may include medical cost inflation, increased use of services, business mix, unexpected differences among new customer populations, increased cost of individual services, costs to deliver care, large-scale medical emergencies, the potential effects of climate change, pandemics, the introduction of new or costly drugs or increases in drug prices, treatments and technology, new treatment guidelines, newly mandated benefits or other regulatory changes and insured population characteristics. Cost increases in excess of our forecasts typically cannot be recovered in the fixed premium period through higher premiums. For Optum Health’s fully accountable value-based care, any inability to provide higher-quality outcomes and better experiences at lower costs or to integrate our care delivery models could impact our results of operations, financial positions and cash flows.

In addition, the financial results we report for any particular period include estimates of costs incurred for which claims are still outstanding. These estimates involve an extensive degree of judgment. If these estimates prove inaccurate, our results of operations could be materially and adversely affected.

If we fail to maintain properly the integrity or availability of our data or successfully consolidate, integrate, upgrade or expand our existing information systems, or if our technology products do not operate as intended, our business could be materially and adversely affected.

Our business depends on the integrity and timeliness of the data we use to serve our members, customers and health care professionals and to operate our business. If the data we rely upon to run our businesses is found to be inaccurate or unreliable or if we fail to effectively maintain or protect the integrity of our data and information systems, including systems powered by or incorporating artificial intelligence and machine learning (AI/ML), we could experience failures in our health, wellness and information technology products; lose existing customers; have difficulty attracting new customers; experience problems in determining medical cost estimates and establishing appropriate pricing; have difficulty preventing, detecting and controlling fraud; have disputes with customers, physicians and other health care professionals; become subject to regulatory sanctions, penalties, investigations or audits; incur increases in operating expenses; or suffer other adverse consequences.

The volume of health care data generated, and the uses of data, including electronic health records, are rapidly expanding. We depend on the integrity of the data in our information systems to implement new and innovative services, automate and deploy new technologies to simplify administrative processes and clinical decision making, price our products and services adequately, provide effective service to our customers and consumers in an efficient and uninterrupted fashion, provide timely payments to care providers, and accurately report our results of operations. In addition, increasing connectivity among technologies and recent trends toward greater consumer engagement in health care require new and enhanced technologies, including more sophisticated applications for mobile devices and new tools and products that leverage AI/ML to improve the customer experience. We anticipate that fast-evolving AI/ML technologies, including generative AI, will play an increasingly important role in our information systems and customer-facing technology products. Our ability to protect and enhance existing systems and develop new systems to keep pace with changes in information processing technology (including AI/ML), regulatory standards and changing customer preferences will require an ongoing commitment of significant development and operational resources. If these commitments fail to provide the anticipated benefits, if we are unable to successfully anticipate future technology developments, or if the cost to keep pace with the technological changes exceeds our estimates, we could be exposed to reputational harm and experience adverse effects on our business.

We may not successfully implement our initiatives to consolidate the number of systems we operate, upgrade and expand our information systems' capabilities, integrate and enhance our systems and develop new systems to keep pace with recent regulations and changes in information processing technology. Failure to protect, consolidate and integrate our systems successfully could result in higher than expected costs.

Some of our businesses sell and install software products which may contain unexpected design defects or may encounter unexpected complications during installation or when used with other technologies utilized by the customer. A failure of our technology products to operate as intended and in a seamless fashion with other products could materially and adversely affect our results of operations, financial position and cash flows.

Uncertain and rapidly evolving U.S. federal and state, non-U.S. and international laws and regulations related to health data and health information technologies, including those powered by or incorporating AI/ML, may alter the competitive landscape or impose new compliance requirements and could materially and adversely affect the configuration of our information systems and platforms, and our ability to compete in our markets.

If we or third parties we rely on sustain cyberattacks or other privacy or data security incidents resulting in disruption to our operations or the disclosure of protected personal information or proprietary or confidential information, we could suffer a loss of revenue and increased costs, negative operational effects, exposure to significant liability, reputational harm and other serious negative consequences.

We routinely process, store and transmit large amounts of data in our operations, including protected personal information subject to privacy, security or data breach notification laws, as well as proprietary or confidential information relating to our business or third parties. Some of the data we process, store and transmit may be outside of the United States due to our information technology systems and international business operations. We are regularly the target of attempted cyberattacks and other security threats and have previously been, and may in the future be, subject to compromises of the information technology systems we use, information we hold, or information held on our behalf by third parties. For example, we previously reported our Change Healthcare business, which we had recently acquired, was subject to a cyberattack in 2024, in which the data involved contained protected health information or personally identifiable information.

While we have programs in place to detect, contain and respond to data security incidents and provide employee awareness training regarding phishing, malware and other cyber threats to protect against cybersecurity risks and incidents, we expect that we will continue to experience these incidents, some of which may negatively affect our business. Further, because the techniques used to obtain unauthorized access, disable or degrade service, or sabotage systems change frequently and are increasing in sophistication, in part due to use of evolving AI/ML technologies (including generative AI), and because our businesses are changing as well, we may be unable to anticipate these techniques and threats, timely detect data security

incidents or implement adequate preventive measures. Threat actors and hackers have previously been, and may in the future be, able to negatively affect our operations by penetrating our security controls and causing system and operational disruptions or shutdowns, accessing, misappropriating or otherwise compromising protected personal information or proprietary or confidential information or that of third parties, and developing and deploying viruses, ransomware and other malware that can attack our systems, exploit any security vulnerabilities, and disrupt or shutdown our systems and operations. In addition, hardware, software, or applications we develop or procure from third parties may contain defects or other problems which could unexpectedly compromise our information security controls. Our systems may also be vulnerable to financial fraud schemes, misplaced or lost data, error, malicious social engineering, or other events which could negatively affect the data or financial accounts, proprietary or confidential information relating to our business or third parties, or our operations. There have previously been and may be in the future heightened vulnerabilities due to recently-acquired or non-integrated businesses. We rely in some circumstances on third-party vendors to process, store and transmit large amounts of data for our business. The operations of these vendors are subject to similar risks, but are outside our direct oversight and control.

The costs to eliminate or address the foregoing security threats and vulnerabilities before or after a cybersecurity incident could be material. We have business continuation and resiliency plans which we maintain, update and test regularly in an effort to contain and remediate potential disruptions or cybersecurity events. If our remediation efforts are not successful, we may experience operational interruptions, delays, or cessation of service and loss of existing or potential customers. In addition, compromises of our security measures or the unauthorized dissemination of sensitive personal information, proprietary information or confidential information about us, our customers or other third parties, previously and in the future, could expose us or them to the risk of financial or medical identity theft, negative operational impacts, and loss or misuse of this information, result in litigation and liability, including regulatory penalties, for us, damage our brand and reputation, or otherwise harm our business.

If we fail to develop and maintain satisfactory relationships with health care payers, physicians, hospitals and other service providers, our business could be materially and adversely affected.

We depend substantially on our continued ability to contract with health care payers (as a service provider to those payers), as well as physicians, hospitals, pharmaceutical benefit service providers, pharmaceutical manufacturers and other care and service providers at competitive prices. If we fail to develop and maintain satisfactory relationships with health care providers, whether in-network or out-of-network, our failure to do so could materially and adversely affect our business, results of operations, financial position and cash flows. In addition, some of our activities related to network design, provider participation in networks and provider payments could result in disputes, which may be costly and attract negative publicity.

In any particular market, physicians and health care providers could refuse to contract with us, demand higher payments, or take other actions which could result in higher medical costs, less desirable products for customers or difficulty meeting regulatory or accreditation requirements. In some markets, certain health care providers, particularly hospitals, physician and hospital organizations or multi-specialty physician groups, may have significant market positions which could diminish our bargaining power. In addition, Accountable Care Organizations (ACOs); physician group management services organizations (which aggregate physician practices for administrative efficiency); and other organizational structures adopted by physicians, hospitals and other care providers may change the way in which these providers do business with us and may change the competitive landscape. Such organizations or groups of physicians may compete directly with us, which could adversely affect our business, and our results of operations, financial position and cash flows by impacting our relationships with these providers or affecting the way we price our products and estimate our costs, which might require us to incur costs to change our operations in an effort to mitigate these impacts. In addition, if these providers refuse to contract with us, use their market position to negotiate favorable contracts or place us at a competitive disadvantage, our ability to market products or to be profitable in those areas could be materially and adversely affected.

Our health care benefits businesses have risk-based arrangements with some physicians, hospitals and other health care providers. These arrangements limit our exposure to the risk of increasing medical costs, but expose us to risk related to the adequacy of the financial and medical care resources of the health care providers. To the extent a risk-based health care provider organization faces financial difficulties or otherwise is unable to perform its obligations under the arrangement, we may be held responsible for unpaid health care claims which should have been the responsibility of the health care provider and for which we have already paid the provider. Further, payment or other disputes between a primary care provider and specialists with whom the primary care provider contracts could result in a disruption in the provision of services to our members or a reduction in the services available to our members. Health care providers with which we contract may not properly manage the costs of services, maintain financial solvency or avoid disputes with other providers. They may also fail to provide us with the information we need to effectively conduct our businesses, such as information enabling us to estimate costs of care. Any of these events could have a material adverse effect on the provision of services to our members and our operations.

Some providers that render services to our members do not have contracts with us. In some instances, those providers may dispute the payment for these services and may institute litigation or arbitration relying on state and federal laws that define the compensation that must be paid to out-of-network providers in some circumstances.

The success of some of our businesses depends on maintaining satisfactory relationships with employed, affiliated, and independently contracted physicians and joint venture partners. The physicians who practice medicine or contract with our affiliated physician organizations could terminate their provider contracts or otherwise become unable or unwilling to continue practicing medicine or contracting with us. We face and will likely continue to face heightened competition to acquire or manage physician practices or to employ or contract with individual physicians. Our revenues could be materially and adversely affected if we are unable to maintain or expand satisfactory relationships with physicians, to acquire, recruit or, in some instances, employ physicians, or to retain enrollees following physician departures. In addition, our affiliated physician organizations contract with competitors of UnitedHealthcare. Our businesses could suffer if our affiliated physician organizations fail to maintain relationships with or fail to adequately price their contracts with these third-party payer competitors.

Further, physicians, hospitals, pharmaceutical benefit service providers, pharmaceutical manufacturers and certain health care providers are customers of our Optum businesses. Physicians also provide medical services at facilities owned by our Optum businesses. Given the importance of health care providers and other constituents to our businesses, failure to maintain satisfactory relationships with them could materially and adversely affect our results of operations, financial position and cash flows.

If we fail to compete effectively to maintain or increase our market share, including maintaining or increasing enrollments in businesses providing health benefits, our results of operations, financial position and cash flows could be materially and adversely affected.

Our businesses face significant competition in all of the markets in which we operate. In many geographies or product segments, our competitors have and may continue to have certain competitive advantages. Our competitive position may also be adversely affected by significant merger and acquisition activity in the industries in which we operate, among both our competitors and suppliers. Consolidation among competitors may make it more difficult for us to retain or increase our customer base, maintain or improve the terms on which we do business with our suppliers, or maintain or increase our profitability.

In addition, our success in the health care marketplace and future growth depends on our ability to develop and deliver innovative and potentially disruptive products and services to satisfy evolving market demands. If we do not continue to innovate and provide products and services which are useful and relevant to health care payers, consumers and our customers, we may not remain competitive and risk losing market share to existing competitors and disruptive new market entrants. We may face risks from new technologies and market entrants which could affect our existing relationship with health plan enrollees in the affected markets. We could sustain competitive disadvantages and loss of market share if we fail to continue developing innovative care models, including by accelerating the transition of care to value-based models that achieve higher quality outcomes and better experiences at lower costs and expand access to virtual and in-home care. If health care payers or providers are unwilling or unable to enter into value-based agreements with us, we may be unable to successfully establish or maintain the contractual or employment relationships necessary to achieve the quality and cost objectives we have for value-based contracting. Additionally, our competitive position could be adversely affected by any failure to develop and apply innovative technologies and other effective data and analytics capabilities or to provide services to our clients focused on these technologies and capabilities.

Our business, results of operations, financial position and cash flows also could be materially and adversely affected if we do not compete effectively in our markets, if our reputation suffers harm, if we set rates too high or too low in highly competitive markets, if we do not design and price our products properly and competitively, if we are unable to innovate and deliver products and services demonstrating value to our customers, if we do not provide a satisfactory level of services, if membership or demand for other services does not increase as we expect or declines, or if we lose accounts with more profitable products while retaining or increasing membership in accounts with less profitable products.

We are routinely subject to various private party and governmental legal actions and investigations, which could damage our reputation and, if resolved unfavorably, could result in substantial penalties or monetary damages and materially and adversely affect our results of operations, financial position and cash flows.

We are routinely made party to a variety of private party and governmental legal actions and investigations related to, among other matters, the design, management and delivery of our product and service offerings. Any failure by us to adhere to the laws and regulations applicable to our businesses could subject us to civil and criminal penalties.

Legal actions to which we are a party have included and in the future could include matters related to health care benefits coverage and payment of claims (including disputes with enrollees, customers and contracted and non-contracted physicians, hospitals and other health care professionals), tort claims (including claims related to the delivery of health care services, such as medical malpractice by personnel at our affiliates' facilities, or by health care practitioners who are employed by us, have contractual relationships with us, or serve as providers to our managed care networks, including as a result of a failure to adhere to applicable clinical, quality and/or patient safety standards), antitrust claims (including as a result of changes in the

enforcement of antitrust laws), whistleblower claims (including claims under the False Claims Act or similar statutes), matters related to our use of or alleged failure to adequately safeguard personal information or other proprietary data, claims related to alleged failure of our technology products to operate properly or fairly, contract and labor disputes, tax claims and claims related to disclosure of certain business practices. In addition, some of our pharmacy services operations are subject to clinical quality, patient safety and other risks inherent in the dispensing, packaging and distribution of drugs, including claims related to purported dispensing and other operational errors. We may also be party to certain class action lawsuits brought by health care professional groups and consumers. We operate in jurisdictions outside of the United States where contractual rights, tax positions and applicable regulations may be subject to interpretation or uncertainty to a greater degree than in the United States, and therefore subject to dispute by customers, government authorities or others.

We are largely self-insured with regard to litigation risks, including claims of medical malpractice against our affiliated physicians and us. Although we record liabilities for our estimates of the probable costs resulting from self-insured matters, it is possible the level of actual losses will significantly exceed the liabilities recorded. Additionally, physicians and other healthcare providers have become subject to an increasing number of legal actions alleging medical malpractice and general professional liabilities. Even in states that have imposed caps on damages for such actions, litigants are seeking recoveries under theories of liability that might not be subject to the caps on damages. These actions involve significant defense costs and could result in substantial monetary damages or damage to our reputation.

We cannot predict the outcome of significant legal actions in which we are involved. Even in situations where we engage external insurers, our coverage may be disputed or may not be sufficient to cover the entirety of certain claims. We incur expenses to resolve these matters and current and future legal actions could further increase our cost of doing business, require us to potentially change the way we conduct our business, and materially and adversely affect our results of operations, financial position and cash flows. Moreover, certain legal actions could result in adverse publicity which could damage our reputation and materially and adversely affect our ability to retain our current business or grow our market share in some markets and businesses.

Our business could suffer, and our results of operations, financial position and cash flows could be materially and adversely affected, if we fail to successfully manage our strategic alliances, or to complete, manage or integrate acquisitions and other significant strategic transactions or relationships.

As part of our business strategy, we frequently engage in discussions with third parties regarding possible investments, acquisitions, divestitures, strategic alliances, joint ventures and outsourcing transactions and often enter into agreements relating to such transactions. If we fail to meet the needs of our alliance or joint venture partners, including by developing additional products and services, providing high levels of service, pricing our products and services competitively or responding effectively to applicable federal and state regulatory changes, our alliances and joint ventures could be damaged or terminated, which in turn could adversely impact our reputation, business and results of operations. Further, governmental actions, such as actions by the FTC or DOJ, may affect our ability to complete strategic transactions, which could adversely affect our future growth. If we fail to identify and successfully complete transactions to meet our strategic objectives, including as a result of antitrust regulatory enforcement actions, such as those that have been brought against us in the past, we may be required to expend resources to develop products and technology internally, be placed at a competitive disadvantage or be adversely affected by negative market perceptions, any of which may have a material adverse effect on our results of operations, financial position or cash flows.

Successful acquisitions also require us to effectively integrate the acquired business into our existing operations, including our internal control environment and culture, or otherwise leveraging its operations which may present risks different from those presented by organic growth and may be difficult for us to manage. For example, we have experienced and in the future may encounter more acute information technology system vulnerabilities or different litigation risk profiles in recently acquired business than we have historically managed. We may be unable to address such vulnerabilities, inadequacies, differences, or failures soon after acquiring a business, which could undermine integration activities, delay launch of acquired products, and increase infrastructure risk. In addition, even with appropriate diligence, pre-acquisition practices of an acquired business have exposed us in the past and may expose us in the future to legal challenges and investigations that could subject us to criminal fines or reputational harm. Even if we are ultimately successful in resolving these matters, defending such claims may be costly and result in negative publicity. If we cannot successfully integrate our acquired businesses and realize contemplated revenue growth opportunities, cost savings and other synergies, our business, prospects, results of operations, financial position and cash flows could be materially and adversely affected.

We are subject to risks associated with public health crises arising from large-scale medical emergencies, pandemics, natural disasters and other extreme events, which have had and could have an adverse effect on our business, results of operations, financial condition and financial performance.

Large-scale medical emergencies, pandemics, natural disasters, public health crises and other extreme events could have a material adverse effect on our business operations, cash flows, financial conditions and results of operations. For example, disruptions in public and private infrastructure resulting from such events could increase our operating costs and impair our ability to provide services to our clients and customers. In addition, as a result of these events, the premiums and fees we charge may not be sufficient to cover our medical and administrative costs, deferred medical care could be sought in future periods at potentially higher acuity levels, we could experience reduced demand for our services, and our clinical and non-clinical workforce could be affected and sustain a reduced capacity to handle demand for care. Public health crises arising from natural disasters, such as wildfires, hurricanes, and snowstorms, or effects of climate change could impact our business operations and result in increased medical care costs. Government enactment of emergency powers in response to public health crises could disrupt our business operations, including by restricting availability of, or our ability to deliver, pharmaceuticals or other supplies, and could increase the risk of shortages of necessary items.

Our sales performance will suffer if we do not adequately attract, retain and provide support to a network of independent producers and consultants.

Our products and services are sold in part through nonexclusive producers and consultants for whose services and allegiance we must compete. Our sales could be materially and adversely affected if we are unable to attract, retain and support independent producers and consultants or if our sales strategy is not appropriately aligned across distribution channels. Our relationships with producers could be impaired by changes in our business practices and the terms of our relationships, including commission levels.

Our businesses are subject to risks associated with unfavorable economic conditions.

Unfavorable economic conditions may have a range of impacts on the demand for our products and services. Such conditions also have caused and in future periods could continue to cause employers to stop offering certain health care coverage as an employee benefit or elect to offer particular coverage on a voluntary, employee-funded basis to reduce their operating costs. In addition, unfavorable economic conditions could adversely impact our ability to increase premiums or result in the cancellation by certain customers of our products and services. These conditions could lead to a decrease in people served and in the premium and fee revenues we generate.

A prolonged unfavorable economic environment could constrain state and federal budgets and result in reduced reimbursements or payments in our federal and state government health care coverage programs, including Medicare, Medicaid and CHIP. A reduction in state Medicaid reimbursement rates could be implemented retroactively to apply to payments already negotiated or received from the government. In addition, state and federal budgetary pressures could cause the affected governments to impose new or a higher level of taxes or assessments for our commercial programs, such as premium taxes on health insurance and surcharges or fees on select fee-for-service and capitated medical claims. Any of these developments or actions could materially and adversely affect our results of operations, financial position and cash flows.

A prolonged unfavorable economic environment could also adversely impact the financial position of hospitals and other care providers which could negatively affect our contracted rates with these parties and increase our medical costs or materially and adversely affect their ability to purchase our service offerings. Further, unfavorable economic conditions could have a material adverse effect on our financial results by impacting the customers of our Optum businesses, including health plans, hospitals, care providers, employers and others.

Our failure to attract, develop, retain, and manage the succession of key employees and executives could adversely affect our business, results of operations and future performance.

We depend on our ability to attract, develop and retain qualified employees and executives, including those with diverse talents, backgrounds, experiences and perspectives, to operate and expand our business. While we have development and succession plans in place for our key employees and executives, these plans do not guarantee that the services of our key employees and executives will continue to be available to us. If we are unable to attract, develop, retain and effectively manage the development and succession plans for key employees and executives, our business, results of operations and future performance could be adversely affected. Experienced and highly skilled employees and executives in the health care and technology industries are in high demand and the market for their services is competitive. We may have difficulty in replacing key executives because of the limited number of qualified individuals in these industries with the breadth of skills and experience required to operate and successfully expand our business. Adverse changes to our corporate culture could harm our business operations and our ability to retain key employees and executives.

Our investment portfolio may sustain losses which could adversely affect our profitability.

Market fluctuations could impair the value of our investment portfolio and our profitability. Volatility in interest rates affects our interest income and the market value of our investments in debt securities of varying maturities which constitute the substantial majority of the fair value of our investments as of December 31, 2024. In addition, a delay in payment of principal or interest by issuers, or defaults by issuers (primarily issuers of our investments in corporate and municipal bonds), could reduce our investment income and require us to write down the value of our investments which could adversely affect our profitability and equity.

Our investments may not produce total positive returns and we may sell investments at prices which are less than their carrying values. Changes in the value of our investment assets, as a result of interest rate fluctuations, changes in issuer financial or market conditions, illiquidity or otherwise, could have an adverse effect on our equity. In addition, if it should become necessary for us to liquidate a material portion of our investment portfolio on an accelerated basis, such an action could have an adverse effect on our results of operations and the capital position of our regulated subsidiaries.

If the value of our intangible assets is materially impaired, our results of operations, equity and credit ratings could be materially and adversely affected.

As of December 31, 2024, our goodwill and other intangible assets had a carrying value of \$130 billion, representing 44% of our total consolidated assets. We periodically evaluate our goodwill and other intangible assets to determine whether all or a portion of their carrying values may be impaired, in which case a charge to earnings may be necessary. The value of our goodwill may be materially and adversely impacted if businesses we acquire perform in a manner inconsistent with our assumptions. In addition, from time to time we divest businesses, and any such divestiture could result in significant asset impairment and disposition charges, including those related to goodwill and other intangible assets. Any future evaluations requiring an impairment of our goodwill and other intangible assets could materially and adversely affect our results of operations and equity in the period in which the impairment occurs. A material decrease in equity could, in turn, adversely affect our credit ratings.

If we are not able to protect our proprietary rights to our databases, software and related products, or other intellectual property, our ability to market our knowledge and information-related businesses could suffer.

We rely on our agreements with customers, confidentiality agreements with employees and third parties, and our trademarks, trade secrets, copyrights and patents to protect our proprietary rights. These legal protections and precautions may not prevent misappropriation of our proprietary information. In addition, intellectual property rights inherent in software are the subject of substantial litigation, and we expect our software products to be increasingly subject to third-party infringement claims as the number of products and competitors in the health care-focused software industry segment grows. Such litigation and misappropriation of our proprietary information could hinder our ability to market and sell products and services which could materially and adversely affect our results of operations, financial position and cash flows.

Any downgrades in our credit ratings could increase our borrowing and operating costs.

Claims paying ability, financial strength and debt ratings by nationally recognized statistical rating organizations are important factors in establishing the competitive position of insurance companies. Ratings information is broadly disseminated and generally used by customers and creditors. We believe our claims paying ability and financial strength ratings are important factors in marketing our products to certain of our customers. Our credit ratings impact both the cost and availability of future borrowings. Each of the credit rating agencies reviews its ratings periodically. Our ratings reflect each credit rating agency's opinion of our financial strength, operating performance and ability to meet our debt obligations or obligations to policyholders. We may not be able to maintain our current credit ratings in the future. Any downgrades in our credit ratings could materially increase our costs of or ability to access funds in the debt capital markets and otherwise materially increase our operating costs.

Risks Related to the Regulation of Our Business

Our business activities in the United States and other countries are highly regulated and new laws or regulations or changes in existing laws or regulations or their enforcement or application could materially and adversely affect our business.

We are regulated by federal, state and local governments in the United States and other countries where we do business. Our insurance and HMO subsidiaries must be licensed by and are subject to regulation in the jurisdictions in which they conduct business. For example, states require periodic financial reports and enforce minimum capital or restricted cash reserve requirements. Health plans and insurance companies are also regulated under state insurance holding company regulations and some of our activities may be subject to other health care-related regulations and requirements, including regulations and licensure requirements related to PPOs, MCOs, UR and TPAs. Under state guaranty association laws, certain insurance companies can be assessed (up to prescribed limits) for certain obligations to the policyholders and claimants of impaired or insolvent insurance companies which write the same line or similar lines of business. Any such assessment could expose our

insurance entities and other insurers to the risk they would be required to pay a portion of an impaired or insolvent insurance company's claims through state guaranty associations.

Some of our businesses provide products or services to government agencies. For example, some of our Optum and UnitedHealthcare businesses hold government contracts or provide services related to government contracts and are subject to U.S. federal and state and non-U.S. self-referral, anti-kickback, medical necessity, risk adjustment, false claims and other laws and regulations governing government contractors and the use of government funds. Our relationships with these government agencies are subject to the terms of our contracts with the agencies and to laws and regulations regarding government contracts. Among others, certain laws and regulations restrict or prohibit companies from performing work for government agencies which might be viewed to involve an actual or potential conflict of interest. These laws and regulations may limit our ability to pursue and perform certain types of engagements, thereby materially and adversely affecting our results of operations, financial position and cash flows.

Some of our Optum businesses are also subject to regulations distinct from those faced by our insurance and HMO subsidiaries, some of which could impact our relationships with physicians, hospitals and customers. These regulations include state telemedicine regulations; debt collection laws; banking regulations; distributor and producer licensing requirements; state corporate practice of medicine restrictions; fee-splitting rules; and health care facility licensure and certificate of need requirements. These risks and uncertainties may materially and adversely affect our ability to market or provide our products and services, or to achieve targeted operating margins, or may increase the regulatory burdens under which we operate.

The laws and rules governing our businesses and interpretations of those laws and rules are subject to frequent and often unpredictable change. For example, legislative, administrative and public policy changes to the ACA have been and likely will continue to be considered, and we cannot predict if the ACA will be further modified. Additionally, changes in tax laws or unfavorable resolutions of exams could create additional tax liabilities.

The integration of entities we acquire into our businesses may affect the way in which existing laws and rules apply to us, including by subjecting us to laws and rules which did not previously apply to us. The broad latitude given to the agencies administering, interpreting and enforcing current and future regulations governing our businesses could compel us to change how we do business, renegotiate existing contracts and other arrangements, restrict revenue and enrollment growth, increase our health care and administrative costs and capital requirements, or expose us to increased liability in courts for coverage determinations, resolution of commercial disputes and other actions.

We also must obtain and maintain regulatory approvals to market many of our products and services, increase prices for some regulated products and services and complete or integrate strategic transactions. For example, premium rates for our health insurance and managed care products are subject to regulatory review or approval in many states and by the federal government. Additionally, we must submit data on proposed rate increases to HHS on many of our products for monitoring purposes. Geographic and product expansions of our businesses may be subject to state and federal regulatory approvals. Delays in obtaining necessary approvals or our failure to obtain or maintain adequate approvals could materially and adversely affect our results of operations, financial position and cash flows.

We also currently operate outside of the United States and in the future may acquire or commence additional businesses based outside of the United States, increasing our exposure to non-U.S. regulatory regimes. Our failure to comply with U.S. or non-U.S. laws and regulations governing our conduct outside the United States or to establish constructive relationships with non-U.S. regulators could adversely affect our ability to market our products and services or to do so at targeted operating margins, which may have a material adverse effect on our business, financial condition and results of operations. Non-U.S. regulatory regimes, which vary by jurisdiction, encompass, among other matters, local and cross-border taxation, licensing, tariffs, intellectual property, investment, capital (including minimum solvency margin and reserve requirements), management control, labor, anti-fraud, anti-corruption and privacy and data protection regulations (including requirements for cross-border data transfers). Any foreign regulator or court may take an approach to the interpretation, implementation and enforcement of industry regulations which could differ from the approach taken by U.S. regulators or courts. In addition, our non-U.S. businesses and operations are subject to U.S. laws regulating the conduct and activities of U.S.-based businesses operating outside the United States, such as the FCPA, which prohibits offering, promising, providing or authorizing others to give anything of value to a foreign government official to obtain or retain business or otherwise secure a business advantage.

The health care industry is regularly subject to negative publicity, including as a result of governmental investigations, adverse media coverage and political debate concerning industry regulation. Negative publicity may adversely affect our stock price, damage our reputation, and expose us to unexpected or unwarranted regulatory scrutiny.

As a result of our participation in various government health care programs, both as a payer and as a service provider to payers, we are exposed to additional risks associated with program funding, enrollments, payment adjustments, audits and government investigations which could materially and adversely affect our business, results of operations, financial position and cash flows.

We participate in various federal, state and local government health care benefit programs, including as a payer in Medicare Advantage, Medicare Part D, various Medicaid programs and CHIP, and receive substantial revenues from these programs. Some of our Optum businesses also provide services to payers participating in government health care programs. A reduction or less than expected increase, or a protracted delay, in government funding for these programs or change in allocation methodologies, or termination of the contract at the option of the government, has affected and in future periods may materially and adversely affect our results of operations, financial position and cash flows.

The government health care programs in which we participate are generally subject to frequent changes, including changes which may reduce the number of persons enrolled or eligible for coverage (such as Medicaid eligibility redeterminations in certain states), reduce the amount of reimbursement or payment levels, reduce our participation in, or prevent our expansion into, certain service areas or markets, or increase our administrative or medical costs under such programs. Revenues for these programs depend on periodic funding from the federal government or applicable state governments and allocation of the funding through various payment mechanisms. Funding for these government programs depends on many factors outside of our control, including general economic conditions and budgetary constraints at the federal or applicable state level. For example, CMS in the past has reduced or frozen Medicare Advantage benchmarks and additional cuts to Medicare Advantage benchmarks are possible. In addition, from time to time, CMS makes changes to the way it calculates Medicare Advantage risk adjustment payments. Although we have adjusted members' benefits and premiums on a selective basis, ceased to offer benefit plans in certain counties, and intensified both our medical and operating cost management in response to the benchmark reductions and other funding pressures, these or other strategies may not fully address the funding pressures in the Medicare Advantage program. In addition, payers in the Medicare Advantage program may be subject to reductions in payments from CMS as a result of decreased funding or recoupment pursuant to government audit. States have also made changes in rates and reimbursements for Medicaid members and audits can result in unexpected recoupments.

Under the Medicaid managed care program, state Medicaid agencies solicit bids from eligible health plans to continue their participation in the acute care Medicaid health programs. If we are not successful in obtaining renewals of state Medicaid managed care contracts, we risk losing the members who were enrolled in those Medicaid programs. Under the Medicare Part D program, to qualify for automatic enrollment of low income members, our bids must result in an enrollee premium below a regional benchmark, which is calculated by the government after all regional bids are submitted. If the enrollee premium is not below the government benchmark, we risk losing the members who were auto-assigned to us and will not have additional members auto-assigned to us. Chronic failure to meet the benchmarks could result in termination of these government contracts. In general, our bids are based upon certain assumptions regarding enrollment, utilization, medical costs and other factors. If any of these assumptions are materially incorrect, either as a result of unforeseen changes to the programs on which we bid, implementation of material program or policy changes after our bid submission, or submissions by our competitors at lower rates than our bids, our results of operations, financial position and cash flows could be materially and adversely affected.

Many of the government health care coverage programs we participate in are subject to the prior satisfaction of certain conditions or performance standards or benchmarks. For example, as part of the ACA, CMS has a system providing various quality bonus payments to Medicare Advantage plans meeting specified quality star ratings at the individual plan or local contract level. The star rating system considers various measures adopted by CMS, including, among others, quality of care, preventive services, chronic illness management, handling of appeals and customer satisfaction. Plans must have a rating of four stars or higher to qualify for bonus payments, and CMS has and may make changes to the star rating program that impact the ability of plans to achieve four-star or higher ratings. If we do not maintain or continue to improve our star ratings, our plans may not be eligible for quality bonuses and we may experience a negative impact on our revenues and the benefits our plans can offer, which could materially and adversely affect the marketability of our plans and the number of people we serve. Any changes in standards or care delivery models applying to government health care programs, including Medicare and Medicaid, or our inability to maintain or improve our quality scores and star ratings to meet evolving government performance requirements or to match the performance of our competitors could result in limitations to our participation in or exclusion from these or other government programs, which could materially and adversely affect our results of operations, financial position and cash flows.

CMS uses various payment mechanisms to allocate funding and adjust monthly capitation payments for Medicare programs. For Medicare Advantage plans, these adjustments are made according to the predicted health status of each beneficiary as supported by data from health care providers. For Medicare Part D plans, payment adjustments are driven by risk-sharing provisions based on a comparison of costs forecasted in our annual bids to actual prescription drug costs. Some state Medicaid programs utilize a similar process. For example, our UnitedHealthcare Medicare & Retirement and UnitedHealthcare Community & State businesses submit information relating to the health status of enrollees to CMS or state agencies for

purposes of determining the amount of certain payments to us. CMS and the Office of Inspector General for HHS periodically perform risk adjustment data validation (RADV) audits of selected Medicare health plans to validate the coding practices of and supporting documentation maintained by health care providers. Some of our local plans have been selected for such audits, which in the past have resulted and in future periods could result in retrospective adjustments to payments made to our health plans, fines, corrective action plans or other adverse action by CMS.

We have been and in the future may become involved in routine, regular and special governmental investigations, audits, reviews and assessments. Such investigations, audits, reviews or assessments sometimes arise out of, or prompt claims by private litigants or whistleblowers regarding, among other allegations, claims that we failed to disclose certain business practices or, as a government contractor, submitted false or erroneous claims to the government. Government investigations, audits, reviews and assessments could lead to government actions, which have resulted and in future periods could result in adverse publicity, the assessment of damages, civil or criminal fines or penalties, or other sanctions, including restrictions or changes in the way we conduct business, loss of licensure or exclusion from participation in government programs, any of which could have a material adverse effect on our business, results of operations, financial position and cash flows.

Our pharmacy care services businesses face regulatory and operational risks and uncertainties which may differ from the risks of our other businesses.

We provide pharmacy care services through our Optum Rx and UnitedHealthcare businesses. Each business is subject to federal and state anti-kickback, beneficiary inducement and other laws governing the relationships of the business with pharmaceutical manufacturers, physicians, pharmacies, customers and consumers. In addition, federal and state legislatures regularly consider new regulations for the industry which could materially affect current industry practices, including potential new legislation and regulations regarding the receipt or disclosure of rebates and other fees from pharmaceutical companies, the development and use of formularies and other utilization management tools, the use of average wholesale prices or other pricing benchmarks, pricing for specialty pharmaceuticals, limited access to networks and pharmacy network reimbursement methodologies. Further, various governmental agencies have conducted and continue to conduct investigations and studies into certain PBM practices, which have resulted and in future periods may result in PBMs agreeing to civil penalties, including the payment of money and entry into corporate integrity agreements, or could materially and adversely impact the PBM business model. As a provider of pharmacy benefit management services, Optum Rx is also subject to an increasing number of licensure, registration and other laws and accreditation standards. Optum Rx conducts business through home delivery, specialty and compounding pharmacies, pharmacies located in community mental health centers and home infusion, which subjects it to extensive federal, state and local laws and regulations, including those of the DEA and individual state controlled substance authorities, the Food and Drug Administration and Boards of Pharmacy.

We could face potential claims in connection with purported errors by our home delivery, specialty or compounding or clinic-based pharmacies or the provision of home infusion services, as well as claims related to the inherent risks in the packaging and distribution of pharmaceuticals and other health care products. Disruptions from any of our home delivery, specialty pharmacy or home infusion services could materially and adversely affect our results of operations, financial position and cash flows.

In addition, our pharmacy care services businesses provide services to sponsors of health benefit plans subject to ERISA. A private party or the DOL, which is the agency that enforces ERISA, could assert that fiduciary obligations imposed by the statute apply to some or all of the services provided by our pharmacy care services businesses even where those businesses are not contractually obligated to assume fiduciary obligations. If a court were to determine such fiduciary obligations apply, we could be subject to claims for breaches of fiduciary obligations or claims we entered into prohibited transactions.

If we fail to comply with applicable privacy, security, technology and data laws, regulations and standards, including with respect to third-party service providers utilizing protected personal information on our behalf, our business, reputation, results of operations, financial position and cash flows could be materially and adversely affected.

The collection, maintenance, protection, use, transmission, disclosure and disposal of protected personal information are regulated at the federal, state, international and industry levels and addressed in requirements of our customer contracts. Additionally, legislative and regulatory action in the United States at the federal, state and local levels, as well as internationally, is emerging in the areas of AI/ML and automation. These laws, regulations and requirements are subject to change. Compliance with new privacy, security, technology and data laws, regulations and requirements may result in increased operating costs, and may constrain or require us to alter our business model or operations.

Internationally, many of the jurisdictions in which we operate have established their own data security and privacy legal framework with which we or our customers must comply. We expect there will continue to be new proposed laws, regulations and industry standards concerning privacy, data protection, information security, and AI/ML and automation in the European Union, UK, Chile, India and other jurisdictions, and we cannot yet determine the impacts such future laws, regulations and standards may have on our businesses or the businesses of our customers.

Some of our businesses are also subject to the Payment Card Industry Data Security Standard, which is a multifaceted security standard designed to protect payment card account data.

HIPAA requires business associates as well as covered entities to comply with specified privacy and security requirements. While we provide for appropriate protections through our contracts with our third-party service providers and in certain cases assess their security controls, we have limited oversight or control over their actions and practices. Several of our businesses act as business associates to their covered entity customers and, as a result, collect, use, disclose and maintain protected personal information in order to provide services to these customers. If HHS alleges or finds noncompliance with HIPAA privacy or security requirements, the allegations or findings could damage our reputation and subject us to monetary and other sanctions.

Through our Optum businesses, we maintain a database of administrative and clinical data statistically de-identified in accordance with HIPAA standards. Noncompliance or findings of noncompliance with applicable laws, regulations or requirements, or the occurrence of any privacy or security breach involving the misappropriation, loss or other unauthorized disclosure of protected personal information, whether by us or by one of our third-party service providers, could have an adverse effect on our reputation and business and, among other consequences, could subject us to mandatory disclosure to affected customers and the media, loss of existing or new customers, significant increases in the cost of managing and remediating privacy or security incidents, and could also result in significant fines, penalties and litigation awards. Any of these consequences could have a material and adverse effect on our results of operations, financial position and cash flows.

As an enterprise, we increasingly rely on new and evolving technologies, including those powered by or incorporating AI/ML, as part of our internal operations and in the delivery of our products and services. New technologies have potential and power to improve and optimize operational processes and clinical outcomes across the healthcare system, but also present ethical, technological, legal, regulatory and other risks. With respect to AI/ML, we have developed and implemented policies and procedures intended to promote and sustain responsible design, development, and use of AI/ML, consistent with industry best practices. Any inadequacy or failure in compliance with our responsible use of AI/ML policies and procedures or emerging laws, regulations and standards governing AI/ML use could cause our technology products not to operate as intended or to produce outcomes, including possible regulatory enforcement action or litigation that could have a material and adverse effect on our business, reputation, results of operations, financial position and cash flows.

Restrictions on our ability to obtain funds from our regulated subsidiaries could materially and adversely affect our ability to reinvest in our business, service our debt and return capital to our shareholders.

Because we operate as a holding company, we are dependent on dividends and administrative expense reimbursements from our subsidiaries to fund our obligations. Many of these subsidiaries are regulated by state departments of insurance or similar regulatory authorities. We are also required by law or regulation to maintain specific prescribed minimum amounts of capital in these subsidiaries. The levels of capitalization required depend primarily on the volume of premium revenues generated by the applicable subsidiary. In most states, we are required to seek approval by state regulatory authorities before we transfer money or pay dividends from our regulated subsidiaries exceeding specified amounts. An inability of our regulated subsidiaries to pay dividends to their parent companies in the desired amounts or at the time of our choosing could adversely affect our ability to reinvest in our business through capital expenditures or business acquisitions, as well as our ability to maintain our corporate quarterly dividend payment, repurchase shares of our common stock and repay our debt. If we are unable to obtain sufficient funds from our subsidiaries to fund our obligations, our results of operations, financial position and cash flows could be materially and adversely affected.

ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

ITEM 1C. CYBERSECURITY

UnitedHealth Group manages cybersecurity and data protection through a continuously evolving framework. The framework allows us to identify, assess and mitigate the risks we face, and assists us in establishing policies and safeguards to protect our systems and the information of those we serve.

Our cybersecurity program is managed by our Chief Digital and Technology Officer and our Chief Security Officer. The Audit and Finance Committee of the Board of Directors has oversight of our cybersecurity program and is responsible for reviewing and assessing the effectiveness of the Company's cybersecurity and data protection policies, procedures and resource commitment, including key risk areas and mitigation strategies. As part of this process, the Audit and Finance Committee receives regular updates from the Chief Digital and Technology Officer and the Chief Security Officer on critical issues related to our information security risks, cybersecurity strategy, supplier risk and business continuity capabilities. The Audit and Finance Committee has also added a leading cybersecurity incident and response firm to serve as its advisor on cybersecurity matters.

The Company's framework includes an incident management and response program that continuously monitors the Company's information systems for vulnerabilities, threats and incidents; manages and takes action to contain incidents that occur; remediates vulnerabilities; and communicates the details of significant threats and incidents to management, including the Chief Digital and Technology Officer and the Chief Security Officer, as deemed necessary or appropriate. Pursuant to the Company's incident response plan, incidents are reported to the Audit and Finance Committee and appropriate government agencies and other authorities, as deemed necessary or appropriate, considering the actual or potential impact, significance and scope.

We require our third-party partners and contractors to handle data in accordance with our data privacy and information security requirements and applicable laws. We regularly engage with our suppliers, partners, contractors, service providers and internal development teams to identify and remediate vulnerabilities in a timely manner and monitor system upgrades to mitigate future risk, and evaluate whether they employ appropriate and effective controls and continuity plans for their systems and operations.

To ensure that our program is designed and operating effectively, our infrastructure and information systems are audited periodically by internal and external auditors. We have obtained various certifications from industry-recognized certifying organizations as a result of certain external audits. We also perform regular vulnerability assessments and penetration tests to improve system security and address emerging security threats. Our internal audit team independently assesses security controls against our enterprise policies to evaluate compliance and leverages a combination of auditing and security frameworks to evaluate how leading practices are applied throughout our enterprise. Audit results and remediation progress are reported to and monitored by senior management and the Audit and Finance Committee. We also periodically partner with industry-leading cybersecurity firms to assess our cybersecurity program. These assessments complement our other assessment work by evaluating our cybersecurity program as a whole.

We complete an enterprise information risk assessment as part of our overall enterprise information security risk management assessment, which is overseen by our Chief Security Officer. This risk assessment is a review of internal and external threats that evaluates changes to the information risk landscape to inform the investments and program enhancements to be made in the future to rapidly respond and recover from potential attacks, including rebuild and recovery protocols for key systems. We evaluate our enterprise information security risk to address unexpected or unforeseen changes in the risk environment or our systems and the resulting impacts are communicated to the Company's overall enterprise risk management program.

We believe our Chief Digital and Technology Officer and our Chief Security Officer have the appropriate knowledge and expertise to effectively manage our cybersecurity program. The Chief Digital and Technology Officer has experience leading enterprise digital transformation efforts for a large multinational corporation and held several leadership and growth positions at a global technology consulting and services firm before joining UnitedHealth Group. Our Chief Security Officer has more than 30 years of experience as a security professional in both the private and public sectors, including in law enforcement. Prior to joining UnitedHealth Group, he served in security leadership roles at several large multinational corporations and has additionally served on cybersecurity advisory boards for some of the largest corporations in the country.

As of December 31, 2024, the Company has not identified any risks from cybersecurity threats that have materially affected or are reasonably likely to materially affect the Company, including our business strategy, results of operations or financial condition, but there can be no assurance that any such risk will not materially affect the Company in the future. For further information about the cybersecurity risks we face, and potential impacts, see Part I, Item 1A, "Risk Factors."

ITEM 2. PROPERTIES

We own and lease real properties to support our business operations in the United States and other countries. Our reportable segments use these facilities for their respective business purposes, and we believe the current facilities are suitable for their respective uses and are adequate for our anticipated future needs.

ITEM 3. LEGAL PROCEEDINGS

The information required by this Item 3 is incorporated herein by reference to the information set forth under the captions “Legal Matters” and “Government Investigations, Audits and Reviews” in Note 12 of the Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data”

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable.

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

MARKET AND HOLDERS

Our common stock is traded on the New York Stock Exchange (NYSE) under the symbol UNH. On January 31, 2025, there were 9,323 holders of record of our common stock.

DIVIDEND POLICY

In June 2024, our Board of Directors increased the Company’s quarterly cash dividend to shareholders to an annual rate of \$8.40 compared to \$7.52 per share, which the Company had paid since June 2023. Declaration and payment of future quarterly dividends is at the discretion of the Board and may be adjusted as business needs or market conditions change.

ISSUER PURCHASES OF EQUITY SECURITIES

Issuer Purchases of Equity Securities (a) Fourth Quarter 2024

For the Month Ended	Total Number of Shares Purchased	Average Price Paid Per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number of Shares That May Yet Be Purchased Under The Plans or Programs
	(in millions)		(in millions)	(in millions)
October 31, 2024	2.6	\$ 568.70	2.6	39.6
November 30, 2024	0.9	593.39	0.9	38.7
December 31, 2024	5.6	513.93	5.6	33.1
Total	<u>9.1</u>	<u>\$ 537.14</u>	<u>9.1</u>	


- (a) In November 1997, our Board of Directors adopted a share repurchase program, which the Board of Directors evaluates periodically. In June 2024, the Board of Directors amended our share repurchase program to authorize the repurchase of up to 35 million shares of our common stock in open market purchases or other types of transactions (including prepaid or structured repurchase programs), in addition to all remaining shares authorized to be repurchased under the Board’s 2018 renewal of the program. There is no established expiration date for the program. The Board of Directors from time to time may further amend the share repurchase program in order to increase the authorized number of shares which may be repurchased under the program.

PERFORMANCE GRAPH

The following performance graph compares the cumulative five-year total return to shareholders on our common stock relative to the cumulative total returns of the S&P 500 Health Care Index, the Dow Jones US Industrial Average Index and the S&P 500 Index for the five-year period ended December 31, 2024. The comparisons assume the investment of \$100 on December 31, 2019 in our common stock and in each index, and the reinvestment of dividends when paid.

COMPARISON OF 5 YEAR CUMULATIVE TOTAL RETURN

Among UnitedHealth Group, the S&P 500 Health Care Index, the Dow Jones US Industrial Average Index and the S&P 500 Index



	12/19	12/20	12/21	12/22	12/23	12/24
UnitedHealth Group	\$ 100.00	\$ 121.20	\$ 176.01	\$ 188.23	\$ 189.73	\$ 185.15
S&P 500 Health Care Index	100.00	113.45	143.09	140.29	143.18	146.87
Dow Jones US Industrial Average	100.00	109.72	132.71	123.60	143.60	165.12
S&P 500 Index	100.00	118.40	152.39	124.79	157.59	197.02

The stock price performance included in this graph is not necessarily indicative of future stock price performance. The preceding stock performance graph shall not be deemed incorporated by reference by any general statement incorporating by reference this Annual Report on Form 10-K into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates such information by reference, and shall not otherwise be deemed filed under such Acts.

ITEM 6. RESERVED

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read together with the accompanying Consolidated Financial Statements and Notes to the Consolidated Financial Statements thereto included in Part II Item 8, "Financial Statements and Supplementary Data." Readers are cautioned the statements, estimates, projections or outlook contained in this report, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item 7, may constitute forward-looking statements within the meaning of the PSLRA. These forward-looking statements involve risks and uncertainties which may cause our actual results to differ materially from the expectations expressed or implied in the forward-looking statements. A description of some of the risks and uncertainties can be found further below in this Item 7 and in Part I, Item 1A, "Risk Factors."

Discussions of year-over-year comparisons between 2023 and 2022 are not included in this Form 10-K and can be found in Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" of the Company's Form 10-K for the fiscal year ended December 31, 2023.

EXECUTIVE OVERVIEW

General

UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. Our two distinct, yet complementary businesses — Optum and UnitedHealthcare — are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations we are privileged to serve.

We have four reportable segments across our two businesses:

- Optum Health;
- Optum Insight;
- Optum Rx; and
- UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and UnitedHealthcare Community & State.

Further information on our business and reportable segments is presented in Part I, Item 1, "Business" and in Note 14 of the Notes to the Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data."

Change Healthcare Cyberattack

As previously announced, on February 21, 2024, we identified that cybercrime threat actors had gained access to certain Change Healthcare information technology systems. Upon detection of this outside threat, we isolated the impacted systems to protect our partners and customers.

We have substantially mitigated the impact to consumers and care providers of the unprecedented cyberattack on the U.S. health system and restored or replaced the majority of the affected Change Healthcare services. To support care providers we provided interest-free loans of more than \$9 billion through December 31, 2024. For the year ended December 31, 2024, we incurred \$2.2 billion of direct response costs, including costs associated with providing interest-free loans; increased medical care expenditures, as we suspended some care management activities to help care providers with their workflow processes; network restoration; and notifications of impacted persons. Optum Insight also experienced estimated business disruption impacts of \$867 million for the year ended December 31, 2024, reflecting lost revenue while maintaining full readiness of the affected Change Healthcare services. We expect to continue to incur direct response costs and experience business disruption impacts at a lesser extent in 2025 as we work to bring transaction volumes back to pre-event levels and win new business.

We have determined the estimated total number of individuals impacted by the Change Healthcare cyberattack is approximately 190 million. The vast majority of those people have already been provided individual or substitute notice. The final number will be confirmed and filed with the Office for Civil Rights. Change Healthcare is not aware of any misuse of individuals' information as a result of this incident and has not seen electronic medical record databases appear in the data during the analysis. It is possible that future risks and uncertainties resulting from the Change Healthcare cyberattack, including risks related to impacted data, litigation, reputational harm, and regulatory actions could adversely affect our financial condition or results of operations.

Business Trends

Our businesses participate in the United States and certain other international health markets. In the United States, health care spending has grown consistently for many years and comprises 18% of gross domestic product (GDP). We expect overall spending on health care to continue to grow in the future, due to inflation, medical technology and pharmaceutical advancement, regulatory requirements, demographic trends in the population and national interest in health and well-being. The rate of market growth may be affected by a variety of factors, including macroeconomic conditions, which could impact our results of operations, including our continued efforts to control health care costs.

Pricing Trends. To price our health care benefits, products and services, we start with our view of expected future costs, including medical care patterns, inflation and labor market dynamics. We frequently evaluate and adjust our approach in each of the local markets we serve, considering relevant factors, such as product positioning, price competitiveness and environmental, competitive, legislative and regulatory considerations, including minimum medical loss ratio (MLR) thresholds and similar revenue adjustments. We will continue seeking to balance growth and profitability across all these dimensions.

The commercial risk market remains highly competitive in the small group, large group and individual segments. We expect broad-based competition to continue as the industry adapts to individual and employer needs.

Medicare Advantage funding continues to be pressured, as discussed below in “Regulatory Trends and Uncertainties” and we have observed increased care patterns as discussed below in “Medical Cost Trends.” Our 2025 benefit design approach contemplates these trends.

In Medicaid, we believe the payment rate environment creates the risk of continued downward pressure on Medicaid margin percentages. We continue to take a prudent, market-sustainable posture for both new business and maintenance of existing relationships. We continue to advocate for actuarially sound rates commensurate with our medical cost trends and we remain dedicated to partnering with those states that are committed to the long-term viability of their programs.

Medical Cost Trends. Our medical cost trends primarily relate to changes in unit costs, care activity and prescription drug costs. As expected and contemplated in our benefits design, we have continued to observe increased care patterns, which may continue in future periods. We also observed an upshift in hospital coding intensity and an acceleration in the prescribing of certain high-cost medications in early response to the Inflation Reduction Act (IRA). We expect these additional factors to continue into future periods. We endeavor to mitigate those increases by engaging hospitals, physicians and consumers with information and helping them make clinically sound choices, with the objective of helping them achieve high-quality, affordable care.

As a result of the Change Healthcare cyberattack, we incurred medical costs related to the impact of the temporary suspension of some care management activities, impacting our UnitedHealthcare and Optum Health businesses, to help care providers with their workflow processes. Early in the second quarter we resumed these activities. For the year ended December 31, 2024, medical costs related to the temporary suspension of some care management activities were approximately \$640 million.

Medicaid Redeterminations. Medicaid redeterminations have impacted the number of people served through our Medicaid offerings, partially offset by an increase in consumers served through our commercial offerings as we endeavor to ensure that people and families have continued access to care. The Medicaid redetermination process has also caused a timing mismatch between the current health status of people served through Medicaid and state rate updates, which remained well short of current care activity. We expect this gap between people’s health status and rates will narrow in 2025.

Delivery System and Payment Modernization. The health care market continues to change based on demographic shifts, new regulations, political forces and both payer and patient expectations. Health plans and care providers are being called upon to work together to close gaps in care and improve overall care quality and patient experience, improve the health of populations and reduce costs. We are working to accelerate this vision through the innovation and integration of our care delivery models including in-clinic, in-home, behavioral and virtual care, and by using our data and analytics to provide clinicians with the necessary information in order to provide the best possible care in the most cost efficient setting. We continue to see a greater number of people enrolled in fully accountable value-based plans rewarding high-quality, affordable care and fostering collaboration.

This trend is creating needs for health management services which can coordinate care around the primary care physician, including new primary care channels, and for investments in new clinical and administrative information and management systems, which we believe provide growth opportunities for our Optum business platform. A key focus of our future growth is to accelerate the transition from fee-for-service care delivery and payment models to fully accountable value-based care. This transition requires initial costs such as system enhancements, integrated care coordination technology, physician training and clinical engagement. Enhanced clinical engagement is a critical step to improving the experience and health outcomes of the people we serve and should result in lower costs to the overall health system over time.

Regulatory Trends and Uncertainties

Following is a summary of management's view of the trends and uncertainties related to regulatory matters. For additional information regarding regulatory trends and uncertainties, see Part I, Item 1 "Business - Government Regulation" and Item 1A, "Risk Factors."

Medicare Advantage Rates. Medicare Advantage rate notices over the years have at times resulted in industry base rates well below industry forward medical trend. For example, the Final Notice for 2024 and 2025 rates resulted in an industry base rate decrease, both of which are well short of what is an increasing industry forward medical cost trend. The Advance Notice for 2026 rates proposes an industry base rate increase also well short of forward medical cost trend, creating continued pressure in the Medicare Advantage program. Further, substantial revisions to the risk adjustment model, which serves to adjust rates to reflect a patient's health status and care resource needs, will result in reduced funding and potentially benefits for people, especially those with some of the greatest health and social challenges.

As a result of ongoing Medicare funding pressures, there are adjustments we can make to partially offset these rate pressures and reductions for a particular period. For example, we can seek to intensify our medical and operating cost management, make changes to the size and composition of our care provider networks, adjust member benefits and implement or increase the member premiums supplementing the monthly payments we receive from the government. Additionally, we decide annually on a county-by-county basis where we will offer Medicare Advantage plans.

SELECTED OPERATING PERFORMANCE ITEMS

The following summarizes select 2024 year-over-year operating comparisons to 2023 and other financial results.

- Consolidated revenues grew 8%, UnitedHealthcare revenues grew 6% and Optum revenues grew 12%.
- UnitedHealthcare served 2.1 million more people domestically, driven by growth in commercial offerings, partially offset by the impact of Medicaid redeterminations.
- Earnings from operations of \$32.3 billion compared to \$32.4 billion last year.
- Diluted earnings per common share was \$15.51, impacted by the loss on sale of subsidiary and subsidiaries held for sale.
- Cash flows from operations were \$24.2 billion.

RESULTS SUMMARY

The following table summarizes our consolidated results of operations and other financial information:

(in millions, except percentages and per share data)	For the Years Ended December 31,			Change	
	2024	2023	2022	2024 vs. 2023	
Revenues:					
Premiums	\$ 308,810	\$ 290,827	\$ 257,157	\$ 17,983	6%
Products	50,226	42,583	37,424	7,643	18
Services	36,040	34,123	27,551	1,917	6
Investment and other income	5,202	4,089	2,030	1,113	27
Total revenues	400,278	371,622	324,162	28,656	8
Operating costs:					
Medical costs	264,185	241,894	210,842	22,291	9
Operating costs	53,013	54,628	47,782	(1,615)	(3)
Cost of products sold	46,694	38,770	33,703	7,924	20
Depreciation and amortization	4,099	3,972	3,400	127	3
Total operating costs	367,991	339,264	295,727	28,727	8
Earnings from operations	32,287	32,358	28,435	(71)	—
Interest expense	(3,906)	(3,246)	(2,092)	(660)	20
Loss on sale of subsidiary and subsidiaries held for sale	(8,310)	—	—	(8,310)	nm
Earnings before income taxes	20,071	29,112	26,343	(9,041)	(31)
Provision for income taxes	(4,829)	(5,968)	(5,704)	1,139	(19)
Net earnings	15,242	23,144	20,639	(7,902)	(34)
Earnings attributable to noncontrolling interests	(837)	(763)	(519)	(74)	10
Net earnings attributable to UnitedHealth Group common shareholders	\$ 14,405	\$ 22,381	\$ 20,120	\$ (7,976)	(36)%
Diluted earnings per share attributable to UnitedHealth Group common shareholders	\$ 15.51	\$ 23.86	\$ 21.18	\$ (8.35)	(35)%
Medical care ratio (a)	85.5 %	83.2 %	82.0 %	2.3 %	
Operating cost ratio	13.2	14.7	14.7	(1.5)	
Operating margin	8.1	8.7	8.8	(0.6)	
Tax rate	24.1	20.5	21.7	3.6	
Net earnings margin (b)	3.6	6.0	6.2	(2.4)	
Return on equity (c)	15.9 %	27.0 %	27.2 %	(11.1)%	

nm = not meaningful

(a) Medical care ratio (MCR) is calculated as medical costs divided by premium revenue.

(b) Net earnings margin attributable to UnitedHealth Group common shareholders.

(c) Return on equity is calculated as net earnings attributable to UnitedHealth Group common shareholders divided by average shareholders' equity. Average shareholders' equity is calculated using the shareholders' equity balance at the end of the preceding year and the shareholders' equity balances at the end of each of the four quarters of the year presented.

2024 RESULTS OF OPERATIONS COMPARED TO 2023 RESULTS

Consolidated Financial Results

Revenues

The increases in revenues were primarily driven by growth in Optum Rx, UnitedHealthcare's domestic offerings and Optum Health, partially offset by the sale of UnitedHealthcare's Brazil operations.

Medical Costs and MCR

Medical costs increased primarily due to growth in people served through Medicare Advantage and domestic commercial offerings and member mix. The MCR increased as a result of the revenue effects of the Medicare funding reductions, Medicaid timing mismatch between people's health status and rates, upshift in hospital coding intensity, specialty pharmaceutical prescribing patterns, member mix and due to incremental medical costs for accommodations made to care providers as a result of the Change Healthcare cyberattack.

Operating Cost Ratio

The operating cost ratio decreased primarily due to operating cost management and gains related to business portfolio refinement, including strategic transactions, partially offset by the impact of our direct response efforts to the Change Healthcare cyberattack and investments to support future growth.

Loss on Sale of Subsidiary and Subsidiaries Held for Sale

On February 6, 2024, the Company completed the sale of its Brazil operations. During the year ended December 31, 2024, we recorded a loss of \$7.1 billion, of which \$4.1 billion related to the impact of cumulative foreign currency translation losses previously included in accumulated other comprehensive loss.

In the second quarter of 2024, the Company initiated a plan to sell its remaining South American operations, which were classified as held for sale as of December 31, 2024. During the year ended December 31, 2024, we recorded a loss of \$1.2 billion, of which \$855 million related to the impact of cumulative foreign currency translation losses.

Reportable Segments

See Note 14 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” for more information on our segments. We utilize various metrics to evaluate and manage our reportable segments, including individuals served by UnitedHealthcare by major market segment and funding arrangement, people served by Optum Health and adjusted scripts for Optum Rx. These metrics are the main drivers of revenue, earnings and cash flows at each business. The metrics also allow management and investors to evaluate and understand business mix, including the level and scope of services provided to people and pricing trends when comparing the metrics to revenue by segment.

The following table presents a summary of the reportable segment financial information:

(in millions, except percentages)	For the Years Ended December 31,			Change	
	2024	2023	2022	2024 vs. 2023	
Revenues					
UnitedHealthcare	\$ 298,208	\$ 281,360	\$ 249,741	\$ 16,848	6%
Optum Health	105,358	95,319	71,174	10,039	11
Optum Insight	18,757	18,932	14,581	(175)	(1)
Optum Rx	133,231	116,087	99,773	17,144	15
Optum eliminations	(4,389)	(3,703)	(2,760)	(686)	19
Optum	252,957	226,635	182,768	26,322	12
Eliminations	(150,887)	(136,373)	(108,347)	(14,514)	11
Consolidated revenues	<u>\$ 400,278</u>	<u>\$ 371,622</u>	<u>\$ 324,162</u>	<u>\$ 28,656</u>	8%
Earnings from operations					
UnitedHealthcare	\$ 15,584	\$ 16,415	\$ 14,379	\$ (831)	(5)%
Optum Health	7,770	6,560	6,032	1,210	18
Optum Insight	3,097	4,268	3,588	(1,171)	(27)
Optum Rx	5,836	5,115	4,436	721	14
Optum	16,703	15,943	14,056	760	5
Consolidated earnings from operations	<u>\$ 32,287</u>	<u>\$ 32,358</u>	<u>\$ 28,435</u>	<u>\$ (71)</u>	— %
Operating margin					
UnitedHealthcare	5.2 %	5.8 %	5.8 %	(0.6)%	
Optum Health	7.4	6.9	8.5	0.5	
Optum Insight	16.5	22.5	24.6	(6.0)	
Optum Rx	4.4	4.4	4.4	—	
Optum	6.6	7.0	7.7	(0.4)	
Consolidated operating margin	8.1 %	8.7 %	8.8 %	(0.6)%	

UnitedHealthcare

The following table summarizes UnitedHealthcare revenues by business:

(in millions, except percentages)	For the Years Ended December 31,			Change	
	2024	2023	2022	2024 vs. 2023	
UnitedHealthcare Employer & Individual - Domestic	\$ 74,489	\$ 67,187	\$ 63,599	\$ 7,302	11 %
UnitedHealthcare Employer & Individual - Global	3,667	9,307	8,668	(5,640)	(61)
UnitedHealthcare Employer & Individual - Total	78,156	76,494	72,267	1,662	2
UnitedHealthcare Medicare & Retirement	139,482	129,862	113,671	9,620	7
UnitedHealthcare Community & State	80,570	75,004	63,803	5,566	7
Total UnitedHealthcare revenues	<u>\$ 298,208</u>	<u>\$ 281,360</u>	<u>\$ 249,741</u>	<u>\$ 16,848</u>	<u>6 %</u>

The following table summarizes the number of individuals served by our UnitedHealthcare businesses, by major market segment and funding arrangement:

(in thousands, except percentages)	December 31,			Change	
	2024	2023	2022	2024 vs. 2023	
Commercial - domestic:					
Risk-based	8,845	8,115	8,045	730	9 %
Fee-based	20,885	19,200	18,640	1,685	9
Total commercial - domestic	29,730	27,315	26,685	2,415	9
Medicare Advantage	7,845	7,695	7,105	150	2
Medicaid	7,435	7,845	8,170	(410)	(5)
Medicare Supplement (Standardized)	4,335	4,355	4,375	(20)	—
Total community and senior	19,615	19,895	19,650	(280)	(1)
Total UnitedHealthcare - domestic medical	49,345	47,210	46,335	2,135	5
Commercial - global	1,330	5,540	5,360	(4,210)	(76)
Total UnitedHealthcare - medical	<u>50,675</u>	<u>52,750</u>	<u>51,695</u>	<u>(2,075)</u>	<u>(4)%</u>
Supplemental Data:					
Medicare Part D stand-alone	3,050	3,315	3,295	(265)	(8)%

UnitedHealthcare's revenues increased due to growth in the number of people served through Medicare Advantage and domestic commercial offerings, partially offset by decreased people served globally due to the sale of the Brazil operations and in Medicaid offerings due to redeterminations. Earnings from operations decreased due to Medicare Advantage funding reductions, the impacts of Medicaid redeterminations, member mix and incremental medical costs for accommodations to support care providers as a result of the Change Healthcare cyberattack, partially offset by gains related to business portfolio refinement, including strategic transactions, and the growth in the number of people served through Medicare Advantage and domestic commercial offerings.

Optum

Total revenues increased due to growth at Optum Rx and Optum Health. Earnings from operations increased with growth at Optum Health and Optum Rx, partially offset by decreased earnings from operations at Optum Insight. The results by segment were as follows:

Optum Health

Revenues at Optum Health increased primarily due to organic growth in patients served under value-based care arrangements. Earnings from operations increased due to gains related to business portfolio refinement, including strategic transactions, increased investment income and cost management initiatives, partially offset by Medicare Advantage funding reductions, costs associated with serving newly added patients under value-based care arrangements and medical care activity. Optum Health served approximately 100 million people as of December 31, 2024 compared to 103 million people as of December 31, 2023.

Optum Insight

Revenues at Optum Insight decreased primarily due the business disruption impacts from the Change Healthcare cyberattack, partially offset by growth in technology services. Earnings from operations decreased primarily due to direct response costs and business disruption impacts related to the Change Healthcare cyberattack, partially offset by gains related to business portfolio refinement, including strategic transactions.

Optum Rx

Revenues and earnings from operations at Optum Rx increased due to higher script volumes from both new clients and growth in existing clients and growth in pharmacy services. Earnings from operations also increased due to operating cost efficiencies and supply chain initiatives. Optum Rx fulfilled 1,623 million and 1,542 million adjusted scripts in 2024 and 2023, respectively.

LIQUIDITY, FINANCIAL CONDITION AND CAPITAL RESOURCES

Liquidity

Introduction

We manage our liquidity and financial position in the context of our overall business strategy. We continually forecast and manage our cash, investments, working capital balances and capital structure to meet the short-term and long-term obligations of our businesses while seeking to maintain liquidity and financial flexibility. Cash flows generated from operating activities are principally derived from earnings before noncash expenses.

Our regulated subsidiaries generate significant cash flows from operations and are subject to, among other things, minimum levels of statutory capital, as defined by their respective jurisdictions, and restrictions on the timing and amount of dividends paid to their parent companies.

Our U.S. regulated subsidiaries paid their parent companies dividends of \$9.2 billion and \$8.0 billion in 2024 and 2023, respectively. See Note 10 of the Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” for further detail concerning our regulated subsidiary dividends.

Our nonregulated businesses also generate significant cash flows from operations available for general corporate use. Cash flows generated by these entities, combined with dividends from our regulated entities and financing through the issuance of long-term debt as well as issuance of commercial paper or the ability to draw under our committed credit facilities, further strengthen our operating and financial flexibility. We use these cash flows to expand our businesses through acquisitions, reinvest in our businesses through capital expenditures, repay debt and return capital to our shareholders through dividends and repurchases of our common stock.

Summary of our Major Sources and Uses of Cash and Cash Equivalents

(in millions)	For the Years Ended December 31,			Change
	2024	2023	2022	2024 vs. 2023
Sources of cash:				
Cash provided by operating activities	\$ 24,204	\$ 29,068	\$ 26,206	\$ (4,864)
Issuances of long-term debt and short-term borrowings, net of repayments	14,660	4,280	12,536	10,380
Proceeds from common share issuances	1,846	1,353	1,253	493
Customer funds administered	—	—	5,548	—
Cash received for dispositions	2,041	685	3,414	1,356
Sales and maturities of investments, net of purchases	525	—	—	525
Total sources of cash	43,276	35,386	48,957	7,890
Uses of cash:				
Cash paid for acquisitions and other transactions, net of cash assumed	(13,408)	(10,136)	(21,458)	(3,272)
Common share repurchases	(9,000)	(8,000)	(7,000)	(1,000)
Cash dividends paid	(7,533)	(6,761)	(5,991)	(772)
Purchases of property, equipment and capitalized software	(3,499)	(3,386)	(2,802)	(113)
Purchases of investments, net of sales and maturities	—	(1,777)	(6,837)	1,777
Purchases of redeemable noncontrolling interests	(280)	(730)	(176)	450
Loans to care providers - cyberattack, net of repayments	(4,519)	—	—	(4,519)
Customer funds administered	(1,560)	(521)	—	(1,039)
Other	(3,312)	(2,110)	(2,737)	(1,202)
Total uses of cash	(43,111)	(33,421)	(47,001)	(9,690)
Effect of exchange rate changes on cash and cash equivalents	(61)	97	34	(158)
Net increase in cash and cash equivalents, including cash within businesses held for sale	\$ 104	\$ 2,062	\$ 1,990	\$ (1,958)
Less: cash within businesses held for sale	(219)	—	—	(219)
Net (decrease) increase in cash and cash equivalents	\$ (115)	\$ 2,062	\$ 1,990	\$ (2,177)

2024 Cash Flows Compared to 2023 Cash Flows

Decreased cash flows provided by operating activities were primarily driven by CMS Medicare funding reductions, Change Healthcare cyberattack response actions, increased medical costs and changes in working capital accounts. Other significant changes in sources or uses of cash year-over-year included increased net issuances of short-term borrowings and long-term debt, net sales and maturities of investments and cash received from dispositions, offset by loans to care providers in response to the Change Healthcare cyberattack, increased cash paid for acquisitions and other transactions, decreased customer funds administered and increased share repurchases.

Financial Condition

As of December 31, 2024, our cash, cash equivalent, available-for-sale debt securities and equity securities balances of \$77.1 billion included \$25.3 billion of cash and cash equivalents (of which approximately \$800 million was available for general corporate use), \$46.9 billion of debt securities and \$4.9 billion of equity securities. Given the significant portion of our portfolio held in cash equivalents, we do not anticipate fluctuations in the aggregate fair value of our financial assets to have a material impact on our liquidity or capital position. Other sources of liquidity, primarily from operating cash flows and our commercial paper program, which is fully supported by our bank credit facilities, reduce the need to sell investments during adverse market conditions. See Note 4 of the Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” for further detail concerning our fair value measurements.

Our available-for-sale debt portfolio had a weighted-average duration of 4.2 years and a weighted-average credit rating of “Double A” as of December 31, 2024. When multiple credit ratings are available for an individual security, the average of the available ratings is used to determine the weighted-average credit rating.

Capital Resources and Uses of Liquidity

Cash Requirements. The Company's cash requirements within the next twelve months include medical costs payable, accounts payable and accrued liabilities, short-term borrowings and current maturities of long-term debt, other current liabilities, and purchase commitments and other obligations. We expect the cash required to meet these obligations to be primarily generated through cash flows from current operations; cash available for general corporate use; and the realization of current assets, such as accounts receivable.

Our long-term cash requirements under our various contractual obligations and commitments include:

- *Debt obligations.* See Note 8 of the Notes to the Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" for further detail of our long-term debt and the timing of expected future payments. Interest coupon payments are typically paid semi-annually.
- *Operating leases.* See Note 12 of the Notes to the Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" for further detail of our obligations and the timing of expected future payments.
- *Purchase and other obligations.* These include \$11.5 billion, \$2.4 billion of which is expected to be paid within the next twelve months, of fixed or minimum commitments under existing purchase obligations for goods and services, including agreements cancelable with the payment of an early termination penalty, and remaining capital commitments for venture capital funds, strategic transactions and other funding commitments. These amounts exclude agreements cancelable without penalty and liabilities to the extent recorded in our Consolidated Balance Sheets as of December 31, 2024.
- *Other liabilities.* These include other long-term liabilities reflected in our Consolidated Balance Sheets as of December 31, 2024, including obligations associated with certain employee benefit programs, unrecognized tax benefits and various long-term liabilities, which have some inherent uncertainty in the timing of these payments.
- *Redeemable noncontrolling interests.* See Note 2 of the Notes to the Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" for further detail. We do not have any material potential required redemptions in the next twelve months.

We expect the cash required to meet our long-term obligations to be primarily generated through future cash flows from operations. However, we also have the ability to generate cash to satisfy both our current and long-term requirements through the issuance of commercial paper, issuance of long-term debt, or drawing under our committed credit facilities or the ability to sell investments. We believe our capital resources are sufficient to meet future, short-term and long-term, liquidity needs.

Short-Term Borrowings. Our revolving bank credit facilities provide liquidity support for our commercial paper borrowing program, which facilitates the private placement of senior unsecured debt through independent broker-dealers, and are available for general corporate purposes. For more information on our commercial paper and bank credit facilities, see Note 8 of the Notes to the Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data."

As of December 31, 2024, we were in compliance with the various covenants under our bank credit facilities.

Long-Term Debt. Periodically, we access capital markets to issue long-term debt for general corporate purposes, such as to meet our working capital requirements, to refinance debt, to finance acquisitions or for share repurchases. For more information on our debt, see Note 8 of the Notes to the Consolidated Financial Statements included in Part II, Item 8 "Financial Statements and Supplementary Data."

Credit Ratings. Our credit ratings as of December 31, 2024 were as follows:

	Moody's		S&P Global		Fitch		A.M. Best	
	Ratings	Outlook	Ratings	Outlook	Ratings	Outlook	Ratings	Outlook
Senior unsecured debt.....	A2	Stable	A+	Stable	A	Stable	A	Stable
Commercial paper.....	P-1	n/a	A-1	n/a	F1	n/a	AMB-1+	n/a

The availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions, regulatory requirements and economic and market conditions. A significant downgrade in our credit ratings or adverse conditions in the capital markets may increase the cost of borrowing for us or limit our access to capital.

Share Repurchase Program. In June 2024, our Board of Directors amended our share repurchase program to authorize the repurchase of up to 35 million shares of Common Stock, in addition to all remaining shares authorized to be repurchased under the Board's 2018 renewal of the program. As of December 31, 2024, we had Board of Directors' authorization to purchase up to 33 million shares of our common stock. The Board of Directors from time to time may further amend the share repurchase program in order to increase the authorized number of shares which may be repurchased under the program. For more information on our share repurchase program, see Note 10 of the Notes to the Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data."

Dividends. In June 2024, our Board of Directors increased the Company's quarterly cash dividend to shareholders to an annual rate of \$8.40 compared to \$7.52 per share. For more information on our dividend, see Note 10 of the Notes to the Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data."

Pending Acquisitions. As of December 31, 2024, we have entered into agreements to acquire companies in the health care sector, subject to regulatory approval and other customary closing conditions. The total anticipated capital required for these acquisitions, excluding the payoff of acquired indebtedness, is approximately \$4 billion.

We do not have other significant contractual obligations or commitments requiring cash resources. However, we continually evaluate opportunities to expand our operations, which include internal development of new products, programs and technology applications and may include acquisitions.

CRITICAL ACCOUNTING ESTIMATES

Critical accounting estimates are those estimates requiring management to make challenging, subjective or complex judgments, often because they must estimate the effects of matters inherently uncertain and may change in subsequent periods. Critical accounting estimates involve judgments and uncertainties which are sufficiently sensitive and may result in materially different results under different assumptions and conditions.

Medical Costs Payable

Medical costs and medical costs payable include estimates of our obligations for medical care services rendered on behalf of consumers, but for which claims have either not yet been received or processed. Depending on the health care professional and type of service, the typical billing lag for services can be up to 90 days from the date of service. Approximately 90% of claims related to medical care services are known and settled within 90 days from the date of service.

In each reporting period, our operating results include the effects of more completely developed medical costs payable estimates associated with previously reported periods. If the revised estimate of prior period medical costs is less than the previous estimate, we will decrease reported medical costs in the current period (favorable development). If the revised estimate of prior period medical costs is more than the previous estimate, we will increase reported medical costs in the current period (unfavorable development). Medical costs in 2024, 2023 and 2022 included favorable medical cost development related to prior years of \$700 million, \$840 million and \$410 million, respectively.

In developing our medical costs payable estimates, we apply different estimation methods depending on the month for which incurred claims are being estimated. For example, for the most recent two months, we estimate claim costs incurred by applying observed medical cost trend factors to the average per member per month (PMPM) medical costs incurred in prior months for which more complete claim data is available, supplemented by a review of near-term completion factors.

Completion Factors. A completion factor is an actuarial estimate, based upon historical experience and analysis of current trends, of the percentage of incurred claims during a given period adjudicated by us at the date of estimation. Completion factors are the most significant factors we use in developing our medical costs payable estimates for periods prior to the most recent two months. Completion factors include judgments in relation to claim submissions such as the time from date of service to claim receipt, claim levels and processing cycles, as well as other factors. If actual claims submission rates from providers (which can be influenced by a number of factors, including provider mix and electronic versus manual submissions), actual care activity incurred (which can be influenced by pandemics or seasonal illnesses, such as influenza), or our claim processing patterns are different than estimated, our reserve estimates may be significantly impacted.

The following table illustrates the sensitivity of these factors and the estimated potential impact on our medical costs payable estimates for those periods as of December 31, 2024:

Completion Factors (Decrease) Increase in Factors	Increase (Decrease) In Medical Costs Payable (in millions)
(0.75)%	\$ 973
(0.50)	647
(0.25)	322
0.25	(321)
0.50	(640)
0.75	(958)

Medical Cost Per Member Per Month Trend Factors. Medical cost PMPM trend factors are significant factors we use in developing our medical costs payable estimates for the most recent two months. Medical cost trend factors are developed through a comprehensive analysis of claims incurred in prior months, provider contracting and expected unit costs, benefit design and a review of a broad set of health care utilization indicators. These factors include but are not limited to pharmacy utilization trends, inpatient hospital authorization data and seasonal and other incidence data from the National Centers for Disease Control. We also consider macroeconomic variables such as GDP growth, employment and disposable income. A large number of factors can cause the medical cost trend to vary from our estimates, including: our ability and practices to manage medical and pharmaceutical costs, changes in level and mix of services utilized; mix of benefits offered, including the impact of co-pays and deductibles; changes in medical practices; and catastrophes, epidemics and pandemics.

The following table illustrates the sensitivity of these factors and the estimated potential impact on our medical costs payable estimates for the most recent two months as of December 31, 2024:

Medical Cost PMPM Quarterly Trend Increase (Decrease) in Factors	Increase (Decrease) In Medical Costs Payable (in millions)
3%	\$ 1,264
2	843
1	421
(1)	(421)
(2)	(843)
(3)	(1,264)

The completion factors and medical costs PMPM trend factors analyses above include outcomes considered reasonably likely based on our historical experience estimating liabilities for incurred but not reported benefit claims.

Management believes the amount of medical costs payable is reasonable and adequate to cover our liability for unpaid claims as of December 31, 2024; however, actual claim payments may differ from established estimates as discussed above. Assuming a hypothetical 1% difference between our December 31, 2024 estimates of medical costs payable and actual medical costs payable, 2024 net earnings would have increased or decreased by approximately \$260 million.

For more detail related to our medical cost estimates, see Note 2 of the Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data.”

Goodwill

We evaluate goodwill for impairment annually or more frequently when an event occurs or circumstances change indicating the carrying value may not be recoverable. When testing goodwill for impairment, we may first assess qualitative factors to determine if it is more likely than not the carrying value of a reporting unit exceeds its estimated fair value. During a qualitative analysis, we consider the impact of changes, if any, to the following factors: macroeconomic, industry and market factors; cost factors; changes in overall financial performance; and any other relevant events and uncertainties impacting a reporting unit. If our qualitative assessment indicates a goodwill impairment is more likely than not, we perform additional quantitative analyses. We may also elect to skip the qualitative testing and proceed directly to the quantitative testing. For reporting units where a quantitative analysis is performed, we perform a test measuring the fair values of the reporting units and comparing them to their carrying values, including goodwill. If the fair value is less than the carrying value of the reporting unit, an impairment is recognized for the difference, up to the carrying amount of goodwill.

We estimate the fair values of our reporting units using a discounted cash flow method which includes assumptions about a wide variety of internal and external factors. Significant assumptions used in the discounted cash flow method include financial projections of free cash flow, including revenue trends, medical costs trends, operating productivity, income taxes and capital levels; long-term growth rates for determining terminal value beyond the discretely forecasted periods; and discount rates. For each reporting unit, comparative market multiples are used to corroborate the results of our discounted cash flow test.

Financial projections and long-term growth rates used for our reporting units are consistent with, and use inputs from, our internal long-term business plan and strategies. Discount rates are determined for each reporting unit and include consideration of the implied risk inherent in their forecasts. Our most significant estimate in the discount rate determinations involves our adjustments to the peer company weighted average costs of capital reflecting reporting unit-specific factors. We have not made any adjustments to decrease a discount rate below the calculated peer company weighted average cost of capital for any reporting unit. Company-specific adjustments to discount rates are subjective and thus are difficult to measure with certainty. The passage of time and the availability of additional information regarding areas of uncertainty with respect to the reporting units' operations could cause these assumptions to change in the future. Additionally, as part of our quantitative impairment testing, we perform various sensitivity analyses on certain key assumptions, such as discount rates and cash flow projections to analyze the potential for a material impact. As of October 1, 2024, we completed our annual impairment tests for goodwill with all of our reporting units having fair values substantially in excess of their carrying values.

LEGAL MATTERS

A description of our legal proceedings is presented in Note 12 of Notes to the Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data."

CONCENTRATIONS OF CREDIT RISK

Investments in financial instruments such as marketable securities and accounts receivable may subject us to concentrations of credit risk. Our investments in marketable securities are managed under an investment policy authorized by our Board of Directors. This policy limits the amounts which may be invested in any one issuer and generally limits our investments to U.S. government and agency securities, state and municipal securities and corporate debt obligations of investment grade. Concentrations of credit risk with respect to accounts receivable are limited due to the large number of employer groups and other customers constituting our client base. As of December 31, 2024, there were no significant concentrations of credit risk.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our primary market risks are exposures to changes in interest rates impacting our investment income and interest expense and the fair value of certain of our fixed-rate investments and debt.

As of December 31, 2024, we had \$33 billion of financial assets on which the interest rates received vary with market interest rates, which may significantly impact our investment income. Also as of December 31, 2024, \$27 billion of our financial liabilities, which include debt and deposit liabilities, were at interest rates which vary with market rates, either directly or through the use of related interest rate swap contracts.

The fair value of our fixed-rate investments and debt also varies with market interest rates. As of December 31, 2024, \$46 billion of our investments were fixed-rate debt securities and \$49 billion of our debt was non-swapped fixed-rate term debt. An increase in market interest rates decreases the market value of fixed-rate investments and fixed-rate debt. Conversely, a decrease in market interest rates increases the market value of fixed-rate investments and fixed-rate debt.

We manage exposure to market interest rates by diversifying investments across different fixed-income market sectors and debt across maturities, as well as by matching a portion of our floating-rate assets and liabilities, either directly or through the use of interest rate swap contracts. Unrealized gains and losses on investments in available-for-sale debt securities are reported in comprehensive income.

The following tables summarize the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of December 31, 2024 and 2023 on our investment income and interest expense per annum and the fair value of our investments and debt (in millions, except percentages):

December 31, 2024				
Increase (Decrease) in Market Interest Rate	Investment Income Per Annum	Interest Expense Per Annum	Fair Value of Financial Assets	Fair Value of Financial Liabilities
2 %	\$ 666	\$ 537	\$ (4,151)	\$ (8,866)
1	333	268	(2,182)	(4,828)
(1)	(333)	(252)	2,082	5,831
(2)	(666)	(503)	4,311	12,935
December 31, 2023				
Increase (Decrease) in Market Interest Rate	Investment Income Per Annum	Interest Expense Per Annum	Fair Value of Financial Assets	Fair Value of Financial Liabilities
2%	\$ 688	\$ 393	\$ (3,642)	\$ (8,142)
1	344	196	(1,871)	(4,444)
(1)	(344)	(180)	1,954	5,391
(2)	(688)	(360)	3,964	11,992

Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on the fair value of financial assets and liabilities as the rates are assumed to not fall below zero.

As of December 31, 2024, we had \$4.9 billion of investments in equity securities, primarily consisting of venture investments and employee savings plan related investments.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

	<u>Page</u>
Report of Independent Registered Public Accounting Firm (PCAOB ID No 34)	38
Consolidated Balance Sheets	40
Consolidated Statements of Operations	41
Consolidated Statements of Comprehensive Income	42
Consolidated Statements of Changes in Equity	43
Consolidated Statements of Cash Flows	44
Notes to the Consolidated Financial Statements	45
1. Description of Business	45
2. Basis of Presentation, Use of Estimates and Significant Accounting Policies	45
3. Investments	50
4. Fair Value	51
5. Property, Equipment and Capitalized Software	54
6. Goodwill and Other Intangible Assets	54
7. Medical Costs Payable	55
8. Short-Term Borrowings and Long-Term Debt	57
9. Income Taxes	58
10. Shareholders' Equity	60
11. Share-Based Compensation	61
12. Commitments and Contingencies	63
13. Dispositions and Held for Sale	64
14. Segment Financial Information	65

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the shareholders and the Board of Directors of UnitedHealth Group Incorporated and Subsidiaries:

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of UnitedHealth Group Incorporated and Subsidiaries (the “Company”) as of December 31, 2024 and 2023, the related consolidated statements of operations, comprehensive income, changes in equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 27, 2025 expressed an unqualified opinion on the Company’s internal control over financial reporting.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the Audit and Finance Committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Medical Care Services Incurred but not Reported (IBNR) - Refer to Notes 2 and 7 to the financial statements.

Critical Audit Matter Description

Medical costs payable includes estimates of the Company’s obligations for medical care services rendered on behalf of insured consumers, for which claims have either not yet been received or processed. The Company develops estimates for medical care services incurred but not reported (IBNR) using an actuarial model that requires management to exercise certain judgments in developing its estimates. Judgments made by management include medical cost per member per month trend factors and completion factors, which include assumptions over the time from date of service to claim receipt, the impact of actual care activity, and processing cycles.

We identified medical care services IBNR as a critical audit matter because it requires significant management assumptions in estimating the liability. This required complex auditor judgment, and an increased extent of effort, including the involvement of actuarial specialists in performing procedures to evaluate the reasonableness of management’s methods, assumptions, and judgments in developing estimates for medical care services IBNR.

How the Critical Audit Matter Was Addressed in the Audit

Our audit procedures related to medical care services IBNR included the following, among others:

- We tested the effectiveness of controls over management’s estimate of the IBNR for these services, including controls over the judgments in both the completion factors and the medical cost per member per month trend factors, as well as controls over the claims and membership data used in the estimation process.
- We tested the underlying claims and membership data and other information that served as the basis for the actuarial analysis, to test that the inputs to the actuarial estimate were complete and accurate.
- With the assistance of actuarial specialists, we evaluated the reasonableness of the actuarial methods and assumptions used by management to estimate IBNR for these services by:
 - Performing an overlay of the historical claims data used in management’s current year model to the data used in prior periods to validate that there were no material changes to the claims data tested in prior periods.
 - Developing an independent estimate of the IBNR for these services and comparing our estimate to management’s estimate.
 - Performing a retrospective review comparing management’s prior year estimate of IBNR to claims processed in 2024 with dates of service in 2023 or prior.

/s/ DELOITTE & TOUCHE LLP

Minneapolis, Minnesota

February 27, 2025

We have served as the Company's auditor since 2002.

UnitedHealth Group
Consolidated Balance Sheets

(in millions, except per share data)	December 31, 2024	December 31, 2023
Assets		
Current assets:		
Cash and cash equivalents	\$ 25,312	\$ 25,427
Short-term investments	3,801	4,201
Accounts receivable, net of allowances of \$985 and \$1,000	22,365	21,276
Other current receivables, net of allowances of \$2,864 and \$2,084	26,089	17,694
Assets under management	—	3,755
Prepaid expenses and other current assets	8,212	6,084
Total current assets	85,779	78,437
Long-term investments	52,354	47,609
Property, equipment and capitalized software, net of accumulated depreciation and amortization of \$6,971 and \$7,039	10,553	11,450
Goodwill	106,734	103,732
Other intangible assets, net of accumulated amortization of \$8,350 and \$7,279	23,268	15,194
Other assets	19,590	17,298
Total assets	\$ 298,278	\$ 273,720
Liabilities, redeemable noncontrolling interests and equity		
Current liabilities:		
Medical costs payable	\$ 34,224	\$ 32,395
Accounts payable and accrued liabilities	34,337	31,958
Short-term borrowings and current maturities of long-term debt	4,545	4,274
Unearned revenues	3,317	3,355
Other current liabilities	27,346	27,072
Total current liabilities	103,769	99,054
Long-term debt, less current maturities	72,359	58,263
Deferred income taxes	3,620	3,021
Other liabilities	15,939	14,463
Total liabilities	195,687	174,801
Commitments and contingencies (Note 12)		
Redeemable noncontrolling interests	4,323	4,498
Equity:		
Preferred stock, \$0.001 par value - 10 shares authorized; no shares issued or outstanding ..	—	—
Common stock, \$0.01 par value - 3,000 shares authorized; 915 and 924 issued and outstanding	9	9
Retained earnings	96,036	95,774
Accumulated other comprehensive loss	(3,387)	(7,027)
Nonredeemable noncontrolling interests	5,610	5,665
Total equity	98,268	94,421
Total liabilities, redeemable noncontrolling interests and equity	\$ 298,278	\$ 273,720

See Notes to the Consolidated Financial Statements

UnitedHealth Group
Consolidated Statements of Operations

(in millions, except per share data)	For the Years Ended December 31,		
	2024	2023	2022
Revenues:			
Premiums	\$ 308,810	\$ 290,827	\$ 257,157
Products	50,226	42,583	37,424
Services	36,040	34,123	27,551
Investment and other income	5,202	4,089	2,030
Total revenues	400,278	371,622	324,162
Operating costs:			
Medical costs	264,185	241,894	210,842
Operating costs	53,013	54,628	47,782
Cost of products sold	46,694	38,770	33,703
Depreciation and amortization	4,099	3,972	3,400
Total operating costs	367,991	339,264	295,727
Earnings from operations	32,287	32,358	28,435
Interest expense	(3,906)	(3,246)	(2,092)
Loss on sale of subsidiary and subsidiaries held for sale	(8,310)	—	—
Earnings before income taxes	20,071	29,112	26,343
Provision for income taxes	(4,829)	(5,968)	(5,704)
Net earnings	15,242	23,144	20,639
Earnings attributable to noncontrolling interests	(837)	(763)	(519)
Net earnings attributable to UnitedHealth Group common shareholders	<u>\$ 14,405</u>	<u>\$ 22,381</u>	<u>\$ 20,120</u>
Earnings per share attributable to UnitedHealth Group common shareholders:			
Basic	<u>\$ 15.64</u>	<u>\$ 24.12</u>	<u>\$ 21.47</u>
Diluted	<u>\$ 15.51</u>	<u>\$ 23.86</u>	<u>\$ 21.18</u>
Basic weighted-average number of common shares outstanding	921	928	937
Dilutive effect of common share equivalents	8	10	13
Diluted weighted-average number of common shares outstanding	<u>929</u>	<u>938</u>	<u>950</u>
Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents	6	6	3

See Notes to the Consolidated Financial Statements

UnitedHealth Group
Consolidated Statements of Comprehensive Income

(in millions)	For the Years Ended December 31,		
	2024	2023	2022
Net earnings	<u>\$ 15,242</u>	<u>\$ 23,144</u>	<u>\$ 20,639</u>
Other comprehensive income (loss):			
Gross unrealized gains (losses) on investment securities during the period ...	29	1,139	(4,292)
Income tax effect	(7)	(263)	984
Total unrealized gains (losses), net of tax	<u>22</u>	<u>876</u>	<u>(3,308)</u>
Gross reclassification adjustment for net realized (gains) losses included in net earnings	(369)	(90)	139
Income tax effect	92	21	(32)
Total reclassification adjustment, net of tax	<u>(277)</u>	<u>(69)</u>	<u>107</u>
Foreign currency translation (losses) gains	(319)	559	192
Reclassification adjustment for translation losses included in net earnings	4,214	—	—
Total foreign currency translation gains	<u>3,895</u>	<u>559</u>	<u>192</u>
Other comprehensive income (loss)	<u>3,640</u>	<u>1,366</u>	<u>(3,009)</u>
Comprehensive income	18,882	24,510	17,630
Comprehensive income attributable to noncontrolling interests	<u>(837)</u>	<u>(763)</u>	<u>(519)</u>
Comprehensive income attributable to UnitedHealth Group common shareholders	<u><u>\$ 18,045</u></u>	<u><u>\$ 23,747</u></u>	<u><u>\$ 17,111</u></u>

See Notes to the Consolidated Financial Statements

UnitedHealth Group
Consolidated Statements of Changes in Equity

(in millions, except per share data)	Common Stock		Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)		Nonredeemable Noncontrolling Interests	Total Equity
	Shares	Amount			Net Unrealized Gains (Losses) on Investments	Foreign Currency Translation (Losses) Gains		
Balance at January 1, 2022	941	\$ 10	\$ —	\$ 77,134	\$ 423	\$ (5,807)	\$ 3,285	\$ 75,045
Net earnings				20,120			406	20,526
Other comprehensive (loss) income					(3,201)	192		(3,009)
Issuances of common stock, and related tax effects	7	—	903					903
Share-based compensation			875					875
Common share repurchases	(14)	(1)	(1,892)	(5,107)				(7,000)
Cash dividends paid on common shares (\$6.40 per share)				(5,991)				(5,991)
Redeemable noncontrolling interests fair value and other adjustments			114					114
Acquisition and other adjustments of nonredeemable noncontrolling interests							374	374
Distributions to nonredeemable noncontrolling interests							(387)	(387)
Balance at December 31, 2022	934	9	—	86,156	(2,778)	(5,615)	3,678	81,450
Net earnings				22,381			575	22,956
Other comprehensive income					807	559		1,366
Issuances of common stock, and related tax effects	6	—	1,231					1,231
Share-based compensation			1,027					1,027
Common share repurchases	(16)	—	(2,057)	(6,002)				(8,059)
Cash dividends paid on common shares (\$7.29 per share)				(6,761)				(6,761)
Redeemable noncontrolling interests fair value and other adjustments			(201)					(201)
Acquisition and other adjustments of nonredeemable noncontrolling interests							1,928	1,928
Distributions to nonredeemable noncontrolling interests							(516)	(516)
Balance at December 31, 2023	924	9	—	95,774	(1,971)	(5,056)	5,665	94,421
Net earnings				14,405			663	15,068
Other comprehensive (loss) income					(255)	3,895		3,640
Issuances of common stock, and related tax effects	8	—	1,485					1,485
Share-based compensation			963					963
Common share repurchases	(17)	—	(2,395)	(6,610)				(9,005)
Cash dividends paid on common shares (\$8.18 per share)				(7,533)				(7,533)
Redeemable noncontrolling interests fair value and other adjustments			(53)					(53)
Acquisition and other adjustments of nonredeemable noncontrolling interests							26	26
Distributions to nonredeemable noncontrolling interests							(744)	(744)
Balance at December 31, 2024	915	\$ 9	\$ —	\$ 96,036	\$ (2,226)	\$ (1,161)	\$ 5,610	\$ 98,268

See Notes to the Consolidated Financial Statements

UnitedHealth Group
Consolidated Statements of Cash Flows

(in millions)	For the Years Ended December 31,		
	2024	2023	2022
Operating activities			
Net earnings	\$ 15,242	\$ 23,144	\$ 20,639
Noncash items:			
Depreciation and amortization	4,099	3,972	3,400
Deferred income taxes	(296)	(245)	(673)
Share-based compensation	1,018	1,059	925
Loss on sale of subsidiary and subsidiaries held for sale	8,310	—	—
Gains on dispositions and other strategic transactions	(3,333)	(489)	(588)
Other, net	(28)	(16)	257
Net change in other operating items, net of effects from acquisitions and dispositions:			
Accounts receivable	(1,437)	(3,114)	(2,523)
Other assets	(4,140)	(2,444)	(1,374)
Medical costs payable	2,503	3,482	4,053
Accounts payable and other liabilities	2,463	3,516	1,964
Unearned revenues	(197)	203	126
Cash flows from operating activities	<u>24,204</u>	<u>29,068</u>	<u>26,206</u>
Investing activities			
Purchases of investments	(27,308)	(18,314)	(18,825)
Sales of investments	18,514	7,307	5,907
Maturities of investments	9,319	9,230	6,081
Cash paid for acquisitions and other transactions, net of cash assumed	(13,408)	(10,136)	(21,458)
Purchases of property, equipment and capitalized software	(3,499)	(3,386)	(2,802)
Loans to care providers - cyberattack	(9,033)	—	—
Repayments of care provider loans - cyberattack	4,514	—	—
Cash received from dispositions and other strategic transactions, net	2,041	685	3,414
Other, net	(1,667)	(960)	(793)
Cash flows used for investing activities	<u>(20,527)</u>	<u>(15,574)</u>	<u>(28,476)</u>
Financing activities			
Common share repurchases	(9,000)	(8,000)	(7,000)
Cash dividends paid	(7,533)	(6,761)	(5,991)
Proceeds from common stock issuances	1,846	1,353	1,253
Repayments of long-term debt	(3,000)	(2,125)	(3,015)
(Repayments of) proceeds from short-term borrowings, net	(151)	11	732
Proceeds from issuance of long-term debt	17,811	6,394	14,819
Customer funds administered	(1,560)	(521)	5,548
Purchases of redeemable noncontrolling interests	(280)	(730)	(176)
Other, net	(1,645)	(1,150)	(1,944)
Cash flows (used for) from financing activities	<u>(3,512)</u>	<u>(11,529)</u>	<u>4,226</u>
Effect of exchange rate changes on cash and cash equivalents	(61)	97	34
Increase in cash and cash equivalents, including cash within businesses held for sale	<u>104</u>	<u>2,062</u>	<u>1,990</u>
Less: cash within businesses held for sale	(219)	—	—
Net (decrease) increase in cash and cash equivalents	<u>(115)</u>	<u>2,062</u>	<u>1,990</u>
Cash and cash equivalents, beginning of period	<u>25,427</u>	<u>23,365</u>	<u>21,375</u>
Cash and cash equivalents, end of period	<u>\$ 25,312</u>	<u>\$ 25,427</u>	<u>\$ 23,365</u>
Supplemental cash flow disclosures			
Cash paid for interest	\$ 3,594	\$ 3,035	\$ 1,945
Cash paid for income taxes	4,620	6,078	5,222

See Notes to the Consolidated Financial Statements

UnitedHealth Group
Notes to the Consolidated Financial Statements

1. Description of Business

UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and “the Company”) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. The Company’s two distinct, yet complementary businesses — Optum and UnitedHealthcare — are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations the Company is privileged to serve.

2. Basis of Presentation, Use of Estimates and Significant Accounting Policies

Basis of Presentation

The Company has prepared the Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries.

Use of Estimates

These Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted.

Revenues

Premiums

Premium revenues are primarily derived from risk-based arrangements in which the premium is typically at a fixed rate per individual served for a one-year period, and the Company assumes the economic risk of funding its customers’ health care and related administrative costs.

Premium revenues are recognized in the period in which eligible individuals are entitled to receive health care benefits. Health care premium payments received from the Company’s customers in advance of the service period are recorded as unearned revenues. Fully insured commercial products of U.S. health plans, Medicare Advantage and Medicare Prescription Drug Benefit (Medicare Part D) plans with medical loss ratios (MLRs) as calculated under the definitions in the Patient Protection and Affordable Care Act (ACA) and related federal and state regulations and implementing regulation, falling below certain targets are required to rebate ratable portions of their premiums annually. Commercial premiums within the Company’s individual and small group markets are also subject to the ACA risk adjustment program. Medicare Advantage premium revenue includes the impact of the Centers for Medicare & Medicaid Services (CMS) quality bonuses based on plans’ Star rating. Certain of the Company’s Medicaid business is also subject to state minimum MLR rebates.

Premium revenues are recognized based on the estimated premiums earned, net of projected rebates, because the Company is able to reasonably estimate the ultimate premiums of these contracts. The Company also records premium revenues for certain value-based arrangements at its Optum Health care delivery businesses. Under these value-based arrangements, the Company enters into agreements with health plans to stand ready to deliver, integrate, direct and control certain health care services for patients. In exchange, the Company receives a premium that is typically paid on a per-patient per-month basis. The Company considers these value-based arrangements to represent a single performance obligation where premium revenues are recognized in the period in which health care services are made available.

The Company’s Medicare Advantage and Medicare Part D premium revenues are subject to periodic adjustment under CMS’ risk adjustment payment methodology. CMS deploys a risk adjustment model which apportions premiums paid to all health plans according to health severity and certain demographic factors. The CMS risk adjustment model provides higher per member payments for enrollees diagnosed with certain conditions and lower payments for enrollees who are healthier. Under this risk adjustment methodology, CMS calculates the risk adjusted premium payment using diagnosis and encounter data from hospital inpatient, hospital outpatient and physician treatment settings. The Company and health care providers collect, capture and submit the necessary and available data to CMS within prescribed deadlines. The Company estimates risk adjustment premium revenues based upon the data submitted and expected to be submitted to CMS. Risk adjustment data for the Company’s plans are subject to review by the government, including audit by regulators. See Note 12 for additional information regarding these audits.

Products and Services

For the Company's Optum Rx pharmacy care services business, the majority of revenues are derived from products sold through a contracted network of retail pharmacies or home delivery, specialty and community health pharmacies. Product revenues include the cost of pharmaceuticals (net of rebates), a negotiated dispensing fee and customer co-payments. Pharmacy products are billed to customers based on the number of transactions occurring during the billing period. Product revenues are recognized when the prescriptions are dispensed. The Company has entered into contracts in which it is primarily obligated to pay its network pharmacy providers for benefits provided to their customers regardless of whether the Company is paid. The Company is also involved in establishing the prices charged by retail pharmacies, determining which drugs will be included in formulary listings and selecting which retail pharmacies will be included in the network offered to plan sponsors' members and accordingly, product revenues are reported on a gross basis.

Services revenue includes a number of services and products sold through Optum. Optum Health's service revenues include net patient service revenues recorded based upon established billing rates, less allowances for contractual adjustments, and are recognized as services are provided. For its financial services offerings, Optum Health charges fees and earns investment income on managed funds. Optum Insight provides software and information products, advisory consulting arrangements and managed services outsourcing contracts, which may be delivered over several years. Optum Insight revenues are generally recognized over time and measured for each period based on the progress to date as services are performed or made available to customers.

Services revenue also consists of fees derived from services performed for customers who self-insure the health care costs of their employees and employees' dependents. Under service fee contracts, the Company receives a monthly fixed fee per employee, which is recognized as revenue as the Company performs, or makes available, the applicable services to the customer. The customers retain the risk of financing health care costs for their employees and employees' dependents, and the Company administers the payment of customer funds to physicians and other health care professionals from customer-funded bank accounts. As the Company has neither the obligation for funding the health care costs, nor the primary responsibility for providing the medical care, the Company does not recognize premium revenue and medical costs for these contracts in its Consolidated Financial Statements. For these fee-based customer arrangements, the Company provides coordination and facilitation of medical services; transaction processing; customer, consumer and care professional services; and access to contracted networks of physicians, hospitals and other health care professionals. These services are performed throughout the contract period.

As of December 31, 2024 and 2023, accounts receivables related to products and services were \$9.9 billion and \$8.6 billion, respectively. In 2024 and 2023, the Company had no material bad-debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the Consolidated Balance Sheets as of December 31, 2024 or 2023.

For the years ended December 31, 2024, 2023 and 2022, revenue recognized from performance obligations related to prior periods (for example, due to changes in transaction price) was not material.

As of December 31, 2024, revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts having an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, was \$12.7 billion, of which approximately half is expected to be recognized in the next three years.

See Note 14 for disaggregation of revenue by segment and type.

Medical Costs and Medical Costs Payable

The Company's estimate of medical costs payable represents management's best estimate of its liability for unpaid medical costs as of December 31, 2024.

Each period, the Company re-examines previously established medical costs payable estimates based on actual claim submissions and other changes in facts and circumstances. As more complete claim information becomes available, the Company adjusts the amount of the estimates and includes the changes in estimates in medical costs in the period in which the change is identified. Approximately 90% of claims related to medical care services are known and settled within 90 days from the date of service and substantially all within twelve months.

Medical costs and medical costs payable include estimates of the Company's obligations for medical care services rendered on behalf of consumers, but for which claims have either not yet been received, processed, or paid. The Company develops estimates for medical care services incurred but not reported (IBNR), which includes estimates for claims which have not been received or fully processed, using an actuarial process consistently applied, centrally controlled and automated. The actuarial models consider factors such as time from date of service to claim processing, seasonal variances in medical care consumption, health care professional contract rate changes, care activity and other medical cost trends, membership volume and

demographics, the introduction of new technologies, benefit plan changes and business mix changes related to products, customers and geography.

In developing its medical costs payable estimates, the Company applies different estimation methods depending on which incurred claims are being estimated. For the most recent two months, the Company estimates claim costs incurred by applying observed medical cost trend factors to the average per member per month medical costs incurred in prior months for which more complete claim data are available, supplemented by a review of near-term completion factors (actuarial estimates, based upon historical experience and analysis of current trends, of the percentage of incurred claims during a given period adjudicated by the Company at the date of estimation). For months prior to the most recent two months, the Company applies the completion factors to actual claims adjudicated-to-date to estimate the expected amount of ultimate incurred claims for those months.

Cost of Products Sold

The Company's cost of products sold includes the cost of pharmaceuticals dispensed to unaffiliated customers either directly at its home delivery, specialty and community pharmacy locations, or indirectly through its nationwide network of participating pharmacies. Rebates attributable to unaffiliated clients are accrued as rebates receivable and a reduction of cost of products sold, with a corresponding payable for the amounts of the rebates to be remitted to those unaffiliated clients in accordance with their contracts and recorded in the Consolidated Statements of Operations as a reduction of product revenue. Cost of products sold also includes the cost of personnel to support the Company's transaction processing services, system sales, maintenance and professional services.

Cash, Cash Equivalents and Investments

Cash and cash equivalents are highly liquid investments having an original maturity of three months or less. The fair value of cash and cash equivalents approximates their carrying value because of the short maturity of the instruments. Investments with maturities of less than one year are classified as short-term. Because of regulatory requirements, certain investments are included in long-term investments regardless of their maturity date. The Company classifies these investments as held-to-maturity and reports them at amortized cost. Substantially all other investments are classified as available-for-sale and reported at fair value based on quoted market prices, where available. Equity investments are measured at fair value, with certain exceptions where the Company has elected to measure investments with unobservable inputs at cost, subject to fair value adjustments upon an impairment or a transaction of the same or similar security. Changes in fair value of equity investments are recognized in net earnings.

The Company excludes unrealized gains and losses on available-for-sale debt securities from net earnings and reports them as comprehensive income and, net of income tax effects, as a separate component of equity. To calculate realized gains and losses on the sale of debt securities, the Company specifically identifies the cost of each investment sold.

The Company evaluates an available-for-sale debt security for credit-related impairment by considering the present value of expected cash flows relative to a security's amortized cost, the extent to which fair value is less than amortized cost, the financial condition and near-term prospects of the issuer and specific events or circumstances which may influence the operations of the issuer. Credit-related impairments are recorded as an allowance, with an offset to investment and other income. Non-credit related impairments are recorded through other comprehensive income. If the Company intends to sell an impaired security, or will likely be required to sell a security before recovery of the entire amortized cost, the entire impairment is included in net earnings.

New information and the passage of time can change these judgments. The Company manages its investment portfolio to limit its exposure to any one issuer or market sector, and largely limits its investments to investment grade quality.

Assets Under Management

In July 2024, the Company amended its Medicare Supplement Program with a membership organization (the Medicare Supplement Program). The amendments provide the Company the right to use a trade name and other intellectual property in marketing efforts for Medicare Supplement offerings. Amounts previously reported as assets under management are now included within the Company's Consolidated Balance Sheet based upon their classification.

For periods prior to the amended Medicare Supplement Program, the Company excluded the effects of certain balance sheet amounts in its Consolidated Statements of Cash Flows, while these effects are included for periods after the amendments.

Other Current Receivables

Other current receivables include amounts due from pharmaceutical manufacturers for rebates and Medicare Part D drug discounts, loans to care providers in response to the Change Healthcare cyberattack, accrued interest and other miscellaneous amounts due to the Company.

The Company's pharmacy care services businesses contract with pharmaceutical manufacturers, some of which provide rebates based on use of the manufacturers' products by its affiliated and unaffiliated clients. The Company accrues rebates as they are earned by its clients on a monthly basis based on the terms of the applicable contracts, historical data and current estimates. The pharmacy care services businesses bill these rebates to the manufacturers on a monthly or quarterly basis depending on the contractual terms and record rebates attributable to affiliated clients as a reduction to medical costs. The Company generally receives rebates two to five months after billing. As of December 31, 2024 and 2023, total pharmaceutical manufacturer rebates receivable included in other receivables in the Consolidated Balance Sheets amounted to \$12.5 billion and \$11.0 billion, respectively.

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets included pharmaceutical drug and supplies inventory of \$3.8 billion and \$2.8 billion as of December 31, 2024 and 2023, respectively.

Property, Equipment and Capitalized Software

Property, equipment and capitalized software are stated at cost, net of accumulated depreciation and amortization. Capitalized software consists of certain costs incurred in the development of internal-use software, including external direct costs of materials and services and applicable payroll costs of employees devoted to specific software development.

The Company calculates depreciation and amortization using the straight-line method over the estimated useful lives of the assets. The useful lives for property, equipment and capitalized software are:

Furniture, fixtures and equipment	3 to 10 years
Buildings	35 to 40 years
Capitalized software	3 to 5 years

Leasehold improvements are depreciated over the shorter of the remaining lease term or their estimated useful economic life.

Operating Leases

The Company leases facilities and equipment under long-term operating leases which are non-cancelable and expire on various dates. At the lease commencement date, lease right-of-use (ROU) assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term, which includes all fixed obligations arising from the lease contract. If an interest rate is not implicit in a lease, the Company utilizes its incremental borrowing rate for a period closely matching the lease term.

The Company's ROU assets are included in other assets, and lease liabilities are included in other current liabilities and other liabilities in the Company's Consolidated Balance Sheet.

Goodwill

To determine whether goodwill is impaired, annually or more frequently if needed, the Company performs impairment tests. The Company may first assess qualitative factors to determine if it is more likely than not the carrying value of a reporting unit exceeds its estimated fair value. If our qualitative assessment indicates a goodwill impairment is more likely than not, we perform additional quantitative analyses. The Company may also elect to skip the qualitative testing and proceed directly to the quantitative testing. When performing quantitative testing, the Company first estimates the fair values of its reporting units using discounted cash flows. To determine fair values, the Company must make assumptions about a wide variety of internal and external factors. Significant assumptions used in the impairment analysis include financial projections of free cash flow (including significant assumptions about operations, capital levels and income taxes), long-term growth rates for determining terminal value and discount rates. Comparative market multiples are used to corroborate the results of the discounted cash flow test. If the fair value is less than the carrying value of the reporting unit, an impairment is recognized for the difference, up to the carrying amount of goodwill.

There was no impairment of goodwill during the years ended December 31, 2024, 2023 and 2022.

Intangible Assets

The Company's finite-lived intangible assets are subject to impairment tests when events or circumstances indicate an intangible asset (or asset group) may be impaired. The Company's indefinite-lived intangible assets are also tested for impairment annually. There was no impairment of intangible assets during the years ended December 31, 2024, 2023 and 2022.

Other Current Liabilities

Other current liabilities include health savings account deposits (\$13.7 billion and \$13.5 billion as of December 31, 2024 and 2023, respectively), accruals for premium rebates payable, the current portion of future policy benefits and customer balances.

Policy Acquisition Costs

The Company's short duration health insurance contracts typically have a one-year term and may be canceled by the customer with at least 30 days' notice. Costs related to the acquisition and renewal of short duration customer contracts are primarily charged to expense as incurred.

Redeemable Noncontrolling Interests

Redeemable noncontrolling interests in the Company's subsidiaries whose redemption is outside of the Company's control are classified as temporary equity. These interests primarily relate to put options on unowned shares, which are typically redeemable at fair value after a certain time period. The Company accretes changes in the redemption value to the earliest redemption date utilizing the interest method. If all interests were currently redeemable, the difference between the carrying value and the estimated redemption value is not material. The following table provides details of the Company's redeemable noncontrolling interests' activity for the years ended December 31, 2024 and 2023:

(in millions)	2024	2023
Redeemable noncontrolling interests, beginning of period	\$ 4,498	\$ 4,897
Net earnings	174	188
Acquisitions	33	122
Redemptions	(280)	(730)
Distributions	(125)	(144)
Fair value and other adjustments	23	165
Redeemable noncontrolling interests, end of period	<u>\$ 4,323</u>	<u>\$ 4,498</u>

Share-Based Compensation

The Company recognizes compensation expense for share-based awards, including stock options and restricted stock and restricted stock units (collectively, restricted shares), on a straight-line basis over the related service period (generally the vesting period) of the award, or to an employee's eligible retirement date under the award agreement, if earlier. Restricted shares vest ratably, primarily over four years, and compensation expense related to restricted shares is based on the share price on the date of grant. Stock options vest ratably primarily over four years and may be exercised up to 10 years from the date of grant. Compensation expense related to stock options is based on the fair value at the date of grant, which is estimated on the date of grant using a binomial option-pricing model. Under the Company's Employee Stock Purchase Plan (ESPP), eligible employees are allowed to purchase the Company's stock at a discounted price, which is 90% of the market price of the Company's common stock at the end of the six-month purchase period. Share-based compensation expense for all programs is recognized in operating costs in the Consolidated Statements of Operations.

Net Earnings Per Common Share

The Company computes basic earnings per common share attributable to UnitedHealth Group common shareholders by dividing net earnings attributable to UnitedHealth Group common shareholders by the weighted-average number of common shares outstanding during the period. The Company determines diluted net earnings per common share attributable to UnitedHealth Group common shareholders using the weighted-average number of common shares outstanding during the period, adjusted for potentially dilutive shares associated with stock options, restricted shares and the ESPP (collectively, common stock equivalents), using the treasury stock method. The treasury stock method assumes a hypothetical issuance of shares to settle the share-based awards, with the assumed proceeds used to purchase common stock at the average market price for the period. Assumed proceeds include the amount the employee must pay upon exercise and the average unrecognized compensation cost. The difference between the number of shares assumed issued and number of shares assumed purchased represents the dilutive shares.

3. Investments

A summary of debt securities by major security type is as follows:

(in millions)	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value
December 31, 2024				
Debt securities - available-for-sale:				
U.S. government and agency obligations	\$ 4,600	\$ 1	\$ (274)	\$ 4,327
State and municipal obligations	7,357	2	(375)	6,984
Corporate obligations	24,391	56	(1,140)	23,307
U.S. agency mortgage-backed securities	10,577	1	(994)	9,584
Non-U.S. agency mortgage-backed securities	2,890	2	(175)	2,717
Total debt securities - available-for-sale	<u>49,815</u>	<u>62</u>	<u>(2,958)</u>	<u>46,919</u>
Debt securities - held-to-maturity:				
U.S. government and agency obligations	444	—	(2)	442
State and municipal obligations	28	—	(2)	26
Corporate obligations	40	—	—	40
Total debt securities - held-to-maturity	<u>512</u>	<u>—</u>	<u>(4)</u>	<u>508</u>
Total debt securities	<u>\$ 50,327</u>	<u>\$ 62</u>	<u>\$ (2,962)</u>	<u>\$ 47,427</u>
December 31, 2023				
Debt securities - available-for-sale:				
U.S. government and agency obligations	\$ 4,674	\$ 3	\$ (234)	\$ 4,443
State and municipal obligations	7,636	39	(322)	7,353
Corporate obligations	23,136	67	(1,186)	22,017
U.S. agency mortgage-backed securities	8,982	22	(708)	8,296
Non-U.S. agency mortgage-backed securities	3,023	3	(240)	2,786
Total debt securities - available-for-sale	<u>47,451</u>	<u>134</u>	<u>(2,690)</u>	<u>44,895</u>
Debt securities - held-to-maturity:				
U.S. government and agency obligations	506	1	(6)	501
State and municipal obligations	28	—	(2)	26
Corporate obligations	69	—	—	69
Total debt securities - held-to-maturity	<u>603</u>	<u>1</u>	<u>(8)</u>	<u>596</u>
Total debt securities	<u>\$ 48,054</u>	<u>\$ 135</u>	<u>\$ (2,698)</u>	<u>\$ 45,491</u>

Nearly all of the Company's investments in mortgage-backed securities were rated "Double A" or better as of December 31, 2024.

The Company held \$4.9 billion of equity securities as of December 31, 2024 and 2023. The Company's investments in equity securities primarily consist of venture investments and employee savings plan related investments. Additionally, the Company's investments included \$3.8 billion and \$1.4 billion of equity method investments primarily in operating businesses in the health care sector, as of December 31, 2024 and 2023, respectively. The allowance for credit losses on held-to-maturity securities as of December 31, 2024 and 2023 was not material.

The amortized cost and fair value of debt securities as of December 31, 2024, by contractual maturity, were as follows:

(in millions)	Available-for-Sale		Held-to-Maturity	
	Amortized Cost	Fair Value	Amortized Cost	Fair Value
Due in one year or less	\$ 3,952	\$ 3,932	\$ 320	\$ 319
Due after one year through five years	14,845	14,384	161	161
Due after five years through ten years	12,110	11,213	14	13
Due after ten years	5,441	5,089	17	15
U.S. agency mortgage-backed securities	10,577	9,584	—	—
Non-U.S. agency mortgage-backed securities	2,890	2,717	—	—
Total debt securities	<u>\$ 49,815</u>	<u>\$ 46,919</u>	<u>\$ 512</u>	<u>\$ 508</u>

The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position were as follows:

(in millions)	Less Than 12 Months		12 Months or Greater		Total	
	Fair Value	Gross Unrealized Losses	Fair Value	Gross Unrealized Losses	Fair Value	Gross Unrealized Losses
December 31, 2024						
U.S. government and agency obligations	\$ 1,475	\$ (51)	\$ 2,152	\$ (223)	\$ 3,627	\$ (274)
State and municipal obligations	2,593	(58)	4,085	(317)	6,678	(375)
Corporate obligations	7,402	(213)	11,449	(927)	18,851	(1,140)
U.S. agency mortgage-backed securities	4,791	(191)	4,674	(803)	9,465	(994)
Non-U.S. agency mortgage-backed securities	416	(5)	1,863	(170)	2,279	(175)
Total debt securities - available-for-sale	<u>\$ 16,677</u>	<u>\$ (518)</u>	<u>\$ 24,223</u>	<u>\$ (2,440)</u>	<u>\$ 40,900</u>	<u>\$ (2,958)</u>
December 31, 2023						
U.S. government and agency obligations	\$ 1,270	\$ (7)	\$ 2,077	\$ (227)	\$ 3,347	\$ (234)
State and municipal obligations	907	(7)	4,063	(315)	4,970	(322)
Corporate obligations	1,826	(17)	14,696	(1,169)	16,522	(1,186)
U.S. agency mortgage-backed securities	1,337	(12)	5,069	(696)	6,406	(708)
Non-U.S. agency mortgage-backed securities	279	(6)	2,202	(234)	2,481	(240)
Total debt securities - available-for-sale	<u>\$ 5,619</u>	<u>\$ (49)</u>	<u>\$ 28,107</u>	<u>\$ (2,641)</u>	<u>\$ 33,726</u>	<u>\$ (2,690)</u>

The Company's unrealized losses from all securities as of December 31, 2024 were generated from approximately 34,000 positions out of a total of 43,000 positions. The Company believes it will timely collect the principal and interest due on its debt securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities which impacted the Company's assessment on collectibility of principal and interest. At each reporting period, the Company evaluates available-for-sale debt securities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the expected cash flows, the underlying credit quality and credit ratings of the issuers, noting no significant credit deterioration since purchase. As of December 31, 2024, the Company did not have the intent to sell any of the securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary. The allowance for credit losses on available-for-sale debt securities as of December 31, 2024 and 2023 was not material.

4. Fair Value

Certain assets and liabilities are measured at fair value in the Consolidated Financial Statements or have fair values disclosed in the Notes to the Consolidated Financial Statements. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP. In instances in which the inputs used to measure fair value fall into different levels of the fair value hierarchy, the fair value measurement is categorized in its entirety based on the lowest level input which is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular item to the fair value measurement in its entirety requires judgment, including the consideration of inputs specific to the asset or liability.

The fair value hierarchy is summarized as follows:

Level 1 — Quoted prices (unadjusted) for identical assets/liabilities in active markets.

Level 2 — Other observable inputs, either directly or indirectly, including:

- Quoted prices for similar assets/liabilities in active markets;
- Quoted prices for identical or similar assets/liabilities in inactive markets (e.g., few transactions, limited information, noncurrent prices, high variability over time);
- Inputs other than quoted prices observable for the asset/liability (e.g., interest rates, yield curves, implied volatilities, credit spreads); and
- Inputs corroborated by other observable market data.

Level 3 — Unobservable inputs cannot be corroborated by observable market data.

There were no transfers in or out of Level 3 financial assets or liabilities during the years ended December 31, 2024 or 2023.

Nonfinancial assets and liabilities or financial assets and liabilities measured at fair value on a nonrecurring basis are subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. For the years ended December 31, 2024, 2023 and 2022, the Company recognized \$710 million, \$276 million and \$211 million respectively, of unrealized gains in investment and other income related to fair value adjustments on equity securities primarily in the Company's venture portfolio, based upon transactions of the same or similar security. The assets and liabilities within our South American operations held for sale as of December 31, 2024 were measured at the lower of carrying value or fair value less cost to sell. Fair value is measured based upon unobservable amounts, such as estimated selling price derived from Company-specific information and market conditions. There were no other significant fair value adjustments for these assets and liabilities recorded during the years ended December 31, 2024, 2023 or 2022.

The following methods and assumptions were used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument included in the tables below:

Cash and Cash Equivalents. The carrying value of cash and cash equivalents approximates fair value as maturities are less than three months. Fair values of cash equivalent instruments which do not trade on a regular basis in active markets are classified as Level 2.

Debt and Equity Securities. Fair values of debt securities and equity securities reported at fair value on a recurring basis are based on quoted market prices, where available. The Company obtains one price for each security primarily from a third-party pricing service (pricing service), which generally uses quoted or other observable inputs for the determination of fair value. The pricing service normally derives the security prices through recently reported trades for identical or similar securities, and, if necessary, makes adjustments through the reporting date based upon available observable market information. For securities not actively traded, the pricing service may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs currently observable in the markets for similar securities. Inputs often used in the valuation methodologies include, but are not limited to, benchmark yields, credit spreads, default rates, prepayment speeds and nonbinding broker quotes. As the Company is responsible for the determination of fair value, it performs quarterly analyses on the prices received from the pricing service to determine whether the prices are reasonable estimates of fair value. Specifically, the Company compares the prices received from the pricing service to prices reported by a secondary pricing source, such as its custodian, its investment consultant and third-party investment advisors. Additionally, the Company compares changes in the reported market values and returns to relevant market indices to test the reasonableness of the reported prices. The Company's internal price verification procedures and reviews of fair value methodology documentation provided by independent pricing services have not historically resulted in adjustment to the prices obtained from the pricing service.

Fair values of debt securities which do not trade on a regular basis in active markets but are priced using other observable inputs are classified as Level 2.

Fair value estimates for Level 1 and Level 2 equity securities reported at fair value on a recurring basis are based on quoted market prices for actively traded equity securities and/or other market data for the same or comparable instruments and transactions in establishing the prices.

The fair values of Level 3 investments in corporate bonds, which are not a significant portion of our investments, are estimated using valuation techniques relying heavily on management assumptions and qualitative observations.

Throughout the procedures discussed above in relation to the Company's processes for validating third-party pricing information, the Company validates the understanding of assumptions and inputs used in security pricing and determines the proper classification in the hierarchy based on such understanding.

Long-Term Debt. The fair values of the Company's long-term debt are estimated and classified using the same methodologies as the Company's investments in debt securities.

The following table presents a summary of fair value measurements by level and carrying values for items measured at fair value on a recurring basis in the Consolidated Balance Sheets:

(in millions)	Quoted Prices in Active Markets (Level 1)	Other Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	Total Fair and Carrying Value
December 31, 2024				
Cash and cash equivalents	\$ 25,248	\$ 64	\$ —	\$ 25,312
Debt securities - available-for-sale:				
U.S. government and agency obligations	4,194	133	—	4,327
State and municipal obligations	—	6,984	—	6,984
Corporate obligations	29	22,841	437	23,307
U.S. agency mortgage-backed securities	—	9,584	—	9,584
Non-U.S. agency mortgage-backed securities	—	2,717	—	2,717
Total debt securities - available-for-sale	4,223	42,259	437	46,919
Equity securities	1,859	24	65	1,948
Total assets at fair value	\$ 31,330	\$ 42,347	\$ 502	\$ 74,179
Percentage of total assets at fair value	42 %	57 %	1 %	100 %
December 31, 2023				
Cash and cash equivalents	\$ 25,345	\$ 82	\$ —	\$ 25,427
Debt securities - available-for-sale:				
U.S. government and agency obligations	4,167	276	—	4,443
State and municipal obligations	—	7,353	—	7,353
Corporate obligations	15	21,800	202	22,017
U.S. agency mortgage-backed securities	—	8,296	—	8,296
Non-U.S. agency mortgage-backed securities	—	2,786	—	2,786
Total debt securities - available-for-sale	4,182	40,511	202	44,895
Equity securities	2,468	16	69	2,553
Assets under management	1,505	2,140	110	3,755
Total assets at fair value	\$ 33,500	\$ 42,749	\$ 381	\$ 76,630
Percentage of total assets at fair value	44 %	55 %	1 %	100 %

The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Consolidated Balance Sheets:

(in millions)	Quoted Prices in Active Markets (Level 1)	Other Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	Total Fair Value	Total Carrying Value
December 31, 2024					
Debt securities - held-to-maturity	\$ 482	\$ 26	\$ —	\$ 508	\$ 512
Long-term debt and other financing obligations	\$ —	\$ 70,565	\$ —	\$ 70,565	\$ 75,604
December 31, 2023					
Debt securities - held-to-maturity	\$ 524	\$ 72	\$ —	\$ 596	\$ 603
Long-term debt and other financing obligations	\$ —	\$ 59,851	\$ —	\$ 59,851	\$ 61,449

The carrying amounts reported on the Consolidated Balance Sheets for other current financial assets and liabilities approximate fair value because of their short-term nature. These assets and liabilities are not listed in the table above.

5. Property, Equipment and Capitalized Software

A summary of property, equipment and capitalized software is as follows:

(in millions)	December 31, 2024	December 31, 2023
Land and improvements	\$ 364	\$ 712
Buildings and improvements	4,215	5,573
Computer equipment	2,267	2,007
Furniture and fixtures	1,694	2,375
Less accumulated depreciation	(3,645)	(4,210)
Property and equipment, net	4,895	6,457
Capitalized software	8,984	7,822
Less accumulated amortization	(3,326)	(2,829)
Capitalized software, net	5,658	4,993
Total property, equipment and capitalized software, net	\$ 10,553	\$ 11,450

Depreciation expense for property and equipment for the years ended December 31, 2024, 2023 and 2022 was \$1.0 billion, \$1.1 billion, and \$1.1 billion, respectively. Amortization expense for capitalized software for the years ended December 31, 2024, 2023 and 2022 was \$1.4 billion, \$1.2 billion and \$1.0 billion, respectively.

6. Goodwill and Other Intangible Assets

Changes in the carrying amount of goodwill, by reportable segment, were as follows:

(in millions)	UnitedHealthcare	Optum Health	Optum Insight	Optum Rx	Consolidated
Balance at January 1, 2023	\$ 27,395	\$ 29,238	\$ 17,244	\$ 19,475	\$ 93,352
Acquisitions	296	8,023	1,802	—	10,121
Foreign currency effects and other adjustments, net	187	(182)	261	(7)	259
Balance at December 31, 2023	27,878	37,079	19,307	19,468	103,732
Acquisitions	—	2,071	—	2,305	4,376
Dispositions, foreign currency effects and other adjustments, net	(717)	(324)	(327)	(6)	(1,374)
Balance at December 31, 2024	\$ 27,161	\$ 38,826	\$ 18,980	\$ 21,767	\$ 106,734

The gross carrying value, accumulated amortization and net carrying value of other intangible assets were as follows:

(in millions)	December 31, 2024			December 31, 2023		
	Gross Carrying Value	Accumulated Amortization	Net Carrying Value	Gross Carrying Value	Accumulated Amortization	Net Carrying Value
Customer-related	\$ 17,190	\$ (6,675)	\$ 10,515	\$ 16,636	\$ (5,909)	\$ 10,727
Trademarks and technology	2,917	(1,284)	1,633	2,508	(958)	1,550
Trade names, trademarks, operating licenses and certificates and other indefinite-lived	10,454	—	10,454	2,116	—	2,116
Other	1,057	(391)	666	1,213	(412)	801
Total	\$ 31,618	\$ (8,350)	\$ 23,268	\$ 22,473	\$ (7,279)	\$ 15,194

The fair values and weighted-average useful lives assigned to intangible assets as a result of transactions completed during years ended:

(in millions, except years)	2024		2023	
	Fair Value	Weighted-Average Useful Life	Fair Value	Weighted-Average Useful Life
Customer-related	\$ 1,258	12 years	\$ 477	12 years
Trademarks and technology	527	6 years	226	5 years
Other	22	8 years	44	9 years
Total finite-lived	<u>\$ 1,807</u>	10 years	<u>\$ 747</u>	9 years
Total indefinite-lived - trade names, trademarks, operating licenses and certificates and other	8,795		1,427	
Total intangible assets	<u>\$ 10,602</u>		<u>\$ 2,174</u>	

Estimated full year amortization expense relating to intangible assets for each of the next five years ending December 31 is as follows:

(in millions)	
2025	\$ 1,655
2026	1,503
2027	1,424
2028	1,344
2029	1,211

Amortization expense relating to intangible assets for the years ended December 31, 2024, 2023 and 2022 was \$1.7 billion, \$1.6 billion and \$1.3 billion, respectively.

7. Medical Costs Payable

The following table shows the components of the change in medical costs payable for the years ended December 31:

(in millions)	2024	2023	2022
Medical costs payable, beginning of period	\$ 32,395	\$ 29,056	\$ 24,483
Acquisitions (dispositions), net	(755)	1	308
Reported medical costs:			
Current year	264,885	242,734	211,252
Prior years	(700)	(840)	(410)
Total reported medical costs	<u>264,185</u>	<u>241,894</u>	<u>210,842</u>
Medical payments:			
Payments for current year	(231,890)	(211,380)	(184,049)
Payments for prior years	(29,532)	(27,176)	(22,528)
Total medical payments	<u>(261,422)</u>	<u>(238,556)</u>	<u>(206,577)</u>
Less: medical costs payable included within businesses held for sale	(179)	—	—
Medical costs payable, end of period	<u>\$ 34,224</u>	<u>\$ 32,395</u>	<u>\$ 29,056</u>

For the years ended December 31, 2024, 2023 and 2022, prior years' medical cost reserve development included no individual factors that were significant. Medical costs payable included IBNR of \$23.7 billion and \$22.3 billion at December 31, 2024 and 2023, respectively. Substantially all of the IBNR balance as of December 31, 2024 relates to the current year.

The following is information about incurred and paid medical cost development as of December 31, 2024:

(in millions) Year	Net Incurred Medical Costs	
	For the Years Ended December 31,	
	2023	2024
2023	\$ 242,734	\$ 242,156
2024		264,885
Total		\$ 507,041

(in millions) Year	Net Cumulative Medical Payments	
	For the Years Ended December 31,	
	2023	2024
2023	\$ (211,380)	\$ (240,112)
2024		(231,890)
Total		(472,002)
Net remaining outstanding liabilities prior to 2023		119
Acquisitions (dispositions), net		(755)
Medical costs payable included within businesses held for sale		(179)
Total medical costs payable		\$ 34,224

8. Short-Term Borrowings and Long-Term Debt

Short-term borrowings and senior unsecured long-term debt consisted of commercial paper and notes as follows:

(in millions, except percentages)	Carrying Value as of December 31,		(continued)	Carrying Value as of December 31,	
	2024	2023		2024	2023
Commercial paper	\$ 1,300	\$ 1,088	\$1,000 4.625%, Jul 2035	971	1,014
\$750 3.5%, Feb 2024	—	750	\$850 5.8%, Mar 2036	838	838
\$1,000 0.55%, May 2024	—	999	\$500 6.5%, Jun 2037	492	491
\$750 2.375%, Aug 2024	—	750	\$650 6.625%, Nov 2037	641	640
\$500 5%, Oct 2024	—	499	\$1,100 6.875%, Feb 2038	1,079	1,078
\$2,000 3.75%, Jul 2025	1,999	1,997	\$1,250 3.5%, Aug 2039	1,243	1,242
\$750 5.15%, Oct 2025	749	748	\$1,000 2.75%, May 2040	970	968
\$300 3.7%, Dec 2025	300	299	\$300 5.7%, Oct 2040	296	296
\$500 1.25%, Jan 2026	499	498	\$350 5.95%, Feb 2041	346	346
\$1,000 3.1%, Mar 2026	999	998	\$1,500 3.05%, May 2041	1,485	1,484
\$1,000 1.15%, May 2026	953	924	\$600 4.625%, Nov 2041	590	590
\$500 floating rate, Jul 2026	499	—	\$502 4.375%, Mar 2042	487	486
\$650 4.75%, Jul 2026	648	—	\$625 3.95%, Oct 2042	610	609
\$750 3.45%, Jan 2027	749	748	\$750 4.25%, Mar 2043	737	736
\$500 4.6%, Apr 2027	496	—	\$1,500 5.5%, Jul 2044	1,475	—
\$625 3.375%, Apr 2027	623	622	\$2,000 4.75%, Jul 2045	1,976	1,975
\$600 3.7%, May 2027	598	598	\$750 4.2%, Jan 2047	739	739
\$950 2.95%, Oct 2027	946	944	\$725 4.25%, Apr 2047	718	718
\$1,000 5.25%, Feb 2028	998	1,011	\$950 3.75%, Oct 2047	935	935
\$1,150 3.85%, Jun 2028	1,147	1,146	\$1,350 4.25%, Jun 2048	1,332	1,331
\$850 3.875%, Dec 2028	847	846	\$1,100 4.45%, Dec 2048	1,087	1,087
\$1,250 4.25%, Jan 2029	1,221	1,238	\$1,250 3.7%, Aug 2049	1,237	1,236
\$400 4.7%, Apr 2029	398	—	\$1,250 2.9%, May 2050	1,212	1,211
\$900 4%, May 2029	854	862	\$2,000 3.25%, May 2051	1,972	1,972
\$1,000 2.875%, Aug 2029	902	908	\$2,000 4.75%, May 2052	1,966	1,966
\$1,250 4.8%, Jan 2030	1,225	—	\$2,000 5.875%, Feb 2053	1,968	1,968
\$1,250 5.3%, Feb 2030	1,243	1,275	\$2,000 5.05%, Apr 2053	1,969	1,969
\$1,250 2%, May 2030	1,240	1,238	\$1,750 5.375%, Apr 2054	1,729	—
\$1,000 4.9%, Apr 2031	982	—	\$2,750 5.625%, Jul 2054	2,724	—
\$1,500 2.3%, May 2031	1,271	1,290	\$1,250 3.875%, Aug 2059	1,229	1,229
\$1,500 4.95%, Jan 2032	1,489	—	\$1,000 3.125%, May 2060	967	966
\$1,500 4.2%, May 2032	1,372	1,412	\$1,000 4.95%, May 2062	981	981
\$2,000 5.35%, Feb 2033	1,966	2,046	\$1,500 6.05%, Feb 2063	1,466	1,466
\$1,500 4.5%, Apr 2033	1,410	1,463	\$1,750 5.2%, Apr 2063	1,710	1,709
\$1,250 5%, Apr 2034	1,214	—	\$1,100 5.5%, Apr 2064	1,085	—
\$2,000 5.15%, Jul 2034	1,959	—	\$1,850 5.75%, Jul 2064	1,822	—
			Total short-term borrowings and long-term debt	<u>\$ 76,180</u>	<u>\$ 61,473</u>

The Company's long-term debt obligations also included \$0.7 billion and \$1.1 billion of other financing obligations, of which \$197 million and \$188 million were current as of December 31, 2024 and 2023, respectively.

Maturities of short-term borrowings and long-term debt for the years ending December 31 are as follows:

(in millions)	
2025	\$ 4,548
2026	3,756
2027	3,531
2028	3,106
2029	3,656
Thereafter	59,908

Short-Term Borrowings

Commercial paper consists of short-duration, senior unsecured debt privately placed on a discount basis through broker-dealers. As of December 31, 2024, the Company's outstanding commercial paper had a weighted-average annual interest rate of 4.4%.

The Company has \$7.0 billion five-year, \$7.0 billion three-year and \$7.0 billion 364-day revolving bank credit facilities with 26 banks, which mature in December 2029, December 2027 and December 2025, respectively. These facilities provide full liquidity support for the Company's commercial paper program and are available for general corporate purposes. As of December 31, 2024, no amounts had been drawn on any of the bank credit facilities. The annual interest rates, which are variable based on term, are calculated based on one-month term Secured Overnight Financing Rate (SOFR) plus a SOFR Adjustment of 10 basis points plus a credit spread based on the Company's senior unsecured credit ratings. If amounts had been drawn on the bank credit facilities as of December 31, 2024, annual interest rates would have ranged from 4.9% to 7.5%.

Debt Covenants

As of December 31, 2024, the Company was in compliance with the various covenants under its bank credit facilities.

9. Income Taxes

The current income tax provision reflects the tax consequences of revenues and expenses currently taxable or deductible on various income tax returns for the year reported. The deferred income tax provision or benefit generally reflects the net change in deferred income tax assets and liabilities during the year, excluding any deferred income tax assets and liabilities of acquired businesses.

The components of income before income taxes, based upon tax jurisdiction, for the years ended December 31 are as follows:

(in millions)	2024	2023	2022
Income before income taxes:			
Domestic	\$ 28,264	\$ 29,210	\$ 26,685
Foreign	(8,193)	(98)	(342)
Total income before income taxes	<u>\$ 20,071</u>	<u>\$ 29,112</u>	<u>\$ 26,343</u>

The components of the provision for income taxes for the years ended December 31 are as follows:

(in millions)	2024	2023	2022
Current Provision:			
Federal	\$ 3,453	\$ 4,418	\$ 4,842
State and local	416	716	855
Foreign	1,256	1,079	680
Total current provision	5,125	6,213	6,377
Deferred benefit	(296)	(245)	(673)
Total provision for income taxes	<u>\$ 4,829</u>	<u>\$ 5,968</u>	<u>\$ 5,704</u>

The reconciliation of the tax provision at the U.S. federal statutory rate to the provision for income taxes and the effective tax rate for the years ended December 31 is as follows:

(in millions, except percentages)	2024		2023		2022	
Tax provision at the U.S. federal statutory rate	\$ 4,215	21.0 %	\$ 6,114	21.0 %	\$ 5,532	21.0 %
State income taxes, net of federal benefit	343	1.7	567	2.0	621	2.4
Share-based awards - excess tax benefit	(96)	(0.5)	(75)	(0.3)	(110)	(0.4)
Non-deductible compensation	171	0.9	174	0.6	150	0.6
Foreign rate differential	(369)	(1.8)	(442)	(1.5)	(265)	(1.0)
Tax effect of dispositions and other strategic transactions	1,215	6.1	(29)	(0.1)	(215)	(0.8)
Other, net	(650)	(3.3)	(341)	(1.2)	(9)	(0.1)
Provision for income taxes	<u>\$ 4,829</u>	<u>24.1 %</u>	<u>\$ 5,968</u>	<u>20.5 %</u>	<u>\$ 5,704</u>	<u>21.7 %</u>

Deferred income tax assets and liabilities are recognized for the differences between the financial and income tax reporting bases of assets and liabilities based on enacted tax rates and laws. The components of deferred income tax assets and liabilities as of December 31 are as follows:

(in millions)	2024	2023
Deferred income tax assets:		
Accrued expenses and allowances	\$ 1,055	\$ 754
U.S. federal and state net operating loss carryforwards	442	417
Share-based compensation	189	173
Nondeductible liabilities	343	329
Non-U.S. tax loss carryforwards	21	1,061
Lease liability	846	930
Net unrealized losses on investments	669	586
Other-domestic	597	327
Other-non-U.S.	59	484
Subtotal	4,221	5,061
Less: valuation allowances	(397)	(366)
Total deferred income tax assets	<u>3,824</u>	<u>4,695</u>
Deferred income tax liabilities:		
U.S. federal and state intangible assets	(4,479)	(3,712)
Non-U.S. goodwill and intangible assets	(82)	(731)
Capitalized software	(288)	(415)
Depreciation and amortization	(400)	(371)
Prepaid expenses	(374)	(326)
Outside basis in partnerships	(960)	(811)
Lease right-of-use asset	(833)	(914)
Other-non-U.S.	(28)	(436)
Total deferred income tax liabilities	<u>(7,444)</u>	<u>(7,716)</u>
Net deferred income tax liabilities	<u>\$ (3,620)</u>	<u>\$ (3,021)</u>

Valuation allowances are provided when it is considered more likely than not deferred tax assets will not be realized. The valuation allowances primarily relate to future tax benefits on certain federal, state and non-U.S. net operating loss carryforwards. Substantially all of the federal net operating loss carryforwards have indefinite carryforward periods; state net operating loss carryforwards expire beginning in 2025 through 2044, with some having an indefinite carryforward period. Additionally, as of December 31, 2024, the Company has historical non-U.S. net operating loss carryforwards for which a deferred tax asset and valuation allowance of \$4.1 billion are not established because realization of the loss carryforwards is remote.

As of December 31, 2024, except for subsidiaries held for sale, the Company's undistributed earnings from non-U.S. subsidiaries are intended to be indefinitely reinvested in non-U.S. operations, and therefore no U.S. deferred taxes have been recorded. Taxes payable on the remittance of such earnings would be minimal.

A reconciliation of the beginning and ending amount of unrecognized tax benefits as of December 31 is as follows:

(in millions)	2024	2023	2022
Gross unrecognized tax benefits, beginning of period	\$ 3,716	\$ 3,081	\$ 2,310
Gross increases:			
Current year tax positions	578	782	586
Prior year tax positions	10	97	206
Gross decreases:			
Prior year tax positions	(121)	(212)	(21)
Statute of limitations lapses and settlements	(60)	(32)	—
Gross unrecognized tax benefits, end of period	<u>\$ 4,123</u>	<u>\$ 3,716</u>	<u>\$ 3,081</u>

The Company believes it is reasonably possible its liability for unrecognized tax benefits will decrease in the next twelve months by \$101 million as a result of audit settlements and the expiration of statutes of limitations.

The Company classifies net interest and penalties associated with uncertain income tax positions as income taxes within its Consolidated Statements of Operations. During the years ended December 31, 2024, 2023 and 2022, the Company recognized \$210 million, \$177 million and \$64 million of net interest and penalties, respectively. The Company had \$637 million and \$430 million of accrued interest and penalties for uncertain tax positions as of December 31, 2024 and 2023, respectively. These amounts are not included in the reconciliation above. As of December 31, 2024, there were \$2.0 billion of unrecognized tax benefits which, if recognized, would affect the effective tax rate.

The Company currently files income tax returns in the United States, various states and localities and non-U.S. jurisdictions. The U.S. Internal Revenue Service (IRS) has completed exams on the consolidated income tax returns for fiscal years 2016 and prior. The Company's 2017 through 2020 tax years are under review by the IRS under its Compliance Assurance Program. The Company is no longer subject to state income tax examinations prior to the 2015 tax year. The Company is subject to examination in non-U.S. jurisdictions for years 2015 and forward.

10. Shareholders' Equity

Regulatory Capital and Dividend Restrictions

The Company's regulated insurance and HMO subsidiaries are subject to regulations and standards in their respective jurisdictions. These standards, among other things, require these subsidiaries to maintain specified levels of statutory capital, as defined by each jurisdiction, and restrict the timing and amount of dividends and other distributions which may be paid to their parent companies. In the United States, most of these state regulations and standards are generally consistent with model regulations established by the NAIC. These standards generally permit dividends to be paid from statutory unassigned surplus of the regulated subsidiary and are limited based on the regulated subsidiary's level of statutory net income and statutory capital and surplus. These dividends are referred to as "ordinary dividends" and generally may be paid without prior regulatory approval. If the dividend, together with other dividends paid within the preceding twelve months, exceeds a specified statutory limit or is paid from sources other than earned surplus, it is generally considered an "extraordinary dividend" and must receive prior regulatory approval.

For the year ended December 31, 2024, the Company's domestic insurance and HMO subsidiaries paid their parent companies dividends of \$9.2 billion, including \$2.6 billion of extraordinary dividends. For the year ended December 31, 2023, the Company's domestic insurance and HMO subsidiaries paid their parent companies dividends of \$8.0 billion, including \$4.9 billion of extraordinary dividends.

The Company's financially regulated subsidiaries had estimated aggregate statutory capital and surplus of \$37.8 billion as of December 31, 2024. The estimated statutory capital and surplus necessary to satisfy regulatory requirements of the Company's financially regulated subsidiaries was approximately \$20.4 billion as of December 31, 2024.

Optum Bank must meet minimum capital requirements of the FDIC under the capital adequacy rules to which it is subject. At December 31, 2024, the Company believes Optum Bank met the FDIC requirements to be considered "Well Capitalized."

Share Repurchase Program

Under its Board of Directors' authorization, the Company maintains a share repurchase program. The objectives of the share repurchase program are to optimize the Company's capital structure and cost of capital, thereby improving returns to shareholders, as well as to offset the dilutive impact of share-based awards. Repurchases may be made from time to time in open market purchases or other types of transactions (including prepaid or structured share repurchase programs), subject to certain restrictions. In June 2024, the Board of Directors amended the Company's share repurchase program to authorize the

repurchase of up to 35 million shares of its common stock, in addition to all remaining shares authorized to be repurchased under the Board's 2018 renewal of the program. The Board of Directors from time to time may further amend the share repurchase program in order to increase the authorized number of shares which may be repurchased under the program.

A summary of common share repurchases for the years ended December 31, 2024 and 2023 is as follows:

(in millions, except per share data)	Years Ended December 31,	
	2024	2023
Common share repurchases, shares.....	17	16
Common share repurchases, average price per share.....	\$ 529.85	\$ 493.79
Common share repurchases, aggregate cost.....	\$ 8,942	\$ 8,000
Board authorized shares remaining.....	33	15

Dividends

In June 2024, the Company's Board of Directors increased the Company's quarterly cash dividend to shareholders to an annual rate of \$8.40 compared to \$7.52 per share, which the Company had paid since June 2023. Declaration and payment of future quarterly dividends is at the discretion of the Board and may be adjusted as business needs or market conditions change.

The following table provides details of the Company's 2024 dividend payments:

Payment Date	Amount per Share	Total Amount Paid
		(in millions)
March 19	\$ 1.88	\$ 1,729
June 25	2.10	1,935
September 24.....	2.10	1,937
December 17	2.10	1,932

11. Share-Based Compensation

The Company's outstanding share-based awards consist mainly of non-qualified stock options and restricted shares. As of December 31, 2024, the Company had 48 million shares available for future grants of share-based awards under the 2020 Stock Incentive Plan. As of December 31, 2024, there were 16 million shares of common stock available for issuance under the ESPP.

Stock Options

Stock option activity for the year ended December 31, 2024 is summarized in the table below:

	Shares	Weighted-Average Exercise Price	Weighted-Average Remaining Contractual Life	Aggregate Intrinsic Value
	(in millions)		(in years)	(in millions)
Outstanding at beginning of period.....	21	\$ 320		
Granted.....	3	522		
Exercised.....	(6)	253		
Forfeited.....	(1)	480		
Outstanding at end of period.....	17	370	5.6	\$ 2,338
Exercisable at end of period.....	10	298	4.2	2,115
Vested and expected to vest, end of period.....	17	368	5.5	2,335

Restricted Shares

Restricted share activity for the year ended December 31, 2024 is summarized in the table below:

(shares in millions)	Shares	Weighted-Average Grant Date Fair Value per Share
Nonvested at beginning of period	4	\$ 449
Granted	2	523
Vested	(2)	435
Nonvested at end of period	4	489

Other Share-Based Compensation Data

(in millions, except per share amounts)	For the Years Ended December 31,		
	2024	2023	2022
Stock Options			
Weighted-average grant date fair value of shares granted, per share	\$ 138	\$ 134	\$ 116
Total intrinsic value of stock options exercised	1,886	1,325	1,419
Restricted Shares			
Weighted-average grant date fair value of shares granted, per share	523	493	483
Total fair value of restricted shares vested	690	803	760
Employee Stock Purchase Plan			
Number of shares purchased	1	1	1
Share-Based Compensation Items			
Share-based compensation expense, before tax	\$ 1,018	\$ 1,059	\$ 925
Share-based compensation expense, net of tax effects	896	937	836
Income tax benefit realized from share-based award exercises	216	231	207

(in millions, except years)	December 31, 2024
Unrecognized compensation expense related to share awards	\$ 1,099
Weighted-average years to recognize compensation expense	1.3

Share-Based Compensation Recognition and Estimates

The principal assumptions the Company used in calculating grant-date fair value for stock options were as follows:

	For the Years Ended December 31,		
	2024	2023	2022
Risk-free interest rate	3.6% - 4.4%	3.8% - 4.6%	1.9% - 4.3%
Expected volatility	25.5% - 30.7%	29.7% - 30.6%	30.6% - 30.8%
Expected dividend yield	1.4% - 1.5%	1.3% - 1.5%	1.2%
Forfeiture rate	5.0%	5.0%	5.0%
Expected life in years	4.6	4.6	4.7

Risk-free interest rates are based on U.S. Treasury yields in effect at the time of grant. Expected volatilities are based on the historical volatility of the Company's common stock and the implied volatility from exchange-traded options on the Company's common stock. Expected dividend yields are based on the per share cash dividend paid by the Company. The Company uses historical data to estimate option exercises and forfeitures within the valuation model. The expected lives of options granted represent the periods of time the awards granted are expected to be outstanding based on historical exercise patterns.

Other Employee Benefit Plans

The Company offers a 401(k) plan for its employees. Compensation expense related to this plan was not material for the years ended December 31, 2024, 2023 and 2022.

In addition, the Company maintains non-qualified, deferred compensation plans, which allow certain members of senior management and executives to defer portions of their salary or bonus. The deferrals are recorded within long-term investments

with an approximately equal amount in other liabilities in the Consolidated Balance Sheets. The total deferrals are distributable based upon termination of employment or other periods, as elected under each plan and were \$2.1 billion and \$1.9 billion as of December 31, 2024 and 2023, respectively.

12. Commitments and Contingencies

Leases

Operating lease costs, including immaterial variable and short-term lease costs, were \$1.4 billion, \$1.4 billion and \$1.3 billion for the years ended December 31, 2024, 2023 and 2022, respectively. Cash payments made on the Company's operating lease liabilities were \$1.1 billion, \$1.1 billion and \$1.0 billion for the years ended December 31, 2024, 2023 and 2022, respectively, which were classified within operating activities in the Consolidated Statements of Cash Flows. As of December 31, 2024, the Company's weighted-average remaining lease term and weighted-average discount rate for its operating leases were 9.5 years and 4.7%, respectively.

As of December 31, 2024, future minimum annual lease payments under all non-cancelable operating leases were as follows:

(in millions)	Future Minimum Lease Payments
2025	\$ 1,014
2026	876
2027	688
2028	568
2029	583
Thereafter	2,465
Total future minimum lease payments	6,194
Less imputed interest	(1,305)
Total	<u>\$ 4,889</u>

Other Commitments

The Company provides guarantees related to its service level under certain contracts. If minimum standards are not met, the Company may be financially at risk up to a stated percentage of the contracted fee or a stated dollar amount. None of the amounts accrued, paid or charged to income for service level guarantees were material as of December 31, 2024, 2023 or 2022.

Pending Acquisitions

As of December 31, 2024, the Company has entered into agreements to acquire companies in the health care sector, subject to regulatory approval and other customary closing conditions. The total anticipated capital required for these acquisitions, excluding the payoff of acquired indebtedness, is approximately \$4 billion.

Legal Matters

The Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits brought by members, care providers, consumer advocacy organizations, customers and regulators, relating to the Company's businesses, including management and administration of health benefit plans and other services. These matters include medical malpractice, employment, intellectual property, antitrust, privacy and contract claims and claims related to health care benefits coverage and other business practices.

The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable a loss may be incurred.

Government Investigations, Audits and Reviews

The Company has been involved or is currently involved in various governmental investigations, audits and reviews. These include routine, regular and special investigations, audits and reviews by CMS, state insurance and health and welfare departments, state attorneys general, the Office of the Inspector General, the Office of Personnel Management, the Office for Civil Rights, the Government Accountability Office, the Federal Trade Commission, U.S. Congressional committees, the U.S. Department of Justice (DOJ), the SEC, the IRS, the U.S. Drug Enforcement Administration, the U.S. Department of Labor, the

FDIC, the Consumer Financial Protection Bureau, the Defense Contract Audit Agency, the Food and Drug Administration and other governmental authorities. Similarly, the Company's international businesses are also subject to investigations, audits and reviews by applicable foreign governments and other non-U.S. governmental authorities. Certain of the Company's businesses have been reviewed or are currently under review, including for, among other matters, compliance with coding and other requirements under the Medicare risk-adjustment model. CMS has selected certain of the Company's local plans for risk adjustment data validation (RADV) audits to validate the coding practices of and supporting documentation maintained by health care providers and such audits may result in retrospective adjustments to payments made to the Company's health plans. On February 14, 2017, the DOJ announced its decision to pursue certain claims within a lawsuit initially asserted against the Company and filed under seal by a whistleblower in 2011. The whistleblower's complaint, which was unsealed on February 15, 2017, alleges the Company made improper risk adjustment submissions and violated the False Claims Act. On February 12, 2018, the court granted in part and denied in part the Company's motion to dismiss. In May 2018, the DOJ moved to dismiss the Company's counterclaims, which were filed in March 2018, and moved for partial summary judgment. In March 2019, the court denied the government's motion for partial summary judgment and dismissed the Company's counterclaims without prejudice. The Company cannot reasonably estimate the outcome which may result from this matter given its procedural status.

13. Dispositions and Held for Sale

During the year ended December 31, 2024, the Company completed or initiated various business portfolio refinement and asset disposition activities. The Company recorded a loss of \$7.1 billion related to the sale of its Brazil operations, of which \$4.1 billion related to the impact of cumulative foreign currency translation losses previously included in accumulated other comprehensive loss, and a loss of \$1.2 billion related to the reclassification of the Company's remaining South American operations as held for sale, of which \$855 million related to the impact of cumulative foreign currency translation losses.

As these losses relate to our strategic exit of South American markets and include significant losses related to foreign currency translation effects, these losses are included within loss on sale of subsidiary and subsidiaries held for sale on the Consolidated Statement of Operations. The sales of the Company's remaining South American assets are expected to close within a year, subject to regulatory and other customary closing conditions. Assets and liabilities held for sale have been included within prepaid and other current assets and other current liabilities on the Consolidated Balance Sheet, respectively.

The assets and liabilities of the Brazil and held for sale disposal groups as of the date of the sale and as of December 31, 2024, respectively, were as follows:

(in millions)	Brazil Disposition	Businesses Held for Sale
Assets		
Cash and cash equivalents	\$ 778	\$ 219
Accounts receivable and other current assets	515	573
Long-term investments	788	41
Property, equipment and capitalized software	1,052	641
Deferred tax assets	1,035	—
Goodwill and other intangible assets	317	413
Other long-term assets	439	231
Remeasurement of assets of businesses held for sale to fair value less cost to sell ⁽¹⁾	—	(1,224)
Total assets	<u>\$ 4,924</u>	<u>\$ 894</u>
Liabilities		
Medical costs payable	\$ 701	\$ 179
Accounts payable and other current liabilities	834	338
Other long-term liabilities	136	504
Total liabilities	<u>\$ 1,671</u>	<u>\$ 1,021</u>

⁽¹⁾ Includes the effect of \$855 million of cumulative foreign currency translation losses and \$56 million of noncontrolling interests.

As a result of continued portfolio refinement, the Company sold other businesses and assets and entered into strategic transactions. These transactions resulted in total consideration received of \$3.0 billion and an additional \$1.9 billion of equity method investments related to the valuation of our retained interests in certain transactions. The carrying value for these transactions was \$1.0 billion, primarily related to goodwill. The gains from business portfolio refinement, including strategic

transactions, were recorded within operating costs in the Consolidated Statement of Operations and contributed about 80 basis points (\$3.3 billion) to the operating cost ratio, nearly half (\$1.4 billion) related to Optum Health with the remainder split between UnitedHealthcare (\$1.1 billion) and Optum Insight (\$800 million). Certain transactions also included various put and call options, which were valued at \$630 million and included in other liabilities on the Consolidated Balance Sheet. As of December 31, 2024 the total estimated future obligation under these arrangements if the Company decided or was required to repurchase these interests was up to \$3.4 billion.

14. Segment Financial Information

Factors used to determine the Company's reportable segments include the nature of operating activities, economic characteristics, existence of separate senior management teams and the type of information used by the Company's chief operating decision maker (CODM), which is the Chief Executive Officer, to evaluate its results of operations. Reportable segments with similar economic characteristics, products and services, customers, distribution methods and operational processes which operate in a similar regulatory environment are combined. The CODM uses consolidated expense information and segment earnings from operations to assess performance and determine allocation of resources.

The following is a description of the types of products and services from which each of the Company's four reportable segments derives its revenues:

- *UnitedHealthcare* includes the combined results of operations of UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and UnitedHealthcare Community & State. The businesses share significant common assets, including a contracted network of physicians, health care professionals, hospitals and other facilities, information technology and consumer engagement infrastructure and other resources. UnitedHealthcare Employer & Individual offers an array of consumer-oriented health benefit plans and services for employers and individuals. UnitedHealthcare Medicare & Retirement provides health care coverage and health and well-being services to individuals age 50 and older, addressing their unique needs. UnitedHealthcare Community & State provides diversified health care benefits products and services to state programs caring for the economically disadvantaged, the medically underserved and those without the benefit of employer-funded health care coverage.
- *Optum Health* focuses on care delivery, including value-based care; care management; wellness and consumer engagement and health financial services. Optum Health is building a comprehensive, connected health care delivery and engagement platform by directly providing high-quality care, helping people manage chronic and complex health needs, and proactively engaging consumers in managing their health through in-person, in-home, virtual and digital clinical platforms.
- *Optum Insight* brings together advanced analytics, technology and health care expertise to deliver integrated services and solutions. Hospital systems, physicians, health plans, governments, life sciences companies and other organizations depend on Optum Insight to help them improve performance, achieve efficiency, reduce costs, meet compliance mandates and modernize their core operating systems to meet the changing needs of the health system.
- *Optum Rx* offers pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, purchasing and clinical capabilities, and develops programs in areas such as step therapy, formulary management, drug adherence and disease and drug therapy management. Optum Rx integrates pharmacy and medical care and is positioned to serve patients with complex clinical needs and consumers looking for a better digital pharmacy experience with transparent pricing.

The Company's accounting policies for reportable segment operations are consistent with those described in the Summary of Significant Accounting Policies (see Note 2). Transactions between reportable segments principally consist of sales of pharmacy care products and services to UnitedHealthcare customers by Optum Rx; care delivery, care management services and certain product offerings sold to UnitedHealthcare by Optum Health; and health information and technology solutions, consulting and other services sold to UnitedHealthcare by Optum Insight. These transactions are recorded at management's estimate of fair value. Transactions with affiliated customers are eliminated in consolidation. Assets and liabilities jointly used are assigned to each reportable segment using estimates of pro-rata usage. Cash and investments are assigned so each reportable segment has working capital and/or at least minimum specified levels of regulatory capital.

As a percentage of the Company's total consolidated revenues, premium revenues from CMS were 40%, 40% and 38% for the years ended December 31, 2024, 2023 and 2022, respectively, most of which were generated by UnitedHealthcare Medicare & Retirement and included in the UnitedHealthcare segment. U.S. customer revenue represented approximately 99%, 97% and 97% of consolidated total revenues for 2024, 2023 and 2022, respectively. Long-lived fixed assets located in the United States represented approximately 92% and 82% of the total long-lived fixed assets as of December 31, 2024 and 2023, respectively. The non-U.S. revenues and fixed assets are primarily related to UnitedHealthcare Employer & Individual's international businesses.

The following table presents the reportable segment financial information:

(in millions)	Optum						Corporate and Eliminations	Consolidated
	UnitedHealthcare	Optum Health	Optum Insight	Optum Rx	Optum Eliminations	Optum		
2024								
Revenues - unaffiliated customers:								
Premiums	\$ 286,004	\$ 22,806	\$ —	\$ —	\$ —	\$ 22,806	\$ —	\$ 308,810
Products	—	277	174	49,775	—	50,226	—	50,226
Services	9,791	16,153	6,466	3,630	—	26,249	—	36,040
Total revenues - unaffiliated customers	295,795	39,236	6,640	53,405	—	99,281	—	395,076
Total revenues - affiliated customers	—	63,883	11,881	79,512	(4,389)	150,887	(150,887)	—
Investment and other income	2,413	2,239	236	314	—	2,789	—	5,202
Total revenues	\$ 298,208	\$ 105,358	\$ 18,757	\$ 133,231	\$ (4,389)	\$ 252,957	\$ (150,887)	\$ 400,278
Total operating costs (a)	\$ 282,624	\$ 97,588	\$ 15,660	\$ 127,395	\$ (4,389)	\$ 236,254	\$ (150,887)	\$ 367,991
Earnings from operations	\$ 15,584	\$ 7,770	\$ 3,097	\$ 5,836	\$ —	\$ 16,703	\$ —	\$ 32,287
Interest expense	—	—	—	—	—	—	(3,906)	(3,906)
Loss on sale of subsidiary and subsidiaries held for sale	(8,310)	—	—	—	—	—	—	(8,310)
Earnings before income taxes	\$ 7,274	\$ 7,770	\$ 3,097	\$ 5,836	\$ —	\$ 16,703	\$ (3,906)	\$ 20,071
Total assets	\$ 119,009	\$ 96,472	\$ 34,452	\$ 59,086	\$ —	\$ 190,010	\$ (10,741)	\$ 298,278
Purchases of property, equipment and capitalized software	781	1,008	1,291	419	—	2,718	—	3,499
Depreciation and amortization	889	1,123	1,294	793	—	3,210	—	4,099
2023								
Revenues - unaffiliated customers:								
Premiums	\$ 269,052	\$ 21,775	\$ —	\$ —	\$ —	\$ 21,775	\$ —	\$ 290,827
Products	—	207	162	42,214	—	42,583	—	42,583
Services	10,057	14,109	7,760	2,197	—	24,066	—	34,123
Total revenues - unaffiliated customers	279,109	36,091	7,922	44,411	—	88,424	—	367,533
Total revenues - affiliated customers	—	57,696	10,896	71,484	(3,703)	136,373	(136,373)	—
Investment and other income	2,251	1,532	114	192	—	1,838	—	4,089
Total revenues	\$ 281,360	\$ 95,319	\$ 18,932	\$ 116,087	\$ (3,703)	\$ 226,635	\$ (136,373)	\$ 371,622
Total operating costs (a)	\$ 264,945	\$ 88,759	\$ 14,664	\$ 110,972	\$ (3,703)	\$ 210,692	\$ (136,373)	\$ 339,264
Earnings from operations	\$ 16,415	\$ 6,560	\$ 4,268	\$ 5,115	\$ —	\$ 15,943	\$ —	\$ 32,358
Interest expense	—	—	—	—	—	—	(3,246)	(3,246)
Earnings before income taxes	\$ 16,415	\$ 6,560	\$ 4,268	\$ 5,115	\$ —	\$ 15,943	\$ (3,246)	\$ 29,112
Total assets	\$ 110,943	\$ 89,432	\$ 34,173	\$ 51,266	\$ —	\$ 174,871	\$ (12,094)	\$ 273,720
Purchases of property, equipment and capitalized software	866	1,199	974	347	—	2,520	—	3,386
Depreciation and amortization	989	1,058	1,229	696	—	2,983	—	3,972
2022								
Revenues - unaffiliated customers:								
Premiums	\$ 238,783	\$ 18,374	\$ —	\$ —	\$ —	\$ 18,374	\$ —	\$ 257,157
Products	—	72	180	37,172	—	37,424	—	37,424
Services	10,035	10,917	4,996	1,603	—	17,516	—	27,551
Total revenues - unaffiliated customers	248,818	29,363	5,176	38,775	—	73,314	—	322,132
Total revenues - affiliated customers	—	40,883	9,288	60,936	(2,760)	108,347	(108,347)	—
Investment and other income	923	928	117	62	—	1,107	—	2,030
Total revenues	\$ 249,741	\$ 71,174	\$ 14,581	\$ 99,773	\$ (2,760)	\$ 182,768	\$ (108,347)	\$ 324,162
Total operating costs (a)	\$ 235,362	\$ 65,142	\$ 10,993	\$ 95,337	\$ (2,760)	\$ 168,712	\$ (108,347)	\$ 295,727
Earnings from operations	\$ 14,379	\$ 6,032	\$ 3,588	\$ 4,436	\$ —	\$ 14,056	\$ —	\$ 28,435
Interest expense	—	—	—	—	—	—	(2,092)	(2,092)
Earnings before income taxes	\$ 14,379	\$ 6,032	\$ 3,588	\$ 4,436	\$ —	\$ 14,056	\$ (2,092)	\$ 26,343
Total assets	\$ 107,094	\$ 68,950	\$ 31,090	\$ 47,476	\$ —	\$ 147,516	\$ (8,905)	\$ 245,705
Purchases of property, equipment and capitalized software	799	997	698	308	—	2,003	—	2,802
Depreciation and amortization	973	943	841	643	—	2,427	—	3,400

(a) Total operating costs include medical costs, operating costs, cost of products sold and depreciation and amortization, as applicable for each reportable segment.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A. CONTROLS AND PROCEDURES

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (Exchange Act) designed to provide reasonable assurance the information required to be disclosed by us in reports we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms; and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

In connection with the filing of this Annual Report on Form 10-K, management evaluated, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, 2024. Based upon their evaluation, our Chief Executive Officer and Chief Financial Officer concluded our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2024.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

There have been no changes in our internal control over financial reporting during the quarter ended December 31, 2024 which have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Report of Management on Internal Control Over Financial Reporting as of December 31, 2024

Management of UnitedHealth Group Incorporated and Subsidiaries (the Company) is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. The Company's internal control system is designed to provide reasonable assurance to our management and board of directors regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles. The Company's internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company's assets that could have a material effect on the consolidated financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management assessed the effectiveness of the Company's internal control over financial reporting as of December 31, 2024. In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013). Based on our assessment and the COSO criteria, we believe that, as of December 31, 2024, the Company maintained effective internal control over financial reporting.

The Company's independent registered public accounting firm has audited the Company's internal control over financial reporting as of December 31, 2024, as stated in the Report of Independent Registered Public Accounting Firm, appearing under Item 9A.

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the shareholders and the Board of Directors of UnitedHealth Group Incorporated and Subsidiaries:

Opinion on Internal Control over Financial Reporting

We have audited the internal control over financial reporting of UnitedHealth Group Incorporated and subsidiaries (the “Company”) as of December 31, 2024, based on criteria established in *Internal Control — Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in *Internal Control — Integrated Framework (2013)* issued by COSO.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2024, of the Company and our report dated February 27, 2025, expressed an unqualified opinion on those financial statements.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Report of Management on Internal Control Over Financial Reporting as of December 31, 2024. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ DELOITTE & TOUCHE LLP

Minneapolis, Minnesota

February 27, 2025

ITEM 9B. OTHER INFORMATION

Trading Arrangements

During the quarter ended December 31, 2024, none of the Company's directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or under any non-Rule 10b5-1 trading arrangement.

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

Not Applicable.

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The following sets forth certain information regarding our directors as of February 27, 2025, including their name and principal occupation or employment:

Charles Baker

President
National Collegiate Athletic Association

Michele Hooper

Lead Independent Director
UnitedHealth Group
President and Chief Executive Officer
The Directors' Council

Timothy Flynn

Retired Chair
KPMG International

F. William McNabb III

Former Chairman and Chief Executive Officer
The Vanguard Group, Inc.

Paul Garcia

Retired Chair and Chief Executive Officer
Global Payments Inc.

Valerie Montgomery Rice, M.D.

President and Chief Executive Officer
Morehouse School of Medicine

Kristen Gil

Former Vice President and Business Finance Officer
Alphabet Inc.

John Noseworthy, M.D.

Former Chief Executive Officer and President
Mayo Clinic

Stephen Hemsley

Chair
UnitedHealth Group

Andrew Witty

Chief Executive Officer
UnitedHealth Group

Pursuant to General Instruction G(3) to Form 10-K and the Instruction to Item 401 of Regulation S-K, information regarding our executive officers is provided in Part I, Item 1 under the caption "Information About our Executive Officers."

We have adopted a code of ethics applicable to our principal executive officer and other senior financial officers, who include our principal financial officer, principal accounting officer, controller and persons performing similar functions. The code of ethics, entitled Code of Conduct: Our Principles of Ethics and Integrity, is posted on our website at www.unitedhealthgroup.com. For information about how to obtain the Code of Conduct, see Part I, Item 1, "Business." We intend to satisfy the SEC's disclosure requirements regarding amendments to, or waivers of, the code of ethics for our senior financial officers by posting such information on our website indicated above.

The remaining information required by Items 401, 405, 406 and 407(c)(3), (d)(4) and (d)(5) of Regulation S-K will be included under the headings "Corporate Governance" and "Proposal 1-Election of Directors" in our definitive proxy statement for our 2025 Annual Meeting of Shareholders, and such required information is incorporated herein by reference.

The information required by Item 408(b) of Regulation S-K will be included under the heading "Insider Trading Policy" in our definitive proxy statement for our 2025 Annual Meeting of Shareholders, and such required information is incorporated herein by reference. A copy of our insider trading policy is filed as Exhibit 19.1 to this Form 10-K.

ITEM 11. EXECUTIVE COMPENSATION

The information required by Items 402 and 407(e)(4) and (e)(5) of Regulation S-K will be included under the headings “Executive Compensation,” “Director Compensation,” “Corporate Governance - Risk Oversight” and “Compensation Committee Interlocks and Insider Participation” in our definitive proxy statement for our 2025 Annual Meeting of Shareholders, and such required information is incorporated herein by reference.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

Equity Compensation Plan Information

The following table sets forth certain information as of December 31, 2024, concerning shares of common stock authorized for issuance under all of our equity compensation plans:

Plan category	(a) Number of securities to be issued upon exercise of outstanding options, warrants and rights	(b) Weighted-average exercise price of outstanding options, warrants and rights	(c) Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))
	(in millions)		(in millions)
Equity compensation plans approved by shareholders ⁽¹⁾	17	\$ 370	64 ⁽³⁾
Equity compensation plans not approved by shareholders ⁽²⁾	—		—
Total ⁽²⁾	17	\$ 370	64

(1) Consists of the UnitedHealth Group Incorporated 2020 Stock Incentive Plan (the “2020 Stock Incentive Plan”), as amended, and the UnitedHealth Group 1993 Employee Stock Purchase Plan, as amended (the “ESPP”).

(2) Excludes 60,000 shares underlying stock options assumed by us in connection with acquisitions. These options have a weighted-average exercise price of \$373 and an average remaining term of approximately 2.4 years. These options are administered pursuant to the terms of the plans under which the options originally were granted. No future awards will be granted under these acquired plans.

(3) Includes 16 million shares of common stock available for future issuance under the ESPP as of December 31, 2024, and 48 million shares available under the 2020 Stock Incentive Plan as of December 31, 2024. Shares available under the 2020 Stock Incentive Plan may become the subject of future awards in the form of stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards and other stock-based awards.

The information required by Item 403 of Regulation S-K will be included under the heading “Security Ownership of Certain Beneficial Owners and Management” in our definitive proxy statement for our 2025 Annual Meeting of Shareholders, and such required information is incorporated herein by reference.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

The information required by Items 404 and 407(a) of Regulation S-K will be included under the headings “Certain Relationships and Transactions” and “Corporate Governance” in our definitive proxy statement for our 2025 Annual Meeting of Shareholders, and such required information is incorporated herein by reference.

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

The information required by Item 9(e) of Schedule 14A will be included under the heading “Disclosure of Fees Paid to Independent Registered Public Accounting Firm” in our definitive proxy statement for our 2025 Annual Meeting of Shareholders, and such required information is incorporated herein by reference.

PART IV

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

(a) 1. *Financial Statements*

The financial statements are included under Item 8 of this report:

- Reports of Independent Registered Public Accounting Firm.
- Consolidated Balance Sheets as of December 31, 2024 and 2023.
- Consolidated Statements of Operations for the years ended December 31, 2024, 2023, and 2022.
- Consolidated Statements of Comprehensive Income for the years ended December 31, 2024, 2023, and 2022.
- Consolidated Statements of Changes in Equity for the years ended December 31, 2024, 2023, and 2022.
- Consolidated Statements of Cash Flows for the years ended December 31, 2024, 2023, and 2022.
- Notes to the Consolidated Financial Statements.

2. *Financial Statement Schedules*

The following financial statement schedule of the Company is included in Item 15(c):

- Schedule I - Condensed Financial Information of Registrant (Parent Company Only).

All other schedules for which provision is made in the applicable accounting regulations of the SEC are not required under the related instructions, are inapplicable, or the required information is included in the consolidated financial statements, and therefore have been omitted.

- (b) The following exhibits are filed or incorporated by reference herein in response to Item 601 of Regulation S-K. The Company files Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K pursuant to the Securities Exchange Act of 1934 under Commission File No. 1-10864.

EXHIBIT INDEX**

- 3.1 Certificate of Incorporation of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.1 to UnitedHealth Group Incorporated's Registration Statement on Form 8-A/A, Commission File No. 1-10864, filed on July 1, 2015)
- 3.2 Amended and Restated Bylaws of UnitedHealth Group Incorporated, effective February 23, 2021 (incorporated by reference to Exhibit 3.2 to UnitedHealth Group Incorporated's Current Report on Form 8-K filed on February 26, 2021)
- 4.1 Amended and Restated Indenture, dated as of April 27, 2023, between UnitedHealth Group Incorporated and Wilmington Trust Company, as successor trustee (incorporated by reference to Exhibit 4.1 to UnitedHealth Group Incorporated's Current Report on Form 8-K filed on April 28, 2023)
- 4.2 Indenture, dated as of February 4, 2008, between UnitedHealth Group Incorporated and U.S. Bank National Association (incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-3, SEC File Number 333-149031, filed on February 4, 2008)
- 4.3 Supplemental Indenture, dated as of April 18, 2023, between UnitedHealth Group Incorporated and U.S. Bank Trust Company, National Association, as trustee, relating to the 6.875% Senior Notes due 2038 (incorporated by reference to Exhibit 4.1 to UnitedHealth Group Incorporated's Current Report on Form 8-K filed on April 24, 2023)
- 4.4 Description of Common Stock (incorporated by reference to Exhibit 4.5 to UnitedHealth Group Incorporated's Annual Report on Form 10-K for the year ended December 31, 2019)
- *10.1 UnitedHealth Group 2020 Stock Incentive Plan (incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-8, SEC File Number 333-238854, filed on June 1, 2020)
- *10.2 Form of Agreement for Restricted Stock Unit Award to Executives under UnitedHealth Group Incorporated's 2020 Stock Incentive Plan (2024 Version) (incorporated by reference to Exhibit 10.2 to UnitedHealth Group Incorporated's Annual Report on Form 10-K for the year ended December 31, 2023)
- *10.3 Form of Agreement for Nonqualified Stock Option Award to Executives under UnitedHealth Group Incorporated's 2020 Stock Incentive Plan (2024 Version) (incorporated by reference to Exhibit 10.3 to UnitedHealth Group Incorporated's Annual Report on Form 10-K for the year ended December 31, 2023)
- *10.4 Form of Agreement for Performance-Based Restricted Stock Unit Award to Executives under UnitedHealth Group Incorporated's 2020 Stock Incentive Plan (2024 Version) (incorporated by reference to Exhibit 10.4 to UnitedHealth Group Incorporated's Annual Report on Form 10-K for the year ended December 31, 2023)

- *10.24 Form of Agreement for Deferred Stock Unit Award to Non-Employee Directors under UnitedHealth Group Incorporated's 2011 Stock Incentive Plan (incorporated by reference to Exhibit 10.6 to UnitedHealth Group Incorporated's Current Report on Form 8-K filed on May 27, 2011)
- *10.25 Form of Agreement for Deferred Stock Unit Award to Non-Employee Directors under UnitedHealth Group Incorporated's 2020 Stock Incentive Plan (incorporated by reference to Exhibit 10.11 to UnitedHealth Group Incorporated's Annual Report on Form 10-K for the year ended December 31, 2021)
- *10.26 Form of Indemnification Agreement (incorporated by reference to Exhibit 10.1 to UnitedHealth Group Incorporated's Current Report on Form 8-K filed on July 1, 2015)
- *10.27 Amended and Restated UnitedHealth Group Incorporated 2008 Executive Incentive Plan, effective as of December 31, 2023 (incorporated by reference to exhibit 10.30 to UnitedHealth Group Incorporated's Annual Report on Form 10-K for the year ended December 31, 2023)
- *10.28 UnitedHealth Group Executive Savings Plan (2024 Statement) (incorporated by reference to Exhibit 10.31 to UnitedHealth Group Incorporated's Annual Report on Form 10-K for the year ended December 31, 2023)
- *10.29 Executive Long-Term Disability Program, dated as of January 1, 2021 (incorporated by reference to Exhibit 10.28 to UnitedHealth Group Incorporated's Annual Report on Form 10-K for the year ended December 31, 2022)
- *10.30 Summary of Non-Management Director Compensation, effective as of October 1, 2022 (incorporated by reference to Exhibit 10.29 to UnitedHealth Group Incorporated's Annual Report on Form 10-K for the year ended December 31, 2022)
- *10.31 UnitedHealth Group Directors' Compensation Deferral Plan (2023 Statement) (incorporated by reference to Exhibit 10.30 to UnitedHealth Group Incorporated's Annual Report on Form 10-K for the year ended December 31, 2022)
- *10.32 Avery Parent Holdings, Inc. 2020 Stock Option and Grant Plan (incorporated by reference to Exhibit 10.31 to UnitedHealth Group Incorporated's Annual Report on Form 10-K for the year ended December 31, 2022)
- *10.33 Change Healthcare Inc. 2019 Omnibus Incentive Plan (incorporated by reference to Exhibit 4.3 to UnitedHealth Group Incorporated's Registration Statement on Form S-8, SEC File Number 333-267716, filed on October 3, 2022)
- *10.34 Amended and Restated HCIT Holdings, Inc. 2009 Equity Incentive Plan (incorporated by reference to Exhibit 4.4 to UnitedHealth Group Incorporated's Registration Statement on Form S-8, SEC File Number 333-267716, filed on October 3, 2022)
- *10.35 Audax Health Solutions, Inc. 2010 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 4.4 to UnitedHealth Group Incorporated's Post-Effective Amendment No. 1 to Registration Statement on Form S-8, SEC File Number 333-205826, filed on February 15, 2017)
- *10.36 Surgical Care Affiliates, Inc. 2016 Omnibus Long-Term Incentive Plan (incorporated by reference to Exhibit 4.3 to UnitedHealth Group Incorporated's Post-Effective Amendment No. 1 on Form S-8 to Registration Statement on Form S-4, SEC File Number 333-216153, filed on March 27, 2017)
- *10.37 Surgical Care Affiliates, Inc. 2013 Omnibus Long-Term Incentive Plan (incorporated by reference to Exhibit 4.4 to UnitedHealth Group Incorporated's Post-Effective Amendment No. 1 on Form S-8 to Registration Statement on Form S-4, SEC File Number 333-216153, filed on March 27, 2017)
- *10.38 Surgical Care Affiliates, Inc. Management Equity Incentive Plan (incorporated by reference to Exhibit 4.5 to UnitedHealth Group Incorporated's Post-Effective Amendment No. 1 on Form S-8 to Registration Statement on Form S-4, SEC File Number 333-216153, filed on March 27, 2017)
- *10.39 Surgical Care Affiliates, Inc. Directors and Consultants Equity Incentive Plan (incorporated by reference to Exhibit 4.6 to UnitedHealth Group Incorporated's Post-Effective Amendment No. 1 on Form S-8 to Registration Statement on Form S-4, SEC File Number 333-216153, filed on March 27, 2017)
- *10.40 The Advisory Board Company Amended and Restated 2009 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to The Advisory Board Company's Current Report on Form 8-K filed on June 15, 2015)
- *10.41 The Advisory Board Company 2005 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to The Advisory Board Company's Current Report on Form 8-K filed on November 17, 2005)
- *10.42 Amended and Restated Employment Agreement, effective as of June 7, 2016, between United HealthCare Services, Inc. and John Rex (incorporated by reference to Exhibit 10.1 to UnitedHealth Group Incorporated's Quarterly Report on Form 10-Q for the quarter ended June 30, 2016)
- *10.43 Amended and Restated Employment Agreement, dated February 3, 2021, between the Company and Andrew P Witty (incorporated by reference to Exhibit 5.02 to UnitedHealth Group Incorporated's Current Report on Form 8-K filed on February 8, 2021)
- *10.44 Amended and Restated Employment Agreement, effective as of February 12, 2018, between United HealthCare Services, Inc. and Brian R. Thompson (incorporated by reference to Exhibit 10.38 to UnitedHealth Group Incorporated's Annual Report on Form 10-K for the year ended December 31, 2021)
- *10.45 Amended and Restated Employment Agreement, effective as of April 1, 2024, between United HealthCare Services, Inc. and Heather Cianfrocco

- *10.46 Employment Agreement, effective as of January 9, 2017, between United HealthCare Services, Inc. and Erin McSweeney
- *10.47 Amendment to Employment Agreement, effective as of March 1, 2021, between United HealthCare Services, Inc. and Erin McSweeney
- *10.48 Amended and Restated Employment Agreement, effective as of June 4, 2024, between United HealthCare Services, Inc. and Christopher Zaetta
- 19.1 Insider Trading Policy
- 21.1 Subsidiaries of UnitedHealth Group Incorporated
- 23.1 Consent of Independent Registered Public Accounting Firm
- 24.1 Power of Attorney
- 31.1 Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 32.1 Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
- 97.1 UnitedHealth Group Dodd-Frank Clawback Policy, effective December 1, 2023 (incorporated by reference to Exhibit 97.1 to UnitedHealth Group Incorporated's Annual Report on Form 10-K for the year ended December 31, 2023)
- 101.INS XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
- 101.SCH Inline XBRL Taxonomy Extension Schema Document.
- 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document.
- 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document.
- 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document.
- 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document.
- 104 Cover Page Interactive Data File (formatted as Inline XBRL and embedded within Exhibit 101).

-
- * Denotes management contracts and compensation plans in which certain directors and named executive officers participate and which are being filed pursuant to Item 601(b)(10)(iii)(A) of Regulation S-K.
 - ** Pursuant to Item 601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain holders of long-term debt are not filed. The Company will furnish copies thereof to the SEC upon request.

(c) Financial Statement Schedule

Schedule I - Condensed Financial Information of Registrant (Parent Company Only).

Schedule I

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the shareholders and the Board of Directors of UnitedHealth Group Incorporated and Subsidiaries:

Opinion on the Financial Statement Schedule

We have audited the consolidated financial statements of UnitedHealth Group Incorporated and Subsidiaries (the “Company”) as of December 31, 2024 and 2023, and for each of the three years in the period ended December 31, 2024, and the Company’s internal control over financial reporting as of December 31, 2024, and have issued our reports thereon dated February 27, 2025; such reports are included elsewhere in this Form 10-K. Our audits also included the financial statement schedule of the Company listed in the Index at Item 15. This financial statement schedule is the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statement schedule based on our audits. In our opinion, the financial statement schedule, when considered in relation to the consolidated financial statements taken as a whole, presents fairly, in all material respects, the information set forth therein.

/s/ DELOITTE & TOUCHE LLP

Minneapolis, Minnesota

February 27, 2025

Schedule I

**Condensed Financial Information of Registrant
(Parent Company Only)
UnitedHealth Group
Condensed Balance Sheets**

(in millions, except per share data)	December 31, 2024	December 31, 2023
Assets		
Current assets:		
Cash and cash equivalents	\$ 234	\$ 776
Other current assets	411	570
Total current assets	645	1,346
Equity in net assets of subsidiaries	179,209	153,692
Long-term notes receivable from subsidiaries	6,062	5,693
Other assets	920	831
Total assets	\$ 186,836	\$ 161,562
Liabilities and shareholders' equity		
Current liabilities:		
Accounts payable and accrued liabilities	\$ 1,501	\$ 1,116
Short-term notes payable to subsidiaries	2,016	9,887
Short-term borrowings and current maturities of long-term debt	4,348	4,086
Total current liabilities	7,865	15,089
Long-term debt, less current maturities	71,831	57,387
Long-term notes payable to subsidiaries	14,405	—
Other liabilities	77	330
Total liabilities	94,178	72,806
Commitments and contingencies (Note 4)		
Shareholders' equity:		
Preferred stock, \$0.001 par value -10 shares authorized; no shares issued or outstanding	—	—
Common stock, \$0.01 par value - 3,000 shares authorized; 915 and 924 issued and outstanding	9	9
Retained earnings	96,036	95,774
Accumulated other comprehensive loss	(3,387)	(7,027)
Total UnitedHealth Group shareholders' equity	92,658	88,756
Total liabilities and shareholders' equity	\$ 186,836	\$ 161,562

See Notes to the Condensed Financial Statements of Registrant

Schedule I

**Condensed Financial Information of Registrant
(Parent Company Only)
UnitedHealth Group
Condensed Statements of Comprehensive Income**

(in millions)	For the Years Ended December 31,		
	2024	2023	2022
Revenues:			
Investment and other income	\$ 368	\$ 312	\$ 255
Total revenues	368	312	255
Operating costs:			
Operating costs	108	35	121
Interest expense	4,544	3,469	2,110
Total operating costs	4,652	3,504	2,231
Loss before income taxes	(4,284)	(3,192)	(1,976)
Benefit for income taxes	1,032	654	429
Loss of parent company	(3,252)	(2,538)	(1,547)
Equity in undistributed income of subsidiaries	17,657	24,919	21,667
Net earnings	14,405	22,381	20,120
Other comprehensive income (loss)	3,640	1,366	(3,009)
Comprehensive income	<u>\$ 18,045</u>	<u>\$ 23,747</u>	<u>\$ 17,111</u>

See Notes to the Condensed Financial Statements of Registrant

Schedule I

**Condensed Financial Information of Registrant
(Parent Company Only)
UnitedHealth Group
Condensed Statements of Cash Flows**

(in millions)	For the Years Ended December 31,		
	2024	2023	2022
Operating activities			
Cash flows from operating activities	\$ 4,852	\$ 17,443	\$ 14,754
Investing activities			
Issuances of notes to subsidiaries	(349)	(41)	(567)
Repayments of notes to subsidiaries	225	817	281
Cash paid for acquisitions and other transactions	(13,750)	(8,144)	(20,728)
Return of capital to parent company	21	639	1,424
Capital contributions to subsidiaries	—	(2,472)	(570)
Cash received from dispositions, net	2,444	624	2,787
Other, net	30	286	—
Cash flows used for investing activities	(11,379)	(8,291)	(17,373)
Financing activities			
Common stock repurchases	(9,000)	(8,000)	(7,000)
Proceeds from common stock issuances	1,846	1,353	1,253
Cash dividends paid	(7,533)	(6,761)	(5,991)
(Repayments of) proceeds from short-term borrowings, net	(151)	11	732
Proceeds from issuance of long-term debt	17,811	6,394	14,819
Repayments of long-term debt	(3,000)	(2,125)	(3,015)
(Repayments of) proceeds from short-term notes from subsidiaries, net	(7,966)	1,188	594
Proceeds from long-term notes from subsidiaries	14,396	—	—
Repayments of long-term notes from subsidiaries	(28)	—	—
Other, net	(390)	(702)	(674)
Cash flows from (used for) financing activities	5,985	(8,642)	718
(Decrease) increase in cash and cash equivalents	(542)	510	(1,901)
Cash and cash equivalents, beginning of period	776	266	2,167
Cash and cash equivalents, end of period	\$ 234	\$ 776	\$ 266
Supplemental cash flow disclosures			
Cash paid for interest	\$ 4,241	\$ 3,257	\$ 1,969
Cash paid for income taxes	2,450	4,426	4,298

See Notes to the Condensed Financial Statements of Registrant

Schedule I

Condensed Financial Information of Registrant (Parent Company Only) UnitedHealth Group Notes to Condensed Financial Statements

1. Basis of Presentation

UnitedHealth Group's parent company financial information has been derived from its consolidated financial statements and should be read in conjunction with the consolidated financial statements included in this Form 10-K. The accounting policies for the registrant are the same as those described in Note 2 of the Notes to the Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data."

2. Subsidiary Transactions

Investment in Subsidiaries. UnitedHealth Group's investment in subsidiaries is stated at cost plus equity in undistributed earnings of subsidiaries.

Dividends and Capital Distributions. Cash dividends received from subsidiaries and included in Cash Flows from Operating Activities in the Condensed Statements of Cash Flows were \$19.3 billion, \$18.5 billion and \$15.6 billion in 2024, 2023 and 2022, respectively. Additionally, \$21 million, \$639 million and \$1.4 billion in cash were received as a return of capital to the parent company during 2024, 2023 and 2022, respectively.

3. Short-Term Borrowings and Long-Term Debt

Discussion of short-term borrowings and long-term debt can be found in Note 8 of the Notes to the Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data." Long-term debt obligations of the parent company do not include other financing obligations at subsidiaries which totaled \$0.7 billion and \$1.1 billion at December 31, 2024 and 2023.

Maturities of short-term borrowings and long-term debt for the years ending December 31 are as follows:

(in millions)	
2025	\$ 4,350
2026	3,650
2027	3,425
2028	3,000
2029	3,550
Thereafter	59,802

UnitedHealth Group's parent company had short-term notes payable to subsidiaries of \$2.0 billion and \$9.9 billion as of December 31, 2024 and 2023, respectively, which included on-demand features. UnitedHealth Group's parent company had long-term notes payable to subsidiaries of \$14.4 billion as of December 31, 2024.

4. Commitments and Contingencies

Certain subsidiaries are guaranteed by UnitedHealth Group's parent company in the event of insolvency. UnitedHealth Group's parent company also provides guarantees related to its service level under certain contracts. None of the amounts accrued, paid or charged to income for service level guarantees were material as of December 31, 2024, 2023 or 2022.

For a summary of commitments and contingencies, see Note 12 of the Notes to the Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data."

ITEM 16. FORM 10-K SUMMARY

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: February 27, 2025

UNITEDHEALTH GROUP INCORPORATED

By /s/ ANDREW WITTY

Andrew Witty
Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature	Title	Date
<u> /s/ ANDREW WITTY </u>	Director and Chief Executive Officer (principal executive officer)	February 27, 2025
Andrew Witty		
<u> /s/ JOHN REX </u>	President and Chief Financial Officer (principal financial officer)	February 27, 2025
John Rex		
<u> /s/ THOMAS ROOS </u>	Senior Vice President and Chief Accounting Officer (principal accounting officer)	February 27, 2025
Thomas Roos		
<u> * </u>	Director	February 27, 2025
Charles Baker		
<u> * </u>	Director	February 27, 2025
Timothy Flynn		
<u> * </u>	Director	February 27, 2025
Paul Garcia		
<u> * </u>	Director	February 27, 2025
Kristen Gil		
<u> * </u>	Director	February 27, 2025
Stephen Hemsley		
<u> * </u>	Director	February 27, 2025
Michele Hooper		
<u> * </u>	Director	February 27, 2025
F. William McNabb III		
<u> * </u>	Director	February 27, 2025
Valerie Montgomery Rice, M.D.		
<u> * </u>	Director	February 27, 2025
John Noseworthy, M.D.		

*By /s/ CHRISTOPHER ZAETTA

Christopher Zaetta
As Attorney-in-Fact

c. CHANGE OF OWNERSHIP

If any change in ownership or control of the company is anticipated during the twelve (12) months following the solicitation response due date, the bidder should describe the circumstances of such change and indicate when the change will likely occur. Any change of ownership to an awarded bidder(s) will require notification to the State.

The bidder should state and describe if it recently experienced any workforce realignments and/or recent merger or acquisition activity. Include in this description, any anticipated changes in ownership or business developments, including but not limited to mergers, stock issues, and the acquisition of new venture capital.

No changes anticipated.

d. OFFICE LOCATION

The bidder's office location responsible for performance pursuant to an award of a contract with the State of Nebraska should be identified.

While sales and client management staff operate from a variety of key locations throughout the country, our core pharmacy benefit management services and activities are performed at the following locations along with remote services provided.

Optum Rx Primary Offices	
Location	Hours of Operation
Corporate Headquarters	
11000 Optum Circle Eden Prairie, MN 55344	Monday through Friday 8 a.m. to 5 p.m. CT
Billing	
11000 Optum Circle Eden Prairie, MN 55344	Monday through Friday 8 a.m. to 5 p.m. CT
Manual Claim Processing	
<i>Electronic claim processing is available 24 hours a day, seven days a week.</i>	
11000 Optum Circle Eden Prairie, MN 55344	Monday through Friday 8 a.m. to 5 p.m. CT
Customer Service Call Centers (includes Pharmacy Help Desk, Home Delivery support)	
We use a nationwide virtual call center model.	24 hours a day, seven days a week

Home Delivery Pharmacy <i>Dispensing Pharmacies</i>	
4015 Shopton Road, Suite 600 Charlotte, NC 28217	Monday to Friday 6 a.m. to 2:30 p.m. ET Sunday to Thursday 3 p.m. to 11 p.m. ET
5700 Dot Com Court, Suite 1000 Oviedo, FL 32765	Monday to Friday 5 a.m. to 3:30 p.m.ET (first shift); 3:30 p.m. to 12 a.m. ET (second shift) Thursday to Saturday 5 a.m. to 5:30 p.m. ET
6860 W. 115th Street, Suite 150 Overland Park, KS 66211	Monday to Friday 6:25 a.m. to 2:55 p.m. CT Sunday to Thursday 3:05 p.m. to 11:35 p.m. CT
19D Chapin Road, Suite 8 Pine Brook, NJ 07058	Monday to Friday 6 a.m. to 2:30 p.m. ET Sunday to Thursday 3 p.m. to 11 p.m. ET
5627 University Heights Boulevard, Suite 108 San Antonio, TX 78249	Monday to Friday 5 a.m. to 3:30 p.m. CT (first shift); 3:30 p.m. to 12:00 a.m. CT (second shift) Thursday to Saturday 5 a.m. to 5:30 p.m. CT

8131 W Bostian Road, Suite A350 Woodinville, WA	Monday to Friday 6 a.m. to 2:30 p.m. PT
1830 S. Horne Mesa, AZ 85204	Monday to Friday 8 a.m. to 5 p.m. PT
Information Technology	
11000 Optum Circle Eden Prairie, MN 55344	Monday to Friday 8 a.m. to 5 p.m. CT
Pharmacy Network Management	
11000 Optum Circle Eden Prairie, MN 55344	Monday to Friday 8 a.m. to 5 p.m. CT
Prior Authorization Clinical Call Center	
We use a nationwide virtual call center model.	24 hours a day, seven days a week
Rebate Management	
5701 Katella Avenue Cypress, CA 92630	Monday to Friday 8 a.m. to 5 p.m. PT
Specialty Pharmacy Fulfillment Center	
1050 Patrol Road Jeffersonville, IN 47130	Monday to Friday 8:30 a.m. to 8 p.m. ET Saturday 8:30 a.m. to 5 p.m. ET

Our comprehensive network of 15 specialty pharmacies plus several regional infusion pharmacies provides drug availability for patients anywhere in the United States and its territories, lets us manage weather disruptions and permits us to automatically assign a site to dispense a patient's medication.

Specialty Pharmacy Customer Service Center

We use a nationwide virtual call center model.

24 hours a day, seven days a week

e. RELATIONSHIPS WITH THE STATE

The bidder should describe any dealings with the State over the previous twelve (12) months. If the organization, its predecessor, or any Party named in the bidder's solicitation response has contracted with the State, the bidder should identify the contract number(s) and/or any other information available to identify such contract(s). If no such contracts exist, so declare.

No such contract exists between The State and OptumRx, Inc.

f. BIDDER'S EMPLOYEE RELATIONS TO STATE

If any Party named in the bidder's solicitation response is or was an employee of the State within the past twelve (12) months, identify the individual(s) by name, State agency with whom employed, job title or position held with the State, and separation date. If no such relationship exists or has existed, so declare.

If any employee of any agency of the State of Nebraska is employed by the bidder or is a subcontractor to the bidder, as of the due date for solicitation response submission, identify all such persons by name, position held with the bidder, and position held with the State (including job title and agency). Describe the responsibilities of such persons within the proposing organization. If, after review of this information by the State, it is determined that a conflict of interest exists or may exist, the bidder may be disqualified from further consideration in this solicitation. If no such relationship exists, so declare.

To the best of our knowledge, no such relationships exist.

g. CONTRACT PERFORMANCE

If the bidder or any proposed subcontractor has had a contract terminated for default during the past (three) (3) years, all such instances must be described as required below. Termination for default is defined as a notice to stop performance delivery due to the bidder's non-performance or poor performance, and the issue was either not litigated due to inaction on the part of the bidder or litigated and such litigation determined the bidder to be in default.

It is mandatory that the bidder submit full details of all termination for default experienced during the past (three) (3) years, including the other Party's name, address, and telephone number. The response to this section must present the bidder's position on the matter. The State will evaluate the facts and will score the bidder's solicitation response accordingly. If no such termination for default has been experienced by the bidder in the past (three) (3) years, so declare.

If at any time during the past (three) (3) years, the bidder has had a contract terminated for convenience, non-performance, non-allocation of funds, or any other reason, describe fully all circumstances surrounding such termination, including the name and address of the other contracting Party.

No. To the best of our knowledge, Optum Rx has not had a PBM contract terminated for cause.

I. BANKRUPTCY

The Bidder will state whether, in the last ten years, Bidder or any of its affiliates or subcontractors has filed (or had filed against it) any bankruptcy or insolvency proceeding, whether voluntary or involuntary, or undergone the appointment of a receiver, trustee, or assignee for the benefit of creditors; and if so, an explanation providing relevant details.

Neither Optum Rx nor its parent company have ever filed for bankruptcy.

m. FINANCIAL RATINGS

Indicate the most recent Financial Rating, Financial Rating Modifiers and the Financial Rating Effective Date you have received by the following organizations. Indicate all changes that have occurred in the last 12 months for each of these ratings.

- a) A.M. Best
- b) Standard & Poor's
- c) Moody's
- d) Fitch

The Bidder should indicate if its rating has changed within the past 12 months for any of the rating agencies.

Because ratings by organizations such as A.M. Best, Standard & Poor's, Fitch, and Moody's apply to insurance companies and do not apply to Optum Rx, we have provided the ratings of our parent company, UnitedHealth Group.

Rating Agency	Senior Unsecured Debt Rating	Commercial Paper Rating
S&P Global	A+	A-1
Moody's	A2	P-1
Fitch	A	F1
A.M. Best	A	AMB-1+

Optum Rx is a wholly owned subsidiary of UnitedHealth Group Incorporated. UnitedHealth Group is a public company and registrant with the U.S. Securities and Exchange Commission, with audited financial statements available at the EDGAR pages of www.SEC.gov. UnitedHealth Group is publicly traded on the New York Stock Exchange (NYSE Ticker: UNH).

UHG's long-term debt rating has been "A" since December 2021. Prior to that it was rated "A-".

V. PROJECT DESCRIPTION AND SCOPE OF WORK

The bidder should provide the following information in response to this Solicitation.

A. PROJECT OVERVIEW

The State of Nebraska ("State") employs approximately 17,500 individuals and 13,600 are enrolled in health plans. Enrolled members include active employees, pre-65 retirees, COBRA participants, and their dependents. Members are primarily located throughout the State of Nebraska. The State allows both Union and non-Union employees to be enrolled in one of the three (3) State health plans. The State currently has the following self-insured medical and prescription drug plans:

- Regular Plan
- Consumer Focused Health Plan (with Health Savings Account Eligibility)
- WellNebraska (with or without incentive)

The State's objective is to secure competitive and transparent pricing for pharmacy benefit management (PBM) services while maintaining and enhancing the quality of the pharmacy benefit plan and maximizing employee satisfaction. The State also seeks clinical and utilization management programs that will effectively reduce costs and waste while ensuring the highest standard of patient care.

The State currently has Contract 89546 O4 for Administrative and Support Services for the State of Nebraska Employee Health Care Benefits and Pharmacy Benefit Plans. This includes the administration of the Health Savings Account program and a Specialty Pharmacy Program.

Information about the current health plans offered to plan members is available at:
<http://das.nebraska.gov/benefits.html>

Health Plans (Plan Options: Regular, Consumer Focused, and WellNebraska) can be found at:
<https://das.nebraska.gov/personnel/wellness/health-and-perscription-benefits.html>

The State's Plan Year runs from July 1 to June 30. Note that it is the expectation of the State that work on this contract will begin immediately upon award, with a focus on implementation and Open Enrollment (OE) support (i.e., development of OE documents).

PBM Fees will not be paid until the benefit plan year begins on July 1, 2026.

Optum Rx acknowledges.

B. ENROLLMENT

The following is a table representing State active employees, pre-65 retirees, COBRA participants, and their dependents participation in each health plan by tier, as of February 2025. This may not be an exact match to the Census Data:

Plan/Tier	Regular PPO	Wellness PPO with incentive	Consumer Focused Health Plan (HDHP)	Wellness without Incentive	Total
Employee Only	1,079	4,289	1,137	306	6,811
Employee/Spouse	345	1,400	193	74	2,012
Employee/Child(ren)	227	1,432	193	86	1,938
Family	293	2,136	286	171	2,886
Total	1,944	9,257	1,809	637	13,647

Optum Rx acknowledges.

C. PROJECT OBJECTIVES

The State of Nebraska is looking to provide high quality, cost-effective benefits to its active employees, pre-65 retirees, COBRA participants, and their dependents. The State is soliciting offers for the administration of its self-insured prescription drug plan.

Bidders are required to offer comprehensive PBM services with a full range of customer (client and member) services including, but not limited to:

1. Claims Adjudication
2. Member Enrollment and Eligibility Maintenance
3. ID Card Production and Distribution
4. Formulary Management and Rebate Pass-Through
5. Clinical and Utilization Management
6. Retail Pharmacy Network Management
7. Specialty and Mail Order Pharmacy
8. Patient and Provider Education
9. Systematic Prospective, Concurrent and Retroactive Drug Utilization Review
10. Auditing Rights
11. Account Management Services (including standard/custom reporting and online systems)
12. Member Services (including call center, website portal and mobile app)
13. Claims data sharing with State, healthcare and data analytics vendors

Please note that the State is concurrently conducting a procurement for medical administration services. This RFP is only for PBM services, and any information provided by respondents which pertains to the medical administration RFP or any other service (unless explicitly requested within the RFP), will not be considered in evaluation of this RFP. This includes attempts by Bidders to provide PBM fees that are contingent upon the additional award of business in connection with the medical administration RFP.

Optum Rx acknowledges.

D. SUBROGATION REQUIREMENT

Contractor shall enforce the State's right to seek recovery based on subrogation or other theories from third parties, or other insurance carriers, who have caused injury or illness to a covered person or damages to the plan, except when said third party is the State of Nebraska. Contractor shall provide subrogation recovery service at no additional charge to the State. Contractor may engage a subcontractor to perform specialized services for recovery of funds or discovery of overpayment or fraud. If any subrogation services are subcontracted by contractor, approval of subcontractors and contract terms must be obtained from the State prior to contractor entering into an agreement with any such subcontractor(s). Such subcontractors may be reimbursed based on a reasonable basis other than percent of recovery, but cost of such subcontractors shall be the responsibility of Contractor and shall not be deducted from the subrogated amount. The Contractor shall obtain the approval of the State for any subrogation claim that is less than 100% of the State's loss and shall obtain the State's approval of all settlements. In the event that the State is a party to litigation regarding any such claims, settlement or release of such claims must be approved by the State. This authority regarding recoveries from third parties or their carriers includes participation in consolidated or class action lawsuits alleging such injuries, if authorized by the State. Any recovery from consolidated or class action suits will be apportioned among all insured and self-insured plans or pools in like manner. The proration may be based on number of covered persons, number of injured persons, claims volume, or any other basis determined by contractor and approved by the State. Recoveries made in the same plan year as the original claim payments are made, will be applied to the State's claims liability by immediate credit to the State. Recoveries made in subsequent years will be credited in total to the State's claim liability at the time recovery is made. The State agrees to cooperate with all such recovery efforts.

Optum Rx disagrees. Proposed language has been provided within the exception table in Section III – Vendor Duties.

E. PRESCRIPTION DRUG PLAN DESIGN

At a minimum, the Contractor must duplicate the plan designs and level of coverage presently offered to the State's covered member population.

Optum Rx agrees.

F. **PLAN REQUIREMENTS**

The Contractor must adhere to the following Plan Requirements. These requirements will also explicitly apply to any subcontractors used by the Bidder to deliver services to the State.

1. Provide services to all members (active employees, pre-65 retirees, COBRA participants, and their dependents) enrolled on the program effective date.

Optum Rx agrees.

2. Agree that members who are not actively at work due to disablement on program effective date will be covered.

Optum Rx agrees.

3. Agree that the State owns its data (its financial and operational data, and its member data), may use it for any business purposes it deems necessary, and that such data will be considered proprietary and will not be shared or utilized by Contractor for any purpose other than the provision of services under the agreement, except at the request of the State's Director of Administrative Services, and with full knowledge and express written consent.

Optum Rx agrees.

4. Acknowledges the State will neither recognize the appointment of any agent, general agent or broker nor authorize any payment or remuneration of any kind by the Contractor to a party not approved in writing by the State.

Optum Rx agrees.

5. Advise and assist the State in the preparation of forms and other documentation necessary to fulfill reporting and disclosure requirements.

Optum Rx agrees.

6. Agrees it will not render or administer services (including wellness) offshore, and all work performed will be in the contiguous United States.

Optum Rx agrees.

7. Comply with and adhere to relevant federal and state laws and regulations.

Optum Rx agrees.

8. Monitor Federal and State legislation affecting the plan and report to the State on those issues in a timely fashion and prior to the effective date of any mandated plan changes.

Optum Rx agrees.

9. Assume responsibility for any and all costs associated with any investigation necessary to ensure that claims are adjudicated properly.

Optum Rx agrees.

10. Follow the specified eligibility rules established by the State.

Optum Rx agrees.

11. Agree to all requirements as outlined in Attachment C - Confirmations & Questionnaire, Confirmations tab.

Optum Rx agrees, except where deviations are noted within the document.

12. Assign a dedicated Account Management Team (AMT) who shall be accountable and responsible to the State for proactive management of all aspects of the Contractor's performance to the State and its members. The Contractor shall not change assignment of the Account Executive on the AMT, without written notice provided to the State with a minimum of fourteen (14) business days prior to such change. The State

reserves the right to request assignment of a new Account Executive, and the Contractor shall make such change within 30 calendar days of receipt of written notice from the State. A member of the AMT must respond to any outreach from the State of Nebraska within one (1) business day.

Optum Rx agrees.

13. Provide a mutually agreed upon annual score card so the State can assess Contractor's performance.

Optum Rx agrees.

14. Provide claim line detail for ALL claims as described in this RFP.

Optum Rx agrees.

15. Provide robust, accurate, timely, and comprehensive data and reporting to the State. The State and its healthcare consultants must have the ability to access a reporting portal to download all reports. This provision includes State specific utilization data for State members, upon request.

Optum Rx agrees.

16. Provide data feeds (ex. eligibility file) to the State's vendor partners, as requested. The cost for providing data feeds must be included in the Contractor's administrative fees. Contractor agrees to waive any charges to the State or the State's vendors such as a set-up fee, a programming fee or a monthly fee, for establishing a connection with a third party vendor for real-time, bidirectional data integration, including non-standard data integration formats.

Optum Rx agrees.

17. The Contractor must perform and present to the State, on a quarterly or as requested basis, the State's current plans and service performance, recent issues/challenges encountered, potential savings opportunities, and topics of concern and suggestions for resolution, at no additional cost to the State.

Optum Rx agrees.

18. Attend an annual performance or "stewardship" meeting within 180 days after contract year-end at which time the Contractor will, as directed by the State, summarize activities and performance for the year ended.

Optum Rx agrees.

19. Participate in an Annual Vendor Summit to discuss strategic opportunities for the State's overall health management program.

Optum Rx agrees.

20. Provide final Summary Plan Documents (SPD), written and electronic, including SPD language for any clinical programs to be implemented, to the State prior to the initial Open Enrollment period and subsequent open enrollments. SPDs are subject to the final approval of the State.

Optum Rx disagrees. The responsibility to provide the summary of benefits and coverage (SBC) and the summary plan description (SPD) lies with the plan administrator (if self-funded) or the insurance issuer (if fully insured). However, we can work with The State to review for accuracy, answer questions and provide input and documentation where needed. We do not provide a report of the technical review of the SPD.

21. Agree to provide an opportunity for the State to review and approve all communication materials (including letters, brochures, electronic, website, etc.) prior to being sent to members and/or to providers.

Optum Rx agrees. Our client management team is able to share standard plan communication templates with The State for review and approval. We can support requests for custom materials, however, additional fees may apply. Due to compliance and regulatory restrictions, some materials containing pharmacy operations and care service information are not able to be customized.

- **Examples of these communications include:**
- **Drug recalls**

- **Urgent patient safety communications**
 - **Formulary changes**
 - **PA expiration notifications**
 - **Information specific to a member regarding any changes in status to their medication**
 - **Pharmacy communications from Optum pharmacies**
22. Complete implementation prior to the State's Annual Open Enrollment period each May.
- Optum Rx agrees.**
23. Agree that no external communications material that mentions the State's benefit plans may be circulated without written approval from the State.
- Optum Rx agrees.**
24. Attend and participate in the annual Human Resource Information Group (HRIG) in April of each year. The Contractor may be asked to participate in the informational meetings across the State directly following the HRIG. If requested by other State agencies, the Contractor may participate in agency specific health fair(s).
- Optum Rx agrees.**
25. Offer a program to prevent and detect internal and external fraud and fraudulent practices.
- Optum Rx agrees.**
26. Administer run-out claims for 12 months following termination of the contract. The cost of run-out administration must be included in bidder's proposed administration fees.
- Optum Rx agrees.**
27. Provide complete banking arrangements for claims processing, including the printing and issuing of checks and/or electronic funds transfer.
- Optum Rx agrees.**
28. No covered State members shall lose or gain coverage as a result of vendor change. Any and all transition-of-care-related issues must be expressly waived for the initial enrollment for covered eligibles and their dependents that have already satisfied the limitations under the existing plan, unless otherwise specified in the eligibility rules established by the State.
- Optum Rx agrees.**
29. Complete formulary disruption and retail network disruption analyses as detailed in the Questionnaire.
- Optum Rx agrees. Please refer to Section II, Exhibit F for formulary disruption and Section II, Exhibit G for network disruption.**
30. **Attachments:** Complete all RFP attachments:
- a. Attachment A – Intent to Propose
 - b. Attachment B – Business Associate Agreement (BAA)
 - c. Attachment C – Confirmations & Questionnaire
 - i. Completed Formulary Disruption Analysis as requested in Questionnaire Tab D.3
 - ii. Completed Network Disruption Analysis as requested in Questionnaire Tab F.14
 - d. Attachment D – Performance Guarantees
 - e. Cost Sheet
- Optum Rx agrees.**

G. BUSINESS REQUIREMENTS

1. Contractor must be currently providing self-funded PBM administration services to at least one public sector group health plan with a minimum of 15,000 lives.
2. Contractor must have a minimum of five (5) years of self-funded PBM administration group experience.
3. Contractor must be licensed to offer employer-sponsored, network-based self-funded PBM plan solutions in all 50 states and U.S. territories where State members currently reside.
4. Contractor must not have any bankruptcy filings within the last 5 years; and Offeror's senior officers, board members, or directors must not have any felony convictions.

Optum Rx agrees.

H. DELIVERABLES

Provide the following third-party administration services for the State's prescription drug coverage as listed in this RFP:

1. Claims Adjudication
2. Member Enrollment and Eligibility Maintenance
3. ID Card Production and Distribution
4. Formulary Management and Rebate Pass-Through
5. Clinical and Utilization Management
6. Retail Pharmacy Network Management
7. Specialty and Mail Order Pharmacy
8. Patient and Provider Education
9. Systematic Prospective, Concurrent and Retroactive Drug Utilization Review
10. Auditing Rights
11. Account Management Services (including standard/custom reporting and online systems)
12. Member Services (including call center, website portal and mobile app)
13. Claims data sharing with State, healthcare and data analytics vendors

Optum Rx agrees.

% Work Complete	Milestone	Task Name	Start	Finish
0%	No	Implementation Project Plan Template- 180 Days	Tue 10/21/25	Wed 8/12/26
0%	No	Implementation Timeline	Mon 11/3/25	Tue 5/5/26
0%	No	Effective Date	Wed 7/1/26	Wed 7/1/26
0%	No	Sales/Legal/Underwriting	Mon 11/3/25	Mon 12/1/25
0%	No	Win Client	Mon 11/3/25	Mon 11/3/25
0%	No	Complete NOS and provide to Implementations	Tue 11/4/25	Tue 11/4/25
0%	No	Complete Negotiations and Obtain Approval (Contract or Implementation Agreement)	Tue 11/4/25	Mon 12/1/25
0%	No	Underwriting Process	Tue 11/4/25	Wed 11/26/25
0%	No	Receive Email of Sale	Tue 11/4/25	Tue 11/4/25
0%	No	Complete PDF1 and distribute	Wed 11/5/25	Fri 11/7/25
0%	No	Receive MAC & Network from Industry Relations	Fri 11/7/25	Mon 11/17/25
0%	No	Complete PDF2 and distribute	Tue 11/18/25	Wed 11/26/25
0%	No	Implementation Planning	Mon 11/3/25	Wed 6/17/26
0%	No	Fab 5	Wed 11/5/25	Thu 11/6/25
0%	No	Receive Notice of Sale Form from Sales	Wed 11/5/25	Thu 11/6/25
0%	No	Receive Contract, Implementation Agreement, or Letter of Agreement from Sales	Wed 11/5/25	Thu 11/6/25
0%	No	Receive RFP Response (Request for Proposal) from Sales	Wed 11/5/25	Thu 11/6/25
0%	No	Receive Copy of Finalist Presentation from Sales	Wed 11/5/25	Thu 11/6/25
0%	No	Receive PGs/SLAs (Performance Guarantees/Service Level Agreements)	Wed 11/5/25	Thu 11/6/25
0%	No	Security Questionnaire	Fri 11/7/25	Fri 11/21/25
0%	No	Review Security Questionnaire with Client	Fri 11/7/25	Tue 11/11/25
0%	No	Complete Security Questionnaire	Wed 11/12/25	Thu 11/13/25
0%	No	Final Review with Client	Fri 11/14/25	Tue 11/18/25
0%	No	Client Sign Off	Wed 11/19/25	Fri 11/21/25
0%	No	Implementation Assignments	Fri 11/7/25	Tue 11/18/25
0%	No	Implementation Project Manager Assigned	Fri 11/7/25	Tue 11/11/25
0%	No	Implementation Team Assignments Requested	Wed 11/12/25	Thu 11/13/25
0%	No	All Resources Assigned	Fri 11/14/25	Tue 11/18/25
0%	No	Determine RxCLAIM Environment	Fri 11/7/25	Tue 11/11/25
0%	No	Kick-Off Meeting Preparation	Mon 11/3/25	Tue 11/25/25
0%	No	INTERNAL- Scope of Products & Services Sold Meeting	Wed 11/12/25	Fri 11/14/25

0%	No	EXTERNAL- Introductory Call	Mon 11/3/25	Wed 11/5/25
0%	No	INTERNAL- Core Team Meeting	Wed 11/19/25	Fri 11/21/25
0%	No	IM Prep for Kick-off Meeting	Mon 11/24/25	Tue 11/25/25
0%	No	Project Tracking	Wed 11/12/25	Tue 11/25/25
0%	No	Create Implementation Case in ServiceNow	Wed 11/12/25	Tue 11/25/25
0%	No	Create Project Folders on SharePoint	Wed 11/12/25	Tue 11/25/25
0%	No	Implementation Kick-Off	Mon 11/3/25	Mon 11/24/25
0%	No	Kick-Off Meetings	Mon 11/3/25	Mon 11/24/25
0%	No	Establish Ongoing Internal Meeting Schedule	Mon 11/24/25	Mon 11/24/25
0%	Yes	Conduct Client Kick-Off Meeting	Mon 11/3/25	Mon 11/3/25
0%	No	Establish Ongoing Client Meeting Schedule	Tue 11/4/25	Tue 11/4/25
0%	No	Project Creation	Tue 11/4/25	Fri 11/28/25
0%	No	Initiate Implementation Project Plan	Wed 11/19/25	Tue 11/25/25
0%	No	Initiate Implementation / Issue and Risk Tracking	Mon 11/24/25	Fri 11/28/25
0%	No	Create & Distribute Contact List/Roles & Responsibilities/RAM Matrix (optional)	Tue 11/4/25	Wed 11/5/25
0%	No	Discuss & Schedule Weekly Project Plan Review Meetings	Tue 11/4/25	Wed 11/5/25
0%	No	Requirements Gathering	Tue 11/4/25	Fri 11/28/25
0%	No	Populate Implementation Forms	Tue 11/4/25	Mon 11/17/25
0%	No	Complete Implementation Forms	Tue 11/18/25	Tue 11/18/25
0%	No	Business Structure - Commercial	Tue 11/4/25	Fri 11/28/25
0%	No	Discuss Carrier/Account/Group (CAG) Hierarchy	Tue 11/4/25	Mon 11/10/25
0%	No	Document CAG Hierarchy	Tue 11/11/25	Wed 11/12/25
0%	No	Request Carrier ID Creation & Load in RxClaim	Tue 11/4/25	Mon 11/10/25
0%	No	Assign 3-byte Client Code and GIS Identifier	Tue 11/11/25	Mon 11/17/25
0%	No	Review/Revise CAG Hierarchy	Thu 11/13/25	Wed 11/19/25
0%	Yes	Approve CAG Hierarchy	Thu 11/20/25	Fri 11/21/25
0%	Yes	CAG Hierarchy Built in RxCLAIM	Mon 11/24/25	Fri 11/28/25
0%	No	B/P/G - Commercial	Tue 11/4/25	Fri 11/28/25
0%	No	Secure approval for Custom BIN or PCN	Tue 11/4/25	Wed 11/5/25
0%	Yes	Assign BIN/PCN/GROUP	Mon 11/24/25	Fri 11/28/25
0%	No	Enhanced Onboarding (EO)	Tue 11/4/25	Thu 11/6/25
0%	No	Determine if Enhanced Onboarding is in scope	Tue 11/4/25	Tue 11/4/25
0%	No	Internal Kick Off with Enhanced Onboarding Resource	Wed 11/5/25	Wed 11/5/25
0%	No	Determine Enhanced Onboarding Timeline	Thu 11/6/25	Thu 11/6/25

0%	No	Digital Solutions	Tue 11/4/25	Wed 2/25/26
0%	No	Open Enrollment (OE) Portal Setup	Tue 11/4/25	Thu 12/25/25
0%	No	Review Contract for Specific Details / Costs	Fri 11/7/25	Fri 11/7/25
0%	No	Discuss Setup Details	Tue 11/4/25	Tue 11/4/25
0%	No	Complete OE Portal Implementation Form	Wed 11/5/25	Thu 11/6/25
0%	No	Setup OE Portal	Fri 11/7/25	Thu 12/25/25
0%	No	Member Portal (www.optumrx.com)	Tue 11/18/25	Wed 2/25/26
0%	No	Provide Member Portal Overview	Thu 2/19/26	Wed 2/25/26
0%	No	Determine Member Portal Setup Requirements	Tue 11/18/25	Mon 11/24/25
0%	No	Complete Member Portal Implementation Form	Tue 11/25/25	Wed 11/26/25
0%	No	Configure Member Portal	Thu 11/27/25	Wed 12/17/25
0%	No	Test Member Portal Configuration	Thu 12/18/25	Wed 12/24/25
0%	No	Receive dummy/test login information from Digital Solutions	Thu 12/25/25	Wed 12/31/25
0%	No	Review Web Portal to ensure reference documents and overall information is accurate	Thu 1/1/26	Fri 1/9/26
0%	Yes	Portal Configuration Complete	Mon 1/12/26	Mon 1/12/26
0%	No	SSO (standard)	Tue 11/18/25	Mon 12/8/25
0%	No	Submit SSO request form to Digital Solutions	Tue 11/18/25	Wed 11/19/25
0%	No	Coordinate any technical meetings if needed	Thu 11/20/25	Mon 12/1/25
0%	No	Confirm Connectivity with Client	Tue 12/2/25	Mon 12/8/25
0%	No	SSO (SAML)	Tue 11/18/25	Thu 12/4/25
0%	No	Provide signed amendment for SAML to Digital Solutions	Tue 11/18/25	Wed 11/19/25
0%	No	Coordinate SAML kick off meeting with Client and OptumRx	Tue 11/18/25	Thu 11/27/25
0%	No	Confirm Connectivity with Client	Fri 11/28/25	Thu 12/4/25
0%	No	RxVIEW	Tue 11/18/25	Wed 1/14/26
0%	No	Determine Client Portal Access & Requirements	Tue 11/18/25	Mon 11/24/25
0%	No	Complete RxVIEW User Request Form	Tue 11/25/25	Wed 11/26/25
0%	No	Configure Client Portal	Thu 11/27/25	Wed 12/17/25
0%	No	Create Client Portal User Accounts	Thu 12/18/25	Wed 1/7/26
0%	Yes	Provide User IDs and Passwords for Client Portal	Thu 1/8/26	Wed 1/14/26
0%	Yes	Provide Manual and Coordinate Training Session	Thu 1/8/26	Thu 1/8/26
0%	No	Benefit Plan Requirements-Commercial	Tue 11/4/25	Tue 4/21/26
0%	No	Discuss Benefit Plan Requirements	Tue 11/4/25	Mon 12/22/25
0%	No	Discuss Benefit Documentation Forms	Tue 11/4/25	Mon 11/17/25

0%	No	Determine number of Benefit Plans	Tue 11/18/25	Thu 11/20/25
0%	No	Document Requirements in Benefit Plan Template	Fri 11/21/25	Wed 11/26/25
0%	No	Review/Revise Benefit Plan Template	Thu 11/27/25	Wed 12/3/25
0%	Yes	Approve Benefit Plan Template	Thu 12/4/25	Mon 12/8/25
0%	No	RxBuilder Setup	Tue 12/9/25	Mon 12/22/25
0%	Yes	Benefit Plan Build	Tue 12/9/25	Mon 1/12/26
0%	No	Benefit Documentation Forms requirements	Tue 12/9/25	Fri 1/9/26
0%	No	Clinical Documentation Forms requirements	Tue 12/9/25	Fri 1/9/26
0%	No	Specialty Pricing	Tue 12/9/25	Mon 12/15/25
0%	No	Begin Formulary Setup (Standard Formulary)	Tue 12/9/25	Mon 12/15/25
0%	No	Confirm Plan code(s) available in RxClaim	Mon 1/12/26	Mon 1/12/26
0%	No	Network Creation	Tue 12/16/25	Mon 12/22/25
0%	No	Pricing	Tue 12/23/25	Mon 12/29/25
0%	No	Benefits Coding Completed & Unit Testing In Progress	Tue 1/13/26	Wed 1/14/26
0%	No	RxCCR Requirements	Tue 1/13/26	Wed 1/14/26
0%	No	Determine SOTs are all completed (PDF2, Clinical Documentation Forms, Benefit Documentation Forms, Implementation Documentation Forms)	Tue 1/13/26	Tue 1/13/26
0%	No	Determine Data Interface has been completed	Wed 1/14/26	Wed 1/14/26
0%	No	Determine CSP has been created (Book 1 only)	Wed 1/14/26	Wed 1/14/26
0%	No	Determine Call Center Readiness requirements, Open Enrollment and Portal go-live dates	Wed 1/14/26	Wed 1/14/26
0%	No	Document Requirements in ServiceNow	Wed 1/14/26	Wed 1/14/26
0%	No	Provide SOTs via SN to CSS team (Readiness Task)	Wed 1/14/26	Wed 1/14/26
0%	No	Confirm CAG association completed (Book A specific)-Confirm CAGP is completed	Tue 1/13/26	Tue 1/13/26
0%	No	Confirm Book A Formulary Code is complete	Tue 1/13/26	Tue 1/13/26
0%	No	QA Analysis	Thu 1/15/26	Tue 4/21/26
0%	Yes	Obtain Additional Test Scenarios	Thu 1/15/26	Thu 1/15/26
0%	Yes	QA Benefit Plans Commences	Thu 1/15/26	Wed 2/4/26
0%	No	Document Benefit Plan QA Results	Thu 2/5/26	Wed 2/11/26
0%	No	Confirm QA Testing Complete	Thu 2/12/26	Thu 2/12/26
0%	Yes	Share / Review Test Results with Client	Fri 2/13/26	Thu 2/19/26
0%	No	Client Approval of QA Test Results Due	Fri 2/20/26	Thu 2/26/26
0%	No	Perform Parallel Test in Baseline Test Bed	Fri 2/27/26	Tue 4/21/26
0%	No	Create Parallel Claims Batch for defined dates	Fri 2/27/26	Fri 2/27/26

0%	No	Submit Parallel Claims Batch for Adjudication against Baseline Test Bed	Mon 3/2/26	Mon 3/2/26
0%	No	Extract Adjudication Results	Tue 3/3/26	Tue 3/3/26
0%	No	Produce Comparison Report	Wed 3/4/26	Fri 3/6/26
0%	No	Review Comparison Report against Known Outliers	Mon 3/9/26	Tue 3/10/26
0%	No	Log Defects and Issues for Remediation	Wed 3/11/26	Thu 3/12/26
0%	No	Determine Remediation Strategy	Fri 3/13/26	Mon 3/16/26
0%	No	Assign Remediation Strategy Tasks	Tue 3/17/26	Wed 3/18/26
0%	No	Execute code changes if identified in remediation strategy	Thu 3/19/26	Fri 3/27/26
0%	No	Execute Parallel Test iterations as needed to validate code changes from remediation strategy	Mon 3/30/26	Fri 4/17/26
0%	No	Business Sign Off on Parallel Test	Mon 4/20/26	Tue 4/21/26
0%	Yes	Client Sign Off on Parallel Test Results	Tue 4/21/26	Tue 4/21/26
0%	No	Eligibility- Vendor 1	Tue 11/4/25	Tue 1/6/26
0%	No	Member Eligibility	Tue 11/4/25	Tue 1/6/26
0%	No	Determine Eligibility Provider	Tue 11/4/25	Mon 11/10/25
0%	No	Eligibility Kick Off Call	Tue 11/11/25	Tue 11/11/25
0%	No	Standard Eligibility (v8.0/8.1)	Tue 11/11/25	Mon 11/17/25
0%	No	Provide OptumRx Member Eligibility Layout for review	Tue 11/11/25	Tue 11/11/25
0%	No	Discuss OptumRx Member Eligibility Layout Format	Tue 11/11/25	Mon 11/17/25
0%	Yes	Confirm Eligibility Details	Tue 11/11/25	Mon 11/17/25
0%	No	834 Eligibility	Tue 11/11/25	Mon 11/17/25
0%	No	Discuss 834 Eligibility Layout and Mapping (Requires 6 week lead time for mapping)	Tue 11/11/25	Mon 11/17/25
0%	No	Confirm Eligibility Details	Tue 11/11/25	Mon 11/17/25
0%	No	Custom Eligibility	Tue 11/11/25	Wed 12/10/25
0%	No	Discuss Custom Eligibility Format and Requirements	Tue 11/11/25	Mon 11/17/25
0%	No	Confirm Eligibility Details	Tue 11/11/25	Mon 11/17/25
0%	No	Submit PRF for Custom Eligibility Format	Tue 11/18/25	Wed 11/19/25
0%	No	Develop Custom Eligibility Reformat Program	Thu 11/20/25	Wed 12/10/25
0%	No	Test Custom Eligibility Reformat Program	Thu 11/20/25	Wed 12/3/25
0%	No	Create Eligibility Setup Confirmation Document	Tue 11/18/25	Mon 12/1/25
0%	Yes	Approve Eligibility Setup Confirmation Document	Tue 12/2/25	Mon 12/8/25
0%	No	Request Eligibility Automation and Inventory ID	Tue 11/18/25	Wed 11/19/25
0%	Yes	Complete setup for Eligibility Automation	Thu 11/20/25	Wed 12/17/25
0%	No	Test Eligibility File load #1	Thu 12/4/25	Thu 12/11/25

0%	Yes	Receive Test Member Eligibility File	Thu 12/4/25	Thu 12/4/25
0%	No	Load Test Member Eligibility File	Fri 12/5/25	Tue 12/9/25
0%	No	Review Results of Test Member Eligibility Load	Wed 12/10/25	Thu 12/11/25
0%	No	Test Eligibility File load #2	Fri 12/12/25	Fri 12/19/25
0%	No	Receive Test Member Eligibility File	Fri 12/12/25	Fri 12/12/25
0%	No	Load Test Member Eligibility File	Mon 12/15/25	Wed 12/17/25
0%	No	Review Results of Test Member Eligibility Load	Thu 12/18/25	Fri 12/19/25
0%	No	Test Eligibility File load #3	Mon 12/22/25	Mon 12/29/25
0%	Yes	Receive Test Member Eligibility File	Mon 12/22/25	Mon 12/22/25
0%	No	Load Test Member Eligibility File	Tue 12/23/25	Thu 12/25/25
0%	No	Review Results of Test Member Eligibility Load	Fri 12/26/25	Mon 12/29/25
0%	No	Test Eligibility File load #4	Mon 12/22/25	Mon 12/29/25
0%	Yes	Receive Test Member Eligibility File	Mon 12/22/25	Mon 12/22/25
0%	No	Load Test Member Eligibility File	Tue 12/23/25	Thu 12/25/25
0%	No	Review Results of Test Member Eligibility Load	Fri 12/26/25	Mon 12/29/25
0%	No	Production Eligibility File Load	Tue 12/30/25	Tue 1/6/26
0%	Yes	Provide Production Member Eligibility File	Tue 12/30/25	Tue 12/30/25
0%	Yes	Load Production Member Eligibility File	Wed 12/31/25	Wed 12/31/25
0%	No	Review Results of Production Member Eligibility Load	Thu 1/1/26	Thu 1/1/26
0%	No	Promote Member Eligibility to Production RxCLAIM environment	Fri 1/2/26	Fri 1/2/26
0%	No	Send load confirmation to IPM, Print fulfillment, & Client	Mon 1/5/26	Tue 1/6/26
0%	No	Establish Automated Eligibility Load	Mon 1/5/26	Mon 1/5/26
0%	No	Eligibility-Vendor 2	Tue 11/18/25	Wed 1/14/26
0%	No	Member Eligibility	Tue 11/18/25	Wed 1/14/26
0%	No	Determine Eligibility Provider	Tue 11/18/25	Tue 11/18/25
0%	No	Standard Eligibility (v8.0/8.1)	Wed 11/19/25	Tue 11/25/25
0%	No	Provide OptumRx Member Eligibility Layout for review	Wed 11/19/25	Wed 11/19/25
0%	No	Discuss OptumRx Member Eligibility Layout Format	Wed 11/19/25	Tue 11/25/25
0%	Yes	Confirm Eligibility Details	Wed 11/19/25	Tue 11/25/25
0%	No	834 Eligibility	Wed 11/19/25	Tue 11/25/25
0%	No	Discuss 834 Eligibility Layout and Mapping (Requires 6 week lead time for mapping)	Wed 11/19/25	Tue 11/25/25
0%	No	Confirm Eligibility Details	Wed 11/19/25	Tue 11/25/25
0%	No	Custom Eligibility	Wed 11/19/25	Thu 12/18/25
0%	No	Discuss Custom Eligibility Format and Requirements	Wed 11/19/25	Tue 11/25/25

0%	No	Confirm Eligibility Details	Wed 11/19/25	Tue 11/25/25
0%	No	Submit PRF for Custom Eligibility Format	Wed 11/26/25	Thu 11/27/25
0%	No	Develop Custom Eligibility Reformat Program	Fri 11/28/25	Thu 12/18/25
0%	No	Test Custom Eligibility Reformat Program	Fri 11/28/25	Thu 12/11/25
0%	No	Create Eligibility Setup Confirmation Document	Wed 11/26/25	Tue 12/9/25
0%	Yes	Approve Eligibility Setup Confirmation Document	Wed 12/10/25	Tue 12/16/25
0%	No	Request Eligibility Automation and Inventory ID	Wed 11/26/25	Thu 11/27/25
0%	Yes	Complete setup for Eligibility Automation	Fri 11/28/25	Thu 12/25/25
0%	No	Test Eligibility File load #1	Fri 12/12/25	Fri 12/19/25
0%	Yes	Receive Test Member Eligibility File	Fri 12/12/25	Fri 12/12/25
0%	No	Load Test Member Eligibility File	Mon 12/15/25	Wed 12/17/25
0%	No	Review Results of Test Member Eligibility Load	Thu 12/18/25	Fri 12/19/25
0%	No	Test Eligibility File load #2	Mon 12/22/25	Mon 12/29/25
0%	No	Receive Test Member Eligibility File	Mon 12/22/25	Mon 12/22/25
0%	No	Load Test Member Eligibility File	Tue 12/23/25	Thu 12/25/25
0%	No	Review Results of Test Member Eligibility Load	Fri 12/26/25	Mon 12/29/25
0%	No	Test Eligibility File load #3	Tue 12/30/25	Tue 1/6/26
0%	Yes	Receive Test Member Eligibility File	Tue 12/30/25	Tue 12/30/25
0%	No	Load Test Member Eligibility File	Wed 12/31/25	Fri 1/2/26
0%	No	Review Results of Test Member Eligibility Load	Mon 1/5/26	Tue 1/6/26
0%	No	Test Eligibility File load #4	Tue 12/30/25	Tue 1/6/26
0%	Yes	Receive Test Member Eligibility File	Tue 12/30/25	Tue 12/30/25
0%	No	Load Test Member Eligibility File	Wed 12/31/25	Fri 1/2/26
0%	No	Review Results of Test Member Eligibility Load	Mon 1/5/26	Tue 1/6/26
0%	No	Production Eligibility File Load	Wed 1/7/26	Wed 1/14/26
0%	Yes	Provide Production Member Eligibility File	Wed 1/7/26	Wed 1/7/26
0%	Yes	Load Production Member Eligibility File	Thu 1/8/26	Thu 1/8/26
0%	No	Review Results of Production Member Eligibility Load	Fri 1/9/26	Fri 1/9/26
0%	No	Promote Member Eligibility to Production RxCLAIM environment	Mon 1/12/26	Mon 1/12/26
0%	No	Send load confirmation to IPM, Print fulfillment, & Client	Tue 1/13/26	Wed 1/14/26
0%	No	Establish Automated Eligibility Load	Tue 1/13/26	Tue 1/13/26
0%	No	Clinical- Commercial	Mon 11/17/25	Wed 6/17/26
0%	Yes	Kickoff Call to verify Clinical Requirements	Tue 11/18/25	Tue 11/18/25
0%	No	Prefill Clinical design template	Wed 11/19/25	Tue 12/9/25

0%	No	Clinical Requirement Received	Wed 11/19/25	Tue 12/2/25
0%	No	Obtain Initial Historical claims data from Sales (if available)	Wed 11/19/25	Tue 11/25/25
0%	No	Make Clinical Recommendations	Wed 12/3/25	Tue 12/23/25
0%	No	Update Clinical Documentation Forms	Wed 12/3/25	Fri 12/5/25
0%	No	Review Clinical Documentation Forms with client	Thu 12/4/25	Wed 12/17/25
0%	Yes	Approve Clinical Documentation Forms	Thu 12/18/25	Fri 12/19/25
0%	No	Submit Clinical Documentation Forms to BA or BC	Mon 12/22/25	Mon 12/22/25
0%	Yes	Submit PA guide to RxAUTH	Wed 12/3/25	Thu 12/4/25
0%	No	Custom Requirements if applicable	Wed 12/3/25	Tue 12/16/25
0%	No	Formulary (Requires 4-6 weeks)	Wed 12/3/25	Wed 12/3/25
0%	No	UM Edits	Wed 12/3/25	Wed 12/3/25
0%	No	Copay Design	Wed 12/3/25	Wed 12/3/25
0%	No	Clinical Programs	Wed 12/3/25	Wed 12/3/25
0%	No	Obtain admin fees related to custom formulary	Tue 12/16/25	Tue 12/16/25
0%	No	Obtain necessary information related to custom formulary	Tue 12/16/25	Tue 12/16/25
0%	No	Custom formulary re-pricing	Tue 12/16/25	Tue 12/16/25
0%	No	Drug Intelligence	Mon 12/22/25	Wed 6/17/26
0%	Yes	Discuss Drug Recall Program	Mon 12/22/25	Fri 12/26/25
0%	No	Confirm Drug Recall Requirements with Drug Intelligence	Mon 12/29/25	Fri 1/2/26
0%	No	Set up Client for Drug Recall Program	Mon 1/5/26	Fri 1/9/26
0%	No	Request Clinical Publications	Wed 6/10/26	Wed 6/10/26
0%	Yes	Establish Clinical Publications	Thu 6/11/26	Wed 6/17/26
0%	No	Prior Authorization (Clinical Call Center)	Mon 11/17/25	Fri 3/6/26
0%	Yes	PA Correspondence	Mon 11/17/25	Fri 3/6/26
0%	No	Client approves Orx standard letter inventory or provides custom letter inventory	Tue 12/2/25	Tue 12/2/25
0%	No	Orx Provides Mock Letter templates for client approval	Wed 12/3/25	Tue 12/16/25
0%	No	Client Final Approval on Letter Inventory or Approval of Standard	Mon 11/17/25	Fri 11/28/25
0%	No	PA Correspondence mocks letter templates for coding	Mon 12/1/25	Fri 12/12/25
0%	No	Correspondence Content Management team codes / maps letter templates	Mon 12/15/25	Fri 3/6/26
0%	No	Complete & finalize Prior Authorization Requirements and Processes	Mon 12/22/25	Fri 1/30/26
0%	No	Orx submits Prior Authorization requirements for coding	Mon 12/22/25	Mon 12/22/25
0%	Yes	Orx promotes coding to production	Tue 12/23/25	Tue 12/23/25
0%	No	Data Interfaces Commercial - CLIENT	Tue 11/18/25	Wed 12/10/25
0%	Yes	Discuss and Receive Data Interface Requirements	Tue 11/18/25	Tue 11/18/25

0%	No	Obtain approval for Custom Requirements (if applicable)	Wed 11/19/25	Fri 11/21/25
0%	No	Capture detail Requirements for Custom layout	Mon 11/24/25	Fri 12/5/25
0%	No	Obtain client sign off on Custom Requirements	Mon 12/8/25	Wed 12/10/25
0%	No	Data Interfaces Commercial - Vendor 1	Tue 11/18/25	Tue 12/30/25
0%	Yes	Discuss and Receive Data Interface Requirements	Tue 11/18/25	Tue 11/18/25
0%	No	Obtain approval for Custom Requirements (if applicable)	Wed 11/19/25	Fri 11/21/25
0%	No	Capture detail Requirements for Custom layout	Mon 11/24/25	Fri 12/5/25
0%	No	Obtain client sign off on Custom Requirements	Mon 12/8/25	Wed 12/10/25
0%	No	Obtain necessary NDA and/or PHI Authorization Release Forms for Data Exchange - Vendor 1	Wed 11/19/25	Tue 12/30/25
0%	No	Data Interfaces Commercial - Vendor 2	Tue 11/18/25	Tue 12/30/25
0%	Yes	Discuss and Receive Data Interface Requirements	Tue 11/18/25	Tue 11/18/25
0%	No	Obtain approval for Custom Requirements (if applicable)	Wed 11/19/25	Fri 11/21/25
0%	No	Capture detail Requirements for Custom layout	Mon 11/24/25	Fri 12/5/25
0%	No	Obtain client sign off on Custom Requirements	Mon 12/8/25	Wed 12/10/25
0%	No	Obtain necessary NDA and/or PHI Authorization Release Forms for Data Exchange - Vendor 2	Wed 11/19/25	Tue 12/30/25
0%	No	File Transfer Connectivity- CLIENT	Tue 11/18/25	Tue 12/16/25
0%	No	Discuss sFTP Requirements for File Transfer	Tue 11/18/25	Mon 11/24/25
0%	No	Request sFTP Setup/Structure	Tue 11/25/25	Wed 11/26/25
0%	No	Establish sFTP Site and Structure	Thu 11/27/25	Wed 12/10/25
0%	Yes	Provide Connection & Login Information for sFTP Site	Thu 12/11/25	Fri 12/12/25
0%	Yes	Test sFTP Connectivity	Mon 12/15/25	Tue 12/16/25
0%	No	File Transfer Connectivity-Vendor 1	Tue 11/18/25	Tue 12/16/25
0%	No	Discuss sFTP Requirements for File Transfer	Tue 11/18/25	Mon 11/24/25
0%	No	Request sFTP Setup/Structure	Tue 11/25/25	Wed 11/26/25
0%	No	Establish sFTP Site and Structure	Thu 11/27/25	Wed 12/10/25
0%	Yes	Provide Connection & Login Information for sFTP Site	Thu 12/11/25	Fri 12/12/25
0%	Yes	Test sFTP Connectivity	Mon 12/15/25	Tue 12/16/25
0%	No	File Transfer Connectivity- Vendor 2	Tue 11/18/25	Tue 12/16/25
0%	No	Discuss sFTP Requirements for File Transfer	Tue 11/18/25	Mon 11/24/25
0%	No	Request sFTP Setup/Structure	Tue 11/25/25	Wed 11/26/25
0%	No	Establish sFTP Site and Structure	Thu 11/27/25	Wed 12/10/25
0%	Yes	Provide Connection & Login Information for sFTP Site	Thu 12/11/25	Fri 12/12/25

0%	Yes	Test sFTP Connectivity	Mon 12/15/25	Tue 12/16/25
0%	No	Prescriber Network	Tue 11/18/25	Fri 1/16/26
0%	No	Provide OptumRx Prescriber Load Layout for review	Tue 11/18/25	Tue 11/18/25
0%	Yes	Discuss OptumRx Prescriber Load Layout Format	Wed 11/19/25	Tue 11/25/25
0%	No	Request Prescriber Load Automation and Inventory ID	Wed 11/26/25	Thu 11/27/25
0%	Yes	Complete setup for Prescriber Network	Fri 11/28/25	Thu 12/25/25
0%	Yes	Provide Test Prescriber Load File	Wed 11/26/25	Tue 12/16/25
0%	No	Load Test Prescriber File	Wed 12/17/25	Tue 12/23/25
0%	No	Review Results of Test Prescriber Load	Wed 12/24/25	Tue 12/30/25
0%	Yes	Approve Test Prescriber Load	Wed 12/31/25	Wed 12/31/25
0%	Yes	Provide Production Prescriber Load File	Thu 1/1/26	Wed 1/7/26
0%	Yes	Load Production Prescriber File	Thu 1/8/26	Fri 1/9/26
0%	No	Establish Automated Prescriber Load	Mon 1/12/26	Fri 1/16/26
0%	No	Claim Extract - CLIENT	Tue 11/18/25	Wed 2/11/26
0%	No	Standard Extract	Tue 11/18/25	Wed 2/11/26
0%	No	Provide OptumRx Claim Extract Layout for review	Tue 11/18/25	Tue 11/18/25
0%	No	Discuss Claim Extract Layout Format	Tue 11/18/25	Mon 11/24/25
0%	Yes	Confirm Claim Extract Details	Tue 11/18/25	Mon 11/24/25
0%	No	Request Robot Job for Claim Extract	Tue 11/25/25	Wed 11/26/25
0%	No	Set up Claim Extract Automation	Thu 11/27/25	Wed 12/24/25
0%	No	Obtain Test Claim Extract File Date Range	Thu 12/25/25	Thu 12/25/25
0%	No	Confirm Test Claim Extract Testing Environment	Fri 12/26/25	Fri 12/26/25
0%	Yes	Provide Test Claim Extract File	Mon 12/29/25	Fri 1/16/26
0%	No	Load Test Claim Extract File	Mon 1/19/26	Fri 1/23/26
0%	No	Review Results of Test Claim Extract File	Mon 1/26/26	Fri 1/30/26
0%	No	Additional rounds of Extract Testing	Mon 2/2/26	Fri 2/6/26
0%	Yes	Provide Production Claim Extract File	Mon 2/9/26	Mon 2/9/26
0%	Yes	Obtain client approval	Tue 2/10/26	Wed 2/11/26
0%	No	Establish Automated Extract Process	Fri 2/6/26	Mon 2/9/26
0%	No	Custom Extract	Tue 11/18/25	Fri 1/9/26
0%	No	Obtain Sr. Management Approval for Custom File	Tue 12/2/25	Thu 12/4/25
0%	No	Discuss Custom Claim Extract Format and Requirements	Tue 11/18/25	Mon 12/1/25
0%	Yes	Confirm Claim Extract Details	Tue 11/18/25	Mon 12/1/25
0%	No	Submit PRF for Custom Claim Extract Format	Tue 12/2/25	Wed 12/3/25

0%	No	SR is created and approved	Thu 12/4/25	Fri 12/5/25
0%	Yes	Develop Custom Claim Extract Program	Thu 12/4/25	Wed 12/31/25
0%	No	Test Custom Claim Extract Program	Thu 1/1/26	Thu 1/8/26
0%	Yes	Client Signoff on Testing	Fri 1/9/26	Fri 1/9/26
0%	No	Claim Extract - Vendor 1	Tue 11/18/25	Wed 2/11/26
0%	No	Standard Extract	Tue 11/18/25	Wed 2/11/26
0%	No	Provide OptumRx Claim Extract Layout for review	Tue 11/18/25	Tue 11/18/25
0%	No	Discuss Claim Extract Layout Format	Tue 11/18/25	Mon 11/24/25
0%	Yes	Confirm Claim Extract Details	Tue 11/18/25	Mon 11/24/25
0%	No	Request Robot Job for Claim Extract	Tue 11/25/25	Wed 11/26/25
0%	No	Set up Claim Extract Automation	Thu 11/27/25	Wed 12/24/25
0%	No	Obtain Test Claim Extract File Date Range	Thu 12/25/25	Thu 12/25/25
0%	No	Confirm Test Claim Extract Testing Environment	Fri 12/26/25	Fri 12/26/25
0%	Yes	Provide Test Claim Extract File	Mon 12/29/25	Fri 1/16/26
0%	No	Load Test Claim Extract File	Mon 1/19/26	Fri 1/23/26
0%	No	Review Results of Test Claim Extract File	Mon 1/26/26	Fri 1/30/26
0%	No	Additional rounds of Extract Testing	Mon 2/2/26	Fri 2/6/26
0%	Yes	Provide Production Claim Extract File	Mon 2/9/26	Mon 2/9/26
0%	Yes	Obtain client approval	Tue 2/10/26	Wed 2/11/26
0%	No	Establish Automated Extract Process	Fri 2/6/26	Mon 2/9/26
0%	No	Custom Extract	Tue 11/18/25	Fri 1/9/26
0%	No	Obtain Sr. Management Approval for Custom File	Tue 12/2/25	Thu 12/4/25
0%	No	Discuss Custom Claim Extract Format and Requirements	Tue 11/18/25	Mon 12/1/25
0%	Yes	Confirm Claim Extract Details	Tue 11/18/25	Mon 12/1/25
0%	No	Submit PRF for Custom Claim Extract Format	Tue 12/2/25	Wed 12/3/25
0%	No	SR is created and approved	Thu 12/4/25	Fri 12/5/25
0%	Yes	Develop Custom Claim Extract Program	Thu 12/4/25	Wed 12/31/25
0%	No	Test Custom Claim Extract Program	Thu 1/1/26	Thu 1/8/26
0%	Yes	Client Signoff on Testing	Fri 1/9/26	Fri 1/9/26
0%	No	Claim Extract - Vendor 2	Tue 11/4/25	Thu 7/30/26
0%	No	Standard Extract	Tue 11/18/25	Wed 2/11/26
0%	No	Provide OptumRx Claim Extract Layout for review	Tue 11/18/25	Tue 11/18/25
0%	No	Discuss Claim Extract Layout Format	Tue 11/18/25	Mon 11/24/25
0%	Yes	Confirm Claim Extract Details	Tue 11/18/25	Mon 11/24/25

0%	No	Request Robot Job for Claim Extract	Tue 11/25/25	Wed 11/26/25
0%	No	Set up Claim Extract Automation	Thu 11/27/25	Wed 12/24/25
0%	No	Obtain Test Claim Extract File Date Range	Thu 12/25/25	Thu 12/25/25
0%	No	Confirm Test Claim Extract Testing Environment	Fri 12/26/25	Fri 12/26/25
0%	Yes	Provide Test Claim Extract File	Mon 12/29/25	Fri 1/16/26
0%	No	Load Test Claim Extract File	Mon 1/19/26	Fri 1/23/26
0%	No	Review Results of Test Claim Extract File	Mon 1/26/26	Fri 1/30/26
0%	No	Additional rounds of Extract Testing	Mon 2/2/26	Fri 2/6/26
0%	Yes	Provide Production Claim Extract File	Mon 2/9/26	Mon 2/9/26
0%	Yes	Obtain client approval	Tue 2/10/26	Wed 2/11/26
0%	No	Establish Automated Extract Process	Fri 2/6/26	Mon 2/9/26
0%	No	Custom Extract	Tue 11/18/25	Fri 1/9/26
0%	No	Obtain Sr. Management Approval for Custom File	Tue 12/2/25	Thu 12/4/25
0%	No	Discuss Custom Claim Extract Format and Requirements	Tue 11/18/25	Mon 12/1/25
0%	Yes	Confirm Claim Extract Details	Tue 11/18/25	Mon 12/1/25
0%	No	Submit PRF for Custom Claim Extract Format	Tue 12/2/25	Wed 12/3/25
0%	No	SR is created and approved	Thu 12/4/25	Fri 12/5/25
0%	Yes	Develop Custom Claim Extract Program	Thu 12/4/25	Wed 12/31/25
0%	No	Test Custom Claim Extract Program	Thu 1/1/26	Thu 1/8/26
0%	Yes	Client Signoff on Testing	Fri 1/9/26	Fri 1/9/26
0%	No	Ongoing Accumulations Sharing (HSA/HDHP/etc.)	Tue 11/4/25	Tue 6/9/26
0%	No	IPM inform Accum contact if any of the following scenarios will apply: HIX Reprocessing, Coupons, MedD/Part B, etc.	Tue 11/4/25	Mon 12/15/25
0%	No	Discuss Accumulations Sharing Layout and Requirements (NRT/Batch)	Tue 11/18/25	Mon 11/24/25
0%	No	Determine Accumulation File Type (NRT/Batch)	Tue 12/16/25	Tue 12/16/25
0%	No	Discuss timing and route of File Exchange	Wed 12/17/25	Tue 12/23/25
0%	No	Determine need for Custom Accum Load and/or Extract	Wed 11/19/25	Tue 12/2/25
0%	Yes	Test Accumulations Sharing File Exchange and Load	Wed 12/24/25	Tue 1/13/26
0%	Yes	Provide/Receive Production Accumulation Load File	Thu 6/4/26	Thu 6/4/26
0%	Yes	Load Production Accumulations File	Fri 6/5/26	Fri 6/5/26
0%	No	Review Results of Production Accumulations Load	Mon 6/8/26	Mon 6/8/26
0%	Yes	Provide Production Accumulation Load Extract	Mon 6/8/26	Mon 6/8/26
0%	No	Establish Automated Accumulations Load	Tue 6/9/26	Tue 6/9/26
0%	No	Historical File Loads	Tue 11/18/25	Thu 7/30/26

0%	No	Member ID cross-reference (if needed)	Tue 11/25/25	Thu 11/27/25
0%	No	Historical Claims	Tue 11/18/25	Thu 7/30/26
0%	No	Discuss Historical Claim Transfer Layout and Requirements	Tue 11/18/25	Mon 11/24/25
0%	No	Discuss timing and route of File Exchange	Tue 11/18/25	Mon 11/24/25
0%	No	Adjust Load Program if Necessary	Tue 11/25/25	Mon 12/15/25
0%	No	Set up Historical CAG	Mon 11/24/25	Fri 11/28/25
0%	No	Set up Historical TCT	Mon 11/24/25	Mon 11/24/25
0%	No	Test Historical Claims File	Tue 11/25/25	Wed 12/17/25
0%	Yes	Provide Test/Production Historical Claim File	Tue 11/25/25	Mon 12/1/25
0%	No	Load Test File	Tue 12/2/25	Mon 12/8/25
0%	No	Load and Error report	Tue 12/9/25	Tue 12/9/25
0%	No	Match Historical Data to Test Eligibility	Wed 12/10/25	Tue 12/16/25
0%	No	Share Match Rate with IPM	Wed 12/17/25	Wed 12/17/25
0%	No	Production Historical Claims File	Thu 12/18/25	Mon 1/5/26
0%	Yes	Provide Initial Historical Claim Production File	Thu 12/18/25	Wed 12/24/25
0%	Yes	Load Initial Historical Claim Production File to Historical CAG	Thu 12/25/25	Mon 12/29/25
0%	No	Review/Revise Initial Historical Claim Load	Tue 12/30/25	Wed 12/31/25
0%	No	Match Initial Historical Claim Load to Eligibility	Thu 1/1/26	Fri 1/2/26
0%	No	Share Match Rate with IPM	Mon 1/5/26	Mon 1/5/26
0%	No	Historical Claims Lag File	Thu 7/16/26	Thu 7/30/26
0%	Yes	Provide Lag Historical Claim Production File	Thu 7/16/26	Thu 7/16/26
0%	Yes	Load Lag Historical Claim Production File to Historical CAG	Fri 7/17/26	Mon 7/20/26
0%	No	Review/Revise Lag Historical Claim Load	Tue 7/21/26	Thu 7/23/26
0%	No	Match Lag Historical Claim Load to Eligibility	Fri 7/24/26	Tue 7/28/26
0%	No	Share Match Rate with IPM	Wed 7/29/26	Thu 7/30/26
0%	No	Push Claim History to Data Warehouse (if applicable)	Tue 12/30/25	Mon 1/12/26
0%	No	Historical Accums	Tue 11/18/25	Mon 1/19/26
0%	No	Discuss Historical Accums Transfer Layout and Requirements	Tue 11/18/25	Mon 11/24/25
0%	No	Discuss timing and route of File Exchange	Tue 11/18/25	Mon 11/24/25
0%	No	Adjust Load Program if Necessary	Tue 11/25/25	Mon 12/15/25
0%	Yes	Receive/Test Historical Accums Test File	Tue 11/25/25	Mon 12/15/25
0%	No	Provide Initial Historical Accums Production File	Tue 12/16/25	Mon 1/5/26
0%	Yes	Load Initial Historical Accums Production File	Tue 1/6/26	Mon 1/12/26
0%	No	Review/Revise Initial Historical Accums Load	Tue 1/13/26	Mon 1/19/26

0%	No	Historical PAs	Tue 11/18/25	Tue 7/28/26
0%	No	Discuss Historical PA Transfer Layout and Requirements	Tue 11/18/25	Mon 11/24/25
0%	No	Discuss timing and route of File Exchange	Tue 11/18/25	Mon 11/24/25
0%	No	Adjust Load Program if Necessary	Tue 11/25/25	Mon 12/15/25
0%	No	Map PAs to RxCLAIM Flags	Tue 12/16/25	Mon 12/22/25
0%	No	Test Historical PA's	Tue 11/25/25	Wed 6/17/26
0%	Yes	Receive/Test Historical PA Test File	Tue 11/25/25	Mon 12/15/25
0%	No	Map PAs to RxCLAIM Flags	Thu 6/11/26	Wed 6/17/26
0%	No	Production Historical PA's	Thu 6/4/26	Wed 7/1/26
0%	Yes	Provide Initial Historical PA Production File	Thu 6/4/26	Wed 6/10/26
0%	Yes	Load Initial Historical PA Production File	Thu 6/18/26	Wed 6/24/26
0%	No	Review/Revise Initial Historical PA Load	Thu 6/25/26	Wed 7/1/26
0%	No	Historical PA Lag File	Thu 7/16/26	Tue 7/28/26
0%	Yes	Provide Lag Historical PA Production File	Thu 7/16/26	Thu 7/16/26
0%	No	Map PAs to RxCLAIM Flags	Fri 7/17/26	Mon 7/20/26
0%	Yes	Load Lag Historical PA Production File	Tue 7/21/26	Thu 7/23/26
0%	No	Review/Revise Lag Historical PA Load	Fri 7/24/26	Tue 7/28/26
0%	No	Member Services (Member/Pharmacy Call Center)	Mon 11/3/25	Tue 6/30/26
0%	No	Assign Toll Free #	Mon 11/10/25	Fri 11/21/25
0%	Yes	Discuss Requirements / Service Levels for Member and Pharmacy Call Center	Mon 11/3/25	Fri 11/7/25
0%	No	Provide Final Benefit Documentation Forms & Clinical Documentation Forms	Wed 4/29/26	Wed 4/29/26
0%	No	Complete Member Services Client Sign Off document	Mon 11/10/25	Thu 11/13/25
0%	No	Review/Revise Member Services Client Sign Off document	Fri 11/14/25	Thu 11/20/25
0%	Yes	Approve Member Services Client Sign Off document	Fri 11/21/25	Tue 11/25/25
0%	No	Set up process for Member and Pharmacy Call Center	Wed 11/26/25	Tue 12/2/25
0%	No	Complete Navigator Setup (with Home Delivery if Applicable)	Wed 12/3/25	Thu 12/18/25
0%	No	Member Services Set-up Approved	Fri 12/19/25	Fri 12/19/25
0%	No	Train Member Services Representatives on Client Requirements	Mon 12/22/25	Fri 12/26/25
0%	No	Call Center Metric Reporting Set Up Requested	Mon 12/22/25	Fri 1/16/26
0%	No	Call Center Metric Reporting Set Up Completed	Mon 1/19/26	Mon 1/19/26
0%	No	Test Phone Line	Tue 6/30/26	Tue 6/30/26
0%	No	Home Delivery	Tue 10/21/25	Fri 7/24/26
0%	No	Home Delivery Setup	Tue 10/21/25	Wed 4/29/26
0%	Yes	Discuss Home Delivery Setup Requirements	Tue 10/21/25	Mon 11/3/25

0%	No	Complete OptumRx Home Delivery Implementation Form	Thu 4/23/26	Wed 4/29/26
0%	No	Home Delivery Open Refill Transfer File - Vendor 1	Wed 11/19/25	Fri 7/24/26
0%	No	Discuss Home Delivery Transfer Requirements (ORT/New Rx)	Wed 3/18/26	Wed 4/8/26
0%	No	Discuss timing and route of File Exchange	Wed 3/18/26	Wed 3/18/26
0%	Yes	Complete ORT File Data Grid	Thu 4/2/26	Wed 4/8/26
0%	No	Test ORT File	Wed 5/20/26	Thu 6/4/26
0%	Yes	Provide Test ORT Test File	Wed 5/20/26	Wed 5/20/26
0%	No	Load ORT Test File	Thu 5/21/26	Fri 5/29/26
0%	No	ORT QA	Mon 6/1/26	Wed 6/3/26
0%	No	Summary of Load Provided	Thu 6/4/26	Thu 6/4/26
0%	No	Pre-Production ORT File	Wed 6/10/26	Tue 7/7/26
0%	Yes	Provide ORT Pre-Production File	Wed 6/10/26	Wed 6/10/26
0%	Yes	Load ORT Pre-Production File	Thu 6/11/26	Mon 6/15/26
0%	No	ORTF QA	Tue 6/16/26	Thu 6/18/26
0%	No	Summary of Load Provided	Tue 7/7/26	Tue 7/7/26
0%	No	ORT Production File	Wed 7/1/26	Thu 7/9/26
0%	Yes	Provide ORT Production File	Wed 7/1/26	Wed 7/1/26
0%	No	Load ORT Production File	Thu 7/2/26	Mon 7/6/26
0%	No	ORTF QA	Tue 7/7/26	Thu 7/9/26
0%	No	Summary of Load Provided	Tue 7/7/26	Tue 7/7/26
0%	No	ORT Lag File	Wed 7/15/26	Fri 7/24/26
0%	Yes	Provide ORT Lag File	Wed 7/15/26	Wed 7/15/26
0%	Yes	Load Lag ORT File	Thu 7/16/26	Mon 7/20/26
0%	No	ORTF QA	Tue 7/21/26	Thu 7/23/26
0%	No	Summary of Load Provided	Fri 7/24/26	Fri 7/24/26
0%	No	ORTF Cover Letter Mailing	Wed 11/19/25	Wed 11/19/25
0%	No	Send any new scripts received post-go live	Wed 11/19/25	Wed 11/19/25
0%	No	Home Delivery Open Refill Transfer File - Vendor 2	Wed 11/19/25	Fri 7/24/26
0%	No	Discuss Home Delivery Transfer Requirements (ORT/New Rx)	Wed 3/18/26	Wed 4/8/26
0%	No	Discuss timing and route of File Exchange	Wed 3/18/26	Wed 3/18/26
0%	Yes	Complete ORT File Data Grid	Thu 4/2/26	Wed 4/8/26
0%	No	Test ORT File	Wed 5/20/26	Thu 6/4/26
0%	Yes	Provide Test ORT Test File	Wed 5/20/26	Wed 5/20/26
0%	No	Load ORT Test File	Thu 5/21/26	Fri 5/29/26

0%	No	ORT QA	Mon 6/1/26	Wed 6/3/26
0%	No	Summary of Load Provided	Thu 6/4/26	Thu 6/4/26
0%	No	Pre-Production ORT File	Wed 6/10/26	Fri 6/19/26
0%	Yes	Provide ORT Pre-Production File	Wed 6/10/26	Wed 6/10/26
0%	Yes	Load ORT Pre-Production File	Thu 6/11/26	Mon 6/15/26
0%	No	ORTF QA	Tue 6/16/26	Thu 6/18/26
0%	No	Summary of Load Provided	Fri 6/19/26	Fri 6/19/26
0%	No	ORT Production File	Wed 7/1/26	Fri 7/10/26
0%	Yes	Provide ORT Production File	Wed 7/1/26	Wed 7/1/26
0%	No	Load ORT Production File	Thu 7/2/26	Mon 7/6/26
0%	No	ORTF QA	Tue 7/7/26	Thu 7/9/26
0%	No	Summary of Load Provided	Fri 7/10/26	Fri 7/10/26
0%	No	ORT Lag File	Wed 7/15/26	Fri 7/24/26
0%	Yes	Provide ORT Lag File	Wed 7/15/26	Wed 7/15/26
0%	Yes	Load Lag ORT File	Thu 7/16/26	Mon 7/20/26
0%	No	ORTF QA	Tue 7/21/26	Thu 7/23/26
0%	No	Summary of Load Provided	Fri 7/24/26	Fri 7/24/26
0%	No	ORTF Cover Letter Mailing	Wed 11/19/25	Wed 11/19/25
0%	No	Send any new scripts received post-go live	Wed 11/19/25	Wed 11/19/25
0%	No	Member Communications	Tue 11/18/25	Wed 4/8/26
0%	No	Transition/Introduction Communications	Tue 11/18/25	Mon 4/6/26
0%	No	Send and select member communications	Tue 11/18/25	Mon 12/8/25
0%	No	Discuss Timeline for Material Customization (If applicable)	Tue 11/18/25	Mon 12/8/25
0%	No	Create Timeline for Material Customization (If applicable)	Tue 12/9/25	Mon 12/15/25
0%	No	Provide draft of content to client	Tue 12/9/25	Thu 1/8/26
0%	No	Review & provide edits	Fri 1/9/26	Thu 1/22/26
0%	No	Review edits draft back to client	Fri 1/23/26	Thu 2/5/26
0%	No	Final review/approve content	Fri 2/6/26	Tue 2/24/26
0%	No	Provide data for mailing	Wed 2/25/26	Wed 3/4/26
0%	No	Send art to printer	Thu 3/5/26	Thu 3/5/26
0%	No	Print production	Fri 3/6/26	Thu 3/19/26
0%	No	Review/Approval Print Proofs	Fri 3/20/26	Mon 3/23/26
0%	No	Mailing drops	Tue 3/24/26	Mon 4/6/26
0%	No	Open Enrollment Materials (Optional)	Tue 11/18/25	Mon 4/6/26

0%	No	Send and select member communications	Tue 11/18/25	Mon 12/8/25
0%	No	Provide draft of content to client	Tue 12/9/25	Thu 1/8/26
0%	No	Review & provide edits	Fri 1/9/26	Thu 1/22/26
0%	No	Review edits draft back to client	Fri 1/23/26	Thu 2/5/26
0%	No	Final review/approve content	Fri 2/6/26	Tue 2/24/26
0%	No	Send to IM	Wed 2/25/26	Wed 3/4/26
0%	No	Send to printer (if needed)	Thu 3/5/26	Thu 3/5/26
0%	No	Print Production (if needed)	Fri 3/6/26	Thu 3/19/26
0%	No	Review/Approval Print Proofs (if needed)	Fri 3/20/26	Mon 3/23/26
0%	No	Mailing drops (if needed)	Tue 3/24/26	Mon 4/6/26
0%	No	Member Disruption Communications	Tue 11/18/25	Wed 4/8/26
0%	No	Data Files from Previous PBM	Tue 11/18/25	Mon 12/8/25
0%	No	Request Disruption Analysis	Tue 12/9/25	Mon 1/5/26
0%	No	Disruption Analysis Completed	Tue 1/6/26	Mon 1/19/26
0%	No	Provide draft of content to client	Tue 1/20/26	Mon 2/2/26
0%	No	Review & provide edits	Tue 2/3/26	Thu 2/19/26
0%	No	Review edits draft back to client	Fri 2/20/26	Fri 2/27/26
0%	No	Final review/approve content	Mon 3/2/26	Mon 3/2/26
0%	No	Provide data for mailing	Tue 3/3/26	Mon 3/16/26
0%	No	Send art to printer	Tue 3/17/26	Wed 3/18/26
0%	No	Print production	Thu 3/19/26	Wed 4/1/26
0%	No	Review/Approve Proofs	Thu 4/2/26	Fri 4/3/26
0%	No	Mailing drops	Mon 4/6/26	Wed 4/8/26
0%	No	Optum Specialty Network Communications (Optional Depending Plan)	Tue 11/18/25	Thu 3/19/26
0%	No	Send and select member communications	Tue 11/18/25	Mon 12/8/25
0%	No	Provide draft of content to client	Tue 12/9/25	Mon 12/29/25
0%	No	Review & provide edits	Tue 12/30/25	Mon 1/12/26
0%	No	Review edits draft back to client	Tue 1/13/26	Mon 1/26/26
0%	No	Final review/approve content	Tue 1/27/26	Thu 2/12/26
0%	No	Provide data for mailing	Fri 2/13/26	Mon 2/23/26
0%	No	Send art to printer	Tue 2/24/26	Tue 2/24/26
0%	No	Print Production	Wed 2/25/26	Tue 3/10/26
0%	No	Review/Approval Print Proofs	Wed 3/11/26	Thu 3/12/26
0%	No	Mailing drops	Fri 3/13/26	Thu 3/19/26

0%	No	Home Delivery Product Communications (Walgreens90, CVS90, Mail Service Member Select, etc.)- Optional depending on Plan	Tue 11/18/25	Thu 3/19/26
0%	No	Send and select member communications	Tue 11/18/25	Mon 12/8/25
0%	No	Provide draft of content to client	Tue 12/9/25	Mon 12/29/25
0%	No	Review & Provide edits	Tue 12/30/25	Mon 1/12/26
0%	No	Review edits draft back to client	Tue 1/13/26	Mon 1/26/26
0%	No	Final review/approve content	Tue 1/27/26	Thu 2/12/26
0%	No	Provide data for mailing (if needed)	Fri 2/13/26	Mon 2/23/26
0%	No	Send art to printer (if needed)	Tue 2/24/26	Tue 2/24/26
0%	No	Print production (if needed)	Wed 2/25/26	Tue 3/10/26
0%	No	Review/Approval Print Proofs (if needed)	Wed 3/11/26	Thu 3/12/26
0%	No	Mailing drops (if needed)	Fri 3/13/26	Thu 3/19/26
0%	No	Print Fullfillment - Commercial	Mon 11/3/25	Fri 2/13/26
0%	Yes	Complete New Client Member ID Card & Communication Notification Form	Tue 11/25/25	Mon 12/1/25
0%	No	ID Card Production by OptumRx	Tue 11/18/25	Wed 1/21/26
0%	No	Review ID Card Requirements (NCPDP if applicable)	Tue 11/18/25	Mon 11/24/25
0%	No	Provide Logo/Custom Information for ID Cards	Tue 11/18/25	Mon 11/24/25
0%	No	Mock Up ID Card	Tue 11/25/25	Mon 12/8/25
0%	No	Review/Revise ID Card Proof	Tue 12/9/25	Mon 12/22/25
0%	Yes	Approve ID Card Proof	Tue 12/23/25	Mon 12/29/25
0%	Yes	Build ID Card for Production	Tue 12/30/25	Mon 1/5/26
0%	No	Print ID Cards	Fri 1/9/26	Wed 1/14/26
0%	Yes	Print/Ship ID Cards to Members or Client	Thu 1/15/26	Wed 1/21/26
0%	No	ID Card Production Outside of OptumRx	Thu 11/6/25	Tue 1/13/26
0%	No	Provide BIN/PCN/RxGroup for ID Cards	Thu 11/6/25	Mon 11/10/25
0%	No	Provide Customer Care Phone Number	Mon 11/24/25	Fri 11/28/25
0%	No	Provide OptumRx Logo (optional)	Thu 11/6/25	Wed 11/12/25
0%	No	Provide www.optumrx.com website (optional)	Thu 11/6/25	Wed 11/12/25
0%	Yes	Review and Approve ID Card Proof	Mon 12/1/25	Fri 12/19/25
0%	No	Provide ID Card Proof to Customer Care	Mon 12/22/25	Mon 12/22/25
0%	No	Confirm ID Card Shipment with Print Vendor	Tue 1/13/26	Tue 1/13/26
0%	No	Member Communications	Mon 11/3/25	Fri 2/13/26
0%	No	DYNA (Validate if customer is customizing materials)	Mon 11/3/25	Fri 2/13/26
0%	No	Member Welcome Letter	Mon 11/3/25	Wed 1/21/26

0%	No	Provide Standard Welcome Letter for Review	Mon 11/3/25	Mon 11/3/25
0%	No	Review/Adjust Welcome Letter	Tue 11/4/25	Mon 12/8/25
0%	Yes	Approve Member Welcome Letter	Tue 12/9/25	Mon 12/15/25
0%	No	Create Member Welcome Letter	Tue 12/16/25	Mon 12/22/25
0%	Yes	Print Member Materials	Fri 1/9/26	Wed 1/14/26
0%	Yes	Ship Member Materials to Members or Client	Thu 1/15/26	Wed 1/21/26
0%	No	Member Disruption Analysis	Mon 11/24/25	Mon 1/5/26
0%	No	Request Disruption Analysis	Mon 11/24/25	Tue 11/25/25
0%	No	Disruption Analysis Completed	Wed 11/26/25	Tue 12/16/25
0%	No	Provide Disruption Communication Letter(s) for Review	Wed 12/17/25	Fri 12/19/25
0%	No	Review/Adjust Disruption Letter(s)	Mon 12/22/25	Wed 12/24/25
0%	No	Approve Member Disruption Letter(s)	Thu 12/25/25	Mon 12/29/25
0%	No	Print Member Disruption Letter(s)	Tue 12/30/25	Fri 1/2/26
0%	No	Ship Member Disruption Letter(s) to Members	Mon 1/5/26	Mon 1/5/26
0%	No	Custom Member Kit Communication Materials (if applicable)	Thu 11/27/25	Tue 1/13/26
0%	No	Provide Quote / Approval for Custom Communications	Thu 11/27/25	Wed 12/3/25
0%	Yes	Approve Custom Communications	Thu 1/1/26	Wed 1/7/26
0%	No	Produce Custom Communications	Thu 12/4/25	Wed 12/24/25
0%	No	Review/Revise Custom Communications	Thu 12/25/25	Wed 12/31/25
0%	No	Queue Member Materials to Print Vendor	Tue 1/6/26	Wed 1/7/26
0%	No	Obtain proofs from Print Vendor	Thu 1/8/26	Fri 1/9/26
0%	Yes	Review Print Vendor proofs	Mon 1/12/26	Tue 1/13/26
0%	No	Provide Member Materials to Customer Care	Thu 1/8/26	Thu 1/8/26
0%	No	Manual Claims	Mon 11/17/25	Fri 1/23/26
0%	No	Discuss Requirements for Manual Claims Processing	Mon 11/17/25	Fri 11/21/25
0%	No	Review Manual Claims Process	Mon 11/24/25	Fri 12/12/25
0%	No	Complete Manual Claim Implementation Questionnaire (MCIQ)	Mon 12/15/25	Fri 12/26/25
0%	No	Review/Revise MCIQ	Mon 12/29/25	Fri 1/2/26
0%	Yes	Approve MCIQ	Mon 1/5/26	Fri 1/9/26
0%	No	Set up process for Manual Claims Processing with Benefit Administration	Mon 1/12/26	Fri 1/23/26
0%	No	Pharmacy Networks	Mon 11/10/25	Fri 5/1/26
0%	No	Retail Network	Mon 11/10/25	Fri 1/23/26
0%	Yes	Determine Network Requirements	Mon 11/10/25	Fri 11/14/25
0%	Yes	Determine Pharmacy Contracting Requirements	Mon 11/17/25	Fri 11/21/25

0%	No	Set up Retail Network	Mon 11/17/25	Fri 1/23/26
0%	Yes	Pharmacy Contracting	Mon 11/17/25	Fri 1/23/26
0%	No	Outreach to Pharmacies to add to Network	Mon 11/17/25	Fri 12/26/25
0%	No	Complete addition of Pharmacy to Network	Mon 12/29/25	Fri 1/23/26
0%	No	Home Delivery Network	Mon 11/10/25	Fri 11/28/25
0%	Yes	Determine Network Requirements (Contract/LOA)	Mon 11/10/25	Fri 11/14/25
0%	No	Custom Home Delivery Network	Mon 11/17/25	Fri 11/28/25
0%	Yes	Set up Home Delivery Network	Mon 11/17/25	Fri 11/28/25
0%	No	Specialty Network	Mon 11/10/25	Fri 11/28/25
0%	Yes	Determine Network Requirements (Contract/LOA)	Mon 11/10/25	Fri 11/14/25
0%	No	Custom Specialty Network	Mon 11/17/25	Fri 11/28/25
0%	Yes	Set up Specialty Network	Mon 11/17/25	Fri 11/28/25
0%	No	Pharmacy Notification	Fri 5/1/26	Fri 5/1/26
0%	Yes	Pharmacy Fax Blasts	Fri 5/1/26	Fri 5/1/26
0%	No	Specialty Setup	Tue 11/18/25	Mon 2/9/26
0%	No	Discuss Specialty Volume	Tue 11/18/25	Mon 12/1/25
0%	Yes	Discuss Specialty Outreach Process/Requirements	Tue 11/18/25	Mon 12/1/25
0%	No	Specialty Outreach	Tue 12/2/25	Mon 2/9/26
0%	No	Determine if Specialty ORT file will be used	Tue 12/2/25	Mon 12/8/25
0%	No	Provide list of Specialty Members/Drugs/Providers	Tue 12/2/25	Mon 12/22/25
0%	No	Provide Specialty Outreach Letter for Review	Tue 12/2/25	Tue 12/2/25
0%	Yes	Approve Specialty Outreach Letter	Wed 12/10/25	Tue 12/16/25
0%	No	Adjust Specialty Outreach Letter	Wed 12/3/25	Tue 12/9/25
0%	No	Load Specialty Outreach Letter for Production	Wed 12/17/25	Tue 12/23/25
0%	No	Queue Specialty Outreach Letter to Print Vendor	Wed 12/24/25	Thu 12/25/25
0%	Yes	Print Specialty Outreach Letter	Fri 12/26/25	Wed 12/31/25
0%	Yes	Ship Specialty Outreach Letter	Thu 1/1/26	Wed 1/7/26
0%	Yes	Send Specialty ORT File - Vendor 1	Tue 12/9/25	Mon 1/5/26
0%	No	Load Specialty ORT File - Vendor 1	Tue 1/6/26	Mon 1/12/26
0%	Yes	Send Specialty ORT File - Vendor 2	Tue 12/9/25	Mon 1/5/26
0%	No	Load Specialty ORT File - Vendor 2	Tue 1/6/26	Mon 1/12/26
0%	Yes	Conduct Specialty Outreach Outbound Calls to Member	Tue 1/13/26	Mon 2/2/26
0%	Yes	Conduct Specialty Outreach Outbound Calls to Provider	Tue 1/13/26	Mon 2/2/26
0%	No	Setup Client for Specialty in ScriptMed	Tue 12/2/25	Mon 12/29/25

0%	No	Complete Specialty Script Conversion	Tue 2/3/26	Mon 2/9/26
0%	No	Train Agents on Client Requirements	Tue 1/27/26	Mon 2/9/26
0%	No	Finance	Mon 11/3/25	Wed 12/17/25
0%	No	Payments	Tue 11/4/25	Mon 11/24/25
0%	No	Complete Carrier Payment Setup Request Form	Tue 11/11/25	Mon 11/17/25
0%	No	Complete W-9 Form for Billing	Tue 11/18/25	Mon 11/24/25
0%	Yes	Establish Pharmacy & Member Payments	Tue 11/4/25	Mon 11/24/25
0%	No	Rebates	Tue 11/4/25	Wed 12/17/25
0%	No	Determine Rebate Requirements	Tue 11/4/25	Mon 11/17/25
0%	No	Determine Required Reporting Fields	Tue 11/18/25	Tue 11/18/25
0%	No	Determine Report/Payment Timing (Standard vs Custom)	Wed 11/19/25	Wed 11/19/25
0%	No	Confirm Report Delivery Method (sFTP, etc)	Thu 11/20/25	Thu 11/20/25
0%	No	Confirm Testing Requirements (Custom) for Rebate Process	Fri 11/21/25	Fri 11/21/25
0%	No	Confirm Payee Breakout for Rebate Disbursement	Mon 11/24/25	Mon 11/24/25
0%	No	Provide Rebate Network Information (Brand, Exclusions, Select 90)	Tue 11/25/25	Tue 11/25/25
0%	No	Provide Copy of Custom Specialty List to Rebate Team	Wed 11/26/25	Wed 11/26/25
0%	No	Provide Copy of Contract to Rebate Team (Redline or Final)	Thu 11/27/25	Thu 11/27/25
0%	No	AM Team to Complete Onboarding Checklist	Fri 11/28/25	Fri 11/28/25
0%	No	Complete IRS W-9 Form	Tue 11/4/25	Mon 11/17/25
0%	No	Complete EFT Request Form	Tue 11/4/25	Mon 11/17/25
0%	No	Complete New Client Rebate Implementation Request Form	Tue 11/18/25	Wed 11/19/25
0%	Yes	Set up Client for Rebates	Thu 11/20/25	Wed 12/17/25
0%	No	Invoicing/Billing	Mon 11/3/25	Mon 12/8/25
0%	No	Provide Sample Invoice and Billing Reports	Mon 11/3/25	Mon 11/3/25
0%	No	Review Invoice and Billing Reports and Process	Tue 11/4/25	Mon 11/17/25
0%	No	Provide Primary and Secondary contact for Invoice and Billing	Tue 11/4/25	Mon 11/17/25
0%	No	Complete IRS W-9 Form	Tue 11/4/25	Mon 11/17/25
0%	No	Complete New Client Billing & Invoice Notification Form	Tue 11/18/25	Wed 11/19/25
0%	Yes	Set up Client Invoice and Billing	Tue 11/25/25	Mon 12/8/25
0%	No	System Access	Mon 11/3/25	Wed 1/14/26
0%	No	Client Portal	Tue 11/18/25	Wed 1/14/26
0%	No	Determine Client Portal Access & Requirements	Tue 11/18/25	Mon 12/1/25
0%	No	Complete Client Portal User Request Form	Tue 12/2/25	Wed 12/3/25
0%	No	Add OptumRx and Client Contacts into ServiceNow Account	Thu 12/4/25	Wed 12/10/25

0%	Yes	Configure Client Portal	Thu 12/4/25	Wed 12/24/25
0%	Yes	Provide User IDs and Passwords for Client Portal	Thu 12/25/25	Wed 12/31/25
0%	Yes	Conduct Client Portal Training	Thu 1/1/26	Wed 1/14/26
0%	No	CBS (OptumRx Billing System)	Tue 11/18/25	Wed 12/31/25
0%	Yes	Complete CBS Billing Form	Tue 11/18/25	Mon 11/24/25
0%	No	Provide Billing Samples/Reports	Thu 12/25/25	Wed 12/31/25
0%	No	RxCLAIM	Tue 11/4/25	Mon 1/5/26
0%	No	Determine RxCLAIM Access & Requirements	Tue 11/18/25	Mon 11/24/25
0%	No	Complete RxCLAIM User Request Form	Tue 11/25/25	Wed 11/26/25
0%	No	Create Client Logical	Tue 11/4/25	Mon 11/24/25
0%	Yes	Create RxCLAIM User Accounts	Thu 11/27/25	Wed 12/24/25
0%	Yes	Provide User IDs and Passwords for RxCLAIM	Thu 12/25/25	Wed 12/31/25
0%	Yes	Conduct RxCLAIM Training	Thu 1/1/26	Mon 1/5/26
0%	No	RxTRACK (Reporting)	Mon 11/3/25	Mon 1/12/26
0%	No	Provide RxTRACK Report Catalog	Mon 11/3/25	Mon 11/3/25
0%	No	Determine RxTRACK Access & Requirements	Tue 11/18/25	Mon 11/24/25
0%	No	Complete RxTRACK Security Setup Request Form	Tue 11/25/25	Mon 12/1/25
0%	Yes	Complete RxTRACK Client and User Setup	Tue 12/2/25	Mon 12/29/25
0%	Yes	Provide User IDs and Passwords for RxTRACK	Tue 12/30/25	Mon 1/5/26
0%	Yes	Conduct RxTRACK Training	Tue 1/6/26	Mon 1/12/26
0%	No	Auditing	Tue 11/18/25	Tue 2/10/26
0%	No	Pre Implementation Audit	Tue 11/18/25	Tue 12/16/25
0%	No	Discuss /Determine Pre-Implementation Audit Request	Tue 11/18/25	Tue 11/18/25
0%	Yes	Conduct Audit	Wed 11/19/25	Tue 12/2/25
0%	No	Audit Result Review Meeting Conducted	Wed 12/3/25	Tue 12/16/25
0%	No	Provide Audit Results	Wed 12/3/25	Wed 12/3/25
0%	No	Client/Auditor Review of Audit Results	Thu 12/4/25	Wed 12/10/25
0%	No	Provide Additional Audit Results for Final Review	Thu 12/11/25	Fri 12/12/25
0%	No	Pre Implementation Audit Complete	Mon 12/15/25	Mon 12/15/25
0%	No	Post Implementation Audit	Tue 12/16/25	Tue 2/10/26
0%	No	Discuss /Determine Post Implementation Audit Request	Tue 12/16/25	Wed 12/17/25
0%	Yes	Conduct Audit	Thu 12/18/25	Thu 1/8/26
0%	No	Audit Result Review Meeting Conducted	Fri 1/9/26	Fri 1/9/26
0%	Yes	Provide Audit Results	Fri 1/9/26	Fri 1/30/26

0%	No	Client/Auditor Review of Audit Results	Mon 2/2/26	Fri 2/6/26
0%	No	Provide Additional Audit Results for Final Review	Mon 2/9/26	Tue 2/10/26
0%	No	Post implementation Audit Complete	Mon 2/2/26	Fri 2/6/26
0%	No	Go Live Preparation	Thu 6/11/26	Mon 6/29/26
0%	Yes	Confirm Contract has been Executed	Wed 6/17/26	Wed 6/17/26
0%	Yes	Confirm all tasks have been completed	Fri 6/19/26	Wed 6/24/26
0%	No	Configure Go Live Claim Reports	Tue 6/16/26	Mon 6/29/26
0%	Yes	Determine Go Live Meeting Frequency & Schedule	Thu 6/11/26	Wed 6/17/26
0%	Yes	Determine Go Live Communication & Escalation Process	Thu 6/11/26	Wed 6/17/26
0%	No	Go Live	Wed 7/1/26	Tue 7/14/26
0%	Yes	Process Claims	Wed 7/1/26	Wed 7/1/26
0%	Yes	Monitor & Validate Claims	Wed 7/1/26	Tue 7/14/26
0%	Yes	Provide Status Communications as Scheduled	Wed 7/1/26	Tue 7/14/26
0%	Yes	Conduct Internal Meetings as Scheduled	Wed 7/1/26	Tue 7/14/26
0%	Yes	Conduct Client Meetings as Scheduled	Wed 7/1/26	Tue 7/14/26
0%	No	Project Closure	Wed 7/8/26	Wed 8/12/26
0%	No	Satisfaction Surveys	Wed 7/8/26	Wed 7/29/26
0%	No	Distribute Survey Requests	Wed 7/8/26	Wed 7/8/26
0%	Yes	Complete Survey Requests	Thu 7/9/26	Wed 7/22/26
0%	No	Compile Survey Results	Thu 7/23/26	Wed 7/29/26
0%	No	Transition to Account Management	Mon 7/20/26	Wed 8/12/26
0%	No	Provide all necessary Documentation	Mon 7/20/26	Mon 7/20/26
0%	No	Conduct Internal Transition Call	Tue 7/21/26	Tue 7/21/26
0%	Yes	Conduct Client Transition Call	Wed 7/22/26	Wed 7/22/26
0%	No	Review & Approve 1st Invoice	Wed 7/22/26	Wed 7/22/26
0%	Yes	Complete Implementation Lessons Learned	Wed 8/12/26	Wed 8/12/26
0%	No	Project Tracking	Thu 8/6/26	Wed 8/12/26
0%	No	Archive all Implementation Documentation	Thu 8/6/26	Wed 8/12/26
0%	No	Close Out Implementation Case in ServiceNow	Thu 8/6/26	Wed 8/12/26
0%	No	Close Out Implementation in SharePoint	Thu 8/6/26	Wed 8/12/26

CONTRACTUAL AGREEMENT FORM

BIDDER MUST COMPLETE THE FOLLOWING

By signing this Contractual Agreement Form, the bidder guarantees compliance with the provisions stated in this solicitation and agrees to the terms and conditions unless otherwise indicated in writing and certifies that bidder is not owned by the Chinese Communist Party.

Per Nebraska's Transparency in Government Procurement Act, Neb. Rev Stat § 73-603, DAS is required to collect statistical information regarding the number of contracts awarded to Nebraska Vendors. This information is for statistical purposes only and will not be considered for contract award purposes.

 X NEBRASKA VENDOR AFFIDAVIT: Bidder hereby attests that bidder is a Nebraska Vendor. "Nebraska Vendor" shall mean any bidder who has maintained a bona fide place of business and at least one employee within this state for at least the six (6) months immediately preceding the posting date of this Solicitation. All vendors who are not a Nebraska Vendor are considered Foreign Vendors under Neb. Rev Stat § 73-603 (c).

 I hereby certify that I am a Resident disabled veteran or business located in a designated enterprise zone in accordance with Neb. Rev. Stat. § 73-107 and wish to have preference, if applicable, considered in the award of this contract.

 I hereby certify that I am a blind person licensed by the Commission for the Blind & Visually Impaired in accordance with Neb. Rev. Stat. § 71-8611 and wish to have preference considered in the award of this contract.

THIS FORM MUST BE SIGNED MANUALLY IN INK OR BY DOCUSIGN

COMPANY:	OptumRx, Inc. (Optum Rx)
ADDRESS:	11000 Optum Circle Eden Prairie, MN 55344
PHONE:	(800) 282-3232
EMAIL:	orxsalesproposals@optum.com
BIDDER NAME & TITLE:	Lisa M. Smith, Chief Client Officer
SIGNATURE:	 Lisa Smith (07/09/2025 16:48 CDT)
DATE:	07/09/2025

VENDOR COMMUNICATION WITH THE STATE CONTACT INFORMATION (IF DIFFERENT FROM ABOVE)

NAME:	Jeff Gottlieb
TITLE:	Area Vice President, Public Sector Sales
PHONE:	(443) 739-4028
EMAIL:	Jeff.gottlieb@optum.com

STATE OF NEBRASKA
BUSINESS ASSOCIATE AGREEMENT

THIS BUSINESS ASSOCIATE AGREEMENT ("Agreement") amends and is made a part of all Services Agreements (as defined below) between OptumRx, Inc. ("Business Associate") and State of Nebraska ("Company") on behalf of the Group Health Plans sponsored by Company (the "Plan"). This Agreement is effective July 1, 2026, or upon the effective date of the underlying Services Agreement, whichever is later ("Effective Date"). This Agreement supersedes and replaces any prior Business Associate Agreements between the parties.

1. **Definitions.**

a. **Catch-all definitions.** The following terms used in this Agreement shall have the same meaning as those terms in the HIPAA Rules: Breach, Covered Entity, Data Aggregation, Designated Record Set, Disclose or Disclosure, Electronic Protected Health Information, Health Care Operations, Minimum Necessary, Notice of Privacy Practices, Protected Health Information or PHI, Required By Law, Secretary, Security Incident, Subcontractor, Unsecured Protected Health Information, and Use. Other capitalized terms used but not otherwise defined in this Agreement shall have the meaning ascribed in the HIPAA Rules.

b. **Specific definitions.**

(1) ***"Business Associate"*** shall generally have the same meaning as the term "Business Associate" at 45 CFR 160.103, and in reference to the party to this Agreement, shall mean the party identified above as Business Associate.

(2) ***"Business Associate Functions"*** means functions performed by Business Associate on behalf of the Plan in the course of providing or arranging for plan administration services which involve the creation, receipt, maintenance or transmission of PHI by Business Associate or its agents or Subcontractors. It is anticipated that the services provided by Business Associate will be performed as part of the Plan's "health care operations" as defined in the HIPAA Rules.

(3) ***"HIPAA Rules"*** shall mean the Privacy, Security, Breach Notification, and Enforcement Rules at 45 CFR Part 160 and Part 164. A reference in this Agreement to a section in the HIPAA Rules means the section as in effect or as amended at the time the section is to be applied.

(4) ***"Individual"*** shall generally have the same meaning ascribed in the HIPAA Rules and shall refer only to Individuals who are covered persons under the Plan.

(5) ***"Services Agreements"*** means all agreements whether now in effect or hereafter entered into, between Company and Business Associate for the performance of Business Associate Functions by Business Associate on behalf of the Plan.

2. **Purpose.** The Plan is a Covered Entity under HIPAA. The HIPAA Rules require the Plan to obtain, and Business Associate to provide, satisfactory written contractual assurances before Business Associate may create, receive, maintain, or Disclose PHI to perform Business Associate Functions on behalf of the Plan. This Agreement is entered into to provide the contractual assurances required under the HIPAA Rules.

3. **Obligations of Business Associate.** As an express condition of performing Business Associate Functions, Business Associate agrees to:

a. Not Use or Disclose PHI other than as permitted or required by this Agreement or as otherwise Required by Law.

b. Use appropriate safeguards and comply with Subpart C of 45 CFR Part 164 with respect to Electronic Protected Health Information, to prevent Use or Disclosure of PHI other than as provided for in this Agreement.

c. Report to the Plan's designated privacy official, without unreasonable delay but in no event more than three (3) business days after discovery by Business Associate, any Use or Disclosure of PHI not provided for by this Agreement of which Business Associate becomes aware, including any Breach of Unsecured Protected Health Information as required at 45 CFR 164.410, and any Security Incident of which it becomes aware, together with any remedial or mitigating action taken or proposed to be taken with respect thereto. If Business Associate does not have available complete information in satisfaction of 45 CFR 164.410(c) within three (3) business days of discovery of the impermissible Use or Disclosure, Business Associate shall provide all information it has at such time and immediately update the Plan with additional information as it becomes available through prompt investigation. This Agreement serves as Business Associate's notice to the Plan that attempted but unsuccessful Security Incidents regularly occur and that no further notice will be made by Business Associate unless there has been a successful Security Incident or attempts or patterns of attempts that Business Associate determines to be suspicious.

Business Associate shall cooperate with the Plan in mitigating any harmful effects of any impermissible Use or Disclosure. In the case of a Breach as determined to exist in the sole discretion of the Plan which was due to a violation of this Agreement by Business Associate, Business Associate shall pay for the reasonable costs of investigation, mitigation and notification to affected Individuals. As an alternative to Business Associate reimbursing Company and the Plan for the costs of notification, the Plan may elect to have Business Associate directly provide the notifications to Individuals for breaches caused by Business Associate, provided that Company and the Plan shall have final approval of all content of notifications to Individuals.

d. In accordance with 45 CFR 164.502(e)(1)(ii) and 164.308(b)(2), ensure that any Subcontractors that create, receive, maintain, or transmit PHI on behalf of Business Associate agree in writing to the same restrictions, conditions, and requirements that apply to Business Associate with respect to such information.

e. Within ten (10) business days of request by an Individual or notification by the Plan, make available to the Individual such Individual's PHI maintained by Business Associate in a Designated Record Set in accordance with 45 CFR 164.524. The

parties agree that Individuals will be directed to Business Associate to make all requests for access to PHI. Business Associate will provide such access according to its own procedures for such access in accordance with the requirements of 45 CFR 164.524. If the requested PHI is maintained in one or more Designated Record Sets electronically and if the Individual requests an electronic copy of such PHI, Business Associate must provide the Individual with access to PHI in the electronic form and format requested by the Individual, if it is readily producible in such form and format; or, if not, in a readable electronic form and format as agreed to between Business Associate and the Individual. Business Associate shall provide the requested information directly to the Individual, along with a notice to the Individual that a copy of the individual's request has been furnished to the Plan and that the Plan may provide additional information to the Individual in response to the request.

If the Individual's request covers records not maintained by Business Associate, Business Associate shall notify the Plan within three (3) days of the request. The Plan will be responsible for providing access or otherwise responding directly to the Individual pursuant to the HIPAA Rules with respect to PHI not in the possession of Business Associate or an agent or subcontractor of Business Associate. Business Associate may charge the Individual reasonable fees related to this access, as determined by Business Associate, but only in such amounts as permitted by the HIPAA Rules. The Plan authorizes Business Associate to require payment of such fees from the Individual prior to releasing any records.

f. Business Associate agrees to receive requests for amendment and amend PHI as required by 45 CFR 164.526 on the Plan's behalf for as long as such information is maintained by Business Associate. The parties agree that Individuals will be directed to Business Associate to make all such requests for amendment of PHI. Business Associate will amend such PHI according to its own procedures for such amendment in accordance with the requirements of 45 CFR 164.526. If the Individual's request covers records not maintained by Business Associate, Business Associate shall notify the Plan within three (3) days of such request. The Plan will be responsible for amending or otherwise responding directly to the Individual pursuant to the HIPAA Rules with respect to PHI not in the possession of Business Associate or an agent or contractor of Business Associate. Business Associate shall notify the Plan of any amendments made to PHI.

g. Business Associate agrees to process all requests for disclosure accounting by Individuals for as long as such information is maintained by Business Associate. Individuals will be directed to Business Associate to make all such requests. Business Associate will provide the accounting that is required under 45 CFR 164.528 on the Plan's behalf directly to the Individual. Business Associate will provide such accounting according to its own procedures for such accounting in accordance with the requirements of 45 CFR 164.528.

Business Associate shall notify the Plan within three (3) days of any request made by an Individual for a disclosure accounting. The Plan will be responsible for responding directly to the Individual (or the Individual's personal representative) pursuant to 45 CFR 164.528 with respect to disclosures of PHI by persons or entities other than Business Associate or a subcontractor or agent of Business Associate.

Business Associate shall provide directly to the Individual the requested accounting of disclosures made by Business Associate or a subcontractor or agent of Business Associate, along with a notice to the Individual that a copy of the Individual's request has been furnished to the Plan and that the Plan may provide additional information to the Individual in response to the request.

h. Make its internal practices, books and records relating to this Agreement available to the Secretary of HHS and to the Plan for purposes of determining the Plan's and Business Associate's compliance with the HIPAA Rules.

i. So that the Plan may meet its obligations to evaluate requests for restrictions and confidential communications in connection with the disclosure of PHI under 45 CFR 164.522, Business Associate and the Plan agree that, to the extent that communications are within the control of Business Associate, Business Associate will perform these evaluations on behalf of the Plan. Business Associate will evaluate such requests according to its own procedures for such requests, in accordance with the requirements of 45 CFR 164.522, and shall implement such appropriate operational steps as are required by its own procedures. Such evaluation will not relieve the Plan of any additional and independent obligations to evaluate restrictions or implement confidential communications where requested by an Individual. Accordingly, Business Associate will evaluate requests for restrictions and requests for confidential communications and will respond to these requests as appropriate under Business Associate's procedures. The Plan agrees that it will not agree to such restriction or request that would affect Business Associate without the approval of Business Associate, so that Business Associate can determine whether it can reasonably administer the request.

j. So that the Plan may meet its obligation to evaluate complaints from Individuals regarding their privacy rights or privacy practices of the Plan or Business Associate, the parties agree that Individuals shall be directed to submit any such complaint to Business Associate for review and evaluation. Business Associate will evaluate such complaints according to its own procedures for complaints and shall implement appropriate operation steps as are required by its own procedures. The Privacy Officer of the Plan shall cooperate with Business Associate in the evaluation of any such complaint. Business Associate shall provide a copy of all complaints to the Plan within three (3) days of receipt by Business Associate. If the complaint appears to involve handling of PHI by the Plan, Plan Sponsor, or other Business Associate of the Plan, Business Associate shall notify the Plan, and it shall be the Plan's responsibility to review and evaluate the complaint.

k. Limit the Uses and Disclosures of, or requests for, PHI for purposes described in this Agreement to the Minimum Necessary to perform the required Business Associate Functions. Business Associate shall comply with any additional requirements for the determination of Minimum Necessary as are required from time to time by the HIPAA Rules, as amended, or through additional guidance published by the Secretary.

l. To the extent Business Associate is expressly obligated under the Services Agreements to carry out one or more of the Plan's obligations(s) under Subpart E of

45 CFR Part 164, comply with the requirements of Subpart E that apply to the Plan in the performance of such obligation(s).

m. Except for the specific Uses and Disclosures for the Business Associate's own management and administration or to carry out the legal responsibilities of Business Associate, Business Associate shall not Use or Disclose PHI in a manner that would violate the HIPAA Rules if done by the Plan.

4. **Permitted Uses and Disclosures of PHI.** Business Associate shall only Use or Disclose PHI as follows:

a. Business Associate may Use or Disclose PHI as Required by Law. Business Associate agrees to follow the current law covering the use and disclosure of PHI related to substance abuse and reproductive health.

b. Business Associate may Use or Disclose PHI as necessary to carry out Business Associate Functions.

c. Business Associate may Use PHI for the proper management and administration of Business Associate or to carry out the legal responsibilities of Business Associate.

d. Business Associate may Disclose PHI for the proper management and administration of Business Associate or to carry out the legal responsibilities of Business Associate, provided the Disclosures are Required by Law, or Business Associate obtains reasonable assurances from the person to whom the information is Disclosed that the information will remain confidential and be Used or further Disclosed only as Required by Law or for the purposes for which it was Disclosed to the person, and the person notifies Business Associate in writing of any instances of which it is aware in which the confidentiality of the information has been breached or compromised.

e. If specifically identified as a Business Associate Function in the Services Agreements, Business Associate may provide Data Aggregation services relating to the Health Care Operations of Covered Entity.

f. If de-identification is listed as a Business Associate Function in the Services Agreements, or if Business Associate is expressly permitted to de-identify PHI and use data thus de-identified for its own uses in the Services Agreements, Business Associate may Use PHI to de-identify the information in accordance with 45 CFR 164.514(a)-(c). Business Associate may use de-identified data only for the purposes specified in the Services Agreements.

5. **Responsibilities of the Plan.** The Plan agrees to:

a. Notify Business Associate promptly of any restriction on the Use or Disclosure of PHI that the Plan has agreed to or is required to abide by under 45 CFR 164.522, to the extent such restriction may affect Business Associate's Use or Disclosure of PHI.

b. Notify Business Associate of any changes in, or revocation of, the permission by an Individual to Use or Disclose PHI, to the extent that such changes may affect Business Associate's Use or Disclosure of PHI.

c. Provide Business Associate with a copy of any amendment to PHI which is accepted by Covered Entity under 45 CFR 164.526 which Covered Entity believes will apply to PHI maintained by Business Associate in a Designated Record Set.

d. Not request Business Associate to Use or Disclose PHI in any manner that would not be permissible under the HIPAA Rules if done by the Plan, with exception for any Data Aggregation services permitted under Section 4.

6. **Compliance with Electronic Transactions Rule.** If Business Associate conducts in whole or part electronic Transactions (as defined in 45 CFR 160.103) on behalf of Covered Entity for which the Secretary of HHS has established standards, Business Associate will comply, and will require any Subcontractor involved with the conduct of such Transactions to comply, with each applicable requirement of the Electronic Transactions Rule at 45 CFR Parts 160 and 162 and of any operating rules adopted by the Secretary of HHS with respect to Transactions.

7. **Supervening Law.** Upon the enactment of any law or regulation affecting the Use or Disclosure of PHI, or the publication of any decision of a court of the United States or of this state relating to any such law, or the publication of any interpretive policy or opinion of any governmental agency charged with the enforcement of any such law or regulation, the parties agree to amend this Agreement in such manner as is necessary to comply with such law or regulation. If the parties are unable to agree on an amendment within thirty (30) days, either party may terminate the Services Agreements on not less than thirty (30) days' written notice to the other.

8. **Liability and Indemnification.** Each party shall be responsible for the acts and omissions of its own agents, employees and contractors. Notwithstanding the foregoing, and notwithstanding any limitation of liability or disclaimer of damages in the Services Agreements or elsewhere, to the extent that the Secretary determines that Business Associate is acting as an agent of the Plan under the Services Agreements or this Agreement, Business Associate shall indemnify Company and the Plan for any fines, civil monetary penalties or monetary resolutions incurred by Company or the Plan, plus reasonable attorneys' fees of Company and the Plan, arising out of or relating to the actions or omissions of Business Associate which constitute a breach of this Agreement by Business Associate. This indemnification is in addition to any additional indemnification provided by Business Associate in the Services Agreement.

9. **Term and Termination.**

a. **Term.** This Agreement shall become effective on the Effective Date and shall continue in effect until all obligations of the parties have been met, including return or destruction of all PHI in Business Associate's possession (or in the possession of Business Associate's agents and Subcontractors), unless sooner terminated as provided herein. It is expressly agreed that the terms and conditions of this Agreement designed to safeguard PHI shall survive expiration or other termination of the Services Agreements and shall continue in effect until Business Associate has

performed all obligations under this Agreement and has either returned or destroyed all PHI.

b. **Termination.** Company may immediately terminate this Agreement and the Services Agreements, if Company and/or the Plan makes the determination that Business Associate has breached a material term of this Agreement. Alternatively, Company may choose to provide Business Associate with written notice of the existence of an alleged material breach, and afford Business Associate an opportunity to cure the alleged material breach upon mutually agreeable terms. Failure to take reasonable steps to cure the breach is grounds for the immediate termination of this Agreement.

c. **Business Associate Obligations Upon Termination.** Upon termination of this Agreement for any reason, Business Associate, with respect to PHI received from the Plan, or created, maintained, or received by Business Associate on behalf of the Plan, shall:

- (i) Retain only that PHI which is necessary for Business Associate to continue its proper management and administration or to carry out its legal responsibilities or as to which Business Associate reasonably determines such PHI is technically incapable of being returned or destroyed;
- (ii) Return to the Plan or, if not provided for in the Services Agreements, destroy the PHI retained under 8.c.(i) that the Business Associate maintains in any form;
- (iii) Continue to use appropriate safeguards and comply with Subpart C of 45 CFR Part 164 with respect to Electronic Protected Health Information retained by Business Associate to prevent Use or Disclosure of the PHI, other than as provided for in this Section, for as long as Business Associate retains the PHI;
- (iv) Not Use or Disclose the PHI retained by Business Associate other than for the purposes for which such PHI was retained and subject to the same conditions set out at Sections 4.c. and 4.d. which applied prior to termination; and
- (v) Return to the Plan or, if not provided for in the Services Agreements, destroy the PHI retained by Business Associate under Section 8.c.(i) when it is no longer needed by Business Associate for its proper management and administration or to carry out its legal responsibilities, except where Business Associate reasonably determines such PHI is not technically capable of being returned or destroyed.

10. **Miscellaneous.**

a. **Applicability.** For purposes of this Agreement, and as applicable to the Business Associate Functions of Business Associate under the Services Agreements covered by this Agreement, references to the Plan shall include the named Plan and all

other group health plans subject to HIPAA and sponsored by Company that participate in an organized health care arrangement.

b. **Survival.** The respective rights and obligations of Business Associate and the Plan or Company hereunder shall survive termination of this Agreement according to the terms hereof and the obligations imposed on the Plan or Company and Business Associate under the HIPAA Rules.

c. **Interpretation; Amendment.** This Agreement shall be interpreted and applied in a manner consistent with the Plan's and Business Associate's obligations under the HIPAA Rules. All amendments shall be in writing and signed by both parties, except that this Agreement shall attach to additional Services Agreements entered into between the parties in the future without the necessity of amending this Agreement each time. This Agreement is intended to cover the entire Business Associate *relationship* between the parties, as amended, from time to time, through Services Agreements or other means.

d. **Waiver.** A waiver with respect to one event shall not be construed as continuing, or as a bar to or waiver of any right or remedy as to subsequent events.

e. **No Third-Party Beneficiaries.** Nothing express or implied in this Agreement is intended to confer, nor shall anything herein confer, upon any person other than the parties and their respective successors or assigns, any rights, remedies or obligations.

IN WITNESS WHEREOF, each of the undersigned has caused this Agreement to be duly executed in its name and on its behalf.

Company:

State of Nebraska

Business Associate:

OptumRx, Inc.

Signature: _____

Printed Name: _____

Title: _____

Date Signed: _____

Signature: Matthew Vesledahl
Matthew Vesledahl (07/15/2025 15:22 CDT)

Printed Name: Matthew Vesledahl

Title: CFO

Date Signed: 07/15/2025

DOCS/1204654.1

122436 O5 - Attachment B - Business Associate Agreement_Executable_Date Added

Final Audit Report

2025-07-15

Created:	2025-07-15
By:	Kristin Lerner (kristin.lerner@optum.com)
Status:	Signed
Transaction ID:	CBJCHBCAABAAEnbblyhakm9-CmL9kssqxBbQzzwFMVj
Documents:	122436 O5 - Attachment B - Business Associate Agreement_Executable_Date Added.doc (8 pages)
Number of Documents:	1
Document page count:	8
Number of supporting files:	0
Supporting files page count:	0

"122436 O5 - Attachment B - Business Associate Agreement_Executable_Date Added" History



Document created by Kristin Lerner (kristin.lerner@optum.com)

Documents: 122436 O5 - Attachment B - Business Associate Agreement_Executable_Date Added.doc
2025-07-15 - 7:10:37 PM GMT- IP address: 165.225.62.98



Document emailed to Matthew Vesledahl (matthew.vesledahl@optum.com) for signature

2025-07-15 - 7:11:19 PM GMT



Email viewed by Matthew Vesledahl (matthew.vesledahl@optum.com)

2025-07-15 - 8:22:30 PM GMT- IP address: 170.85.10.111



Agreement viewed by Matthew Vesledahl (matthew.vesledahl@optum.com)

Documents: 122436 O5 - Attachment B - Business Associate Agreement_Executable_Date Added.doc
2025-07-15 - 8:22:30 PM GMT- IP address: 170.85.10.111



Document e-signed by Matthew Vesledahl (matthew.vesledahl@optum.com)

Documents: 122436 O5 - Attachment B - Business Associate Agreement_Executable_Date Added.doc
Signature Date: 2025-07-15 - 8:22:45 PM GMT - Time Source: server- IP address: 170.85.10.111



Agreement completed.

2025-07-15 - 8:22:45 PM GMT



Disbursement Remittance Report

Payee: Client Payee Name
Vendor #: REB-XXXXXXXXXX


Rebate Period	Rebate Earned(\$)	Previously Paid(\$)	Net Amount
Totals	\$0.00	\$0.00	

Total Paid **\$0.00**



Please note that the 'Greater of' Rebate evaluation is done at the Payee Level in aggregate where applicable. Rebate collections and amounts due reflect amounts collected or owed pursuant to the terms of your contract. As applicable, for utilization of authorized brand alternatives, the 'ABA Credit' reflects the difference between the amount ORx would have billed in rebates on the originator brand and the amounts collected in rebates on the applicable authorized brand alternative. Please contact your account management team in the event you require additional information if needed for any government reporting purposes. NDC-11 may be added as requested by customer.

Quarter	Carrier ID	Carrier Name	Account ID	Account Name	Group ID	Group Name	Claim Type	Disb Brand Class	Specialty	Collected \$	Client Share %	Client Share \$	Total Due \$	Paid Previously \$	Current Paid \$
---------	------------	--------------	------------	--------------	----------	------------	------------	------------------	-----------	--------------	----------------	-----------------	--------------	--------------------	-----------------



reporting purposes.



Please note that the 'Greater of' Rebate evaluation is done at the Payee Level in aggregate where applicable. Rebate collections and amounts due reflect amounts collected or owed pursuant to the terms of your contract.

As applicable, for utilization of authorized brand alternatives, the 'ABA Credit' reflects the difference between the amount ORx would have billed in rebates on the originator brand and the amounts collected in rebates on the applicable authorized brand alternative.

Please contact your account management team in the event you require additional information if needed for any government reporting purposes.

Quarter	Carrier ID	Carrier Name	Account ID	Account Name	Group ID	Group Name	Claim Type	Disb Brand Class	Specialty	Guarantee Rx	Guarantee Rx Rate \$	Net Guarantee \$	Plus ABA Credit \$	Guarantee \$	Total Due \$	Paid Previously \$	Current Paid \$
---------	------------	--------------	------------	--------------	----------	------------	------------	------------------	-----------	--------------	----------------------	------------------	--------------------	--------------	--------------	--------------------	-----------------

Optum Rx
PO Box 42000
Hazelwood, MO 63042



[Client Logo]

>000001 001 P51036
FIRSTNAME MI LASTNAME
123 STREET NAME
APT 101
CITY, ST 60000



Scan this code with
your smartphone's
camera to learn more
about Optum Rx and
your plan.



WELCOME KIT SAMPLE
Content subject to change in
relation to plan design

ID cards affixed here

ID cards affixed here

Keep these cards in a safe place until your plan is effective

Dear FIRSTNAME,
Welcome! Optum Rx will manage your prescription drug plan. Here are some helpful things to know.

Identification cards

Once your plan is effective, show the enclosed pharmacy ID card when you pick up a prescription. It will help you pay the lowest price for your medication, and it has contact information for questions.

Pharmacies

Log in to [optumrx.com](https://new.optumrx.com) to search for pharmacies in your network or learn more about your pharmacy options at <https://new.optumrx.com/secure/pharmacy-locator>.

Digital tools

Use our website and mobile app to price medications, find network pharmacies and more. You will even be able to access a copy of your member ID card on the Optum Rx app.

Getting started

Check your member ID card to make sure the information is correct¹ and keep it in a safe place.

- Set up an online account at **optumrx.com**.
- Then, set up paperless delivery.
- Download the Optum Rx app so you'll be ready to manage your medication on the go.
- If you have any concerns about your medication after your coverage starts, contact the pharmacy where you filled your prescription.
- For questions about your pharmacy benefit, call the number on your member ID card after coverage begins.

We look forward to serving you.

Sincerely,

The Optum Rx Team

¹ To report any concerns and/or suspected errors, call the number on the back of your card.

This document and others, if attached, contain information from Optum Rx which is proprietary, confidential and/or may contain protected health information (PHI). We are required to safeguard PHI by applicable law. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately, and return the document(s) by mail to Optum Rx, P.O. Box 2749, Shawnee Mission, KS 66201.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

©2024 Optum, Inc.

The company does not discriminate on the basis of race, color, national origin, sex, age, or disability in health programs and activities.

Free services are provided to help you communicate with us, such as letters in other languages or large print. You may also ask to speak with an interpreter. To ask for help, please call the toll-free number listed on your ID card.

ATENCIÓN: Si habla español (Spanish), La compañía no discrimina por raza, color, nacionalidad, sexo, edad o discapacidad en actividades y programas de salud.

Se brindan servicios gratuitos para ayudarle a comunicarse con nosotros, como cartas en otros idiomas o en letra grande. También puede solicitar comunicarse con un intérprete. Para solicitar ayuda, llame al número de teléfono gratuito que figura en su tarjeta de identificación.

請注意：如果您說中文 (Chinese)，公司不会基于种族、肤色、国籍、性别、年龄或残疾而在健康计划和活动中歧视任何人。

为帮助您与我们沟通，我们提供一些免费服务，例如用其他语言书写的信件或大字体。您也可以要求与口译员对话。欲寻求帮助，请拨打您的 ID 卡上列出的免费电话号码。





Prescription Drug Program

RxBIN [BIN]
RxPCN [PCN]
RxGRP [GROUP]
Issuer (80840) 9151014609
ID 1234MEMID
Name FIRSTNAME MI LASTNAME

999999999999

Printed: 01/11/99



This card does not guarantee coverage. Present your ID card along with your prescription when ordering your medication. Improper or fraudulent use of this card to obtain prescription drugs is punishable by law and may result in termination of benefits. Plan dollar limits subject to change. Go online for full benefit information.

Web: optumrx.com Phone: [PHONE1]

	Individual	Family
Deductible:	\$ DEDIND	\$ DEDFAM
Max out of pocket:	\$ OOPIND	\$ OOPFAM
Optum Specialty Pharmacy:	[PHONE2] specialty.optumrx.com	

Submit claims to: Optum Rx
PO Box 650334
Dallas, TX 75265-0334



Questions?

[We're here to help.]
[Reach out to your HR Benefits
team.][Reach out to your Benefits
team.]

[<Optum Rx OE Phone
Number, TTY 711>[<HOURS OF
OPERATION>][<Client HR Phone
Number>]

Optum Rx®


PO Box 510990
Livonia, MI 48151-6990

<Member First Name> <Member Last Name>
<Address 1>
<Address 2>
<City>, <State> <Zip>

Optum Rx®

[Client logo]

It's checklist time.



Hi <Member First Name>,

We’re doing everything we can to make your transition to Optum Rx easy. And to ensure you’re all set to start using your new benefits on <effective date>, there are just a few things you’ll need to do before then.

Don’t worry. It’s actually a quick and easy list:

- ☐ Prior to <effective date>, visit **optumrx.com/getstarted** to learn more about drug tiers, how to get your prescriptions, and more.
- ☐ Check your new member ID card to make sure the information is correct. Then keep it in a safe place.
- ☐ Create an account at **optumrx.com**.
- ☐ Sign up to go paperless.
- ☐ Download the **Optum Rx app** to manage your medication on the go.
- ☐ Check out your pharmacy benefits at a glance, so you know how prescriptions will be priced.

	30-day supply	90-day supply
Tier 1: Lower-cost generics and some brand names	[\$00]/[00%]	[\$00]/[00%]
Tier 2: Mid-range cost preferred brand names	[\$00]/[00%]	[\$00]/[00%]
Tier 3: Higher-cost brand name and some generics	[\$00]/[00%]	[\$00]/[00%]

[If you take a specialty medication, visit **specialty.optumrx.com/new-fill.**]

On <effective date>:

- ☐ You can start accessing your prescription and benefits information.
- ☐ If you are taking any long-term medications, sign up for Optum Home Delivery at **optumrx.com**.

Scan here to go directly to **optumrx.com/getstarted**

We look forward to serving you.

Sincerely,
The Optum Rx Team



Optum Home Delivery is a service of OptumRx.

The company does not discriminate on the basis of race, color, national origin, sex, age, or disability in health programs and activities.

Free services are provided to help you communicate with us, such as letters in other languages or large print. You may also ask to speak with an interpreter. To ask for help, please call the toll-free phone number listed on your ID card.

ATENCIÓN: Si habla español (Spanish), La compañía no discrimina por raza, color, nacionalidad, sexo, edad o discapacidad en actividades y programas de salud.

Se brindan servicios gratuitos para ayudarle a comunicarse con nosotros, como cartas en otros idiomas o en letra grande. También puede solicitar comunicarse con un intérprete. Para solicitar ayuda, llame al número de teléfono gratuito que figura en su tarjeta de identificación.

請注意：如果您說中文 (Chinese)，我們免費為您提供語言協助服務。請撥打會員卡所列的免付費會員電話號碼。

This document and others if attached contain information from Optum Rx that is proprietary, confidential and/or may contain protected health information (PHI). We are required to safeguard PHI by applicable law. The information in this document is for the sole use of the person(s) or company named above. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately and return the document(s) by mail to Optum Rx, P.O. Box 2749, Shawnee Mission, KS 66201.

All Optum trademarks and logos are owned by Optum, Inc. in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners.

© 2022 Optum, Inc. All rights reserved. WF7982433-A 072622

«wvRetAddressName»
«wvRetAddress1»
«wvRetCity», «wvRetState» «wvRetZip»



EXPLANATION OF BENEFITS STATEMENT

This is not a bill

Member Name: «rxMemberName»
Member ID number: «rxMemberID»

«wvFirstName» «wvLastName»
«wvAddress1» «wvAddress2»
«wvCity», «wvState» «wvZip»

Member Information

Member Name: «rxMemberName»
Member ID number: «rxMemberID»
Plan Provider/Group Name: «rxGroupName»
Group number: «rxGroupNum»
Check Number: «rxCheckNum»
Check Amount: «rxCheckAmount»

Member Year to Date Summary			
Policy Period: «rxPolicyContractDt» - «rxPolicyRenewalDt»			
Deductible Applied	Deductible Remaining	Out of Pocket Remaining	Annual Benefit Limit
«rxMemberPaidAmount»	«rxDeductible»	«rxOutofPocketApplied»	«rxAnnualBenefitLimit»

Family Year to Date Summary		
Policy Period: «rxPolicyContractDt» - «rxPolicyRenewalDt»		
Deductible Applied	Deductible Remaining	Out of Pocket Remaining
«rxFamilyTotalPaidToDate»	«rxDeductibleRemaining»	«rxOutofPocketRemaining»

If you are covered by more than one health benefit plan, you should file all your claims with each plan.
Payment will be received on a separate mailing
An adjusted amount is the difference from your Submitted Amount minus the Contracted rate.

EXPLANATION OF BENEFITS STATEMENT

This is not a bill

Member Name: «rxMemberName»

Member ID number: «rxMemberID»

RxCLAIM Number	Date of Service	Prescription Number	Provider Name	Amount Submitted	Amount Allowed	Copay Applied	Deductibl e Applied	Adjusted Amount	Total Payable	Explanation Code
«TableStart:Claim Details»«rxRxClai mNum»	«rxDateofService»	«rxRxNumber»	«rxProviderName»	«rxAmount Submitted»	«rxAmountAllowed »	«rxCopay Applied»	«rxDeductibleApplied»	«rxAdjustedAmt»	«rxTotalPayable»	«rxExplanationCode»«TableEnd:ClaimDetails»

Explanation Code	Description
«TableStart:ExplnCodes»«rxExplanationCode»	«rxDescription»«TableEnd:ExplnCodes»

If you have any questions regarding your Explanation of Benefits: please contact the Customer Service Department, using the phone number on the back of your member identification card.

Sincerely,

Optum Rx
Manual Claims Department/ «Initials»

If you are covered by more than one health benefit plan, you should file all your claims with each plan.
Payment will be received on a separate mailing
An adjusted amount is the difference from your Submitted Amount minus the Contracted rate.

P.O. Box 639
Richboro, PA 18954-9998
DPS\$\$\$PKG*****



JOHN DOE
2909 W OAK STREET
SIOUX FALLS, ND 57105



Log in to your account at
optumrx.com or
scan the QR Code.



Coverage change alert:
Take action on or before **July 1, 2025**.

March 4, 2025

Dear **John**,

We want to make sure you know about time-sensitive changes to your prescription coverage and what to do next. The following changes take place soon.

If you do not take action on or before **July 1, 2025**, you may pay more for your prescription. Your next refill may also be delayed.

These changes do not mean you should stop taking your medication. If another option works for you, your doctor may need to write a prescription for the new medication. These options are suggestions only. Your doctor can decide if they are right for you. If you are no longer taking this medication, you can disregard this letter.

Coverage change summary

Medication	What's changing	Ask about this
TARGET DRUG (This row = EXCL WALT)	Your medication will no longer be covered.*	PREFERRED DRUG
TARGET DRUG (This row = UP WALT)	Your medication is moving to a higher tier. You may pay more for your medication.	PREFERRED DRUG
TARGET DRUG (This row = ST N/A)	Before your higher-cost medication can be covered, you should try a lower-cost medication first.* This is known as step therapy. Talk with your doctor.	STEP1 MED

This area intentionally left blank for your privacy

Medication	What's changing	Ask about this
TARGET DRUG (This row = QL NOREV)	There is a new quantity limit of your medication that will be covered. You may need a new prescription. Contact your doctor or pharmacist.	NEW LIMIT

Medication	What's changing	Take action
TARGET DRUG (This row = PA N/A)	Prior authorization is needed for your medication.	Talk to your doctor about your options.

***What if my doctor wants me to keep taking my current medication?**

Your doctor will need to ask us for a review on or after **July 1, 2025**. If approved, you may continue to fill your prescription, but you may pay a higher cost. If not approved, you may pay the full cost of the requested prescription.

View this change online and more:

- Review your current medication and past claims.
- Search for a network pharmacy near you.
- Compare medication pricing.

To get started, scan the QR code above or log in to your online account at **optumrx.com**.

Questions?

Please call the number on your member ID card. We'll be here to help.

Thanks for letting us serve you.

Sincerely,

The Optum Rx team



Added requirements for medications

Some medications on your plan's drug list may have added requirements before your plan will cover them. These added requirements help to make sure you're receiving coverage, at the best cost and in the right amount. Here's what each of these changes mean:

Prior authorization (PA) – Your doctor provides information to make sure the use of the medication meets coverage guidelines for the medication. If approved, your plan will cover the medication.

Step therapy (ST) – This program encourages the use of lower-cost medications (step 1) that can be used to treat the same condition as the higher-cost medication (step 2). Your plan doesn't cover the higher-cost medication until you try one or more alternatives first (unless you receive approval from us). The plan will only cover the high-cost medication if your doctor requests and receives approval from us.

Quantity limits (QL) – This program covers up to a certain amount of your medication over a certain length of time. For example, your plan may only cover 15mg per day for 30 days. You will only get that amount each time you fill. The plan will only cover a larger amount if your doctor requests and receives approval from us.



If you are no longer a member of this benefit plan after the effective date of these changes, please disregard this letter.

Members were selected to receive this communication based on pharmacy claims data. Information in this letter is confidential and not shared with any non-medical personnel or personnel not directly managing pharmacy claims. Medications listed in this letter are subject to change. Please visit optumrx.com for the most current formulary information.

This document and others if attached contain information from Optum Rx that is proprietary, confidential and/or may contain protected health information (PHI). We are required to safeguard PHI by applicable law. The information in this document is for the sole use of the person(s) or company named above. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately and return the document(s) by mail to Optum Rx, P.O. Box 2749, Shawnee Mission, KS 66201.

All Optum trademarks and logos are owned by Optum, Inc. All other trademarks are the property of their respective owners.

© 2025 OptumRx, Inc. All rights reserved.

Nondiscrimination notice and access to communication services

We do not discriminate on the basis of race, color, national origin, age, disability, or sex in its health programs or activities.

We provide assistance free of charge to people with disabilities or whose primary language is not English. To request a document in another format such as large print or to get language assistance such as a qualified interpreter, please call the number located on the back of your member identification card, TTY 711. Representatives are available 24 hours a day, 7 days a week.

If you believe that we have failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, or if you need help filing a complaint, please call the number located on the back of your member ID card, TTY 711.

Representatives are available 24 hours a day, 7 days a week. You can also file a complaint directly with the U.S. Dept. of Health and Human services online, by phone, or by mail:

Online <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>

Complaint forms are available at <https://www.hhs.gov/ocr/complaints/index.html>

Phone Toll-free 1-800-368-1019, 1-800-537-7697 (TDD)

Mail U.S. Dept. of Health and Human Services
200 Independence Avenue, SW
Room 509F, HHH Building
Washington, D.C. 20201

Aviso de no discriminación y acceso a servicios de comunicación

No discriminamos por raza, color, nacionalidad, sexo, edad o discapacidad en los programas de salud o actividades.

Proporcionamos asistencia sin cargo para personas con discapacidades o cuyo idioma principal no es el inglés. Para solicitar un documento en otro formato como en letra grande o recibir asistencia de idiomas como un intérprete calificado, llame al número que se encuentra al dorso de su tarjeta de identificación de miembro, TTY 711. Los representantes están disponibles las 24 horas del día, los 7 días de la semana.

Si considera que no hemos proporcionado estos servicios o hemos discriminado de otro modo en función de la raza, el color, la nacionalidad, la edad, una discapacidad o el sexo, o si necesita ayuda para presentar una queja, llame al número que se encuentra al dorso de su tarjeta de identificación de miembro, TTY 711.

Los representantes están disponibles las 24 horas del día, los 7 días de la semana. También puede presentar una queja ante el Departamento de Salud y Servicios Humanos de los EE. UU. (U.S. Department of Health and Human Services) en línea, por teléfono o por correo postal:

En línea <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>

Los formularios de quejas están disponibles en <https://www.hhs.gov/ocr/complaints/index.html>

Por teléfono Línea gratuita 1-800-368-1019, 1-800-537-7697 (TDD)

Por correo postal U.S. Dept. of Health and Human Services
200 Independence Avenue, SW
Room 509F, HHH Building
Washington, D.C. 20201

This information is available in other formats like large print. To ask for another format, please call the telephone number listed on your member plan ID card.

Multi-language interpreter services



ATTENTION: If you speak English, language assistance services, free of charge, are available to you. Please call the toll-free phone number listed on your identification card.

ATENCIÓN: Si habla **español (Spanish)**, hay servicios de asistencia de idiomas, sin cargo, a su disposición. Llame al número de teléfono gratuito que aparece en su tarjeta de identificación.

請注意：如果您說**中文 (Chinese)**，我們免費為您提供語言協助服務。請撥打會員卡所列的免付費會員電話號碼。

XIN LƯU Ý: Nếu quý vị nói tiếng **Việt (Vietnamese)**, quý vị sẽ được cung cấp dịch vụ trợ giúp về ngôn ngữ miễn phí. Vui lòng gọi số điện thoại miễn phí ở mặt sau thẻ hội viên của quý vị.

알림: **한국어(Korean)**를 사용하시는 경우 언어 지원 서비스를 무료로 이용하실 수 있습니다. 귀하의 신분증 카드에 기재된 무료 회원 전화번호로 문의하십시오.

PAUNAWA: Kung nagsasalita ka ng **Tagalog (Tagalog)**, may makukuha kang mga libreng serbisyo ng tulong sa wika. Pakitawagan ang toll-free na numero ng telepono na nasa iyong identification card.

ВНИМАНИЕ: бесплатные услуги перевода доступны для людей, чей родной язык является **русским (Russian)**. Позвоните по бесплатному номеру телефона, указанному на вашей идентификационной карте.

تنبيه: إذا كنت تتحدث **العربية (Arabic)**، فإن خدمات المساعدة اللغوية المجانية متاحة لك. الرجاء الاتصال على رقم الهاتف المجاني الموجود على معرف العضوية الخاص بك.

ATANSYON: Si w pale **Kreyòl ayisyen (Haitian Creole)**, ou kapab benefisye sèvis ki gratis pou ede w nan lang pa w. Tanpri rele nimewo gratis ki sou kat idantifikasyon w.

ATTENTION: Si vous parlez **français (French)**, des services d'aide linguistique vous sont proposés gratuitement. Veuillez appeler le numéro de téléphone gratuit figurant sur votre carte d'identification.

UWAGA: Jeżeli mówisz po **polsku (Polish)**, udostępniliśmy darmowe usługi tłumacza. Prosimy zadzwonić pod bezpłatny numer telefonu podany na karcie identyfikacyjnej.

ATENÇÃO: Se você fala **português (Portuguese)**, contate o serviço de assistência de idiomas gratuito. Ligue gratuitamente para o número encontrado no seu cartão de identificação.

ATTENZIONE: in caso la lingua parlata sia l'**italiano (Italian)**, sono disponibili servizi di assistenza linguistica gratuiti. Per favore chiamate il numero di telefono verde indicato sulla vostra tessera identificativa.

ACHTUNG: Falls Sie **Deutsch (German)** sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Bitte rufen Sie die gebührenfreie Rufnummer auf der Rückseite Ihres Mitgliedsausweises an.

注意事項：日本語**(Japanese)**を話される場合、無料の言語支援サービスをご利用いただけます。健康保険証に記載されているフリーダイヤルにお電話ください。

توجه: اگر زبان شما **فارسی (Farsi)** است، خدمات امداد زبانی به طور رایگان در اختیار شما می باشد. لطفا با شماره تلفن رایگانی که روی کارت شناسایی شما قید شده تماس بگیرید.

ध्यान दें: यदि आप **हिंदी (Hindi)** बोलते हैं, आपको भाषा सहायता सेबाएं, नि:शुल्क उपलब्ध हैं। कृपया अपने पहचान पत्र पर सूचीबद्ध टोल-फ्री फोन नंबर पर कॉल करें।

CEEB TOOM: Yog koj hais Lus **Hmoob (Hmong)**, muaj kev pab txhais lus pub dawb rau koj. Thov hu rau tus xov tooj hu deb dawb uas teev muaj nyob rau ntawm koj daim yuaj cim qhia tus kheej.

ចំណាប់អារម្មណ៍: បើសិនអ្នកនិយាយ**ភាសាខ្មែរ (Khmer)** សេវាជំនួយភាសាដោយឥតគិតថ្លៃ គឺមានសំរាប់អ្នក។ សូមទូរស័ព្ទទៅលេខឥតគិតថ្លៃ ដែលមាននៅលើអត្តសញ្ញាណប័ណ្ណរបស់អ្នក។

PAKDAAR: Nu saritaem ti **Ilocano (Ilocano)**, ti serbisyo para ti baddang ti lengguahe nga awanan bayadna, ket sidadaan para kenyam. Maidawat nga awagan iti toll-free a numero ti telepono nga nakalista ayan iti identification card mo.

DÍÍ BAA'ÁKONÍNÍZIN: **Diné (Navajo)** bizaad bee yáníłt'ígo, saad bee áka'anída'awo'ígíí, t'áá jíík'eh, bee ná'ahóót'í. T'áá shqodí ninaaltsoos nít'ízi bee nééhozinígíí bine'déé' t'áá jíík'ehgo béesh bee hane'í biká'ígíí bee hodiilnih.

OGOW: Haddii aad ku hadasho **Soomaali (Somali)**, adeegyada taageerada luqadda, oo bilaash ah, ayaad heli kartaa. Fadlan wac lambarka telefonka khadka bilaashka ee ku yaalla kaarkaaga aqoonsiga.

LOB

All

Carrier

All

Account

All

Group


All

Month


All

Claims Summary

Interventions By Claim Status




Total Rx By Claim Status




Savings Outcome Analysis Summary

Savings



Successes



NUMBERS FOR DEMONSTRATION PURPOSES ONLY

Claim Status	Total Rx	Interventions	% Total Rxs with Intervention
Reversed	20,397,922	14,712,787	72.13%
Paid	95,957,253	60,528,537	63.08%
Rejected	40,682,232	16,413,093	40.34%
Total	157,037,407	91,654,417	58.36%

Type	Current	Accruing	Total	YTD
Savings	\$756,498,257.82	\$2,353,147,897.66	\$3,109,646,155.48	\$14,449,175,039.58
Success	11,089,882	16,659,268	27,749,150	56,570,862

LOB

Carrier

Account

Group

Month

All

All

All

All

All

UR Detailed Activity Summary : Tabular View

Click for Graphical View

Intervention Type	Total	Paid Rx	Paid Rx%	Rejected Rx	Rejected %	Reversed Rx	Reversed %
	1,549	1,549	100.0%				
Drug/Diagnosis Caution	23,738,619	20,448,782	86.1%		13.9%	3,289,837	13.9%
Drug Age Caution (DRUG_AGE)	4,096,202	3,461,355	84.5%		15.5%	634,851	15.5%
Drug Sex Caution (DRUG_SEX)	174,657	141,315	80.9%		19.1%	33,342	19.1%
Drug Inferred Health State (DINFERRD)	21,351,007	17,153,439	80.3%	13,325	19.6%	4,184,243	19.6%
Duplicate Therapy (DUPOTHER)	6,635,131	4,685,092	70.8%	243,487	25.5%	1,686,612	25.5%
Drug-Drug Interaction (DDI-DTMS)	16,086,837	10,692,284	64.1%	3,422,111	15.4%	2,572,442	15.4%
Dosing/Duration (DOSECHECK)	6,471,576	4,108,880	63.5%	292,943	32.0%	2,069,753	32.0%
Morphine Equivalent Dose Limit Screening (MEDLIMIT)	277,087	73,788	26.6%	133,203	25.3%	70,096	25.3%
Multiple Drug Screening (OVERLAP)	201,088	39,641	19.7%	158,363	1.5%	3,084	1.5%
Drug Safety Screening (CDSAFETY)	1,766,772	273,601	15.5%	1,435,412	3.3%	57,759	3.3%
Therapeutic Dose Limits Screening (THERDOSE)	1,343,540	103,031	7.7%	1,168,559	5.4%	71,950	5.4%
Duplicate Rx (DUPRX)	8,126,521	110,156	1.4%	7,799,895	2.7%	216,470	2.7%
Refill Too Soon	1,864,360			1,864,360			
Total	92,715,006	61,292,909	66.1%	16,531,658	16.1%	14,890,439	16.1%



cDUR Monthly Report

Summary

Detailed Activity

Savings Outcome

DUR LOB

Appendix

LOB

All

Carrier

All

Account

All

Group


All

Month

All

cDUR Detailed Activity Summary : Graphical View

[Click for Tabular View](#)





cDUR Monthly Report

Summary

Detailed Activity

Savings Outcome

DUR LOB

Appendix



LOB

Carrier

Account

Group

Month

All

All

All

All

All

cDUR Detailed Savings Outcome : Tabular View

Click for Graphical View

Intervention Type	Current Success	Current Savings	Accruing Success	Accruing Savings	Total Success	Total Savings	YTD Success	YTD Savings
Duplicate Rx (DUPRX)	5,864,579	\$238,732,497.99	3,247,145	\$226,274,576.05	9,111,724	\$465,007,074.03	29,686,782	\$2,259,171,604.68
Drug/Diagnosis Caution	744,276	\$61,661,058.15	2,811,166	\$346,825,207.10	3,615,444	\$408,486,265.25	4,019,999	\$2,085,544,684.80
Drug Inferred Health State (DINFERRD)	717,104	\$106,767,288.15	2,705,668	\$425,443,344.49	3,422,772	\$532,210,633.04	3,465,074	\$2,319,413,596.13
Drug-Drug Interaction (DDI-DTMS)	668,794	\$44,959,795.21	2,704,897	\$200,935,428.09	3,373,691	\$245,895,223.38	3,348,172	\$1,109,221,953.69
Duplicate Therapy (DUP THER)	395,573	\$84,721,320.27	1,651,917	\$292,422,371.84	2,047,490	\$377,143,692.11	1,908,890	\$1,545,406,939.96
Dosing/Duration (DOSECHK)	129,576	\$110,555,056.74	952,536	\$426,615,099.99	1,382,112	\$537,170,156.73	2,042,856	\$2,368,372,897.23
Drug Safety Screening (CDSAFETY)	164,744	\$14,684,575.63	937,179	\$261,235,895.73	1,098,923	\$275,920,471.36	914,437	\$1,429,582,009.23
Therapeutic Dose Limits Screening (THERDOSE)	278,532	\$9,445,644.79	528,671	\$70,279,439.65	807,203	\$79,725,084.44	1,527,853	\$425,022,142.13
Refill Too Soon	1,632,288	\$67,008,998.77	528,529	\$47,402,626.51	2,160,817	\$114,411,625.28	8,699,548	\$584,667,582.14
Drug Age Caution (DRUG_AGE)	156,995	\$13,666,761.53	483,029	\$45,010,982.67	640,024	\$58,677,744.20	776,924	\$256,329,159.75
Morphine Equivalent Dose Limit Screening (MEDLIMIT)	25,062	\$1,195,252.22	27,329	\$2,057,459.29	52,391	\$3,252,711.51	128,540	\$14,575,459.65
Multiple Drug Screening (OVERLAP)	7,374	\$415,222.07	11,708	\$2,438,327.47	19,082	\$2,853,549.53	31,883	\$11,529,961.99
Drug Sex Caution (DRUG_SEX)	7,985	\$2,684,785.81	9,492	\$6,207,138.79	17,477	\$8,891,924.61	19,904	\$40,337,048.20
Total	11,089,882	\$756,498,257.82	16,659,268	\$2,353,147,897.66	27,749,150	\$3,109,646,155.48	56,570,862	\$14,449,175,039.58

LOB

All

Carrier

All

Account

All

Group

All


Month

All


cDUR Detailed Savings Outcome : Graphical View

Click for Tabular View

Year To Date(YTD) Success/Savings



Total Success/Savings



EXAMPLE CLIENT

Discount and Dispensing Fee Performance

January 2021 thru December 2021

CAG(s): AAA1000



Discount Performance						
Description	Rx	AWP	Ingred Cost	Actual Discount	Contracted Discount	Performance
Retail Brand	5,000	\$1,000,000	\$800,000	20.00%	17.00%	\$30,000
Retail Generic	30,000	\$3,000,000	\$750,000	75.00%	73.50%	\$45,000
Mail Brand	1,000	\$1,000,000	\$800,000	20.00%	22.00%	(\$20,000)
Mail Generic	5,000	\$2,000,000	\$450,000	77.50%	80.00%	(\$50,000)

Dispensing Fee Performance						
Description	Rx		Total Dispensing Fees	Dispensing Fee per Rx	Contracted Dispensing Fee	Performance
Retail Brand	5,000		\$5,500	\$1.10	\$1.00	(\$500)
Retail Generic	30,000		\$29,500	\$0.98	\$1.00	\$500
Mail Brand	1,000		\$0	\$0.00	\$0.00	\$0
Mail Generic	5,000		\$0	\$0.00	\$0.00	\$0

Overall Performance	
Total	\$5,000
Payment Due	\$0

Comments

AWP discounts are based on Medi-Span's Published AWP

Excludes DMR/Paper Claims

Excludes Compounds

Excludes COB

Excludes Vaccines

Excludes all COVID-related items

Excludes 340B

Excludes Limited Distribution Products

Excludes Reversals. Both the original claim and the reversal claim are excluded.

Attestation – ERISA Section 408(b)(2) Disclosures

The Consolidated Appropriations Act mandates that certain service providers, specifically those offering brokerage or consulting services to ERISA-covered group health plans, disclose certain compensation to plan fiduciaries. Based on Optum Rx's interpretation, Optum Rx does not believe that any of the services that Optum Rx will provide ***the State of Nebraska*** falls within the definitions of "brokerage services" or "consulting services." The services we provide are not services defined under ERISA Section 408(b)(2).

Acknowledgement

To the best of my knowledge and belief as of the date this document is signed, I believe the contents of this Attestation are correct.

Denise McCabe, Optum Rx Compliance Officer

Name, Title



Denise McCabe (07/14/2025 08:42 CDT)

Signature, Date

Email inquiries may be sent to: optumrxcompliance@optum.com